ELAN - 1.000 % for the LONG-time - 500 Beiträge pro Seite (Seite 44)
eröffnet am 06.06.05 09:03:17 von
neuester Beitrag 05.12.13 01:23:23 von
neuester Beitrag 05.12.13 01:23:23 von
Beiträge: 22.892
ID: 985.574
ID: 985.574
Aufrufe heute: 0
Gesamt: 853.316
Gesamt: 853.316
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 2 Minuten | 8845 | |
| heute 17:20 | 7109 | |
| vor 16 Minuten | 5622 | |
| vor 1 Stunde | 3198 | |
| heute 18:40 | 3101 | |
| heute 09:20 | 2586 | |
| vor 4 Minuten | 2212 | |
| vor 55 Minuten | 1824 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.941,75 | +0,23 | 231 | |||
| 2. | 2. | 180,89 | +0,50 | 85 | |||
| 3. | 3. | 8,7000 | +4,95 | 76 | |||
| 4. | 4. | 3,8600 | +4,32 | 74 | |||
| 5. | 14. | 0,0164 | +0,61 | 70 | |||
| 6. | 11. | 2.306,98 | +0,93 | 48 | |||
| 7. | 6. | 6,6600 | -0,30 | 40 | |||
| 8. | 9. | 1,1800 | +22,28 | 40 |
Feedback
Bloomberg: Elan’s Martin Denies Pfizer Talks; Sees License Deals (Update1)
http://www.bloomberg.com/apps/news?pid=20601087&sid=a4BgiPm1…
By Trista Kelley
Jan. 9 (Bloomberg) -- Elan Corp. plans to raise as much as $500 million by licensing out experimental cancer drugs and isn’t negotiating to sell the company to Pfizer Inc. or any other drugmaker, Chief Executive Officer Kelly Martin said.
Elan is about “a third of the way through our process” of completing the licensing deals, which should be finished within four months, Martin said in an interview today at the drugmaker’s New York office. The proceeds “will put a dent in our debt” and fund the last stage of trials for Elan and Wyeth’s experimental Alzheimer’s therapy, bapineuzumab, he said.
“We want to show people we have options that mitigate our risk,” Martin said. The deals would include licensing six to 10 molecules that are mostly in the first phase of human tests needed for regulatory approval, he said.
Elan, based in Dublin, has $1.7 billion in debt, about $1.1 billion of which is due in 2011, Martin said. The company, maker of the Tysabri multiple sclerosis medicine, shelved plans last year to sell its EDT drug technology division amid the global credit crisis. The unit was valued at about $1 billion, he said.
Elan rose 6 percent to 6.36 euros in Dublin trading, its highest price in more than two months. Ian Hunter, an analyst at Goodbody Stockbrokers Dublin, attributed the rise to speculation that New York-based Pfizer, the world’s biggest drugmaker, may buy the Irish company.
Elan is “approached consistently” by suitors, Kelly said. Still, the company isn’t talking with Pfizer or any other drugmaker about a potential acquisition, he said.
Martin affirmed Elan’s earnings forecast for its report of 2008 earnings. The company reports fourth-quarter 2008 results on Feb. 11.
“As long as the markets are where the markets are,” Martin said, “then we need to reduce the 2011 debt obligation over the first six months of this year.”
To contact the reporter on this story: Trista Kelley in New York at tkelley2@bloomberg.net
Last Updated: January 9, 2009 17:09 EST
http://www.bloomberg.com/apps/news?pid=20601087&sid=a4BgiPm1…
By Trista Kelley
Jan. 9 (Bloomberg) -- Elan Corp. plans to raise as much as $500 million by licensing out experimental cancer drugs and isn’t negotiating to sell the company to Pfizer Inc. or any other drugmaker, Chief Executive Officer Kelly Martin said.
Elan is about “a third of the way through our process” of completing the licensing deals, which should be finished within four months, Martin said in an interview today at the drugmaker’s New York office. The proceeds “will put a dent in our debt” and fund the last stage of trials for Elan and Wyeth’s experimental Alzheimer’s therapy, bapineuzumab, he said.
“We want to show people we have options that mitigate our risk,” Martin said. The deals would include licensing six to 10 molecules that are mostly in the first phase of human tests needed for regulatory approval, he said.
Elan, based in Dublin, has $1.7 billion in debt, about $1.1 billion of which is due in 2011, Martin said. The company, maker of the Tysabri multiple sclerosis medicine, shelved plans last year to sell its EDT drug technology division amid the global credit crisis. The unit was valued at about $1 billion, he said.
Elan rose 6 percent to 6.36 euros in Dublin trading, its highest price in more than two months. Ian Hunter, an analyst at Goodbody Stockbrokers Dublin, attributed the rise to speculation that New York-based Pfizer, the world’s biggest drugmaker, may buy the Irish company.
Elan is “approached consistently” by suitors, Kelly said. Still, the company isn’t talking with Pfizer or any other drugmaker about a potential acquisition, he said.
Martin affirmed Elan’s earnings forecast for its report of 2008 earnings. The company reports fourth-quarter 2008 results on Feb. 11.
“As long as the markets are where the markets are,” Martin said, “then we need to reduce the 2011 debt obligation over the first six months of this year.”
To contact the reporter on this story: Trista Kelley in New York at tkelley2@bloomberg.net
Last Updated: January 9, 2009 17:09 EST
Antwort auf Beitrag Nr.: 36.347.761 von dasHaendchen am 10.01.09 13:18:25auch gut, dann sind die übernahme spekulationen scheinbar vom tisch!
Antwort auf Beitrag Nr.: 36.348.263 von GuHu1 am 10.01.09 15:49:32....so einfach ist es nicht (getreu der Weisheit:NICHTS ist wie es scheint...
) Ich finde folgende Überlegungen ziemlich plausibel.....:
Author: winonefortheteam
Thoughts on possibility of Pfizer bid
<Elan Corp. plans to raise as much as $500 million by licensing out experimental cancer drugs and isn’t negotiating to sell the company to Pfizer Inc. or any other drugmaker, Chief Executive Officer Kelly Martin said.>
<Elan is about “a third of the way through our process” of completing the licensing deals, which should be finished within four months,>
<Elan is “approached consistently” by suitors, Kelly said. Still, the company isn’t talking with Pfizer or any other drugmaker about a potential acquisition, he said.>
Let’s get something straight: Elan’s PPS didn’t rise on the basis of a licensing deal which is four months away. Especially since it is difficult to see how you raise a bunch of money from Phase I molecules.
I do believe that Pfizer is considering a bid for Elan. They don’t need to go into merger discussions to find stuff out about the company. It is all out there:
1) Pfizer knows everything about Elan’s early-stage pipeline because KM is out there hawking it. (Believe it or not, KM might have done too good a job in marketing the pipeline!!)
2) Pfizer know that Biogen (and Elan) is very bullish on Tysabri. And Biogen should know.
3) Pfizer know that Wyeth (and Elan) expect to be successful in Alzheimer’s with AAB-001. And Pfizer would respect Wyeth’s opinion as well
4) Pfizer know that EDT is set to receive a boost from Acorda’s famipridine when it gets approved in the latter part of this year
Pfizer wants to be big in Alzheimer’s. And Pfizer has been interested in Biogen, so it is very familiar with Tysabri. Pfizer would certainly prefer to buy Biogen or Wyeth rather than Elan, but those acquisitions would be very expensive and very difficult. Elan is cheap and extremely vulnerable.
Based on KM’s statement about being approached consistently by suitors, Pfizer knows that KM does not want to deal. So there is no point in trying to enter into negotiations. The better approach is to go to investors directly.
There are a core of large institutional shareholders who are sick of the roller-coaster ride and want to get off. It was interesting to see Jack Schuler’s comments in mid-December about KM being supported by Matt Strobeck of Westfield Capital Management Co. and Larry Feinberg of Oracle Investment. Those guys are heavy hitters. And if the following comment by Schuler is true, there is a real revolt amongst the top shareholders: "Every large Elan shareholder has come to me with concerns about Martin and that includes Fidelity and Wellington,"
Given the above, Pfizer knows that an unsolicited offer for Elan would actually be well-received by the shareholder base. And while KM would resist, the board would start to worry about their own legal liability if they ignore Pfizer’s $20 bid for a stock that was trading at $5 a few weeks prior. It wouldn’t be easy, but Pfizer would have a reasonable chance of winning the company, although they would probably have to pay a few dollars more per share to nail down the agreement. My guess is $25 in the end.
In terms of the “poison pills” with Wyeth and Biogen, I don’t see them as a big deal. My suspicion is that Pfizer can offer something to both Wyeth and Biogen to agree not to cause any problems with the deal. For example, Pfizer can agree to a stand-still agreement which would certainly make the CEOs of those firms rest easier at night.
Pfizer desperately needs pipeline. Elan is tremendously vulnerable – low share price, disgusted investors, no near-term catalysts. So my bet is that Pfizer is thinking about a bid, and that it will be through an unsolicited offer. If KM and the board resist, Pfizer will threaten a proxy fight at the upcoming AGM. Remember, timing is everything in M&A and I think the stars are aligned at this point in time.
For those who think that Elan is worth more than $20 or $25 per share, I agree with you. But it doesn’t really matter, because it is Fidelity, Wellington, Oracle, Westifield, etc., who will ultimately decide if the takeover bid is acceptable.
) Ich finde folgende Überlegungen ziemlich plausibel.....:Author: winonefortheteam
Thoughts on possibility of Pfizer bid
<Elan Corp. plans to raise as much as $500 million by licensing out experimental cancer drugs and isn’t negotiating to sell the company to Pfizer Inc. or any other drugmaker, Chief Executive Officer Kelly Martin said.>
<Elan is about “a third of the way through our process” of completing the licensing deals, which should be finished within four months,>
<Elan is “approached consistently” by suitors, Kelly said. Still, the company isn’t talking with Pfizer or any other drugmaker about a potential acquisition, he said.>
Let’s get something straight: Elan’s PPS didn’t rise on the basis of a licensing deal which is four months away. Especially since it is difficult to see how you raise a bunch of money from Phase I molecules.
I do believe that Pfizer is considering a bid for Elan. They don’t need to go into merger discussions to find stuff out about the company. It is all out there:
1) Pfizer knows everything about Elan’s early-stage pipeline because KM is out there hawking it. (Believe it or not, KM might have done too good a job in marketing the pipeline!!)
2) Pfizer know that Biogen (and Elan) is very bullish on Tysabri. And Biogen should know.
3) Pfizer know that Wyeth (and Elan) expect to be successful in Alzheimer’s with AAB-001. And Pfizer would respect Wyeth’s opinion as well
4) Pfizer know that EDT is set to receive a boost from Acorda’s famipridine when it gets approved in the latter part of this year
Pfizer wants to be big in Alzheimer’s. And Pfizer has been interested in Biogen, so it is very familiar with Tysabri. Pfizer would certainly prefer to buy Biogen or Wyeth rather than Elan, but those acquisitions would be very expensive and very difficult. Elan is cheap and extremely vulnerable.
Based on KM’s statement about being approached consistently by suitors, Pfizer knows that KM does not want to deal. So there is no point in trying to enter into negotiations. The better approach is to go to investors directly.
There are a core of large institutional shareholders who are sick of the roller-coaster ride and want to get off. It was interesting to see Jack Schuler’s comments in mid-December about KM being supported by Matt Strobeck of Westfield Capital Management Co. and Larry Feinberg of Oracle Investment. Those guys are heavy hitters. And if the following comment by Schuler is true, there is a real revolt amongst the top shareholders: "Every large Elan shareholder has come to me with concerns about Martin and that includes Fidelity and Wellington,"
Given the above, Pfizer knows that an unsolicited offer for Elan would actually be well-received by the shareholder base. And while KM would resist, the board would start to worry about their own legal liability if they ignore Pfizer’s $20 bid for a stock that was trading at $5 a few weeks prior. It wouldn’t be easy, but Pfizer would have a reasonable chance of winning the company, although they would probably have to pay a few dollars more per share to nail down the agreement. My guess is $25 in the end.
In terms of the “poison pills” with Wyeth and Biogen, I don’t see them as a big deal. My suspicion is that Pfizer can offer something to both Wyeth and Biogen to agree not to cause any problems with the deal. For example, Pfizer can agree to a stand-still agreement which would certainly make the CEOs of those firms rest easier at night.
Pfizer desperately needs pipeline. Elan is tremendously vulnerable – low share price, disgusted investors, no near-term catalysts. So my bet is that Pfizer is thinking about a bid, and that it will be through an unsolicited offer. If KM and the board resist, Pfizer will threaten a proxy fight at the upcoming AGM. Remember, timing is everything in M&A and I think the stars are aligned at this point in time.
For those who think that Elan is worth more than $20 or $25 per share, I agree with you. But it doesn’t really matter, because it is Fidelity, Wellington, Oracle, Westifield, etc., who will ultimately decide if the takeover bid is acceptable.
Elan has 'poison pill' strategy to halt Pfizer bid
By Nick Webb
Sunday January 11 2009
As speculation mounts that Pfizer is planning a €4bn bid for Irish drug company Elan, it has emerged that Kelly Martin's firm has implemented a 'poison pill' strategy to protect it against hostile takeovers.
Tysabri is the plum bauble in Elan's drug cabinet. Some analysts expect the controversial drug, which treats MS, to generate sales of more than $1bn per year soon.
As major drug companies struggle to maintain a strong pipeline of blockbuster products, Elan's Tysabri is viewed as being particularly attractive.
However, Elan, which is chaired by Davy Stockbrokers skipper Kyran McLaughlin, would be "messy" to take out.
It has emerged that Elan has protected itself from unwanted takeover by entering an arrangement whereby it may have to sell its share in Tysabri if it is taken over.
"Our collaborative agreement with Biogen provides Biogen with an option to buy the rights to Tysabri in the event we undergo a change of control which may limit our attractiveness to potential acquirors," according to Elan documents.
Elan is also protected from a takeover by Biogen itself, with the two companies agreeing a deal where Biogen cannot bid for Elan before 2010.
However, last year US investor Carl Icahn alleged that Elan had agreed not to change its Tysabri drug development partnership with Biogen, if the US company was taken over. Icahn also alleged that Elan had been approached for talks about the ownership of Tysabri by a company bidding for Biogen.
The $41bn pharmaceutical firm Wyeth is also prevented from taking over Elan "in some circumstances" under the terms of a development joint venture.
A takeover of Elan may also trigger certain debt covenants or indentures, forcing the new owners to repurchase the debt for cash.
Loss-making Elan is €1.15bn in debt. This is due to be repaid in 2011.
Shares in Elan rocketed 40 per cent last week as US investors ploughed into the company on suggestions that a big pharmaceutical company was about to pounce.
Pfizer has been widely linked as a potential predator, fuelled by chief executive Jeffrey Kindler's admission that it was to acquire a large rival drug company "to improve its financial health".
However this is widely thought to have been a reference to another pharma firm, Amgen.
Both Elan and Pfizer have declined to comment. However Goodbody analyst Ian Hunter suggested that Elan would be too small a target for Pfizer and that much of the share price rally may have been simply down to rumours of forecast-busting Tysabri sales.
Elan chief executive Kelly Martin would be the big winner out of any takeover.
The company amended his contract to entitle the former banker to three times his annual remuneration if the company was taken over.
This deal replaced a 2003 agreement which stipulated that Martin was entitled to just two-year pay in the event of a takeover.
Since taking over the helm of Elan, Martin has eschewed cash bonuses in favour of massive stock options grants.
Elan's latest annual report shows that Martin holds options over 3.85 million stock options, although some of these were granted at prices of nearly $14.
He was also granted $1m worth of options at prices up to $25 last year.
- Nick Webb
By Nick Webb
Sunday January 11 2009
As speculation mounts that Pfizer is planning a €4bn bid for Irish drug company Elan, it has emerged that Kelly Martin's firm has implemented a 'poison pill' strategy to protect it against hostile takeovers.
Tysabri is the plum bauble in Elan's drug cabinet. Some analysts expect the controversial drug, which treats MS, to generate sales of more than $1bn per year soon.
As major drug companies struggle to maintain a strong pipeline of blockbuster products, Elan's Tysabri is viewed as being particularly attractive.
However, Elan, which is chaired by Davy Stockbrokers skipper Kyran McLaughlin, would be "messy" to take out.
It has emerged that Elan has protected itself from unwanted takeover by entering an arrangement whereby it may have to sell its share in Tysabri if it is taken over.
"Our collaborative agreement with Biogen provides Biogen with an option to buy the rights to Tysabri in the event we undergo a change of control which may limit our attractiveness to potential acquirors," according to Elan documents.
Elan is also protected from a takeover by Biogen itself, with the two companies agreeing a deal where Biogen cannot bid for Elan before 2010.
However, last year US investor Carl Icahn alleged that Elan had agreed not to change its Tysabri drug development partnership with Biogen, if the US company was taken over. Icahn also alleged that Elan had been approached for talks about the ownership of Tysabri by a company bidding for Biogen.
The $41bn pharmaceutical firm Wyeth is also prevented from taking over Elan "in some circumstances" under the terms of a development joint venture.
A takeover of Elan may also trigger certain debt covenants or indentures, forcing the new owners to repurchase the debt for cash.
Loss-making Elan is €1.15bn in debt. This is due to be repaid in 2011.
Shares in Elan rocketed 40 per cent last week as US investors ploughed into the company on suggestions that a big pharmaceutical company was about to pounce.
Pfizer has been widely linked as a potential predator, fuelled by chief executive Jeffrey Kindler's admission that it was to acquire a large rival drug company "to improve its financial health".
However this is widely thought to have been a reference to another pharma firm, Amgen.
Both Elan and Pfizer have declined to comment. However Goodbody analyst Ian Hunter suggested that Elan would be too small a target for Pfizer and that much of the share price rally may have been simply down to rumours of forecast-busting Tysabri sales.
Elan chief executive Kelly Martin would be the big winner out of any takeover.
The company amended his contract to entitle the former banker to three times his annual remuneration if the company was taken over.
This deal replaced a 2003 agreement which stipulated that Martin was entitled to just two-year pay in the event of a takeover.
Since taking over the helm of Elan, Martin has eschewed cash bonuses in favour of massive stock options grants.
Elan's latest annual report shows that Martin holds options over 3.85 million stock options, although some of these were granted at prices of nearly $14.
He was also granted $1m worth of options at prices up to $25 last year.
- Nick Webb
Trading Spotlight
....hat jmd. eine neue Quelle für kostenlose realtime-Kurse für Elan in USA?? Level2quotes/daytrade wollen nun Geld....?????
Antwort auf Beitrag Nr.: 36.356.110 von Birgit.Tersteegen am 12.01.09 15:57:24Vielleicht hilft Dir folgende Quelle:
http://finance.google.com/finance?q=NYSE:ELN
Gruß,
d.H.
http://finance.google.com/finance?q=NYSE:ELN
Gruß,
d.H.
Antwort auf Beitrag Nr.: 36.356.453 von dasHaendchen am 12.01.09 16:28:41....Danke,werde ich gleich anschauen....ansonsten gehts mit Anmeldung auch hier http://moneycentral.msn.com/detail/realtime_quote?Symbol=ELN" target="_blank" rel="nofollow ugc noopener">
http://moneycentral.msn.com/detail/realtime_quote?Symbol=ELN
http://moneycentral.msn.com/detail/realtime_quote?Symbol=ELN
ELN msg # 315739 1/13/2009 2:12:28 AM
By: Thurly
DJ Newswire @ 2 AM - Bombshell
Link not available as it came from my trading platform
Elan to Review Strategic Business Alternatives
DUBLIN, Ireland NEW YORK, SAN FRANCISCO--(BUSINESS WIRE)-- Elan Corporation,
plc (NYSE: [ELN]) announced today that the Board of Directors has engaged
Citigroup Global Markets Inc. to conduct, in conjunction with executive
management and other external advisors, a review of the Company's strategic
alternatives. The goal is to secure access to the necessary financial resources
and commercial infrastructure to allow Elan to accelerate the development and
commercialization of its extensive pipeline and product portfolio while
maximizing the ability of its shareholders to participate in the resulting
longer term value creation. The range of alternatives that will be assessed
could include minority investment or strategic alliance, a merger or sale.
"We recently concluded our annual review of the Company's scientific
capabilities, clinical portfolio, and commercial opportunities in Alzheimer's,
Parkinson's, and Multiple Sclerosis. Our progress to date has been significant.
Given our many scientific, clinical and commercial opportunities and the
capabilities of the industry participants that surround us, the Board of
Directors has determined that this is an appropriate time for the Board to
explore potential alternative paths forward for the Company," stated Kyran
McLaughlin, Chairman of the Board of Directors.
The Company is committed to completing its review of potential alternatives as
promptly as practicable. However, there can be no assurances that any particular
alternative will be pursued or that any transaction will occur, or on what
terms. The Company does not plan to release additional information about the
status of the review of alternatives until a definitive agreement is entered
into or the process is otherwise completed.
By: Thurly
DJ Newswire @ 2 AM - Bombshell
Link not available as it came from my trading platform
Elan to Review Strategic Business Alternatives
DUBLIN, Ireland NEW YORK, SAN FRANCISCO--(BUSINESS WIRE)-- Elan Corporation,
plc (NYSE: [ELN]) announced today that the Board of Directors has engaged
Citigroup Global Markets Inc. to conduct, in conjunction with executive
management and other external advisors, a review of the Company's strategic
alternatives. The goal is to secure access to the necessary financial resources
and commercial infrastructure to allow Elan to accelerate the development and
commercialization of its extensive pipeline and product portfolio while
maximizing the ability of its shareholders to participate in the resulting
longer term value creation. The range of alternatives that will be assessed
could include minority investment or strategic alliance, a merger or sale.
"We recently concluded our annual review of the Company's scientific
capabilities, clinical portfolio, and commercial opportunities in Alzheimer's,
Parkinson's, and Multiple Sclerosis. Our progress to date has been significant.
Given our many scientific, clinical and commercial opportunities and the
capabilities of the industry participants that surround us, the Board of
Directors has determined that this is an appropriate time for the Board to
explore potential alternative paths forward for the Company," stated Kyran
McLaughlin, Chairman of the Board of Directors.
The Company is committed to completing its review of potential alternatives as
promptly as practicable. However, there can be no assurances that any particular
alternative will be pursued or that any transaction will occur, or on what
terms. The Company does not plan to release additional information about the
status of the review of alternatives until a definitive agreement is entered
into or the process is otherwise completed.
Antwort auf Beitrag Nr.: 36.360.499 von Birgit.Tersteegen am 13.01.09 08:39:32Tja Jungs,WAS hat das zu bedeuten????Hier wird offiziell ein Verkauf NICHT ausgeschlossen.... Ich sage nur----nicht unter35$.....
Antwort auf Beitrag Nr.: 36.360.546 von Birgit.Tersteegen am 13.01.09 08:47:09AHA
mit unserem Baby kann man schon eine Menge Kohle machen.
Bin bei 7,- Euro auch wieder in der Gewinnzone, allerdings benötige ich noch ordentlich "Schmerzensgeld" für die letzten Wochen und Monate.
Bin bei 7,- Euro auch wieder in der Gewinnzone, allerdings benötige ich noch ordentlich "Schmerzensgeld" für die letzten Wochen und Monate.
Folgende institutionelle Anleger haben ELAN-Aktien seit Beginn des Jahres gekauft:
- Hsbc Investor Oppurtunity Fund (Hsbc Investor Funds): 251,000 Stk
- International Fund (Old Westbury Funds Inc): 238,700 Stk
(Report Date: 09.01.2009)
Verkauft haben institutionelle Anleger Aktien in folgender Stückzahl (seit Beginn des Jahres):
- 13,690
Angaben sind bitte ohne Gewähr.
Quelle: MFFAIS
Gruß,
d.H.
- Hsbc Investor Oppurtunity Fund (Hsbc Investor Funds): 251,000 Stk
- International Fund (Old Westbury Funds Inc): 238,700 Stk
(Report Date: 09.01.2009)
Verkauft haben institutionelle Anleger Aktien in folgender Stückzahl (seit Beginn des Jahres):
- 13,690
Angaben sind bitte ohne Gewähr.
Quelle: MFFAIS
Gruß,
d.H.
finanzen.net
Elan erwägt strategische Alternativen, Aktie +10 Prozent
Dienstag 13. Januar 2009, 11:49 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) meldete am Montag, dass er die Citigroup Global Markets Inc (CEIS.PK - Nachrichten) ., eine Sparte der Citigroup Inc (NYSE: C - Nachrichten) . (ISIN US1729671016/ WKN 871904), engagiert hat, um strategische Alternativen auszuloten.
Den Angaben zufolge verfolgt Elan (Dublin: DRX.IR - Nachrichten) das Ziel, den Zugang zu notwendigen finanziellen Ressourcen und zu kommerzieller Infrastruktur zu sichern, damit das Unternehmen die Entwicklung und Vermarktung seiner umfangreichen Pipeline und seines Produkt-Portfolios beschleunigen kann. Zu den Optionen, die in diesem Zusammenhang geprüft werden, gehören ein Minderheits-Investment oder eine strategische Allianz, eine Fusion oder ein Verkauf des Unternehmens.
Die Aktie von Elan notiert aktuell an der Heimatbörse mit einem Plus von 9,83 Prozent bei 6,59 Euro. (13.01.2009/ac/n/a)
Elan erwägt strategische Alternativen, Aktie +10 Prozent
Dienstag 13. Januar 2009, 11:49 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) meldete am Montag, dass er die Citigroup Global Markets Inc (CEIS.PK - Nachrichten) ., eine Sparte der Citigroup Inc (NYSE: C - Nachrichten) . (ISIN US1729671016/ WKN 871904), engagiert hat, um strategische Alternativen auszuloten.
Den Angaben zufolge verfolgt Elan (Dublin: DRX.IR - Nachrichten) das Ziel, den Zugang zu notwendigen finanziellen Ressourcen und zu kommerzieller Infrastruktur zu sichern, damit das Unternehmen die Entwicklung und Vermarktung seiner umfangreichen Pipeline und seines Produkt-Portfolios beschleunigen kann. Zu den Optionen, die in diesem Zusammenhang geprüft werden, gehören ein Minderheits-Investment oder eine strategische Allianz, eine Fusion oder ein Verkauf des Unternehmens.
Die Aktie von Elan notiert aktuell an der Heimatbörse mit einem Plus von 9,83 Prozent bei 6,59 Euro. (13.01.2009/ac/n/a)
möglich,dass es so gelaufen ist....
Author: MarkyP_98
Shakeout - Hypothesis
(1) In seeking partneships for Phase 1 compounds, ELN received a significant 'realistic' offer from a third party.
(2) Kelly Martin is against accepting the offer. He issues a statement denying Take-Over talks with Pfizer:
NEW YORK, Jan 9 (Reuters) - Elan Corp Plc (ELN.I) (ELN.L) Chief Executive Kelly Martin told Bloomberg Friday that the Irish drugmaker is not negotiating to sell itself to Pfizer Inc (PFE.N), or any other drug company, even though Kelly said Elan is "approached consistently" by suitors. Spokespersons from neither Elan nor Pfizer could be reached for comment.
http://www.reuters.com/article/americasMergersNews/idUSN0931…
(3) Kelly Martin must present details of the offer to the Board.
(4) There is disagreement at Board level as to how to react to the offer, with some arguing that all options should be considered.
(5) Kelly is over-ruled by the board. A board majority votes in favour of investigating all strategic options.
"Given our many scientific, clinical and commercial opportunities and the capabilities of the industry participants that surround us, the board of directors has determined that this is an appropriate time for the board to explore potential alternative paths forward for the company," said Chairman Kyran McLaughlin in a statement.
http://www.thestreet.com/story/10457494/1/elan-mulling-possi…
Cheers,
MarkyP
Author: MarkyP_98
Shakeout - Hypothesis
(1) In seeking partneships for Phase 1 compounds, ELN received a significant 'realistic' offer from a third party.
(2) Kelly Martin is against accepting the offer. He issues a statement denying Take-Over talks with Pfizer:
NEW YORK, Jan 9 (Reuters) - Elan Corp Plc (ELN.I) (ELN.L) Chief Executive Kelly Martin told Bloomberg Friday that the Irish drugmaker is not negotiating to sell itself to Pfizer Inc (PFE.N), or any other drug company, even though Kelly said Elan is "approached consistently" by suitors. Spokespersons from neither Elan nor Pfizer could be reached for comment.
http://www.reuters.com/article/americasMergersNews/idUSN0931…
(3) Kelly Martin must present details of the offer to the Board.
(4) There is disagreement at Board level as to how to react to the offer, with some arguing that all options should be considered.
(5) Kelly is over-ruled by the board. A board majority votes in favour of investigating all strategic options.
"Given our many scientific, clinical and commercial opportunities and the capabilities of the industry participants that surround us, the board of directors has determined that this is an appropriate time for the board to explore potential alternative paths forward for the company," said Chairman Kyran McLaughlin in a statement.
http://www.thestreet.com/story/10457494/1/elan-mulling-possi…
Cheers,
MarkyP
http://finance.yahoo.com/news/Drugmaker-Pfizer-cutting-up-ap…
Drugmaker Pfizer cutting up to 800 scientist jobs
Tuesday January 13, 11:46 am ET
Drugmaker Pfizer cutting up to 800 scientist jobs due to looming revenue cliff from generics
NEW YORK (AP) -- The world's biggest drug company is laying off up to 800 research scientists and expects to reduce its research staff by 5 percent to 8 percent this year.
Tuesday's move by New York-based Pfizer comes after the company narrowed its research focus and reorganized its business units last fall. Looming patent expirations threaten to wipe out much of Pfizer's revenue.
Analysts have said they expect Pfizer to make a big move, such as a major acquisition that would allow massive job cuts to save money.
Pfizer makes the world's top-selling drugs, cholesterol fighter Lipitor, which is expected to face generic competition late in 2011. That will slash Lipitor's sales, now nearly $13 billion but under pressure from a generic version of a similar drug.
Drugmaker Pfizer cutting up to 800 scientist jobs
Tuesday January 13, 11:46 am ET
Drugmaker Pfizer cutting up to 800 scientist jobs due to looming revenue cliff from generics
NEW YORK (AP) -- The world's biggest drug company is laying off up to 800 research scientists and expects to reduce its research staff by 5 percent to 8 percent this year.
Tuesday's move by New York-based Pfizer comes after the company narrowed its research focus and reorganized its business units last fall. Looming patent expirations threaten to wipe out much of Pfizer's revenue.
Analysts have said they expect Pfizer to make a big move, such as a major acquisition that would allow massive job cuts to save money.
Pfizer makes the world's top-selling drugs, cholesterol fighter Lipitor, which is expected to face generic competition late in 2011. That will slash Lipitor's sales, now nearly $13 billion but under pressure from a generic version of a similar drug.
Davy
Price $7.86 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Elan’s presentation at the JPM conference was watched with interest in light of its
decision to review strategic alternatives for the business. In the event, CEO, Kelly
Martin, and president, Carlos Paya, presented an upbeat outlook for 2009,
building on the message provided by the CEO at the Davy Irish Equity Market
Conference on January 9th (see our note 'Pharma and healthcare companies strike
resilient tone', issued January 12th).
Only a little more colour was provided on the strategic review process. Elan’s clear
objectives are to secure additional financial flexibility, and to secure access to
global commercial infrastructure. The review itself is the culmination of up to two
years of internal discussions and analysis. How quickly this process can now be
completed remains unclear; however, the public attention it brings, and the
prospective entry of new industry investors, may serve to focus the minds of both
BIIB and WYE on how to secure their respective interests in the Elan product and
pipeline base. BIIB said at the conference that it will now 'step back and see what
happens' at Elan.
One other significant point to note in Elan’s presentation was that phase II data on
Bapineuzumab has now been submitted for publication in leading medical journals
– this will probably occur in H1 2009.
BIIB also released Q4 patient numbers for Tysabri at the conference. Tysabri
commercial patients at end-year totalled 37,100 — growth of 6.7% on Q3. This
was a little below our year-end forecast of 37,400. The outturn translates to a net
addition rate of 177/week (based on 13 weeks). Our forecasts were for a 200/week
addition rate for the period. By region, US growth fell back significantly in the
quarter on the first PML case there (54/week compared to 131/week in Q3). In
RoW, growth of 123/week compares to 146/week in Q3. Discontinuations had
increased during the period but the CEO said this has now 'stabilised' at a rate
similar to other MS therapies.
Our view is that the Q4 outturn is fairly positive in a challenging quarter. Tysabri is
still growing despite this being the first full quarter with newly confirmed PML
cases. Momentum now needs to be injected to highlight efficacy, and to highlight
that PML outcomes are potentially less severe than originally perceived. Our
forecast is for a net addition rate of 200/week for the coming quarters, and our
instinct is to leave this
Price $7.86 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Elan’s presentation at the JPM conference was watched with interest in light of its
decision to review strategic alternatives for the business. In the event, CEO, Kelly
Martin, and president, Carlos Paya, presented an upbeat outlook for 2009,
building on the message provided by the CEO at the Davy Irish Equity Market
Conference on January 9th (see our note 'Pharma and healthcare companies strike
resilient tone', issued January 12th).
Only a little more colour was provided on the strategic review process. Elan’s clear
objectives are to secure additional financial flexibility, and to secure access to
global commercial infrastructure. The review itself is the culmination of up to two
years of internal discussions and analysis. How quickly this process can now be
completed remains unclear; however, the public attention it brings, and the
prospective entry of new industry investors, may serve to focus the minds of both
BIIB and WYE on how to secure their respective interests in the Elan product and
pipeline base. BIIB said at the conference that it will now 'step back and see what
happens' at Elan.
One other significant point to note in Elan’s presentation was that phase II data on
Bapineuzumab has now been submitted for publication in leading medical journals
– this will probably occur in H1 2009.
BIIB also released Q4 patient numbers for Tysabri at the conference. Tysabri
commercial patients at end-year totalled 37,100 — growth of 6.7% on Q3. This
was a little below our year-end forecast of 37,400. The outturn translates to a net
addition rate of 177/week (based on 13 weeks). Our forecasts were for a 200/week
addition rate for the period. By region, US growth fell back significantly in the
quarter on the first PML case there (54/week compared to 131/week in Q3). In
RoW, growth of 123/week compares to 146/week in Q3. Discontinuations had
increased during the period but the CEO said this has now 'stabilised' at a rate
similar to other MS therapies.
Our view is that the Q4 outturn is fairly positive in a challenging quarter. Tysabri is
still growing despite this being the first full quarter with newly confirmed PML
cases. Momentum now needs to be injected to highlight efficacy, and to highlight
that PML outcomes are potentially less severe than originally perceived. Our
forecast is for a net addition rate of 200/week for the coming quarters, and our
instinct is to leave this
January 13, 2009 - 12:55 AM EST
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials
Elan Corporation, plc (NYSE: ELN) today clarified recent reports that the duration of the bapineuzumab Phase 3 clinical trials may be extended. The protocols for the four Phase 3 trials for bapineuzumab, which are approved by regulatory authorities, are designed for patients to participate for a duration of 18 months. The planned duration of the trials has not changed since the program was announced in December 2007.
There are currently no plans to extend the duration of the Phase 3 trials.
http://www1.investorvillage.com/iv1/smbd.asp?mb=160&pt=qn
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials
Elan Corporation, plc (NYSE: ELN) today clarified recent reports that the duration of the bapineuzumab Phase 3 clinical trials may be extended. The protocols for the four Phase 3 trials for bapineuzumab, which are approved by regulatory authorities, are designed for patients to participate for a duration of 18 months. The planned duration of the trials has not changed since the program was announced in December 2007.
There are currently no plans to extend the duration of the Phase 3 trials.
http://www1.investorvillage.com/iv1/smbd.asp?mb=160&pt=qn
Antwort auf Beitrag Nr.: 36.381.255 von bernie55 am 15.01.09 15:10:47Selbst unabhägig vom Ergebnis
scheint es manche nervös zu machen,
dass das Ende der PhaseIII näher und näher kommt.
posimist
scheint es manche nervös zu machen,
dass das Ende der PhaseIII näher und näher kommt.
posimist
Lundbeck may have revived its interest in Elan
Sunday January 18 2009
Danish pharmaceutical firm Lundbeck is understood to be interested in acquiring €4bn Irish drug group Elan.
Last week, Elan revealed that it had appointed Citigroup to advise it on "strategic review" of the company's options. These include the sale of the company, a merger or the sale of a stake in the business. Pfizer had been strongly linked with an approach for Elan, although last week the Sunday Independent revealed that the existence of a "poison pill" arrangement could deter Pfizer from making a bid. Both companies subsequently denied that they were in talks.
It is thought that Lundbeck may have been interested in acquiring Elan some time ago, although no formal approach was made. Last week, Elan chief executive Kelly Martin revealed that the company had received a number of informal approaches from potential buyers.
Elan's MS drug Tysabri is considered to be its key attraction, although Alzheimer's drug Bapineuzumab may be of particular interest to Lundbeck, which has invested heavily in the area. Lundbeck declined to comment on an approach last week. Wyeth and Biogen have also been linked with the company.
Elan has over €1.1bn in debt that must be refinanced by 2011. The company was forced to cancel the planned €1bn sale of its EDT drug unit after the collapse of Lehman Brothers. The drug company, which was set up in an Athlone house by entrepreneur Don Panoz to make nicotine patches, continues to lose money.
Investors have reacted badly to Elan's dismal stock price performance. Shares in the drug firm fell 70 per cent last year. The company has defended itself against allegations that it was wasting too much money on executive jet transport. Elan rolled out a restructuring plan just before Christmas which saw it shut offices in New York and Tokyo in a bid to shave $25m off its cost base.
http://www.independent.ie/business/irish/lundbeck-may-have-r…
Sunday January 18 2009
Danish pharmaceutical firm Lundbeck is understood to be interested in acquiring €4bn Irish drug group Elan.
Last week, Elan revealed that it had appointed Citigroup to advise it on "strategic review" of the company's options. These include the sale of the company, a merger or the sale of a stake in the business. Pfizer had been strongly linked with an approach for Elan, although last week the Sunday Independent revealed that the existence of a "poison pill" arrangement could deter Pfizer from making a bid. Both companies subsequently denied that they were in talks.
It is thought that Lundbeck may have been interested in acquiring Elan some time ago, although no formal approach was made. Last week, Elan chief executive Kelly Martin revealed that the company had received a number of informal approaches from potential buyers.
Elan's MS drug Tysabri is considered to be its key attraction, although Alzheimer's drug Bapineuzumab may be of particular interest to Lundbeck, which has invested heavily in the area. Lundbeck declined to comment on an approach last week. Wyeth and Biogen have also been linked with the company.
Elan has over €1.1bn in debt that must be refinanced by 2011. The company was forced to cancel the planned €1bn sale of its EDT drug unit after the collapse of Lehman Brothers. The drug company, which was set up in an Athlone house by entrepreneur Don Panoz to make nicotine patches, continues to lose money.
Investors have reacted badly to Elan's dismal stock price performance. Shares in the drug firm fell 70 per cent last year. The company has defended itself against allegations that it was wasting too much money on executive jet transport. Elan rolled out a restructuring plan just before Christmas which saw it shut offices in New York and Tokyo in a bid to shave $25m off its cost base.
http://www.independent.ie/business/irish/lundbeck-may-have-r…
Author: smellybadger2003
Davy: Well if Bap is mildly effective, sky is the limit
Elan Corp (USc)
ELN US
Good growth from AD drug Namenda
Jack Gorman
Closing Price $6.78 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Namenda, marketed by Forest Labs, is a symptomatic treatment for moderate and severe AD. Despite its lack of disease-modifying effects, sales are still very significant – highlighting the large unmet need in this therapeutic area. Sales in the December 2008 quarter rose by 10% to $241m. With existing patents set to expire in April 2010, generics are circling (as they are around lead AD product Aricept). Forest Labs is confident that a patent extension application will be successfully processed, providing additional protection until September 2013. The read-through for Elan is that the AD market remains very open for potential disease-modifying therapies like Bapineuzumab; even if generic competition erodes the sales of existing symptomatic AD treatments, we believe that truly innovative products will still command relative pricing power.
JNJ reported a surprising 2.4% decline in Remicade sales in Q4 to $886m. Remicade is an anti-TNF inhibitor and is indicated for several autoimmune disorders including Crohn’s Disease (thus competing with Tysabri). The decline was driven by lower US market share (growth only 1.7%) and the timing of export shipments (exports from the US fell by 15% year-on-year). For the full year sales were $3.7bn, a 12.7% increase year-on-year. The read-through for Elan is that the Crohn’s market remains intensely competitive with well-resourced players such as JNJ supporting established products. Tysabri will continue to find it very difficult to make inroads, especially given its scaled-back promotional support this year.
Davy: Well if Bap is mildly effective, sky is the limit
Elan Corp (USc)
ELN US
Good growth from AD drug Namenda
Jack Gorman
Closing Price $6.78 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Namenda, marketed by Forest Labs, is a symptomatic treatment for moderate and severe AD. Despite its lack of disease-modifying effects, sales are still very significant – highlighting the large unmet need in this therapeutic area. Sales in the December 2008 quarter rose by 10% to $241m. With existing patents set to expire in April 2010, generics are circling (as they are around lead AD product Aricept). Forest Labs is confident that a patent extension application will be successfully processed, providing additional protection until September 2013. The read-through for Elan is that the AD market remains very open for potential disease-modifying therapies like Bapineuzumab; even if generic competition erodes the sales of existing symptomatic AD treatments, we believe that truly innovative products will still command relative pricing power.
JNJ reported a surprising 2.4% decline in Remicade sales in Q4 to $886m. Remicade is an anti-TNF inhibitor and is indicated for several autoimmune disorders including Crohn’s Disease (thus competing with Tysabri). The decline was driven by lower US market share (growth only 1.7%) and the timing of export shipments (exports from the US fell by 15% year-on-year). For the full year sales were $3.7bn, a 12.7% increase year-on-year. The read-through for Elan is that the Crohn’s market remains intensely competitive with well-resourced players such as JNJ supporting established products. Tysabri will continue to find it very difficult to make inroads, especially given its scaled-back promotional support this year.
JANUARY 23, 2009, 3:26 A.M. ET
Pfizer in Talks to Buy Wyeth
By MATTHEW KARNITSCHNIG and JONATHAN D. ROCKOFF
Pfizer Inc. is in talks to acquire rival drug maker Wyeth in a deal that could be valued at more than $60 billion, said people familiar with the matter.
A combination of these two U.S. pharmaceutical giants would redraw the boundaries of the global drug industry, which has suffered from flagging product development and high fixed costs. It would also represent a high-stakes gambit for Pfizer, which has been stung in the past by expensive acquisitions.
The two sides have been in discussions for months and a deal isn't imminent, the people said. Given recent market volatility and overall economic uncertainty, the talks are especially fragile and could collapse, the people warned.
...weiter zu lesen unter...
http://online.wsj.com/article/SB123268511212809429.html?mod=…" target="_blank" rel="nofollow ugc noopener">
http://online.wsj.com/article/SB123268511212809429.html?mod=…
Pfizer in Talks to Buy Wyeth
By MATTHEW KARNITSCHNIG and JONATHAN D. ROCKOFF
Pfizer Inc. is in talks to acquire rival drug maker Wyeth in a deal that could be valued at more than $60 billion, said people familiar with the matter.
A combination of these two U.S. pharmaceutical giants would redraw the boundaries of the global drug industry, which has suffered from flagging product development and high fixed costs. It would also represent a high-stakes gambit for Pfizer, which has been stung in the past by expensive acquisitions.
The two sides have been in discussions for months and a deal isn't imminent, the people said. Given recent market volatility and overall economic uncertainty, the talks are especially fragile and could collapse, the people warned.
...weiter zu lesen unter...
http://online.wsj.com/article/SB123268511212809429.html?mod=…" target="_blank" rel="nofollow ugc noopener">
http://online.wsj.com/article/SB123268511212809429.html?mod=…
Davy
Elan Corp (USc)
ELN US
Pfizer pursues Wyeth
Jack Gorman
Closing Price $7.13 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Now the cat is among the pigeons. Pfizer’s reported approach for Wyeth changes both the overall pharma environment and the ongoing strategic review at Elan.
It is not surprising that Pfizer is acquiring. It has been quite public on the issue as it faces into the abyss of Lipitor’s patent expiry. However, it has conducted mega-deals previously, and one could argue that these deals (Warner Lambert, Pharmacia) gave plenty of cost savings but little in the way of enhanced R&D productivity. Nothing has been confirmed, but a $60bn value has been mooted that would be c.20% above current Wyeth levels and represents a P/E of (not racy) 13x.
From Elan’s perspective, this would create a new partner for its AD programmes. Pfizer is already committed to Alzheimer’s R&D and is building an array of approaches, mostly via acquisition, for the disorder. It is possible that Pfizer could fully acquire Elan too, although this was very recently denied by Elan’s CEO. However, it does leave the possibility that it could be a potential minority investor. Most importantly, the Pfizer/Wyeth speculation creates that competitive tension that may inspire BIIB to secure its Tysabri investment or at least to spark a discussion in this regard.
Separately, Merck kgAa has this morning (January 23rd) announced Phase III results on oral cladribine for MS. Given the paucity of prior data, the 55-58% reported reduction in relapses is very impressive. That said, the primary side effect, lymphopenia or reduced white blood cell count, may have important immune implications. There were slightly conflicting messages on dose response too (higher dose had slightly lower efficacy). The company plans to submit the drug for approval by mid-2009, implying prospective approval in 2010. We believe that the strong efficacy will surpass what we believe were low expectations for cladribine. This would potentially increase competition for Tysabri and other MS therapies in coming years.
http://www.investorvillage.com/smbd.asp?mb=160&mn=319414&pt=…
Elan Corp (USc)
ELN US
Pfizer pursues Wyeth
Jack Gorman
Closing Price $7.13 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Now the cat is among the pigeons. Pfizer’s reported approach for Wyeth changes both the overall pharma environment and the ongoing strategic review at Elan.
It is not surprising that Pfizer is acquiring. It has been quite public on the issue as it faces into the abyss of Lipitor’s patent expiry. However, it has conducted mega-deals previously, and one could argue that these deals (Warner Lambert, Pharmacia) gave plenty of cost savings but little in the way of enhanced R&D productivity. Nothing has been confirmed, but a $60bn value has been mooted that would be c.20% above current Wyeth levels and represents a P/E of (not racy) 13x.
From Elan’s perspective, this would create a new partner for its AD programmes. Pfizer is already committed to Alzheimer’s R&D and is building an array of approaches, mostly via acquisition, for the disorder. It is possible that Pfizer could fully acquire Elan too, although this was very recently denied by Elan’s CEO. However, it does leave the possibility that it could be a potential minority investor. Most importantly, the Pfizer/Wyeth speculation creates that competitive tension that may inspire BIIB to secure its Tysabri investment or at least to spark a discussion in this regard.
Separately, Merck kgAa has this morning (January 23rd) announced Phase III results on oral cladribine for MS. Given the paucity of prior data, the 55-58% reported reduction in relapses is very impressive. That said, the primary side effect, lymphopenia or reduced white blood cell count, may have important immune implications. There were slightly conflicting messages on dose response too (higher dose had slightly lower efficacy). The company plans to submit the drug for approval by mid-2009, implying prospective approval in 2010. We believe that the strong efficacy will surpass what we believe were low expectations for cladribine. This would potentially increase competition for Tysabri and other MS therapies in coming years.
http://www.investorvillage.com/smbd.asp?mb=160&mn=319414&pt=…
Antwort auf Beitrag Nr.: 36.433.937 von bernie55 am 23.01.09 11:21:56.....DU warst wieder schneller---grrrrrh
WAS passiert wohl mit uns???Grüsse!B.
WAS passiert wohl mit uns???Grüsse!B.
http://online.wsj.com/article/SB123275483209111729.html
›Pfizer Nears Giant Drug Deal
JANUARY 24, 2009
By MATTHEW KARNITSCHNIG and SARAH RUBENSTEIN
Pfizer Inc. is expected to pay between $65 billion and $70 billion to acquire rival Wyeth, people familiar with the matter say, as the drug maker makes a risky effort to shore itself up ahead of huge disruptions in the next few years.
Pfizer plans to pay for about two-thirds of the total cost in cash and use its stock for the remainder, the people said. It has raised about $25 billion in bank financing for the deal and will tap its cash reserves for the rest. The per-share price is expected to be about $50 per Wyeth share, a nearly 30% premium from Wyeth's price in trading Thursday, before The Wall Street Journal disclosed news of the talks. A merger agreement could be reached as early as next week, the people close to the situation say, but the timing remains uncertain and the deal could still fall apart.
The market appeared to welcome the deal yesterday, with Pfizer shares rising 1.4% to $17.45 and Wyeth shares jumping about 13% to $43.74.
The clock is ticking for Pfizer as it confronts the removal of its cholesterol-drug Lipitor from patent protection in 2011. Lipitor provided $12.7 billion in revenue last year, or about a quarter of the company's overall sales. Pfizer's hope is that Wyeth, which has become the world's third-largest biotechnology company, has enough drugs to fill much of that hole.
Pfizer CEO Jeff Kindler has cut costs and laid off thousands of employees since taking the New York drug giant's helm in the summer of 2006, but analysts and investors consider those cuts insufficient to make up for the pending loss of Lipitor.
A merger agreement could be reached as early as next week, the people close to the situation say, but the timing remains uncertain and the deal could still fall apart. But if an agreement is reached, Pfizer is expected to pay between $65 billion and $70 billion for Wyeth with a combination of cash and stock.
That would represent a rough per-share price of $49 to $52.50 for Wyeth, based on its latest shares outstanding. That's a 26% to 35% premium from its price in trading Thursday, before The Wall Street Journal disclosed news of the talks. The market appeared to welcome the deal yesterday, with Pfizer shares rising 1.4% to $17.45 and Wyeth shares jumping about 13% to $43.74.
A deal would be a harbinger of change in the pharma business as well as the broader financial markets. Takeovers have come to a virtual halt since the financial crisis deepened in mid-September 2008. Funding a purchase of this size would thus be a tentative sign that some deals can work their way through the clogged financial system.
Yet bankers concede that only companies like Pfizer -- with its strong credit rating and cash flow -- can attract such a large financing package. Pfizer has substantial cash reserves of nearly $30 billion, though much of that is overseas and impossible to repatriate without incurring a substantial tax bill. That means the drug maker is likely to borrow a substantial portion of the money it needs to complete the transaction. Pfizer will also have to pay higher funding costs than it is accustomed to.
But Wyeth's existing products and those in its pipeline won't offset the loss in Pfizer's revenue from generic competition to Lipitor and other drugs. Wyeth's late-stage drug pipeline is meager, consisting primarily of existing drugs for which the company trying to find new uses. Even Prevnar-13, Wyeth's key investigational product, which should be a multibillion-dollar blockbuster, won't be a cure for Pfizer.
Still, given the high profile of the deal and the dearth of other business, a number of banks have been vying to play a role in the deal financing, including Goldman Sachs, Morgan Stanley, Credit Suisse and Barclays PLC, among others.
With American and British banks and other natural buyers of corporate debt in crisis, the market's capacity to absorb new debt is limited. That could make it more difficult for other pharmaceutical companies to pursue deals of their own. The wave of consolidation in the drug sector that many analysts are predicting may be no more than a trickle.
Pfizer is itself the poster child for the argument made by some in the pharmaceutical industry that big mergers stifle research productivity. A new Pfizer-Wyeth could cut 70% of Wyeth's R&D budget within a few years, analysts predict. Pfizer declined to comment.
By contrast, British pharmaceutical giant GlaxoSmithKline PLC, the product of one of these big deals in 2000, has spent the past four years trying to recreate an entrepreneurial and creative research culture by slicing up its R&D operation into small, semiautonomous labs. Glaxo's new chief executive, Andrew Witty, has been pushing that logic further by giving the labs their own three-year budgets and setting up a review board that includes outside members to assess their progress once a year.
That's why the deal poses a larger risk to Wyeth. The company is finally hitting its stride after a decade of setbacks, having quietly reinvented itself as a biotech company. Its valuation has held up over the last year, dropping just 7.5%, compared with a 38% drop in the Standard & Poor's 500 Index. In accepting Pfizer shares, Wyeth would be putting itself in the hands of a company that has struggled to absorb large acquisitions in the past.
Most analysts discount the likelihood that another company will enter the fray and try to snatch Wyeth from Pfizer's clutches. Pfizer is already the biggest drug maker in the world by revenue and has more cash than its rivals. One company with the wherewithal to challenge Pfizer is Johnson & Johnson. But like Wyeth, which makes painkiller Advil, J&J has a large over-the-counter drug business, including Tylenol. Such overlap might make a combination of the two difficult to get past regulators.
Wyeth's attractiveness is still a big turnabout for a company that was in disarray nearly a decade ago. Formerly known as American Home Products, it made everything from food products to home goods like pots and pans.
During the 1990s and the early part of this decade, it became mired in lawsuits and controversies over the safety of its major drugs, including diet drugs that were pulled from the market after being linked to heart-valve damage. In 1999, it allotted $3.75 billion for a class-action settlement. Its legal costs eventually ballooned to more than $21 billion as new claims emerged and many patients opted out of the settlement and continued to sue the company.
In the intervening years, Wyeth has transformed itself into a leader in vaccines and biotechnology. It co-markets Enbrel, an anti-inflammatory biologic, with Amgen Inc. Wyeth's share of revenue from Enbrel amounted to $2.9 billion in the first nine months of 2008. Sales of Enbrel continue to grow briskly, and because it is a biologic, generic competition isn't on the horizon.
Wyeth also built Prevnar, a childhood vaccine against pneumonia, ear infections and meningitis, into the first vaccine to exceed $1 billion in annual sales. Breaking with industry practice, Wyeth priced Prevnar expensively: It costs about $335 for a four-shot regimen. The tactic was copied by other companies such as Merck & Co., which introduced an expensive cervical-cancer vaccine in 2006.
At the same time, Wyeth's struggles with traditional pills contributed to a falling share price and made the company a cheaper takeover target. For instance, expecting that its blockbuster antidepressant Effexor XR would face generic competition by 2010, Wyeth developed a replacement, called Pristiq, that was derived from Effexor and is the sort of follow-on drug that has led to criticism of major drug makers. The company had trouble winning Food and Drug Administration approval for Pristiq, and since it went on the market in early 2008, sales have been disappointing.
Sales of another blockbuster Wyeth pharmaceutical product, the heartburn remedy Protonix, plunged last year after a generic competitor surprised Wyeth on Christmas Eve 2007 by launching a copycat version in the middle of litigation over Protonix's patent.
Another cloud hanging over Wyeth's stock price has been disappointing data from its experimental Alzheimer's vaccine, which it is co-developing with Ireland's Elan Corp. The vaccine, like Enbrel and Prevnar before it, shows Wyeth's willingness to gamble. Many scientists are skeptical of its efficacy. But, if it does end up working and is approved by the FDA, the payoff could be big.‹
›Pfizer Nears Giant Drug Deal
JANUARY 24, 2009
By MATTHEW KARNITSCHNIG and SARAH RUBENSTEIN
Pfizer Inc. is expected to pay between $65 billion and $70 billion to acquire rival Wyeth, people familiar with the matter say, as the drug maker makes a risky effort to shore itself up ahead of huge disruptions in the next few years.
Pfizer plans to pay for about two-thirds of the total cost in cash and use its stock for the remainder, the people said. It has raised about $25 billion in bank financing for the deal and will tap its cash reserves for the rest. The per-share price is expected to be about $50 per Wyeth share, a nearly 30% premium from Wyeth's price in trading Thursday, before The Wall Street Journal disclosed news of the talks. A merger agreement could be reached as early as next week, the people close to the situation say, but the timing remains uncertain and the deal could still fall apart.
The market appeared to welcome the deal yesterday, with Pfizer shares rising 1.4% to $17.45 and Wyeth shares jumping about 13% to $43.74.
The clock is ticking for Pfizer as it confronts the removal of its cholesterol-drug Lipitor from patent protection in 2011. Lipitor provided $12.7 billion in revenue last year, or about a quarter of the company's overall sales. Pfizer's hope is that Wyeth, which has become the world's third-largest biotechnology company, has enough drugs to fill much of that hole.
Pfizer CEO Jeff Kindler has cut costs and laid off thousands of employees since taking the New York drug giant's helm in the summer of 2006, but analysts and investors consider those cuts insufficient to make up for the pending loss of Lipitor.
A merger agreement could be reached as early as next week, the people close to the situation say, but the timing remains uncertain and the deal could still fall apart. But if an agreement is reached, Pfizer is expected to pay between $65 billion and $70 billion for Wyeth with a combination of cash and stock.
That would represent a rough per-share price of $49 to $52.50 for Wyeth, based on its latest shares outstanding. That's a 26% to 35% premium from its price in trading Thursday, before The Wall Street Journal disclosed news of the talks. The market appeared to welcome the deal yesterday, with Pfizer shares rising 1.4% to $17.45 and Wyeth shares jumping about 13% to $43.74.
A deal would be a harbinger of change in the pharma business as well as the broader financial markets. Takeovers have come to a virtual halt since the financial crisis deepened in mid-September 2008. Funding a purchase of this size would thus be a tentative sign that some deals can work their way through the clogged financial system.
Yet bankers concede that only companies like Pfizer -- with its strong credit rating and cash flow -- can attract such a large financing package. Pfizer has substantial cash reserves of nearly $30 billion, though much of that is overseas and impossible to repatriate without incurring a substantial tax bill. That means the drug maker is likely to borrow a substantial portion of the money it needs to complete the transaction. Pfizer will also have to pay higher funding costs than it is accustomed to.
But Wyeth's existing products and those in its pipeline won't offset the loss in Pfizer's revenue from generic competition to Lipitor and other drugs. Wyeth's late-stage drug pipeline is meager, consisting primarily of existing drugs for which the company trying to find new uses. Even Prevnar-13, Wyeth's key investigational product, which should be a multibillion-dollar blockbuster, won't be a cure for Pfizer.
Still, given the high profile of the deal and the dearth of other business, a number of banks have been vying to play a role in the deal financing, including Goldman Sachs, Morgan Stanley, Credit Suisse and Barclays PLC, among others.
With American and British banks and other natural buyers of corporate debt in crisis, the market's capacity to absorb new debt is limited. That could make it more difficult for other pharmaceutical companies to pursue deals of their own. The wave of consolidation in the drug sector that many analysts are predicting may be no more than a trickle.
Pfizer is itself the poster child for the argument made by some in the pharmaceutical industry that big mergers stifle research productivity. A new Pfizer-Wyeth could cut 70% of Wyeth's R&D budget within a few years, analysts predict. Pfizer declined to comment.
By contrast, British pharmaceutical giant GlaxoSmithKline PLC, the product of one of these big deals in 2000, has spent the past four years trying to recreate an entrepreneurial and creative research culture by slicing up its R&D operation into small, semiautonomous labs. Glaxo's new chief executive, Andrew Witty, has been pushing that logic further by giving the labs their own three-year budgets and setting up a review board that includes outside members to assess their progress once a year.
That's why the deal poses a larger risk to Wyeth. The company is finally hitting its stride after a decade of setbacks, having quietly reinvented itself as a biotech company. Its valuation has held up over the last year, dropping just 7.5%, compared with a 38% drop in the Standard & Poor's 500 Index. In accepting Pfizer shares, Wyeth would be putting itself in the hands of a company that has struggled to absorb large acquisitions in the past.
Most analysts discount the likelihood that another company will enter the fray and try to snatch Wyeth from Pfizer's clutches. Pfizer is already the biggest drug maker in the world by revenue and has more cash than its rivals. One company with the wherewithal to challenge Pfizer is Johnson & Johnson. But like Wyeth, which makes painkiller Advil, J&J has a large over-the-counter drug business, including Tylenol. Such overlap might make a combination of the two difficult to get past regulators.
Wyeth's attractiveness is still a big turnabout for a company that was in disarray nearly a decade ago. Formerly known as American Home Products, it made everything from food products to home goods like pots and pans.
During the 1990s and the early part of this decade, it became mired in lawsuits and controversies over the safety of its major drugs, including diet drugs that were pulled from the market after being linked to heart-valve damage. In 1999, it allotted $3.75 billion for a class-action settlement. Its legal costs eventually ballooned to more than $21 billion as new claims emerged and many patients opted out of the settlement and continued to sue the company.
In the intervening years, Wyeth has transformed itself into a leader in vaccines and biotechnology. It co-markets Enbrel, an anti-inflammatory biologic, with Amgen Inc. Wyeth's share of revenue from Enbrel amounted to $2.9 billion in the first nine months of 2008. Sales of Enbrel continue to grow briskly, and because it is a biologic, generic competition isn't on the horizon.
Wyeth also built Prevnar, a childhood vaccine against pneumonia, ear infections and meningitis, into the first vaccine to exceed $1 billion in annual sales. Breaking with industry practice, Wyeth priced Prevnar expensively: It costs about $335 for a four-shot regimen. The tactic was copied by other companies such as Merck & Co., which introduced an expensive cervical-cancer vaccine in 2006.
At the same time, Wyeth's struggles with traditional pills contributed to a falling share price and made the company a cheaper takeover target. For instance, expecting that its blockbuster antidepressant Effexor XR would face generic competition by 2010, Wyeth developed a replacement, called Pristiq, that was derived from Effexor and is the sort of follow-on drug that has led to criticism of major drug makers. The company had trouble winning Food and Drug Administration approval for Pristiq, and since it went on the market in early 2008, sales have been disappointing.
Sales of another blockbuster Wyeth pharmaceutical product, the heartburn remedy Protonix, plunged last year after a generic competitor surprised Wyeth on Christmas Eve 2007 by launching a copycat version in the middle of litigation over Protonix's patent.
Another cloud hanging over Wyeth's stock price has been disappointing data from its experimental Alzheimer's vaccine, which it is co-developing with Ireland's Elan Corp. The vaccine, like Enbrel and Prevnar before it, shows Wyeth's willingness to gamble. Many scientists are skeptical of its efficacy. But, if it does end up working and is approved by the FDA, the payoff could be big.‹
Author: elmer92692
All Righty Then.........
Soooo, as Splay predicted months ago, Pfe wants Wye. Sounds good to me. In the last few months Pfe would have been doing their dd. Yep. Pouring over all the data including the Phase 2 AAB-001 results. With Jack Schuler putting the squeeze on Elan's BOD, this scenerio is shaping up to be one of the better '09 dramas.
A little history lesson seems appropriate. Kelly Martin had a nice dinner with the CEO of Pfe in '08. As I understand it, Pfe's CEO, Jack Kindler, was enthralled with KM's ability to have such an outstanding pipeline with so few researchers. Well, as the Elanians know, science is our strong suit. Unfortunately for Kindler he needs both gross sales and some decent R&R. The Wye purchase makes strategic sense for Pfizer.
That having been said, there appears to be some fly poop in the pepper. Pfizer doesn't particularly like JV's especially those that would involve a 50% split on one of the best selling drugs of all time (AAB-001). As you know, hostile takeovers are rare in the pharma field. So what will Pfe do? Good question.
I've always felt ICAD was a success, but gee, the shorts know how to spoil a dinner party. AAB-001 works. We know. Wye knows it. Pfizer knows it. Will Pfe just start piling money on a counting table until Kelly says....done!?
I love these type of situations. Drama. Intrigue. Suspense. This baby has it all. As you noticed, the shorts have left the building. Articles concerning this purchase are talking about Wye's AD pipeline in favorable terms. Go figure. Everything points to a showdown. I'm not sure how it will all end, but I have a strong feeling we're going to need a bigger boat. Cheers
All Righty Then.........
Soooo, as Splay predicted months ago, Pfe wants Wye. Sounds good to me. In the last few months Pfe would have been doing their dd. Yep. Pouring over all the data including the Phase 2 AAB-001 results. With Jack Schuler putting the squeeze on Elan's BOD, this scenerio is shaping up to be one of the better '09 dramas.
A little history lesson seems appropriate. Kelly Martin had a nice dinner with the CEO of Pfe in '08. As I understand it, Pfe's CEO, Jack Kindler, was enthralled with KM's ability to have such an outstanding pipeline with so few researchers. Well, as the Elanians know, science is our strong suit. Unfortunately for Kindler he needs both gross sales and some decent R&R. The Wye purchase makes strategic sense for Pfizer.
That having been said, there appears to be some fly poop in the pepper. Pfizer doesn't particularly like JV's especially those that would involve a 50% split on one of the best selling drugs of all time (AAB-001). As you know, hostile takeovers are rare in the pharma field. So what will Pfe do? Good question.
I've always felt ICAD was a success, but gee, the shorts know how to spoil a dinner party. AAB-001 works. We know. Wye knows it. Pfizer knows it. Will Pfe just start piling money on a counting table until Kelly says....done!?
I love these type of situations. Drama. Intrigue. Suspense. This baby has it all. As you noticed, the shorts have left the building. Articles concerning this purchase are talking about Wye's AD pipeline in favorable terms. Go figure. Everything points to a showdown. I'm not sure how it will all end, but I have a strong feeling we're going to need a bigger boat. Cheers
stern.de - 26.1.2009 - 07:57
URL: http://www.stern.de/wirtschaft/unternehmen/unternehmen/65261…
Milliarden-Übernahme
Pharmagigant Pfizer kauft Konkurrenten Wyeth
Milliarden-Übernahme: Pharmagigant Pfizer kauft Konkurrenten Wyeth
© Justin Lane/DPA
Branchenprimus Pfizer: Durch Zukäufe hat sich das Unternehmen seine gegenwärtige Führungsposition in der Pharmaindustrie erobert
Lange wurde spekuliert, jetzt ist der Deal offenbar perfekt: Der größte Pharmakonzern der Welt, das US-Unternehmen Pfizer, übernimmt die Konkurrenzfirma Wyeth. Medienberichte zufolge soll das Geschäft einen Wert von rund 52 Milliarden Euro haben.
Der weltgrößte Pharmakonzern Pfizer hat offenbar die Übernahme des Konkurrenten Wyeth vereinbart. Das Geschäft werde einen Wert von rund 68 Milliarden Dollar (52 Milliarden Euro) haben und solle noch am Montag bekanntgegeben werden, berichteten die "New York Times" und das "Wall Street Journal" unter Berufung auf informierte Personen. Pfizer bezahle den Kauf in einer Kombination aus Bargeld und Aktien.
Pfizer steht wie auch andere Pharmariesen schwer unter Druck durch konkurrierende billigere Nachahmermedikamente (Generika). Mit dem Kauf von Wyeth bekommt Pfizer Zugang zu neuen Mitteln und Geschäftsfeldern. Außerdem erhofft sich der Branchenführer jährliche Einsparungen von vier Milliarden Dollar, schrieb die "New York Times".
Pfizer biete 50,19 Dollar pro Wyeth-Aktie, ein Aufschlag von 29 Prozent auf den Schlusskurs vom Donnerstag, hieß es übereinstimmend. Das umfasse 33 Dollar Bargeld und 0,985 Pfizer-Aktien.
Der Kauf wäre die größte Übernahme in den USA seit einigen Jahren und die erste bedeutende seit der Verschärfung der Finanzkrise im vergangenen Jahr. In der Krise waren die Banken nicht mehr bereit, die für solche Geschäfte nötigen Milliardenkredite zu vergeben. Für den Wyeth-Kauf habe sich Pfizer eine Finanzierung von 22,5 Milliarden Dollar sicher können, hieß es. Für den Fall, dass das Geschäft noch scheitern sollte, erklärte sich Pfizer laut "New York Times" zur außergewöhnlich hohen Rücktrittszahlung von 4,5 Milliarden Dollar bereit.
Seine gegenwärtige Führungsposition in der Pharmaindustrie verdankt Pfizer Zukäufen. Dazu gehört der Kauf des US-Rivalen Warner-Lambert im Jahr 2000 für rund 88 Milliarden Dollar - die bislang teuerste Übernahme in der Branche. Drei Jahre später war es der US-Konzern Pharmacia für etwa 60 Milliarden Dollar. Mit der Übernahme von Wyeth würde Pfizer die Branche erneut aufmischen und möglicherweise eine neue Fusionswelle unter den Unternehmen einleiten. In Deutschland wurde Pfizer zuletzt als einer der Kandidaten für eine Übernahme des Ulmer Arzneimittelherstellers Ratiopharm gehandelt.
DPA/Reuters
URL: http://www.stern.de/wirtschaft/unternehmen/unternehmen/65261…
Milliarden-Übernahme
Pharmagigant Pfizer kauft Konkurrenten Wyeth
Milliarden-Übernahme: Pharmagigant Pfizer kauft Konkurrenten Wyeth
© Justin Lane/DPA
Branchenprimus Pfizer: Durch Zukäufe hat sich das Unternehmen seine gegenwärtige Führungsposition in der Pharmaindustrie erobert
Lange wurde spekuliert, jetzt ist der Deal offenbar perfekt: Der größte Pharmakonzern der Welt, das US-Unternehmen Pfizer, übernimmt die Konkurrenzfirma Wyeth. Medienberichte zufolge soll das Geschäft einen Wert von rund 52 Milliarden Euro haben.
Der weltgrößte Pharmakonzern Pfizer hat offenbar die Übernahme des Konkurrenten Wyeth vereinbart. Das Geschäft werde einen Wert von rund 68 Milliarden Dollar (52 Milliarden Euro) haben und solle noch am Montag bekanntgegeben werden, berichteten die "New York Times" und das "Wall Street Journal" unter Berufung auf informierte Personen. Pfizer bezahle den Kauf in einer Kombination aus Bargeld und Aktien.
Pfizer steht wie auch andere Pharmariesen schwer unter Druck durch konkurrierende billigere Nachahmermedikamente (Generika). Mit dem Kauf von Wyeth bekommt Pfizer Zugang zu neuen Mitteln und Geschäftsfeldern. Außerdem erhofft sich der Branchenführer jährliche Einsparungen von vier Milliarden Dollar, schrieb die "New York Times".
Pfizer biete 50,19 Dollar pro Wyeth-Aktie, ein Aufschlag von 29 Prozent auf den Schlusskurs vom Donnerstag, hieß es übereinstimmend. Das umfasse 33 Dollar Bargeld und 0,985 Pfizer-Aktien.
Der Kauf wäre die größte Übernahme in den USA seit einigen Jahren und die erste bedeutende seit der Verschärfung der Finanzkrise im vergangenen Jahr. In der Krise waren die Banken nicht mehr bereit, die für solche Geschäfte nötigen Milliardenkredite zu vergeben. Für den Wyeth-Kauf habe sich Pfizer eine Finanzierung von 22,5 Milliarden Dollar sicher können, hieß es. Für den Fall, dass das Geschäft noch scheitern sollte, erklärte sich Pfizer laut "New York Times" zur außergewöhnlich hohen Rücktrittszahlung von 4,5 Milliarden Dollar bereit.
Seine gegenwärtige Führungsposition in der Pharmaindustrie verdankt Pfizer Zukäufen. Dazu gehört der Kauf des US-Rivalen Warner-Lambert im Jahr 2000 für rund 88 Milliarden Dollar - die bislang teuerste Übernahme in der Branche. Drei Jahre später war es der US-Konzern Pharmacia für etwa 60 Milliarden Dollar. Mit der Übernahme von Wyeth würde Pfizer die Branche erneut aufmischen und möglicherweise eine neue Fusionswelle unter den Unternehmen einleiten. In Deutschland wurde Pfizer zuletzt als einer der Kandidaten für eine Übernahme des Ulmer Arzneimittelherstellers Ratiopharm gehandelt.
DPA/Reuters
dann wird es auch für uns interessant.
Weiß einer von Euch, ob es bei dem Vertrag mit Wyeth auch eine Klausel gibt, die die Rechte an den Produkten vollständig an ELAN gehen lassen, wenn Wyeth übernommen werden sollte?
Weiß einer von Euch, ob es bei dem Vertrag mit Wyeth auch eine Klausel gibt, die die Rechte an den Produkten vollständig an ELAN gehen lassen, wenn Wyeth übernommen werden sollte?
Antwort auf Beitrag Nr.: 36.447.451 von Poppholz am 26.01.09 10:01:11um auf Nummer sicher zu gehen sollten die einfach 30,- Euro (45,- US-$) für ELAN bezahlen und fertig.
(ist dann immer noch ein Schnäppchen)
(ist dann immer noch ein Schnäppchen)
Antwort auf Beitrag Nr.: 36.447.464 von Poppholz am 26.01.09 10:03:14meine natürlich 35,- Euro
Antwort auf Beitrag Nr.: 36.447.451 von Poppholz am 26.01.09 10:01:11Weiß einer von Euch, ob es bei dem Vertrag mit Wyeth auch eine Klausel gibt, die die Rechte an den Produkten vollständig an ELAN gehen lassen, wenn Wyeth übernommen werden sollte?
.....das kann ich mir nicht vorstellen......Pfizer hat bei der Übernahme von Wyeth bestimmt auch das laufende BAP Programm für AD im Auge gehabt.......oder nicht ????
.....das kann ich mir nicht vorstellen......Pfizer hat bei der Übernahme von Wyeth bestimmt auch das laufende BAP Programm für AD im Auge gehabt.......oder nicht ????
Antwort auf Beitrag Nr.: 36.447.464 von Poppholz am 26.01.09 10:03:14um auf Nummer sicher zu gehen sollten die einfach 30,- Euro (45,- US-$) für ELAN bezahlen und fertig.
(ist dann immer noch ein Schnäppchen)
..bei den aktuellen Schulden von ELAN ???...ich weiß nicht..
..wäre natürlich super dein Angebot von 45 USD......
.... wenn eine mögliches Übernahmeangebot bei 25 USD ca. 20 € liegen würde, denke ich , dass ELAN gut bedient wäre
..interessant wird es in der nächsten Zeit auf jeden Fall.......
...zuerst Übernahme von ELAN durch Pfizer...
...dann noch Übernahme von Biogen durch Pfizer.......
.....das wärs...
..nur die Frage , wieviel die finanziell noch stemmen können ????
(ist dann immer noch ein Schnäppchen)
..bei den aktuellen Schulden von ELAN ???...ich weiß nicht..
..wäre natürlich super dein Angebot von 45 USD......
.... wenn eine mögliches Übernahmeangebot bei 25 USD ca. 20 € liegen würde, denke ich , dass ELAN gut bedient wäre
..interessant wird es in der nächsten Zeit auf jeden Fall.......
...zuerst Übernahme von ELAN durch Pfizer...
...dann noch Übernahme von Biogen durch Pfizer.......
.....das wärs...
..nur die Frage , wieviel die finanziell noch stemmen können ????
Graffinity and Elan launch fragment-based drug discovery collaboration
HEIDELBERG, Germany — January 26, 2009 / b3c newswire / — Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Elan Pharmaceuticals, Inc., a subsidiary of Elan Corporation, plc (NYSE:ELN). Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a number of drug targets. Elan will gain access to Graffinity’s proprietary fragment-based drug discovery technology which uses chemical microarrays and surface plasmon resonance to screen for small molecule fragments that bind to a variety of drug targets. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.
Mathias Woker, Chief Business Officer of Graffinity, stated, ”We are very pleased that Elan has decided to work with us. With this transaction we are launching our third drug discovery collaboration with a major life science company within the past nine months. This collaboration marks our transition to becoming the leading fragment-based drug discovery company.”
Kristina Schmidt, CEO of Graffinity, remarked, ”The reason for the heightened attention that our fragment screening approach currently receives, lies in three key advantages that only Graffinity offers in combination: First, Graffinity’s technology provides the broadest and deepest primary screen for fragment hits ever developed, second, the platform delivers readily usable novel chemistry within only four months, and thirdly, the Graffinity team possesses unparalleled know-how based on having screened more drug targets than any other team in the fragment space.”
About Graffinity Pharmaceuticals GmbH Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Pfizer and Rigel.
Graffinity’s unique fragment based discovery platform has been invented in 1998, and has been in routine industrial use since 2002 in screening more than 80 drug targets. For more information, please visit www.graffinity.com
Graffinity Media Contact for Europe:
Dr. Kristina Schmidt CEO Graffinity Pharmaceuticals GmbH Tel. +49 6221 6510-112 kristina.schmidt@graffinity.com
http://www.pharmalive.com/News/index.cfm?articleid=599881&ca…
HEIDELBERG, Germany — January 26, 2009 / b3c newswire / — Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Elan Pharmaceuticals, Inc., a subsidiary of Elan Corporation, plc (NYSE:ELN). Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a number of drug targets. Elan will gain access to Graffinity’s proprietary fragment-based drug discovery technology which uses chemical microarrays and surface plasmon resonance to screen for small molecule fragments that bind to a variety of drug targets. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.
Mathias Woker, Chief Business Officer of Graffinity, stated, ”We are very pleased that Elan has decided to work with us. With this transaction we are launching our third drug discovery collaboration with a major life science company within the past nine months. This collaboration marks our transition to becoming the leading fragment-based drug discovery company.”
Kristina Schmidt, CEO of Graffinity, remarked, ”The reason for the heightened attention that our fragment screening approach currently receives, lies in three key advantages that only Graffinity offers in combination: First, Graffinity’s technology provides the broadest and deepest primary screen for fragment hits ever developed, second, the platform delivers readily usable novel chemistry within only four months, and thirdly, the Graffinity team possesses unparalleled know-how based on having screened more drug targets than any other team in the fragment space.”
About Graffinity Pharmaceuticals GmbH Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Pfizer and Rigel.
Graffinity’s unique fragment based discovery platform has been invented in 1998, and has been in routine industrial use since 2002 in screening more than 80 drug targets. For more information, please visit www.graffinity.com
Graffinity Media Contact for Europe:
Dr. Kristina Schmidt CEO Graffinity Pharmaceuticals GmbH Tel. +49 6221 6510-112 kristina.schmidt@graffinity.com
http://www.pharmalive.com/News/index.cfm?articleid=599881&ca…
Nun, ob ich es erleben werde mit ELAN noch in halbwegs angenehme und ungefährliche Gewässer zu kommen (ohne Untiefen und gefährliche Strömungen)... 
Was sagen die Experten hier im Forum zur geplanten bzw. schon bestätigten Übernahme von Wyeth durch Pfizer? Warum wirkt sich das bisher sooo negativ auf Elan aus (heutiger Handelstag: bis jetzt, 21.33 Uhr: -7.84%).
Besten Dank für etwaige Antworten im Vorhinein.
Beste Grüße,
d.H.
Was sagen die Experten hier im Forum zur geplanten bzw. schon bestätigten Übernahme von Wyeth durch Pfizer? Warum wirkt sich das bisher sooo negativ auf Elan aus (heutiger Handelstag: bis jetzt, 21.33 Uhr: -7.84%).
Besten Dank für etwaige Antworten im Vorhinein.
Beste Grüße,
d.H.
Antwort auf Beitrag Nr.: 36.453.107 von dasHaendchen am 26.01.09 21:33:23Hi
gestern gab es Befürchtungen,ob BAP von Pfizer weiter aktiv gemanaged wird.....mir scheint das klar zu sein weil BAP in der Erklärung von Wyeth extra erwähnt wird und weil die ALZ-Forschung von Wyeth/Elan mit ein Grund der Fusion zu sein scheint.....
Adam Feuerstein: "Pfizer Gambles on Alzheimer's Empire"
Pfizer Gambles on Alzheimer's Empire
Adam Feuerstein
01/27/09 - 09:10 AM EST
With Monday's $68 billion bid to acquire Wyeth(WYE Quote - Cramer on WYE - Stock Picks), pharmaceutical giant Pfizer(PFE Quote - Cramer on PFE - Stock Picks) is setting itself up to potentially dominate the Alzheimer's disease treatment market for years to come. But in making such a big bet on one of society's most pressing unmet medical needs, the pharmaceutical giant may also face increased government scrutiny and possibly some resistance from its key partners.
Pfizer and the Japanese drug maker Eisai, currently co-market Aricept, the leading Alzheimer's drug today with worldwide sales of more than $2 billion.
But Aricept loses patent protection at the end of next year, which is one reason why Pfizer has decided to invest heavily in new Alzheimer's drug research.
Last September, Pfizer acquired worldwide commercial rights to Dimebon, an experimental Alzheimer's drug currently in phase III studies. Pfizer paid Medivation(MDVN Quote - Cramer on MDVN - Stock Picks), Dimebon's owner, $225 million upfront for the rights, making it one of the largest drug partnership deals of 2008.
Pfizer also has four Alzheimer's drugs in its own pipeline, most of which are in the early stages of clinical trials. This includes an experimental Alzheimer's drug acquired in 2006 when Pfizer bought privately held Rinat Neuroscience.
Wyeth has 10 Alzheimer's drugs in clinical trials, both internally and through partnerships, the most important of which is with Irish drug maker Elan(ELN Quote - Cramer on ELN - Stock Picks). The two companies share development efforts and marketing rights to bapineuzumab, which is being studied in four phase III clinical trials.
If the $86 billion acquisition of Wyeth announced Monday closes as is, Pfizer would boost its Alzheimer's drug pipeline from five drugs in clinical trials to 15, including two of the four drugs currently in pivotal phase III studies. (Eli Lilly(LLY Quote - Cramer on LLY - Stock Picks) and Baxter(BAX Quote - Cramer on BAX - Stock Picks) own the other two phase III Alzheimer's drugs.)
Any new drug that could potentially stop or even reverse the loss of memory or cognitive decline that makes Alzheimer's such a devastating disease would be a mega-blockbuster. Actual sales estimates vary and are conditional on the efficacy and safety profile of the drug, but it's not out of bounds to forecast a groundbreaking Alzheimer's drug achieving peak sales of well over $10 billion, perhaps even $20 billion a year.
Pfizer's cholesterol drug Lipitor, with $13 billion a year in sales, loses patent protection in 2011. If Pfizer were to hit it big with a groundbreaking Alzheimer's drug, the company and its investors would find it a lot easier to forget about lost Lipitor sales.
Before Pfizer can start counting new Alzheimer's revenue, the company faces a host of challenges, not the least of which is waiting to see how many, if any, of these experimental Alzheimer's drugs will actually wind up working.
Even before that, Pfizer could face scrutiny from the Federal Trade Commission, owing to potential antitrust issues arising from amassing such a large portfolio of Alzheimer's drugs. This could lead to Pfizer having to divest some of its Alzheimer's assets, says Jack Walsh, a commercial litigator with the law firm Lathrop & Gage in St. Louis, Mo.
Pfizer spokesman Jack Cox said, "We can't speculate on the actions of regulators, but we recognize that this is a large, complex transaction. We will work closely with the regulatory bodies to obtain the necessary clearances."
And Pfizer may have a tricky time managing relationships with its two main Alzheimer's partners - Medivation and Elan -- both of which will want to be seen as a priority over the other when it comes to Pfizer's time and financial commitment.
Pfizer singled out bapineuzumab in its press release discussing the Wyeth acquisition and also talked about the importance of the drug and Alzheimer's, in general, on its Monday conference calls.
Corey Davis, drug analyst at Natixis Bleichroeder, says this was likely Pfizer trying to ease any misgivings Elan may have, especially given Pfizer's existing commitment to Medivation.
"The fact that Pfizer specifically talked about bapineuzumab was probably a signal to Elan that Pfizer intends to maintain Wyeth's investment in the drug," said Davis, who covers Elan with a buy rating.
But if Pfizer was sending the love to Elan on Monday, it wasn't necessarily reciprocated.
Elan spokeswoman Mary Stutts said the company expects a federal antitrust review of the Pfizer-Wyeth deal, particularly in terms of the Alzheimer's assets, and that until that review is completed, Elan is taking a wait and see attitude.
"We cannot assume at this point that Pfizer will be Elan's partner for bapineuzumab," said Stutts.
She added that the current contract between Elan and Wyeth for bapineuzumab and a second Alzheimer's drug, ACC-001, does include change of control provisions. Stutts would not elaborate on the details of those provisions.
Doug Petkus, a spokesman for Wyeth, said the focus of both Wyeth and Pfizer continues to be on Alzheimer's research, including bapineuzumab, but he would not say what ultimately happens to the relationship with Elan if and when Pfizer acquires Wyeth.
Data from a phase II study of bapineuzumab, presented last year, raised doubts about the drug's efficacy and safety. While Elan has moved aggressively to enroll patients in two U.S.-based phase III clinical trials, Wyeth has had problems enrolling patients in two international studies due to safety concerns raised primarily by regulators in Europe.
Natixis analyst Davis believes there is little chance that Pfizer will decide to drop bapineuzumab altogether. "The phase III studies are pretty much on auto-pilot now, so I don't think Pfizer has much incentive to make major changes."
Medivation CEO David Hung says his company's partnership with Pfizer remains unchanged.
"We have not been told of any changes, so I assume that we're on track. The partnership [for Dimebon] has gone very well and Pfizer speaks enthusiastically about the drug. Alzheimer's is definitely an area where Pfizer is committed to investing a lot of resources."
Pfizer shares closed Monday down 10% to $15.65 on concerns that the Wyeth acquisition would not generate enough new revenue and growth to make up for shortfalls of both anticipated in the coming years.
gestern gab es Befürchtungen,ob BAP von Pfizer weiter aktiv gemanaged wird.....mir scheint das klar zu sein weil BAP in der Erklärung von Wyeth extra erwähnt wird und weil die ALZ-Forschung von Wyeth/Elan mit ein Grund der Fusion zu sein scheint.....
Adam Feuerstein: "Pfizer Gambles on Alzheimer's Empire"
Pfizer Gambles on Alzheimer's Empire
Adam Feuerstein
01/27/09 - 09:10 AM EST
With Monday's $68 billion bid to acquire Wyeth(WYE Quote - Cramer on WYE - Stock Picks), pharmaceutical giant Pfizer(PFE Quote - Cramer on PFE - Stock Picks) is setting itself up to potentially dominate the Alzheimer's disease treatment market for years to come. But in making such a big bet on one of society's most pressing unmet medical needs, the pharmaceutical giant may also face increased government scrutiny and possibly some resistance from its key partners.
Pfizer and the Japanese drug maker Eisai, currently co-market Aricept, the leading Alzheimer's drug today with worldwide sales of more than $2 billion.
But Aricept loses patent protection at the end of next year, which is one reason why Pfizer has decided to invest heavily in new Alzheimer's drug research.
Last September, Pfizer acquired worldwide commercial rights to Dimebon, an experimental Alzheimer's drug currently in phase III studies. Pfizer paid Medivation(MDVN Quote - Cramer on MDVN - Stock Picks), Dimebon's owner, $225 million upfront for the rights, making it one of the largest drug partnership deals of 2008.
Pfizer also has four Alzheimer's drugs in its own pipeline, most of which are in the early stages of clinical trials. This includes an experimental Alzheimer's drug acquired in 2006 when Pfizer bought privately held Rinat Neuroscience.
Wyeth has 10 Alzheimer's drugs in clinical trials, both internally and through partnerships, the most important of which is with Irish drug maker Elan(ELN Quote - Cramer on ELN - Stock Picks). The two companies share development efforts and marketing rights to bapineuzumab, which is being studied in four phase III clinical trials.
If the $86 billion acquisition of Wyeth announced Monday closes as is, Pfizer would boost its Alzheimer's drug pipeline from five drugs in clinical trials to 15, including two of the four drugs currently in pivotal phase III studies. (Eli Lilly(LLY Quote - Cramer on LLY - Stock Picks) and Baxter(BAX Quote - Cramer on BAX - Stock Picks) own the other two phase III Alzheimer's drugs.)
Any new drug that could potentially stop or even reverse the loss of memory or cognitive decline that makes Alzheimer's such a devastating disease would be a mega-blockbuster. Actual sales estimates vary and are conditional on the efficacy and safety profile of the drug, but it's not out of bounds to forecast a groundbreaking Alzheimer's drug achieving peak sales of well over $10 billion, perhaps even $20 billion a year.
Pfizer's cholesterol drug Lipitor, with $13 billion a year in sales, loses patent protection in 2011. If Pfizer were to hit it big with a groundbreaking Alzheimer's drug, the company and its investors would find it a lot easier to forget about lost Lipitor sales.
Before Pfizer can start counting new Alzheimer's revenue, the company faces a host of challenges, not the least of which is waiting to see how many, if any, of these experimental Alzheimer's drugs will actually wind up working.
Even before that, Pfizer could face scrutiny from the Federal Trade Commission, owing to potential antitrust issues arising from amassing such a large portfolio of Alzheimer's drugs. This could lead to Pfizer having to divest some of its Alzheimer's assets, says Jack Walsh, a commercial litigator with the law firm Lathrop & Gage in St. Louis, Mo.
Pfizer spokesman Jack Cox said, "We can't speculate on the actions of regulators, but we recognize that this is a large, complex transaction. We will work closely with the regulatory bodies to obtain the necessary clearances."
And Pfizer may have a tricky time managing relationships with its two main Alzheimer's partners - Medivation and Elan -- both of which will want to be seen as a priority over the other when it comes to Pfizer's time and financial commitment.
Pfizer singled out bapineuzumab in its press release discussing the Wyeth acquisition and also talked about the importance of the drug and Alzheimer's, in general, on its Monday conference calls.
Corey Davis, drug analyst at Natixis Bleichroeder, says this was likely Pfizer trying to ease any misgivings Elan may have, especially given Pfizer's existing commitment to Medivation.
"The fact that Pfizer specifically talked about bapineuzumab was probably a signal to Elan that Pfizer intends to maintain Wyeth's investment in the drug," said Davis, who covers Elan with a buy rating.
But if Pfizer was sending the love to Elan on Monday, it wasn't necessarily reciprocated.
Elan spokeswoman Mary Stutts said the company expects a federal antitrust review of the Pfizer-Wyeth deal, particularly in terms of the Alzheimer's assets, and that until that review is completed, Elan is taking a wait and see attitude.
"We cannot assume at this point that Pfizer will be Elan's partner for bapineuzumab," said Stutts.
She added that the current contract between Elan and Wyeth for bapineuzumab and a second Alzheimer's drug, ACC-001, does include change of control provisions. Stutts would not elaborate on the details of those provisions.
Doug Petkus, a spokesman for Wyeth, said the focus of both Wyeth and Pfizer continues to be on Alzheimer's research, including bapineuzumab, but he would not say what ultimately happens to the relationship with Elan if and when Pfizer acquires Wyeth.
Data from a phase II study of bapineuzumab, presented last year, raised doubts about the drug's efficacy and safety. While Elan has moved aggressively to enroll patients in two U.S.-based phase III clinical trials, Wyeth has had problems enrolling patients in two international studies due to safety concerns raised primarily by regulators in Europe.
Natixis analyst Davis believes there is little chance that Pfizer will decide to drop bapineuzumab altogether. "The phase III studies are pretty much on auto-pilot now, so I don't think Pfizer has much incentive to make major changes."
Medivation CEO David Hung says his company's partnership with Pfizer remains unchanged.
"We have not been told of any changes, so I assume that we're on track. The partnership [for Dimebon] has gone very well and Pfizer speaks enthusiastically about the drug. Alzheimer's is definitely an area where Pfizer is committed to investing a lot of resources."
Pfizer shares closed Monday down 10% to $15.65 on concerns that the Wyeth acquisition would not generate enough new revenue and growth to make up for shortfalls of both anticipated in the coming years.
Antwort auf Beitrag Nr.: 36.453.107 von dasHaendchen am 26.01.09 21:33:23in den Vergangenen Jahren hat ELAN schon immer auf gute NEWS negativ reagiert.
So auch gestern.
So auch gestern.
Elan Waiting To See If Pfizer, Wyeth Deal Has Fallout
January 26, 2009: 03:46 PM ET
NEW YORK -(Dow Jones)- Elan Corp. Plc (ELN) is waiting to find out if its partnership with Wyeth (WYE) to develop an experimental Alzheimer's disease treatment will be affected by Pfizer Inc.'s (PFE) planned $68 billion takeover of that company.
Elan and Wyeth are developing bapineuzumab, which is currently in late-stage trials. The closely watched drug is designed to remove or reduce a brain substance called amyloid, which is theorized as the primary cause of Alzheimer's symptoms.
"We haven't had any discussion with Pfizer or Wyeth about the merger, so we are waiting to hear more details along with every one else," Elan's Mary Stutts said.
Shares of all related companies are down, with Elan losing 61 cents, or 8%, to $6.92; Pfizer dropping $1.79, or 10%, to $15.64; and Wyeth off 31 cents, or 1%, at $43.43.
The partnership agreement between Wyeth and Elan contains a change of control agreement that can alter the terms of the relationship if one of them is acquired.
Elan Chief Executive Kelly Martin recently explained that "as long as the new entity deems this program as strategic and important, and they put the right resources against it, then you basically step in the shoes of that party."
Stutts declined to elaborate on how the acquisition of Wyeth will change the agreement, if at all, but said the company will evaluate all its options.
"At some point, Elan, Wyeth and Pfizer will engage in substantive communication as to the future of the collaboration," she said.
But the provision doesn't become relevant until the deal actually closes, which Elan expects to take some time.
"We expect that the agreement between Pfizer and Wyeth would necessitate substantial antitrust reviews," Stutts said.
-By Thomas Gryta, Dow Jones Newswires; 201-938-2053; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
01-26-09 1546ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://money.cnn.com/news/newsfeeds/articles/djf500/20090126…
January 26, 2009: 03:46 PM ET
NEW YORK -(Dow Jones)- Elan Corp. Plc (ELN) is waiting to find out if its partnership with Wyeth (WYE) to develop an experimental Alzheimer's disease treatment will be affected by Pfizer Inc.'s (PFE) planned $68 billion takeover of that company.
Elan and Wyeth are developing bapineuzumab, which is currently in late-stage trials. The closely watched drug is designed to remove or reduce a brain substance called amyloid, which is theorized as the primary cause of Alzheimer's symptoms.
"We haven't had any discussion with Pfizer or Wyeth about the merger, so we are waiting to hear more details along with every one else," Elan's Mary Stutts said.
Shares of all related companies are down, with Elan losing 61 cents, or 8%, to $6.92; Pfizer dropping $1.79, or 10%, to $15.64; and Wyeth off 31 cents, or 1%, at $43.43.
The partnership agreement between Wyeth and Elan contains a change of control agreement that can alter the terms of the relationship if one of them is acquired.
Elan Chief Executive Kelly Martin recently explained that "as long as the new entity deems this program as strategic and important, and they put the right resources against it, then you basically step in the shoes of that party."
Stutts declined to elaborate on how the acquisition of Wyeth will change the agreement, if at all, but said the company will evaluate all its options.
"At some point, Elan, Wyeth and Pfizer will engage in substantive communication as to the future of the collaboration," she said.
But the provision doesn't become relevant until the deal actually closes, which Elan expects to take some time.
"We expect that the agreement between Pfizer and Wyeth would necessitate substantial antitrust reviews," Stutts said.
-By Thomas Gryta, Dow Jones Newswires; 201-938-2053; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
01-26-09 1546ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://money.cnn.com/news/newsfeeds/articles/djf500/20090126…
Elan on Wyeth/Pfizer re BAP from Bloomberg
Trista Kelley
Jan. 27 (Bloomberg) -- Elan Corp. said it hasn’t been
contacted by Pfizer Inc. or Wyeth regarding the Irish drugmaker’s
partnership with Wyeth on the experimental Alzheimer’s treatment,
bapineuzumab.
“We have not had any discussions with Pfizer nor Wyeth
about the merger and are waiting to hear more details” about
plans for the drug, Mary Stutts, a spokeswoman for Dublin-based
Elan, said in an e-mailed response to questions. Elan intends to
continue to focus on its Alzheimer’s program, including the late-
stage trial of bapineuzumab, Stutts said.
Pfizer Chief Executive Officer Jeffrey Kindler said on a
conference call yesterday that the company’s $68 billion bid for
Wyeth won’t affect either firm’s “complementary” Alzheimer’s
projects. If Elan or Wyeth undergo a change of control, their
contract permits the acquirer to “assume the role of the
acquired party in most circumstances,” according to Elan’s
filing to the U.S. Securities and Exchange Commission last year.
“The Elan/Wyeth change of control provision will not be
triggered unless and until there is a formal change of control,”
Stutts said. New York-based Pfizer’s proposed takeover of Wyeth
“will necessitate substantial antitrust reviews. Elan,
therefore, does not expect a formal change of control to be
triggered for some time.”
Bapineuzumab’s link to a brain-swelling side effect, along
with delays in testing the drug, contributed to a 73 percent
decline in Elan’s stock last year. Elan and Madison, New Jersey-
based Wyeth last month began the final phase of testing that
bapineuzumab needs before winning approval and plan for the
trials to be completed in 18 months.
“We are pleased and continue to hope for the original
timing that we have for bapineuzumab,” Wyeth CEO Bernard Poussot
said yesterday on the conference call.
The drug has the potential to be the biggest-selling
medication ever, topping the $12.7 billion in annual sales for
Pfizer’s cholesterol treatment Lipitor, said David Moskowitz, an
analyst with Caris & Co., in a telephone interview earlier this
month. Those sales will come only with research success and
worldwide regulatory approval, he said.
For Related News and Information:
Top health stories: HTOP <GO>
Most-read health stories: MNI HEA <GO>
Company news: ELN ID <Equity> CN <GO>
Stories about bapineuzumab: NSE BAPINEUZUMAB <GO>
Stories about Wyeth: WYE US <Equity> CN <GO>
--Editors: Kristen Hallam, Bruce Rule
Trista Kelley
Jan. 27 (Bloomberg) -- Elan Corp. said it hasn’t been
contacted by Pfizer Inc. or Wyeth regarding the Irish drugmaker’s
partnership with Wyeth on the experimental Alzheimer’s treatment,
bapineuzumab.
“We have not had any discussions with Pfizer nor Wyeth
about the merger and are waiting to hear more details” about
plans for the drug, Mary Stutts, a spokeswoman for Dublin-based
Elan, said in an e-mailed response to questions. Elan intends to
continue to focus on its Alzheimer’s program, including the late-
stage trial of bapineuzumab, Stutts said.
Pfizer Chief Executive Officer Jeffrey Kindler said on a
conference call yesterday that the company’s $68 billion bid for
Wyeth won’t affect either firm’s “complementary” Alzheimer’s
projects. If Elan or Wyeth undergo a change of control, their
contract permits the acquirer to “assume the role of the
acquired party in most circumstances,” according to Elan’s
filing to the U.S. Securities and Exchange Commission last year.
“The Elan/Wyeth change of control provision will not be
triggered unless and until there is a formal change of control,”
Stutts said. New York-based Pfizer’s proposed takeover of Wyeth
“will necessitate substantial antitrust reviews. Elan,
therefore, does not expect a formal change of control to be
triggered for some time.”
Bapineuzumab’s link to a brain-swelling side effect, along
with delays in testing the drug, contributed to a 73 percent
decline in Elan’s stock last year. Elan and Madison, New Jersey-
based Wyeth last month began the final phase of testing that
bapineuzumab needs before winning approval and plan for the
trials to be completed in 18 months.
“We are pleased and continue to hope for the original
timing that we have for bapineuzumab,” Wyeth CEO Bernard Poussot
said yesterday on the conference call.
The drug has the potential to be the biggest-selling
medication ever, topping the $12.7 billion in annual sales for
Pfizer’s cholesterol treatment Lipitor, said David Moskowitz, an
analyst with Caris & Co., in a telephone interview earlier this
month. Those sales will come only with research success and
worldwide regulatory approval, he said.
For Related News and Information:
Top health stories: HTOP <GO>
Most-read health stories: MNI HEA <GO>
Company news: ELN ID <Equity> CN <GO>
Stories about bapineuzumab: NSE BAPINEUZUMAB <GO>
Stories about Wyeth: WYE US <Equity> CN <GO>
--Editors: Kristen Hallam, Bruce Rule
Antwort auf Beitrag Nr.: 36.493.834 von surga am 02.02.09 12:17:44wir dümpeln halt weiter so vor uns hin
Antwort auf Beitrag Nr.: 36.493.858 von Poppholz am 02.02.09 12:20:56ja, leider
...immerhin dümpeln wir jetzt 10% höher ob einer Meldung die wir schon kannten...
Cleveland Clinic researchers find way to treat MS drug side effect
Cleveland Clinic researchers find way to treat MS drug side effect
by Brie Zeltner / Plain Dealer reporter
Monday February 02, 2009, 4:00 PM
Researchers at the Cleveland Clinic have found a way to help multiple sclerosis patients with a rare side effect from a common drug used to treat the disease.
Some MS patients taking the drug Tysabri develop a rare infection called progressive multifocal leukoencephalopathy, which is often fatal. Tysabri is used to keep white blood cells from entering the brain and attacking healthy nerves in MS patients. PML is caused by a virus that usually only infects immuno-compromised patients who do not have adequate white blood cells to fend it off.
The drug was temporarily withdrawn from the market in 2005 when the first two cases of PML emerged and was reintroduced a year later with stricter safety guidelines. There have been several more confirmed cases of PML since then.
In the Clinic study, researchers used plasmapheresis to clear Tysabri from the blood of 12 MS patients during a two week period. Stopping treatment and quickly removing the drug from the patient's blood may improve the outcome for patients with PML, said Dr. Robert Fox, medical director of the Clinic's Mellen Center for multiple sclerosis in a news release.
Tysabri can take up to 12 weeks to clear from the bloodstream naturally and can cause reduced red and white blood cell counts for up to six months, the researchers said in the paper.
The study will be published in the Tuesday's issue of the journal Neurology.
Cleveland Clinic researchers find way to treat MS drug side effect
Cleveland Clinic researchers find way to treat MS drug side effect
by Brie Zeltner / Plain Dealer reporter
Monday February 02, 2009, 4:00 PM
Researchers at the Cleveland Clinic have found a way to help multiple sclerosis patients with a rare side effect from a common drug used to treat the disease.
Some MS patients taking the drug Tysabri develop a rare infection called progressive multifocal leukoencephalopathy, which is often fatal. Tysabri is used to keep white blood cells from entering the brain and attacking healthy nerves in MS patients. PML is caused by a virus that usually only infects immuno-compromised patients who do not have adequate white blood cells to fend it off.
The drug was temporarily withdrawn from the market in 2005 when the first two cases of PML emerged and was reintroduced a year later with stricter safety guidelines. There have been several more confirmed cases of PML since then.
In the Clinic study, researchers used plasmapheresis to clear Tysabri from the blood of 12 MS patients during a two week period. Stopping treatment and quickly removing the drug from the patient's blood may improve the outcome for patients with PML, said Dr. Robert Fox, medical director of the Clinic's Mellen Center for multiple sclerosis in a news release.
Tysabri can take up to 12 weeks to clear from the bloodstream naturally and can cause reduced red and white blood cell counts for up to six months, the researchers said in the paper.
The study will be published in the Tuesday's issue of the journal Neurology.
Antwort auf Beitrag Nr.: 36.498.645 von Birgit.Tersteegen am 02.02.09 23:04:09...immerhin dümpeln wir jetzt 10% höher ob einer Meldung die wir schon kannten...
....da wäre noch eine...
Grüße
bernie55
Bloomberg:
Blood-Cleansing Treatment Could Make Tysabri Safer
http://www.bloomberg.com/apps/news?pid=20601103&sid=afWzOTYu…
....da wäre noch eine...Grüße
bernie55
Bloomberg:
Blood-Cleansing Treatment Could Make Tysabri Safer
http://www.bloomberg.com/apps/news?pid=20601103&sid=afWzOTYu…
habe inzwischen wieder ein wenig Geld zusammen, dass nur auf einen guten Einstiegszeitpunkt wartet.
(gebranntes Kind scheut das Feuer)
(gebranntes Kind scheut das Feuer)
Antwort auf Beitrag Nr.: 36.499.273 von bernie55 am 03.02.09 08:23:10 Herzchen,es geht um das Gleiche.... LG in die unverbesserliche Gemeinde.....
Herzchen,es geht um das Gleiche.... LG in die unverbesserliche Gemeinde.....
Antwort auf Beitrag Nr.: 36.499.848 von Birgit.Tersteegen am 03.02.09 09:57:22..........ischschsch weissssss, Herzchen...
..aber das war halt " noch eine " von Bloooooooooooomberg.....
..........ischschsch weissssss, Herzchen.....aber das war halt " noch eine " von Bloooooooooooomberg.....
Adam Feuerstein zu Wyeth- Pfizer und Elan..
...kritisch wie immer sein statemant zu BAP......
It seemed like everyone in the financial press had something to say about Pfizer's acquisition of Wyeth this week, myself included, which prompted this email from Patrick D:
"If Pfizer is eying bapineuzumab as a key asset in its $60-70 billion dollar acquisition of Wyeth, doesn't that give you concern that your analysis of the Elan(ELN Quote - Cramer on ELN - Stock Picks) phase II [bapineuzumab] data is wrong. If Pfizer has looked carefully at the data and thinks it supports a $60-70 billion dollar investment, you don't think perhaps you missed something?"
As I wrote in the article, Pfizer is making a big bet on Alzheimer's disease research, but that's a different proposition from making a big bet on bapineuzumab. If Pfizer had wanted to do that, it could have bought Elan. Pfizer didn't buy Elan, it's buying Wyeth -- and for many reasons that have nothing to do with bapineuzumab.
I'm not privy to Pfizer's strategy or thinking on bapineuzumab, but if I had to guess, I'd say that the company sees maintaining the financial commitment already made by Wyeth in the drug as a prudent business decision and one that doesn't cost much in the context of the entire Wyeth deal since the phase III studies are already under way.
> If bapineuzumab succeeds, Pfizer looks genius;
> if the drug doesn't succeed, the incremental money spent isn't going to break the company's bank and it still has a deep pipeline of earlier-stage Alzheimer's drugs as a fallback.
[And yes, I still believe the latter scenario is more likely.]
And let's not forget that when Pfizer went looking for a late-stage Alzheimer's drug, it shook hands with Medivation first -- not Wyeth, not Elan. That deal tells you 250 million things about where Pfizer is leaning when it comes to potential blockbuster Alzheimer's drugs.
http://www.thestreet.com/story/10460915/2/biotech-stock-mail…
...kritisch wie immer sein statemant zu BAP......
It seemed like everyone in the financial press had something to say about Pfizer's acquisition of Wyeth this week, myself included, which prompted this email from Patrick D:
"If Pfizer is eying bapineuzumab as a key asset in its $60-70 billion dollar acquisition of Wyeth, doesn't that give you concern that your analysis of the Elan(ELN Quote - Cramer on ELN - Stock Picks) phase II [bapineuzumab] data is wrong. If Pfizer has looked carefully at the data and thinks it supports a $60-70 billion dollar investment, you don't think perhaps you missed something?"
As I wrote in the article, Pfizer is making a big bet on Alzheimer's disease research, but that's a different proposition from making a big bet on bapineuzumab. If Pfizer had wanted to do that, it could have bought Elan. Pfizer didn't buy Elan, it's buying Wyeth -- and for many reasons that have nothing to do with bapineuzumab.
I'm not privy to Pfizer's strategy or thinking on bapineuzumab, but if I had to guess, I'd say that the company sees maintaining the financial commitment already made by Wyeth in the drug as a prudent business decision and one that doesn't cost much in the context of the entire Wyeth deal since the phase III studies are already under way.
> If bapineuzumab succeeds, Pfizer looks genius;
> if the drug doesn't succeed, the incremental money spent isn't going to break the company's bank and it still has a deep pipeline of earlier-stage Alzheimer's drugs as a fallback.
[And yes, I still believe the latter scenario is more likely.]
And let's not forget that when Pfizer went looking for a late-stage Alzheimer's drug, it shook hands with Medivation first -- not Wyeth, not Elan. That deal tells you 250 million things about where Pfizer is leaning when it comes to potential blockbuster Alzheimer's drugs.
http://www.thestreet.com/story/10460915/2/biotech-stock-mail…
Antwort auf Beitrag Nr.: 36.500.438 von bernie55 am 03.02.09 11:10:25....ach soooooooooooooooooo!
Report: Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs
http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/…
An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.
The new report entitled Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs finds that a therapy's effect on disability is the attribute that most influences surveyed neurologists' prescribing decisions in relapsing-remitting multiple sclerosis. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec/Elan's Tysabri has advantages in this attribute over Biogen Idec's Avonex, the market sales leading agent.
Decision Resources' proprietary clinical gold standard in 2008 for relapsing-remitting multiple sclerosis was Tysabri, most notably because of its superior efficacy in the three key aspects of the disease --disability progression, relapses, and lesions -- relative to other agents to treat the disease. Based on its robust efficacy, Tysabri will retain Decision Resources' gold standard status through 2017 for relapsing-remitting multiple sclerosis.
"Although Tysabri is disadvantaged by its rare incidence of life-threatening side effects, we do not expect any therapy in development for relapsing-remitting multiple sclerosis to displace it as the clinical gold standard," said Decision Resources Analyst Bethany Kiernan , Ph.D. "While some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that surveyed neurologists say are inferior when compared with Tysabri."
About the Report
Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com
http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/…
An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States
Tysabri is Decision Resources' Gold Standard Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to a New Report from Decision Resources
WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an oral disease-modifying therapy for relapsing-remitting multiple sclerosis would earn a 50 percent patient share in Europe and a 40 percent patient share in the United States, according to surveyed U.S. and European neurologists.
The new report entitled Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs finds that a therapy's effect on disability is the attribute that most influences surveyed neurologists' prescribing decisions in relapsing-remitting multiple sclerosis. Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec/Elan's Tysabri has advantages in this attribute over Biogen Idec's Avonex, the market sales leading agent.
Decision Resources' proprietary clinical gold standard in 2008 for relapsing-remitting multiple sclerosis was Tysabri, most notably because of its superior efficacy in the three key aspects of the disease --disability progression, relapses, and lesions -- relative to other agents to treat the disease. Based on its robust efficacy, Tysabri will retain Decision Resources' gold standard status through 2017 for relapsing-remitting multiple sclerosis.
"Although Tysabri is disadvantaged by its rare incidence of life-threatening side effects, we do not expect any therapy in development for relapsing-remitting multiple sclerosis to displace it as the clinical gold standard," said Decision Resources Analyst Bethany Kiernan , Ph.D. "While some therapies in development hold promise, most have efficacy, safety and tolerability, and/or delivery features that surveyed neurologists say are inferior when compared with Tysabri."
About the Report
Multiple Sclerosis (Relapsing-Remitting): Emerging Therapies That Offer Improved Convenience Will Not Unseat Current Drugs is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com
Antwort auf Beitrag Nr.: 36.501.759 von Birgit.Tersteegen am 03.02.09 14:06:46Moin liebe ELANIA
Biogen cuts Tysabri outlook
Fri Feb 6, 2009 3:02pm GMT
http://uk.reuters.com/article/companyNewsMolt/idUKTRE5153E12…
By Toni Clarke
BOSTON (Reuters) - Biogen Idec Inc (BIIB.O) scaled back growth projections for its multiple sclerosis drug Tysabri on Friday and said another patient has developed the potentially deadly brain infection known as PML.
Biogen reported higher fourth-quarter earnings but sales of Tysabri fell short of expectations and the company's shares fell more than 3.5 percent in early trading.
Jim Mullen, Biogen's chief executive officer, told analysts on the company's fourth-quarter earnings call that it will be "difficult" to achieve the company's previous forecast that 100,000 patients will be taking Tysabri by the end of 2010.
In addition, the company reported a new case of progressive multifocal leukoecephalopathy, or PML, a potentially deadly brain infection that has curbed the drug's sales.
Tysabri, which the company markets with Elan Corp Plc (ELN.N)(ELN.I), was temporarily withdrawn from the market in 2005 after it was linked with PML but reintroduced in July 2006 with stricter safety warnings. The newest case is the fifth since it was reintroduced and was contracted by a patient in Europe.
Cambridge, Massachusetts-based Biogen said its fourth-quarter net earnings rose 3 percent to $207 million, or 70 cents a share, from $201.2 million, or 67 cents a share, a year earlier.
Earnings excluding one-time items were 93 cents a share. Analysts had expected 92 cents, according to Reuters Estimates. Revenue rose to $1.07 billion from $893.3 million. Analysts were expecting revenue of $1.09 billion.
Total sales of Tysabri, which Biogen sells with Elan Corp Plc(ELN.N) (ELN.I) of Ireland, were $218 million, of which $115 million was in the United States and $103 million in the rest of the world.
That fell short of the consensus estimate of total worldwide sales of Tysabri of $250 million.
"Tysabri sales numbers are going from bad to worse," said Corey Davis, an analyst at Natixis Bleichroeder in a research note. "We anticipate that the sales forecasts will now have to dip below $1 billion for 2009.
Biogen said it expected 2009 earnings excluding one-time items to be above $4 a share. Analysts had forecast $3.63 a share.
The company said it expected revenue growth at a high single-digit percentage rate for the year.
(Reporting by Toni Clarke; Editing by Lisa Von Ahn, Dave Zimmerman)
Fri Feb 6, 2009 3:02pm GMT
http://uk.reuters.com/article/companyNewsMolt/idUKTRE5153E12…
By Toni Clarke
BOSTON (Reuters) - Biogen Idec Inc (BIIB.O) scaled back growth projections for its multiple sclerosis drug Tysabri on Friday and said another patient has developed the potentially deadly brain infection known as PML.
Biogen reported higher fourth-quarter earnings but sales of Tysabri fell short of expectations and the company's shares fell more than 3.5 percent in early trading.
Jim Mullen, Biogen's chief executive officer, told analysts on the company's fourth-quarter earnings call that it will be "difficult" to achieve the company's previous forecast that 100,000 patients will be taking Tysabri by the end of 2010.
In addition, the company reported a new case of progressive multifocal leukoecephalopathy, or PML, a potentially deadly brain infection that has curbed the drug's sales.
Tysabri, which the company markets with Elan Corp Plc (ELN.N)(ELN.I), was temporarily withdrawn from the market in 2005 after it was linked with PML but reintroduced in July 2006 with stricter safety warnings. The newest case is the fifth since it was reintroduced and was contracted by a patient in Europe.
Cambridge, Massachusetts-based Biogen said its fourth-quarter net earnings rose 3 percent to $207 million, or 70 cents a share, from $201.2 million, or 67 cents a share, a year earlier.
Earnings excluding one-time items were 93 cents a share. Analysts had expected 92 cents, according to Reuters Estimates. Revenue rose to $1.07 billion from $893.3 million. Analysts were expecting revenue of $1.09 billion.
Total sales of Tysabri, which Biogen sells with Elan Corp Plc(ELN.N) (ELN.I) of Ireland, were $218 million, of which $115 million was in the United States and $103 million in the rest of the world.
That fell short of the consensus estimate of total worldwide sales of Tysabri of $250 million.
"Tysabri sales numbers are going from bad to worse," said Corey Davis, an analyst at Natixis Bleichroeder in a research note. "We anticipate that the sales forecasts will now have to dip below $1 billion for 2009.
Biogen said it expected 2009 earnings excluding one-time items to be above $4 a share. Analysts had forecast $3.63 a share.
The company said it expected revenue growth at a high single-digit percentage rate for the year.
(Reporting by Toni Clarke; Editing by Lisa Von Ahn, Dave Zimmerman)
....gibt wohl einen neuen PML-Fall in Europa....gvielleicht rafft der Markt langsam,dass das kein Drama ist...Grüsse! Birgit(insg.5 pml-Fälle bei fast 40000 Patienten,nur 1 tödlich....und das bei der ungeheuren Verbesserung die TY für die meisten MSler bringt....ausserdem weit im Label von 1:1000----real eher 1:10000 Patienten....
(insg.5 pml-Fälle bei fast 40000 Patienten,nur 1 tödlich....und das bei der ungeheuren Verbesserung die TY für die meisten MSler bringt....ausserdem weit im Label von 1:1000----real eher 1:10000 Patienten....
Antwort auf Beitrag Nr.: 36.529.564 von Birgit.Tersteegen am 06.02.09 17:17:57Ja, Birgit, der Kurs sieht stabil aus
Antwort auf Beitrag Nr.: 36.529.640 von surga am 06.02.09 17:25:13.....ist doch schon mal ein Fortschritt--man/fra wird ja bescheiden....
Antwort auf Beitrag Nr.: 36.529.730 von Birgit.Tersteegen am 06.02.09 17:33:25so ist es! 
Nice Week End Birgit
Nice Week End Birgit
Elan Corp (ELN) NewsBite - ELN Falls on Lower Tysabri Sales
Posted on Friday, February 06, 2009 10:08 AM
Elan Corp (NYSE: ELN) opened at $7.38. So far today, the stock has hit a low of $7.33 and a high of $7.78. ELN is now trading at $7.69, down $0.32 (-4.00%). Over the last 52 weeks the stock has ranged from a low of $4.99 to a high of $37.45. Shares of ELN are trading lower this morning after Biogen Idec Inc. (BIIB) said sales of Tysabri, a multiple sclerosis drug sold through a partnership with ELN, fell to $218 million in the fourth quarter compared to $216 million in the third quarter. This could be a bad sign for ELN. Technical indicators for the stock are neutral and S&P gives ELN a neutral 3 STARS (out of 5) hold ranking. If you are looking for a hedged play on ELN the stock seems like it could be a candidate for an April out-of-the-money bear-call credit spread above the 10 range. [ABR-Seven Summits Strategic Investments NewsBite]
Click Symbol For More News On: (ELN)
http://www.marketintelligencecenter.com/articles/759578
Posted on Friday, February 06, 2009 10:08 AM
Elan Corp (NYSE: ELN) opened at $7.38. So far today, the stock has hit a low of $7.33 and a high of $7.78. ELN is now trading at $7.69, down $0.32 (-4.00%). Over the last 52 weeks the stock has ranged from a low of $4.99 to a high of $37.45. Shares of ELN are trading lower this morning after Biogen Idec Inc. (BIIB) said sales of Tysabri, a multiple sclerosis drug sold through a partnership with ELN, fell to $218 million in the fourth quarter compared to $216 million in the third quarter. This could be a bad sign for ELN. Technical indicators for the stock are neutral and S&P gives ELN a neutral 3 STARS (out of 5) hold ranking. If you are looking for a hedged play on ELN the stock seems like it could be a candidate for an April out-of-the-money bear-call credit spread above the 10 range. [ABR-Seven Summits Strategic Investments NewsBite]
Click Symbol For More News On: (ELN)
http://www.marketintelligencecenter.com/articles/759578
Seven Summits Research Releases Comments on BAC, FCX, CRM, DKS, and ELN
CHICAGO, Feb. 6 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/0206X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic Investments NewsBites cover the following stocks: Bank of America Corporation (NYSE: BAC), Freeport-McMoRan Copper & Gold Inc. (NYSE: FCX), Salesforce.com (NYSE: CRM), Dick's Sporting Goods Inc. (NYSE: DKS), and Elan Corp. plc (NYSE: ELN)
These brief stock reports may contain details regarding recent or anticipated stock moves, resistance and support price levels, insider trades, upgrades, downgrades, and other news from our network of information resources. Reports may also include hedged trade ideas designed to potentially protect investors from unexpected market shifts. While other market reports provide only stock news, we offer strategies that hedge investments against uncertainty. Hedged trades increase your chances of making a profit, even if a stock goes down.
"Our NewsBites strive to go above and beyond other stock market news reports. Along with brief concise stories, each NewsBite provides useful information and tactics on how to ensure your investments are protected with basic hedging techniques," says Reid Stratton, Seven Summits Senior Analyst. "These essential news items contain information that can benefit both the expert and the novice investor who wants to stay ahead of the market by anticipating changes instead of just reacting to them."
For essential information on stocks that may be poised to move, go to: http://www.go7now.com/nb/0206X to find all available Seven Summits Strategic Investments NewsBites.
Seven Summits Investment Research is an independent investment research group, which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help our clients make the best possible investment decisions. For more information go to www.SevenSummitsInvestmentResearch.com. CRD# 137114
All stocks and options shown are examples only -- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security. Potential returns do not take into account your trade size, brokerage commissions or taxes -- expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available from Catherine at 800-698-9101 or at http://www.cboe.com/Resources/Intro.aspx. Privacy policy available upon request.
SOURCE Seven Summits Investment Research
http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=1…
CHICAGO, Feb. 6 /PRNewswire/ -- Seven Summits Research releases NewsBites on key stocks.
Seven Summits Strategic Investments NewsBites are available to all investors at: http://www.go7now.com/nb/0206X (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's Seven Summits Strategic Investments NewsBites cover the following stocks: Bank of America Corporation (NYSE: BAC), Freeport-McMoRan Copper & Gold Inc. (NYSE: FCX), Salesforce.com (NYSE: CRM), Dick's Sporting Goods Inc. (NYSE: DKS), and Elan Corp. plc (NYSE: ELN)
These brief stock reports may contain details regarding recent or anticipated stock moves, resistance and support price levels, insider trades, upgrades, downgrades, and other news from our network of information resources. Reports may also include hedged trade ideas designed to potentially protect investors from unexpected market shifts. While other market reports provide only stock news, we offer strategies that hedge investments against uncertainty. Hedged trades increase your chances of making a profit, even if a stock goes down.
"Our NewsBites strive to go above and beyond other stock market news reports. Along with brief concise stories, each NewsBite provides useful information and tactics on how to ensure your investments are protected with basic hedging techniques," says Reid Stratton, Seven Summits Senior Analyst. "These essential news items contain information that can benefit both the expert and the novice investor who wants to stay ahead of the market by anticipating changes instead of just reacting to them."
For essential information on stocks that may be poised to move, go to: http://www.go7now.com/nb/0206X to find all available Seven Summits Strategic Investments NewsBites.
Seven Summits Investment Research is an independent investment research group, which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help our clients make the best possible investment decisions. For more information go to www.SevenSummitsInvestmentResearch.com. CRD# 137114
All stocks and options shown are examples only -- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security. Potential returns do not take into account your trade size, brokerage commissions or taxes -- expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available from Catherine at 800-698-9101 or at http://www.cboe.com/Resources/Intro.aspx. Privacy policy available upon request.
SOURCE Seven Summits Investment Research
http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=1…
New Alzheimer's Drug Tested
Posted: Feb 7, 2009 07:00 AM
VIDEOFILM und ARTIKEL
http://www.kold.com/Global/story.asp?S=9805313&nav=menu86_13…
Posted: Feb 7, 2009 07:00 AM
VIDEOFILM und ARTIKEL
http://www.kold.com/Global/story.asp?S=9805313&nav=menu86_13…
Antwort auf Beitrag Nr.: 36.535.966 von bernie55 am 08.02.09 12:16:58 Hi....Nette Grüsse Birgit
Hi....Nette Grüsse Birgit 
Great NewsIt's about time we got some respect.
Biogen and Elan: Tysabri may become more effective over time
By Robert Daniel
Last update: 2:26 a.m. EST Feb. 9, 2009
TEL AVIV (MarketWatch) -- Biogen Idec (BIIB:
ELN 7.94, -0.07, -0.9%) said that a study of the multiple-sclerosis treatment Tysabri showed that five times as many patients taking the drug remained free of disease activity for two years as the number of patients taking a placebo. The study suggests that Tysabri may become more effective over time, they said. Two years after starting treatment with the drug, generically natalizumab, 37% of patients remained free of disease activity compared with 7% of patients who took a placebo, the drug makers, based in Cambridge, Mass., and Dublin, respectively, said. Of the patients in the study, 64% showed no sign of relapse or sustained disability progression and 58% were free of radiological disease activity, they said. The data are published online and in the March 2009 issue of the Lancet Neurology. End of Story
Hi Jungs
Es scheint was im Busch zu sein ....scheinbar erwägt Elan einen Teil von ca.20% der Firma zu verkaufen.....Es gibt wohl einen Gegenpart dazu....blicke noch nicht durch + muss erstmal arbeiten....guckt mal auf http://www.fixelan.com/blog/?p=1
Es scheint was im Busch zu sein ....scheinbar erwägt Elan einen Teil von ca.20% der Firma zu verkaufen.....Es gibt wohl einen Gegenpart dazu....blicke noch nicht durch + muss erstmal arbeiten....guckt mal auf http://www.fixelan.com/blog/?p=1
Ich unterstütze das!!!!!!!!
FOR IMMEDIATE RELEASE
MAJOR SHAREHOLDER HOLDS ELAN BOARD ACCOUNTABLE
Lake Forest, IL, (February 8, 2009) – Crabtree Partners, an independent healthcare and biotechnology investment company, announced today that it has submitted a second letter to Elan Pharmaceuticals Chairman of the Board, Kyran Mclaughlin, calling for the Board to review the performance of Elan’s CEO, Kelly Martin and its own responsibility for the current state of Elan. The move comes following a drop in the company’s stock price from $37 to $8 over the last six months (most of this prior to general market decline).
Jack Schuler is a co-founder and partner of Crabtree Partners, and is one of the largest shareholders of Elan with more than 5.5 million shares. He is a former president of Abbott Laboratories and former board member of Chiron, ICOS and Amgen. Schuler was instrumental in forming two highly successful healthcare companies, Stericycle and Ventana Medical Systems, where he was chairman and the largest shareholder. Recently Ventana was sold to Roche. He is currently on the board of directors of Stericycle, Quidel, and Medtronic and a member of the National Academies Science, Economics, and Planning Policy (STEP) Board.
# # #
LETTER TO ELAN - FEBRUARY 8, 2009
February 8, 2009
Dear Mr. McLaughlin:
This is a follow-up to my letter dated December 11, 2008 in which I outlined investor concerns regarding the manner in which Elan’s Board of Directors is handling the Company’s mounting strategic crisis. At a time where foresight and responsible management are perhaps more important than ever, you and your fellow Directors appear to be flouting your obligation to shareholders not only by allowing a failed management to remain in place, but also by ignoring the need to nominate new Directors with relevant and outstanding pharmaceutical marketing experience, such as the ones I suggested to you, to the Elan Board.
Since his appointment, the path set upon by your current Chief Executive Officer has led to many harmful consequences. Your CEO’s mistakes cover the gamut of poor executive decision-making - from marketing to strategic direction to expense management. A small sample of these errors is listed below to demonstrate their pervasiveness.
* Your CEO has almost completely surrendered the promotion of Tysabri to Biogen, despite an inherent conflict with their drug Avonex, the current market leader in multiple sclerosis and the drug most threatened by Tysabri’s success.
* Last year your CEO announced with great fanfare the creation of an Elan sales force to promote Tysabri for the Crohn’s disease indication. Less than a year later, he disbanded this sales force after investors pointed out that it was a failure.
* Three years ago, your CEO indicated that Elan’s pain management drug, PRIALT, would achieve annual sales of $150 to $250 million. In our eyes, the promotion of PRIALT, an excellent drug, is an absolute failure. Currently, sales are less than $20 million annually, which clearly exemplifies your CEO’s lack of understanding of basic pharmaceutical marketing.
* Over the course of the past year, I have had two lengthy discussions with your CEO regarding this issue. During both conversations, he confidently boasted about his ability to manage the business and how quickly he had learned the intricacies of pharmaceutical marketing.
* Based on the above referenced facts and despite an obvious need for such knowledge, none of the CEO’s top 20 executives, whom your CEO personally hired, have any relevant pharmaceutical marketing experience. Last month, after pressure from shareholders and without a public announcement, he quietly removed the Executive Vice President and Chief Commercial Officer, his former colleague from Merrill Lynch. It is apparent from your CEO’s hiring decisions that he does not believe that pharmaceutical marketing should be a core competency of the Company.
* In early 2008, your CEO attempted to sell the EDT drug-technology division, expecting a sale price in excess of $1 billion. By mismanaging the process, the sale took too long and, with the ongoing credit crisis, is currently unachievable.
* In spring 2008, after seeing the clinical data on Bapineuzumab, your CEO signaled to investors that once these data were presented, the Company’s stock would trade well above $40 per share. Despite the reasonably positive data, the announcement and presentation of these results were so poorly handled that the stock price that day dropped to less than half, at $18 per share. Your CEO clearly does not know how to properly manage the disclosure of clinical data to the investment community.
* After your CEO and several of his Merrill Lynch colleagues were hired, he moved the Company’s headquarters to New York City, where they reside, simply for their convenience. This arrogant decision was recently reversed, only after numerous shareholder objections and a significant waste of shareholder money.
* The Company appears to continue to maintain the use of corporate jets for the CEO and Board, this being a completely inappropriate and excessive cost for an organization of Elan’s size. With Fortune 100 companies canceling their corporate jets, Elan has no place preserving them.
Beyond the financial excesses of the office of your CEO, which are particularly odious in the current environment, the lack of proper guidance on a management and Board level stands the chance to irreversibly destroy the remaining value of this Company.
Your CEO is now embarking on what could be his biggest mistake yet, hiring Citibank to review the Company’s strategic alternatives. With this decision, you, the CEO, and your fellow Board members have announced the limit of your ideas.
Now is NOT the time to put all or part of Elan up for sale. Your investors fear that, in acting from a position of weakness, your CEO will destroy even greater value:
* We fear that he will attempt to craft a partial sale of stock and/or pipeline products that will fall just below the threshold requiring shareholder approval, a vote he knows he would not receive.
* The sale of any Elan shares to a pharmaceutical company would not only dilute shareholders at a time when the stock is depressed, but would also greatly reduce the likelihood that other pharmaceutical companies may express interest in Elan in the future.
* Not only does the Company not have an immediate need to raise cash in the near-term, but investors lack the confidence that your CEO could negotiate a deal favorable to Elan, particularly at a depressed share price.
You have options:
* The Company’s $1.15 billion debt, due at the end of 2011, could be easily managed by reducing wasteful spending and insisting that Biogen fulfill its obligation to promote Tysabri with the same level of emphasis put on its own drug, Avonex. Elan’s general and administration expenses are running in excess of $300 million per year. For a biotech company, that today is essentially a research-based company, these expenses should be less than $100 million per year.
* The sale of the EDT drug-technology division should be revisited, starting now, in anticipation of a recovering credit market.
We realize that, at this point, your CEO may hope that any deal would save his job, but it will also surely limit the upside of all Elan shareholders and mark the evisceration of yet more long-term shareholder value. Instead, your CEO should focus on improving the marketing competency of Elan and reducing unessential expenses.
The Pfizer/Wyeth merger is a threat to Alzheimer patients and Elan, and this should be opposed by Elan:
* Pfizer currently has six Alzheimer drugs under development and one on the market, while Wyeth has four of Elan’s Alzheimer drugs and five Alzheimer drugs of its own in development. If this merger materializes, Pfizer will control 16 Alzheimer drugs, which represents a majority of all Alzheimer drugs currently in clinical development and on the market.
* In addition, Pfizer would control a great deal of the intellectual property in this area, creating a virtual monopoly for itself. If allowed to control all these drugs, Pfizer would undoubtedly be forced to determine which of these compounds would receive priority in clinical development and which would be slowed down. As a result, Pfizer would likely favor those drugs in which it holds a 100% interest rather than the Elan drugs in which it holds only a 50% interest. Once again, Elan would be in the same position with Pfizer as it is with Biogen.
* Ultimately, the biggest loser in this situation would be Alzheimer patients, along with their caregivers and physicians, who would have fewer treatment options available to them.
What plans does your CEO have to face this threat? Has the Company contacted the Federal Trade Commission regarding this matter? Can your shareholders trust the management team to properly handle this issue when they have little to no experience?
Three weeks ago, at my request, you assisted in arranging a meeting between seven of Elan’s largest shareholders, who represent 37% of the Company’s outstanding shares, and two of your Directors, Bill Rohn and Gary Kennedy. Formerly a Chief Operating Officer at IDEC and the only Director with previous pharmaceutical marketing experience, Mr. Rohn’s participation in the meeting was encouraging as we felt that our concerns were heard and taken into consideration. He clearly heard our views opposing the sale of any shares of Elan to a pharmaceutical company at this time, as well as our insistence that the Company’s management and Board be strengthened. He agreed to discuss our concerns with the entire Elan Board of Directors, and respond to us immediately after the next Board meeting. In addition, we requested that Mr. Rohn consider becoming Chairman of the Elan Board.
More than ten days have passed since this meeting took place. Most of the other shareholders at the meeting, including myself, still have not received any verbal feedback from Mr. Rohn, nor from any other member of the Elan Board. Indeed, it took until February 6 to obtain any response, and the brief letter I received is more an attempt to avert further publicity of shareholder concerns than an effort to address them. Worse yet, the points made in the letter of Messrs. Rohn and Kennedy mischaracterize these concerns and ignore two critical issues: the sale of Elan stock to a pharmaceutical and your CEO’s poor performance. This letter so clearly fails to reflect the goodwill Mr. Rohn expressed at our January meeting that I seriously doubt he could have been one of its author. It seems to add weight to my fear that the Board has been hand chosen by your CEO simply to preserve his position and silence dissenting views.
Mr. McLaughlin, you must acknowledge and respond honestly to the urgency expressed privately and publicly by the majority of your largest shareholders. We have remained long-standing owners of Elan shares because we have faith in your scientists and the drugs they are developing, and would very much like for Elan to succeed in the long-term. Our concern is that you allow this failed strategy to continue out of loyalty to your CEO rather than exercising your fiduciary duty to Elan shareholders and its employees, whose interests you are responsible for upholding.
Again, we ask that you quickly add two qualified Directors with relevant pharmaceutical marketing expertise to the Elan Board to help guide the Company through this challenging period. We ask that these individuals be truly outstanding leaders in industry and not just yes-men. We are aware that you are currently considering an executive, who has contacted us for our endorsement. He is not the sort of individual Elan’s Board needs at this time and we will ask him to withdraw his candidacy. If you nominate individuals that will take an active role in monitoring the Company, that are near the same level of experience as those individuals we suggested to you in August, we will enthusiastically endorse them. If you choose individuals of lesser qualification to serve an ulterior motive, we will vigorously oppose them.
Please take advantage of our offer of support to prevent any further loss of value to the Company. A protracted public battle with your shareholders is of benefit to no one, as is a further escalation of this dispute.
Sincerely,
Jack W. Schuler
Crabtree Partners
FOR IMMEDIATE RELEASE
MAJOR SHAREHOLDER HOLDS ELAN BOARD ACCOUNTABLE
Lake Forest, IL, (February 8, 2009) – Crabtree Partners, an independent healthcare and biotechnology investment company, announced today that it has submitted a second letter to Elan Pharmaceuticals Chairman of the Board, Kyran Mclaughlin, calling for the Board to review the performance of Elan’s CEO, Kelly Martin and its own responsibility for the current state of Elan. The move comes following a drop in the company’s stock price from $37 to $8 over the last six months (most of this prior to general market decline).
Jack Schuler is a co-founder and partner of Crabtree Partners, and is one of the largest shareholders of Elan with more than 5.5 million shares. He is a former president of Abbott Laboratories and former board member of Chiron, ICOS and Amgen. Schuler was instrumental in forming two highly successful healthcare companies, Stericycle and Ventana Medical Systems, where he was chairman and the largest shareholder. Recently Ventana was sold to Roche. He is currently on the board of directors of Stericycle, Quidel, and Medtronic and a member of the National Academies Science, Economics, and Planning Policy (STEP) Board.
# # #
LETTER TO ELAN - FEBRUARY 8, 2009
February 8, 2009
Dear Mr. McLaughlin:
This is a follow-up to my letter dated December 11, 2008 in which I outlined investor concerns regarding the manner in which Elan’s Board of Directors is handling the Company’s mounting strategic crisis. At a time where foresight and responsible management are perhaps more important than ever, you and your fellow Directors appear to be flouting your obligation to shareholders not only by allowing a failed management to remain in place, but also by ignoring the need to nominate new Directors with relevant and outstanding pharmaceutical marketing experience, such as the ones I suggested to you, to the Elan Board.
Since his appointment, the path set upon by your current Chief Executive Officer has led to many harmful consequences. Your CEO’s mistakes cover the gamut of poor executive decision-making - from marketing to strategic direction to expense management. A small sample of these errors is listed below to demonstrate their pervasiveness.
* Your CEO has almost completely surrendered the promotion of Tysabri to Biogen, despite an inherent conflict with their drug Avonex, the current market leader in multiple sclerosis and the drug most threatened by Tysabri’s success.
* Last year your CEO announced with great fanfare the creation of an Elan sales force to promote Tysabri for the Crohn’s disease indication. Less than a year later, he disbanded this sales force after investors pointed out that it was a failure.
* Three years ago, your CEO indicated that Elan’s pain management drug, PRIALT, would achieve annual sales of $150 to $250 million. In our eyes, the promotion of PRIALT, an excellent drug, is an absolute failure. Currently, sales are less than $20 million annually, which clearly exemplifies your CEO’s lack of understanding of basic pharmaceutical marketing.
* Over the course of the past year, I have had two lengthy discussions with your CEO regarding this issue. During both conversations, he confidently boasted about his ability to manage the business and how quickly he had learned the intricacies of pharmaceutical marketing.
* Based on the above referenced facts and despite an obvious need for such knowledge, none of the CEO’s top 20 executives, whom your CEO personally hired, have any relevant pharmaceutical marketing experience. Last month, after pressure from shareholders and without a public announcement, he quietly removed the Executive Vice President and Chief Commercial Officer, his former colleague from Merrill Lynch. It is apparent from your CEO’s hiring decisions that he does not believe that pharmaceutical marketing should be a core competency of the Company.
* In early 2008, your CEO attempted to sell the EDT drug-technology division, expecting a sale price in excess of $1 billion. By mismanaging the process, the sale took too long and, with the ongoing credit crisis, is currently unachievable.
* In spring 2008, after seeing the clinical data on Bapineuzumab, your CEO signaled to investors that once these data were presented, the Company’s stock would trade well above $40 per share. Despite the reasonably positive data, the announcement and presentation of these results were so poorly handled that the stock price that day dropped to less than half, at $18 per share. Your CEO clearly does not know how to properly manage the disclosure of clinical data to the investment community.
* After your CEO and several of his Merrill Lynch colleagues were hired, he moved the Company’s headquarters to New York City, where they reside, simply for their convenience. This arrogant decision was recently reversed, only after numerous shareholder objections and a significant waste of shareholder money.
* The Company appears to continue to maintain the use of corporate jets for the CEO and Board, this being a completely inappropriate and excessive cost for an organization of Elan’s size. With Fortune 100 companies canceling their corporate jets, Elan has no place preserving them.
Beyond the financial excesses of the office of your CEO, which are particularly odious in the current environment, the lack of proper guidance on a management and Board level stands the chance to irreversibly destroy the remaining value of this Company.
Your CEO is now embarking on what could be his biggest mistake yet, hiring Citibank to review the Company’s strategic alternatives. With this decision, you, the CEO, and your fellow Board members have announced the limit of your ideas.
Now is NOT the time to put all or part of Elan up for sale. Your investors fear that, in acting from a position of weakness, your CEO will destroy even greater value:
* We fear that he will attempt to craft a partial sale of stock and/or pipeline products that will fall just below the threshold requiring shareholder approval, a vote he knows he would not receive.
* The sale of any Elan shares to a pharmaceutical company would not only dilute shareholders at a time when the stock is depressed, but would also greatly reduce the likelihood that other pharmaceutical companies may express interest in Elan in the future.
* Not only does the Company not have an immediate need to raise cash in the near-term, but investors lack the confidence that your CEO could negotiate a deal favorable to Elan, particularly at a depressed share price.
You have options:
* The Company’s $1.15 billion debt, due at the end of 2011, could be easily managed by reducing wasteful spending and insisting that Biogen fulfill its obligation to promote Tysabri with the same level of emphasis put on its own drug, Avonex. Elan’s general and administration expenses are running in excess of $300 million per year. For a biotech company, that today is essentially a research-based company, these expenses should be less than $100 million per year.
* The sale of the EDT drug-technology division should be revisited, starting now, in anticipation of a recovering credit market.
We realize that, at this point, your CEO may hope that any deal would save his job, but it will also surely limit the upside of all Elan shareholders and mark the evisceration of yet more long-term shareholder value. Instead, your CEO should focus on improving the marketing competency of Elan and reducing unessential expenses.
The Pfizer/Wyeth merger is a threat to Alzheimer patients and Elan, and this should be opposed by Elan:
* Pfizer currently has six Alzheimer drugs under development and one on the market, while Wyeth has four of Elan’s Alzheimer drugs and five Alzheimer drugs of its own in development. If this merger materializes, Pfizer will control 16 Alzheimer drugs, which represents a majority of all Alzheimer drugs currently in clinical development and on the market.
* In addition, Pfizer would control a great deal of the intellectual property in this area, creating a virtual monopoly for itself. If allowed to control all these drugs, Pfizer would undoubtedly be forced to determine which of these compounds would receive priority in clinical development and which would be slowed down. As a result, Pfizer would likely favor those drugs in which it holds a 100% interest rather than the Elan drugs in which it holds only a 50% interest. Once again, Elan would be in the same position with Pfizer as it is with Biogen.
* Ultimately, the biggest loser in this situation would be Alzheimer patients, along with their caregivers and physicians, who would have fewer treatment options available to them.
What plans does your CEO have to face this threat? Has the Company contacted the Federal Trade Commission regarding this matter? Can your shareholders trust the management team to properly handle this issue when they have little to no experience?
Three weeks ago, at my request, you assisted in arranging a meeting between seven of Elan’s largest shareholders, who represent 37% of the Company’s outstanding shares, and two of your Directors, Bill Rohn and Gary Kennedy. Formerly a Chief Operating Officer at IDEC and the only Director with previous pharmaceutical marketing experience, Mr. Rohn’s participation in the meeting was encouraging as we felt that our concerns were heard and taken into consideration. He clearly heard our views opposing the sale of any shares of Elan to a pharmaceutical company at this time, as well as our insistence that the Company’s management and Board be strengthened. He agreed to discuss our concerns with the entire Elan Board of Directors, and respond to us immediately after the next Board meeting. In addition, we requested that Mr. Rohn consider becoming Chairman of the Elan Board.
More than ten days have passed since this meeting took place. Most of the other shareholders at the meeting, including myself, still have not received any verbal feedback from Mr. Rohn, nor from any other member of the Elan Board. Indeed, it took until February 6 to obtain any response, and the brief letter I received is more an attempt to avert further publicity of shareholder concerns than an effort to address them. Worse yet, the points made in the letter of Messrs. Rohn and Kennedy mischaracterize these concerns and ignore two critical issues: the sale of Elan stock to a pharmaceutical and your CEO’s poor performance. This letter so clearly fails to reflect the goodwill Mr. Rohn expressed at our January meeting that I seriously doubt he could have been one of its author. It seems to add weight to my fear that the Board has been hand chosen by your CEO simply to preserve his position and silence dissenting views.
Mr. McLaughlin, you must acknowledge and respond honestly to the urgency expressed privately and publicly by the majority of your largest shareholders. We have remained long-standing owners of Elan shares because we have faith in your scientists and the drugs they are developing, and would very much like for Elan to succeed in the long-term. Our concern is that you allow this failed strategy to continue out of loyalty to your CEO rather than exercising your fiduciary duty to Elan shareholders and its employees, whose interests you are responsible for upholding.
Again, we ask that you quickly add two qualified Directors with relevant pharmaceutical marketing expertise to the Elan Board to help guide the Company through this challenging period. We ask that these individuals be truly outstanding leaders in industry and not just yes-men. We are aware that you are currently considering an executive, who has contacted us for our endorsement. He is not the sort of individual Elan’s Board needs at this time and we will ask him to withdraw his candidacy. If you nominate individuals that will take an active role in monitoring the Company, that are near the same level of experience as those individuals we suggested to you in August, we will enthusiastically endorse them. If you choose individuals of lesser qualification to serve an ulterior motive, we will vigorously oppose them.
Please take advantage of our offer of support to prevent any further loss of value to the Company. A protracted public battle with your shareholders is of benefit to no one, as is a further escalation of this dispute.
Sincerely,
Jack W. Schuler
Crabtree Partners
Print | Close this window
Elan close to stake sale-FT
Sun Feb 8, 2009 8:32pm EST
NEW YORK, Feb 8 (Reuters) - Elan Corp Plc (ELN.I: Quote, Profile, Research, Stock Buzz) is close to selling a 19-25 percent stake in the drug company, Chairman Kyran McLaughlin told the Financial Times.
According to an article on the FT's website on Sunday, McLaughlin said Elan would likely sell the stake within 10 weeks. He said there were "certainly half a dozen" interested buyers, the article said.
Elan, Ireland's top drugmaker, hired Citigroup in January to conduct a strategic review that could lead to a sale or merger of the company. (Reporting by Michael Erman, Editing by Ian Geoghegan)
Elan close to stake sale-FT
Sun Feb 8, 2009 8:32pm EST
NEW YORK, Feb 8 (Reuters) - Elan Corp Plc (ELN.I: Quote, Profile, Research, Stock Buzz) is close to selling a 19-25 percent stake in the drug company, Chairman Kyran McLaughlin told the Financial Times.
According to an article on the FT's website on Sunday, McLaughlin said Elan would likely sell the stake within 10 weeks. He said there were "certainly half a dozen" interested buyers, the article said.
Elan, Ireland's top drugmaker, hired Citigroup in January to conduct a strategic review that could lead to a sale or merger of the company. (Reporting by Michael Erman, Editing by Ian Geoghegan)
Wie heute bei Elan nachzulesen ist,
scheint Tysabri mehr und mehr eine Erfogsgeschichte zu werden.
Im 2.Jahr der Einnahme wirkt es besser noch als im ersten.
Welche Aussichten!
Das wird sich bei Ärzten und Patienten rumsprechen.
Da wird selbst der Ceo nichts dran ändern können.
posimist
scheint Tysabri mehr und mehr eine Erfogsgeschichte zu werden.
Im 2.Jahr der Einnahme wirkt es besser noch als im ersten.
Welche Aussichten!
Das wird sich bei Ärzten und Patienten rumsprechen.
Da wird selbst der Ceo nichts dran ändern können.
posimist
H A L L O-----was sagt Ihr zu dem Schuller Brief und der Verkaufsabsicht von 19% von Elan durch Elan??????????????????Élan (ELN) is considering selling a 19% stake to Switzerland’s Roche (RHHBY.PK), which would give it international rights to some of its drugs. Élan is due to report tomorrow.
Antwort auf Beitrag Nr.: 36.544.458 von Birgit.Tersteegen am 09.02.09 20:28:08das kann ich nicht so ganz nachvollziehen. 
Élan (ELN) is considering selling a 19% stake to Switzerland’s Roche (RHHBY.PK), which would give it international rights to some of its drugs. Élan is due to report tomorrow.
welche sind gemeint?
will elan einer übernahme entgegenwirken?
Élan (ELN) is considering selling a 19% stake to Switzerland’s Roche (RHHBY.PK), which would give it international rights to some of its drugs. Élan is due to report tomorrow.
welche sind gemeint?
will elan einer übernahme entgegenwirken?
Antwort auf Beitrag Nr.: 36.544.619 von GuHu1 am 09.02.09 20:52:32Elan will 19% der eigenen Firma verkaufen um die Schulden abzulösen---wahrscheinlich an Roche...
Ich finde,die spinnen.Bei diesem Kurs und mit dem Verwässeungseffekt....lies mal den Schuler Brief. Grüsse B.
Ich finde,die spinnen.Bei diesem Kurs und mit dem Verwässeungseffekt....lies mal den Schuler Brief. Grüsse B.
oh Gott..........article: Elan Chairman: “We’re Qualified to Run This Drug Company Because We’re Irish”
http://industry.bnet.com/pharma/1000915/elan-chairman-were-q…
Elan Chairman: “We’re Qualified to Run This Drug Company Because We’re Irish”
By Jim Edwards | February 9th, 2009 @ 10:43 am
Angry investor Jack Schuler is firing at Elan once again. The FT reports he’s trying to block the sale of 19-25 percent of the company to outside investors. Roche is reportedly interested. Instead, Schuler wants Elan’s management replaced with people who actually have experience in commercializing drugs.
In response, Elan’s management claim that they’re perfectly qualified and should stay in place because they’re Irish. I am not making this up.
First, the back story …
This is the latest salvo in an entertaining soap opera. Back in December, Schuler sent an amusing letter to Elan’s management, blasting them for:
“Lack of relevant industry experience, gross incompetence related to the management of Tysabri and its partnership with Biogen, and egregious misuse of company resources have caused investors to lose confidence in [CEO] Mr. [Kelly] Martin and his management team.”
Among other things, Schuler highlighted:
* Elan’s management inexperience (”What was the board thinking when they chose a Merrill Lynch employee to be the CEO of Elan? … As I look at Elan’s top ten executives, I do not see anyone with any pharmaceutical marketing experience.”)
* Its use of corporate jets (”… the company provides the CEO access to corporate jets, some of which are the largest and most expensive. For your CEO to fly from his home to the heart of the company in San Francisco would cost between $100,000 and $150,000 depending on the plane he chooses.”)
* And the fact that the management team is located in a bunch of different cities on different continents.
Elan made some compromises for Schuler, and agreed to put two new directors on the board. But Schuler thinks that isn’t enough. The FT:
They [Schuler et al] are concerned that a plan being mooted to sell a 19 per cent stake of Elan to a big pharmaceutical company would restrict the company’s future growth.
… “Elan is a great company that has terrific lifesaving drugs but a management entrenched in arrogance,” said Mr Schuler, who over the weekend dismissed the directors’ reply as inadequate. “They are trying to defend the indefensible. They should have appointed commercial people two years ago.”
Perhaps the best part of the FT’s story is buried near the bottom. It’s chairman Kyran McLaughlin’s explanation of why he and CEO Kelly Martin are the right men for the job. It’s their Irishness, it turns out. The FT:
He had no plans to step down as chairman, adding Elan needed an Irish chairman or chief executive for tax and regulatory purposes. “If there was a remote whisper around the board for me to go, I’d be gone,” he said. “The people who are unhappy are a small minority.”
..........article: Elan Chairman: “We’re Qualified to Run This Drug Company Because We’re Irish”http://industry.bnet.com/pharma/1000915/elan-chairman-were-q…
Elan Chairman: “We’re Qualified to Run This Drug Company Because We’re Irish”
By Jim Edwards | February 9th, 2009 @ 10:43 am
Angry investor Jack Schuler is firing at Elan once again. The FT reports he’s trying to block the sale of 19-25 percent of the company to outside investors. Roche is reportedly interested. Instead, Schuler wants Elan’s management replaced with people who actually have experience in commercializing drugs.
In response, Elan’s management claim that they’re perfectly qualified and should stay in place because they’re Irish. I am not making this up.
First, the back story …
This is the latest salvo in an entertaining soap opera. Back in December, Schuler sent an amusing letter to Elan’s management, blasting them for:
“Lack of relevant industry experience, gross incompetence related to the management of Tysabri and its partnership with Biogen, and egregious misuse of company resources have caused investors to lose confidence in [CEO] Mr. [Kelly] Martin and his management team.”
Among other things, Schuler highlighted:
* Elan’s management inexperience (”What was the board thinking when they chose a Merrill Lynch employee to be the CEO of Elan? … As I look at Elan’s top ten executives, I do not see anyone with any pharmaceutical marketing experience.”)
* Its use of corporate jets (”… the company provides the CEO access to corporate jets, some of which are the largest and most expensive. For your CEO to fly from his home to the heart of the company in San Francisco would cost between $100,000 and $150,000 depending on the plane he chooses.”)
* And the fact that the management team is located in a bunch of different cities on different continents.
Elan made some compromises for Schuler, and agreed to put two new directors on the board. But Schuler thinks that isn’t enough. The FT:
They [Schuler et al] are concerned that a plan being mooted to sell a 19 per cent stake of Elan to a big pharmaceutical company would restrict the company’s future growth.
… “Elan is a great company that has terrific lifesaving drugs but a management entrenched in arrogance,” said Mr Schuler, who over the weekend dismissed the directors’ reply as inadequate. “They are trying to defend the indefensible. They should have appointed commercial people two years ago.”
Perhaps the best part of the FT’s story is buried near the bottom. It’s chairman Kyran McLaughlin’s explanation of why he and CEO Kelly Martin are the right men for the job. It’s their Irishness, it turns out. The FT:
He had no plans to step down as chairman, adding Elan needed an Irish chairman or chief executive for tax and regulatory purposes. “If there was a remote whisper around the board for me to go, I’d be gone,” he said. “The people who are unhappy are a small minority.”
Elan Reports Fourth Quarter and Full-Year 2008 Results
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc, today reported its fourth quarter and full-year 2008 results, highlighted by a 32% increase in full-year 2008 revenue to $1.0 billion, compared to $759.4 million for the same period in 2007, and significant advances in the Company’s biopharmaceutical and drug technology business units.
Elan chief executive officer Kelly Martin said that in 2008 Elan made tangible, measurable progress in moving the company forward, noting, “Financial results improved, clinical programs advanced within our therapeutic areas, our science and discovery programs continued to progress, and we had growth in both of our business units—Biopharmaceuticals and Elan Drug Technologies.” Mr. Martin added that Elan remains committed to building the leading neuroscience-based biopharmaceutical company in the world, complementing its already-leading drug technology venture. “Our focus on science and patients has never been greater,” Mr. Martin said, “and we are committed to demonstrating further progress in 2009.”
Elan executive vice president and chief financial officer Shane Cooke said that the Company was pleased to have met or exceeded all of its financial targets for 2008. Mr. Cooke said that revenues grew by more than 32% to $1.0 billion, led by a solid performance from Tysabri. Combined with improved operating margins and strong cost management, this led to the Company reporting positive Adjusted EBITDA for the full-year 2008, which is earlier than previously guided. At the end of 2008, cash and investments stood at almost $450 million, ahead of the $300 million to $400 million guided in February 2008. The net loss for the year decreased by 82% to $71.0 million as a result of improved operating performance; the recognition of a deferred tax asset of $236.6 million in 2008 as a result of the group’s U.S.-based operations turning profitable; and the inclusion of an impairment charge of $52.2 million in 2007.
Mr. Cooke added, “For 2009, we will continue to focus on reducing our cash burn, derisking our balance sheet and advancing our pipeline.” Mr. Cooke also noted that Elan had announced last month that it had initiated a review of its strategic alternatives, the goal of which is to secure access to financial resources and commercial infrastructure that would enable Elan to accelerate the development and commercialization of its extensive pipeline and product portfolio while maximizing the ability of its shareholders to participate in the resulting longer-term value creation.
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc, today reported its fourth quarter and full-year 2008 results, highlighted by a 32% increase in full-year 2008 revenue to $1.0 billion, compared to $759.4 million for the same period in 2007, and significant advances in the Company’s biopharmaceutical and drug technology business units.
Elan chief executive officer Kelly Martin said that in 2008 Elan made tangible, measurable progress in moving the company forward, noting, “Financial results improved, clinical programs advanced within our therapeutic areas, our science and discovery programs continued to progress, and we had growth in both of our business units—Biopharmaceuticals and Elan Drug Technologies.” Mr. Martin added that Elan remains committed to building the leading neuroscience-based biopharmaceutical company in the world, complementing its already-leading drug technology venture. “Our focus on science and patients has never been greater,” Mr. Martin said, “and we are committed to demonstrating further progress in 2009.”
Elan executive vice president and chief financial officer Shane Cooke said that the Company was pleased to have met or exceeded all of its financial targets for 2008. Mr. Cooke said that revenues grew by more than 32% to $1.0 billion, led by a solid performance from Tysabri. Combined with improved operating margins and strong cost management, this led to the Company reporting positive Adjusted EBITDA for the full-year 2008, which is earlier than previously guided. At the end of 2008, cash and investments stood at almost $450 million, ahead of the $300 million to $400 million guided in February 2008. The net loss for the year decreased by 82% to $71.0 million as a result of improved operating performance; the recognition of a deferred tax asset of $236.6 million in 2008 as a result of the group’s U.S.-based operations turning profitable; and the inclusion of an impairment charge of $52.2 million in 2007.
Mr. Cooke added, “For 2009, we will continue to focus on reducing our cash burn, derisking our balance sheet and advancing our pipeline.” Mr. Cooke also noted that Elan had announced last month that it had initiated a review of its strategic alternatives, the goal of which is to secure access to financial resources and commercial infrastructure that would enable Elan to accelerate the development and commercialization of its extensive pipeline and product portfolio while maximizing the ability of its shareholders to participate in the resulting longer-term value creation.
Elan Swings To Fourth-Quarter Profit
Elan Corp.(ELN Quote - Cramer on ELN - Stock Picks) swung to a profit of $169.5 million, or 36 cents a share, from a year-earlier loss of $83.5 million, or 18 cents a share, as it saw "significant advances" in its biopharmaceutical and drug technology business units.
Revenue in the quarter rose 19% to $269.8 million.
For 2008, Elan reported a loss of $71 million, or 15 cents a share, on revenue of $1 billion, compared with a loss in 2007 of $405 million, or 86 cents a share, on revenue of $759.4 million.
In a statement Tuesday, Elan said a 51% increase in revenue in 2008 in its biopharmaceuticals business was driven by a strong performance from Tysabri, a multiple sclerosis drug, which more than offset reduced sales of Maxipime following the introduction of generic competition in 2007. Elan's recorded sales of Tysabri increased
140% to $557.1 million in 2008 from $231.7 million in 2007. Tysabri is co-marketed with Biogen Idec(BIIB Quote - Cramer on BIIB - Stock Picks).
"Financial results improved, clinical programs advanced within our therapeutic areas, our science and discovery programs continued to progress, and we had growth in both of our business units -- biopharmaceuticals and Elan drug technologies," said Elan CEO Kelly Martin.
Elan said it expects 2009 revenue to grow by double-digit percentages.
Elan Corp.(ELN Quote - Cramer on ELN - Stock Picks) swung to a profit of $169.5 million, or 36 cents a share, from a year-earlier loss of $83.5 million, or 18 cents a share, as it saw "significant advances" in its biopharmaceutical and drug technology business units.
Revenue in the quarter rose 19% to $269.8 million.
For 2008, Elan reported a loss of $71 million, or 15 cents a share, on revenue of $1 billion, compared with a loss in 2007 of $405 million, or 86 cents a share, on revenue of $759.4 million.
In a statement Tuesday, Elan said a 51% increase in revenue in 2008 in its biopharmaceuticals business was driven by a strong performance from Tysabri, a multiple sclerosis drug, which more than offset reduced sales of Maxipime following the introduction of generic competition in 2007. Elan's recorded sales of Tysabri increased
140% to $557.1 million in 2008 from $231.7 million in 2007. Tysabri is co-marketed with Biogen Idec(BIIB Quote - Cramer on BIIB - Stock Picks).
"Financial results improved, clinical programs advanced within our therapeutic areas, our science and discovery programs continued to progress, and we had growth in both of our business units -- biopharmaceuticals and Elan drug technologies," said Elan CEO Kelly Martin.
Elan said it expects 2009 revenue to grow by double-digit percentages.
finanzen.net
Elan verbucht Ergebnisplus im vierten Quartal
Dienstag 10. Februar 2009, 10:13 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) konnte im vierten Quartal einen Umsatz- und Ergebnisanstieg vorweisen.
Wie der Konzern am Dienstag erklärte, lag der Gesamtumsatz im Berichtszeitraum bei 269,8 Mio. Dollar, nach 218,3 Mio. Dollar im Vorjahreszeitraum. Der Vorsteuerverlust reduzierte sich im Vorjahresvergleich von 79,8 Mio. Dollar auf 64,5 Mio. Dollar. Dank eines positiven Steuereffekts verbuchte Elan (Dublin: DRX.IR - Nachrichten) im Berichtszeitraum einen Nettogewinn von 169,5 Mio. Dollar, nach einem Nettoverlust von 83,5 Mio. Dollar im Vorjahreszeitraum.
Für 2009 plant Elan einen Umsatzanstieg im zweistelligen Prozentbereich. Die Bruttomarge soll im Bereich von 45 bis 50 Prozent liegen. Das um Einmaleffekte bereinigte EBITDA soll im Gesamtjahr 2009 ein positives Ergebnis erreichen. Dabei geht der Konzern von einer weiterhin positiven Absatzentwicklung beim Multiple Sklerose-Medikament Tsybari aus.
Die Aktie von Elan gewinnt aktuell an der Heimatbörse 4,26 Prozent auf 6,37 Euro. (10.02.2009/ac/n/a)
http://de.biz.yahoo.com/10022009/85/elan-verbucht-ergebnispl…
Elan verbucht Ergebnisplus im vierten Quartal
Dienstag 10. Februar 2009, 10:13 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) konnte im vierten Quartal einen Umsatz- und Ergebnisanstieg vorweisen.
Wie der Konzern am Dienstag erklärte, lag der Gesamtumsatz im Berichtszeitraum bei 269,8 Mio. Dollar, nach 218,3 Mio. Dollar im Vorjahreszeitraum. Der Vorsteuerverlust reduzierte sich im Vorjahresvergleich von 79,8 Mio. Dollar auf 64,5 Mio. Dollar. Dank eines positiven Steuereffekts verbuchte Elan (Dublin: DRX.IR - Nachrichten) im Berichtszeitraum einen Nettogewinn von 169,5 Mio. Dollar, nach einem Nettoverlust von 83,5 Mio. Dollar im Vorjahreszeitraum.
Für 2009 plant Elan einen Umsatzanstieg im zweistelligen Prozentbereich. Die Bruttomarge soll im Bereich von 45 bis 50 Prozent liegen. Das um Einmaleffekte bereinigte EBITDA soll im Gesamtjahr 2009 ein positives Ergebnis erreichen. Dabei geht der Konzern von einer weiterhin positiven Absatzentwicklung beim Multiple Sklerose-Medikament Tsybari aus.
Die Aktie von Elan gewinnt aktuell an der Heimatbörse 4,26 Prozent auf 6,37 Euro. (10.02.2009/ac/n/a)
http://de.biz.yahoo.com/10022009/85/elan-verbucht-ergebnispl…
Jetzt Conference Call---anmelden auf der Website www.elan.com.
Unfiltered NOtes from ELN 4Q2008 Earnings CC
* Welcome to 4Q2008 earnings CC
* Hope reviewed PR
* KM, Carlos Paya, Shane Cooke
* Fin results, R&D, update
* Safe harbor
* KM
* Welcome on behalf of Kieran McLaughlin and myself
* Appreciate hear our results, 50 companies rpting today
* Brief statement
* First, re 2008, focus was and remains in 3 broad areas
* 1st and foremost fin progress, Shane review, pleased w/progress in 2008 and look forward to 2009
* Pipeline strt focus, biopharma and EDT
* Subst progress mult platforms, thera areas, CP in a few minutes
* People, added dozens of skilled professionals across company
* 4Q2008 additions, M. Stutz and Carlos Paya, President
* Anticipate progress from fin PoV, across all pipeline and people, add selectively as needed basis across company
* Full yr results clal
* Shane Cooke review accomplishments in 2008
* Review fin perf in 2008 vs 2007 and to guidance for 2008 this time last yr, outline expectation 2009, operrataing and liquidity, strat evaluation
* Metrics Tysabri as end of 2008, same as Biogen last week
* In Appendix 1, 2 divisions biopharma and EdT
* Pleased in 2008 met or exceeded all fin targets in challenging global and directly our business
* 1B rev, over 30% growth, T main factor
* Strong op margins, positive EBITDA 4Q2008 and FY2008
* Got here earlier than guided
* Cash and investments 449M, vs guided 300-350M
* Tysabri growth pos
* Replaces loss of Maxipime sale due to generics
* Slower growth in Tysabri, still double digit griwthm pos EBITDA in 2009
* Lower SG&A expenses
* 2008 vs 2006, rve doubled, SG&A down 20%
* SG&A 617M lower than 625-675M guided
* Continue to rigorously manage costs
* SG&A+R&D 625-675M
* Op profit 219.4M, nearly 3x 2007
* 233M improvement in 2 yrs
* Net loss decr 82%, to 71M, incl 52M impairment in 2007, deferred asset recognition as US ops turned profit
* In excess 3B NOL, 600M avail in US, 2.5B in Ireland
* Irish co, US became prof
* US tax losses reduced
* 237M estimated reduced taxes ti use NOL, write off asset as use up
* Once used up, pay tax in mid-teens
* As closer to profitability, strat adv re tax rate, op lev
* In 2009, focus on decr cash burn, B/S mgt
* Manage capex
* Expect adj EBITDA pos
* Expect 1H2009 neg, then pos
* Expect end 2009 cash and investments 200M
* Last 18M explored diff opps to derisk and supplement bus re pipeline and prods
* In 2008 explored selling sign interest in EDT, derisk B/S
* Strong interest from PE firms, but dislocation of credit mkts caused to fail
* Strong C/F from bus
* # of industry players interested in participating w/us
* TO add competitive tension and, hired Citi re start alternatives
* Comm infrastructure and capital resources to help pipeline, prods,
* # of potential outcomes
* Goal very clear
* Not appropriate to further describe until complete
* Pleased w/process
* 26.7M adj EBITDA 4Q2008, 165.5M income
* Incl of 237M tax gain offset by charges re restructuring if T in CD
* Excellent progress, rve gre 32% to 1B, soild growth of T, 37K on Tx
* EBITDA profit 4M, less than 50M losses guided
* Global inmkt 216M T, recorded
* 9% decr from 237M in 3Q2008
* End of 2008, 37K on Tx in commercial setting, 2300 incr, incr 6%
* # patients incr, rve fell due to f/x, # shipping days
* $ strengthened, 1.50 to 1.3, reduced 15M from f/x
* EBITDA minimal due to natural hedge of Euro expenses
* 813M in 2008 for T almost double
* 557M rpted by ELN, incr 140% YoY
* Rate of growth moderated from 3600 to 2300 in 4Q2008, stabilized
* Incr discont, decr rate of prescribing
* Believe 100K target appr, but likely longer than 2010
* 1 of every 5 or 6 ABCR or quitters on T, reasonable target, profound efficacy, 2/3 decr in relapsed
* US 50% incr YoY, FY2008 421.6M almost double in US
* Ex-US, approved in 40 countries, 16.9K on Tx, 101.7M in qtr almost double, ex-US recorded 37.6M, our share of prift+royalties
* FY2008 in mkt ex-US, 125M to 391.4M in 2008
* More than 48K Tx, 20K at least 1 yr, 10.7K 18M or longer, 4.3K over 2 yrs
* Focus 2009
* Better understanding re PML, those most at risk, better diagnostic tools, and better tools to Tx PML
* As understand better risk/reward in debil disease
* Other pharma prods
* Generic Maxipime,decr from 15.8M to 3.1 in 4Q2008, down 80% FY
* Exactam supply issues, 12% ahead 96.9M FY2008
* EDT, 4Q2008 up 14% 89.2M, EBITDA up 40%+
* Strng revs, incr in shipments
* Cost containment, reduced litigation costs
* Over 20 prods
* Rev can vary based on # of factors, timing of orders, shipment
* EDT FY2008 EBITDA 130M vs 126.7M
* EDT potential for strong growth over next 5 yrs
* Some near end of prod cycle
* More than replaced by robust pipeline
* EDT signif progress in pipeline
* Notable devs, ACOR compl P III and NDA filing for Fampridine SR
* If appr, EDT M/F in Athlone
* J&J submitted paliperidone palmitate from approvable latter, nano, not M/F, but royalties
* MAP compl recruitment re asthma in children P III
* EDT extensive patent estate, imp element
* Jun2008 jury ruled Abraxis infringed nano re Abraxane, 55M aware
* Abraxis challenge ruling
* 2009 move EDT forward, expect EBITDA to decline due to generics or next gen like Abbot’s tri-
* Less than 3% incr SG&A+R&D
* 2009 expect SG&A and R&S 625-675M
* Expect R&D over 50%, fund late stage trials, part AD trials P III
* SG&A decr % of that total
* In 2009 SG&A les sthan 2008 269M
* Rigorously manage costs
* Reduced from 363.1M to 289M in 2 yrs with rev incr 80%
* Incr R&D 2006 to 328Min 2008
* 11 trials in autoimmune, neurodegen
* Adj priorities to adv pipeline
* A few ocmments re liquidity
* Approx 450M cash and incv, next debt maturity end of 2011, no revolving credit
* Cash in ST treasures and ST bank deposits
* Target end 2009 200M, after paying last 50M milestone to Biogen, paid last month
* Very challenging backdrop, look forward w/enthusiasm and optimism
* Reduce cash burn, derisk B/S, progress pipeline
* Carlos Paya
* 1st quarterly call, biopharma pipeline
* Very active on mult fronts
* Tysabri shared w/Biogen, growth cont at moderate rate, 2300 in 4Q2008, 37K on Tx
* Interpr of moderation due to few cases of PML, inbal in risk/benefit of unique features
* 2 reasons expect to accel growth of T, refocus communication on T subst efficacy docs and patients, increase docs comfort to diagnose and treat PML
* Lancet LT data, retro from P III AFFIRM study, 37% free of MS ovcer 2 yrs, 58% free of radiologic
* Incr communications re unique features
* Focus efforts re PML ed
* Clin tudy in Jounral of Am Neurology, plasmapheresis, clear T
* Several initiatives, early stages improve diagn and Tx, make PML manageable side effect and avoidable
* P I/II T in MM
* For CD, in Dec2008 adv in inflamm diseases, impr QoL for anti-TNF failures
* AD programs
* P II data for Bap submitted for peer review
* PET PBI later this qtr
* Manage P III N Am Bap trials
* Fully enrolled APOE4 carriers, cont to enroll non-carriers
* Wyeth good progress ex-US
* Sub-Q in Bap dosing in P II
* Inject weekly, enroll 120 patients
* May add convenience, geo opps
* Active immunization, ACC-001, P II n=240 continues
* Have back-up compounds, AIL
* ELND-005 oral, P II w/Transition, enrolled 240 patients, may move to early AD
* Gamma secretase in P I safety study, have follow-up compounds
* 4 P III Bap, ACC-001, ELND-005 P II
* Early P I addit 5 trials ELND-006, ELND-004 small mol VLA 4 UC, CD, ELND-002 hema malign, pot SBMS
* Very excited novel science, improve lives of patients
* Thank you
* Q&A
* Q1: Corey Davis, Natixis
* First, Carlos, 30 patient AD study in Europe, breakdown carrier and non-carrier, if P II small #s, pot inconclusive.
* A1: Believe no segmentation re carrier status, get back to you re dosing.
* Q2: # stabilized re T adds, is it 177 per 4Q?
* A2: Yes,in that region.
* Q3: What restrictions, new cost containment re moving early pipeline like ELND-005, gamma secretase?
* A3: Really support and sustain, maybe even further that which is core, ELND-005 is, anything neuroregen.
* Q4: Ian Sanderson, Cowen
* Follow-up on Corey’s Q re pipeline. Break out R&D, likely incr in 2009. Second, provide more color on patient enrollment for APOE4 non-carriers, enhanced tactics. Still expect cpmpl in 1H2009.
* A4: KM: SC respond to 1st half, then CP. SC: R&D spend, 40-50M re EDT, 120-140M re immuneTx, rest re Tysabri research and other programs. Large part of incr related to immuneTx advances and enrollment, 4 P III Bap trials. KM: For ELND-005, if have more data review and have opp to make decision re program whether stay in P II or add P III, it is dynamic, use budget to guide us, but dynamic Presume asking for non-carrier enrollment. CP: Did finish carrier enrollment, fact that non-carrier different speed. # non-carrier in clin setting is lower than carrier. Second higher attrition in screening. Re dates, premature to say. Last 2-3M, enh recruitment speed. Closer to end of 1Q2009, say more, # 1 focus.
* Q5: Ian Hunter, Goodbody’s
* Plans for CD franchise re Tysabri w/SF rationalization?
* A5: CP: Net growth in CD not slowed down, very few wks of data, signif effort, proactive re med liaison and med ed. Continue to do that. Addit clarity around PML, then re-engage more aggr.
* Q6: Re guidance, double digit percentage rev growth, low to mid teens, any other ways to cut costs or as efficient as can be? Addit pipeline devs, contained due to cost mgt?
* A6: SC: Double digit means >10%, see where we go, Tysabri big pt of that, see how well reaccel growth. Re costs, continuously look at how to manage. Succ reducing SG&A, look for other reductions. Look at R&D and how structured to see where reduce costs, but reinvest saving in pipeline, adv as quickly as can. CP: Compliment mgt re progress, great opp to be more flexible, nimble, focus on core activities. Deep review, biopharma setting, make appr changes going forward.
* Q7: Hon Lee, Stanford Group
* Color re Tysabri holiday, talked last earnings CC?
* A7: SC: Hard for us to get to firm conclusions re drug holidays. Have a lot of data in US from TOUCH re # infusions, track w/patients, some anecdotal data some drug holidays, better data over time. More diff in EU. CP: Diff to measure, docs have in mind re LT Tx, help to get info.
* Q8: Stopped mkting CD in 4Q2008, contr to sales decline?
* A8: No
* Q9: EBITDA profitability in 2009, give shares?
* A9: SC: Make around rev growth, costs, how manage to get to 200M balance at YE2009. Where end up EBITDA, depends how well reaccel Tysabri sales. Have lots of leverage, 10M new sales, 4M op profit. Shares outstanding 475M basic, maybe 20M more fully diluted.
* Q10: Rich Silver, Barclay’s
* EDT business and generic competition, when expect rev return to 2008 rate w/incr rev from new prods?
* A10: SC: Depends when generic comp arrives, sometimes earlier, sometimes later, in a couple yrs out at same levels or higher. Depends on approval of prods in pipelines and succ of launches.
* Q11: Potential impact re PFE acq of WYE? Impact on Bap.
* A11: Not privy before, but now communicated, work to aggr move forward on Bap, AIP.
* Q12: Bill Tanner, Leerink Swann
* Strategic review, possible to rank order, provide liquidity need. Two most valuable assets, one is Tysabri. Does repr fair value? Any thought re EDT revisit? A lot of chatter, needing shareholder approval?
* A12: KM: Give broad answer, in Jan2009 announced strategic review, hire advisor, multiple goals, given mkt condition lots going on. Lots of activity going on, from ELN persp, enormous progress operationally and adv science, fantastic prospective opps, grow in depth and #. 2 main objs of strat transaction, one, derisk B/S and fin construct, due to mult of sci opps, abundance of opps to move forward. In inetrmed to LT, participate in signif value creation if sci can be progr. From sci PoV, goal to be very focused on what best at. Deep unique sci, deep clin knowledge, want to invest aggr. Some participation commercially. If look at AD, 10x size of MS mkt, 140 countries around world, infrastructure subst, has to be far and wide, avail sooner than later. Pleased w/interest. Keep going thru process, allow umbrella, us, to talk w/# of players, walk thru process w/advisor come back to us, BOD w/options. Lots of parts to your Q, hope positioned way helpful to you.
* Q13: Any initiatives req s/h vote?
* A13: KM: Absolutely, some types of transactions req s/h vote, some don’t. Premature until know options. Like any public company, diff levels of appr reqd.
* Q14: Annie Change, Bryant Garnier
* Tysabri Q, perception of PML risk., mgt re docs. What are you telling them, not just #s but outcomes. What kind of communications re outcome of PML?
* A14: CP: Our group internally, discuss w/Biogen, PML used to be fatal disease, esp w/HIV positive or transplantations. Can remove Tysabri (like other drugs), remove quickly, lead to less mortality. Only 1 of 5 w/PML died. Once remove immunosuppr, could get IRIS, rebound, looking at best mgt. Trying to figure out. Lots of thought going on. Get more aggr, PRP, even though PML lower than label incidence, make PML manageable disease.
* Q15: Jack Gorman, Davy’s
* First, Tysabri in oncology, MM, timelines re study? Re communicating T message and broader message, give color what hear at AAN2009? Broader Q, KM, housekeeping re strat revew, original partnering plan of300-500M superceded?
* A15: KM: SC outlined, everything under one umbrella, frankly easier for us, one process, one of major intents. Other Q more directed to CP.
* CP: Re MM, shared publicly, started in Sep2008, enrolling trial, provide addit timing down the line. #1 focus communication re PML, workw/Biogen, not sure what appr focus. Add to Corey’s P II PIB PET study, trial is ascending dose 3 up to 4 doses, no segmentation re genotype.
* Q16: Vincent Meunier, BNP Paribas
* Tysabri pricing trends US and ROW? Bap recruitment, any idea, potential pace US vs ROW? Guidance 200M cash and inv YE2009, does this include milestone payments apparently paid to Biogen?
* A16: SC: 200M includes 50M paid to Biogen in Jan2009. Pricing ex-US set at launch, doesn’t change. However, f/x can impact, charge in euro, rpt in US. In US 3% price incr beg of 2009. CP: Bap, aggr pursue non-carrier enrollment. Good progress, indiv countries ex-US, P II data, imp re P III, WYE shared at JPM, signif progress, all but 1 country agreed to continue enrollment of P III. Expect signif ramp of ex-US enrollment.
* Q17: Fair if enrollment completed in 2009, 18M Tx, expect launch in 2012?
* A17: Can’t give guidance now, 4 trials, see what strategy when to submit. If only 1, yes, but have 4.
* Q18: Scott Bardo, CS
* One Q is strategy, understand hesitant to comment, board members discussing. What are preferred options, selling more options to raise $, what component to pay off ST debt, what component re M/F for Bap?
* A18: KM: Preferred outcome find minority investor for ELN, if had global comm. I/S, would be attractive, many do, given pipeline. Preferred global player. What do w/cash is multiple things, premature to outline, depends on size and construct of investment. Have ability, unique in industry, to change breadth and depth of pipeline, given dearth of industry pipeline, good things. Drastic shift in Sep2008 given Lehman failure, changed macro view, mkt telling us that, derisk financially, strat also whether biological plants, EDT things to invest. Derisk and give R&D in biopharma and EDT more to invest in pipeline, bring prods forward.
* In concl thank everyone for joining us.
* Welcome to 4Q2008 earnings CC
* Hope reviewed PR
* KM, Carlos Paya, Shane Cooke
* Fin results, R&D, update
* Safe harbor
* KM
* Welcome on behalf of Kieran McLaughlin and myself
* Appreciate hear our results, 50 companies rpting today
* Brief statement
* First, re 2008, focus was and remains in 3 broad areas
* 1st and foremost fin progress, Shane review, pleased w/progress in 2008 and look forward to 2009
* Pipeline strt focus, biopharma and EDT
* Subst progress mult platforms, thera areas, CP in a few minutes
* People, added dozens of skilled professionals across company
* 4Q2008 additions, M. Stutz and Carlos Paya, President
* Anticipate progress from fin PoV, across all pipeline and people, add selectively as needed basis across company
* Full yr results clal
* Shane Cooke review accomplishments in 2008
* Review fin perf in 2008 vs 2007 and to guidance for 2008 this time last yr, outline expectation 2009, operrataing and liquidity, strat evaluation
* Metrics Tysabri as end of 2008, same as Biogen last week
* In Appendix 1, 2 divisions biopharma and EdT
* Pleased in 2008 met or exceeded all fin targets in challenging global and directly our business
* 1B rev, over 30% growth, T main factor
* Strong op margins, positive EBITDA 4Q2008 and FY2008
* Got here earlier than guided
* Cash and investments 449M, vs guided 300-350M
* Tysabri growth pos
* Replaces loss of Maxipime sale due to generics
* Slower growth in Tysabri, still double digit griwthm pos EBITDA in 2009
* Lower SG&A expenses
* 2008 vs 2006, rve doubled, SG&A down 20%
* SG&A 617M lower than 625-675M guided
* Continue to rigorously manage costs
* SG&A+R&D 625-675M
* Op profit 219.4M, nearly 3x 2007
* 233M improvement in 2 yrs
* Net loss decr 82%, to 71M, incl 52M impairment in 2007, deferred asset recognition as US ops turned profit
* In excess 3B NOL, 600M avail in US, 2.5B in Ireland
* Irish co, US became prof
* US tax losses reduced
* 237M estimated reduced taxes ti use NOL, write off asset as use up
* Once used up, pay tax in mid-teens
* As closer to profitability, strat adv re tax rate, op lev
* In 2009, focus on decr cash burn, B/S mgt
* Manage capex
* Expect adj EBITDA pos
* Expect 1H2009 neg, then pos
* Expect end 2009 cash and investments 200M
* Last 18M explored diff opps to derisk and supplement bus re pipeline and prods
* In 2008 explored selling sign interest in EDT, derisk B/S
* Strong interest from PE firms, but dislocation of credit mkts caused to fail
* Strong C/F from bus
* # of industry players interested in participating w/us
* TO add competitive tension and, hired Citi re start alternatives
* Comm infrastructure and capital resources to help pipeline, prods,
* # of potential outcomes
* Goal very clear
* Not appropriate to further describe until complete
* Pleased w/process
* 26.7M adj EBITDA 4Q2008, 165.5M income
* Incl of 237M tax gain offset by charges re restructuring if T in CD
* Excellent progress, rve gre 32% to 1B, soild growth of T, 37K on Tx
* EBITDA profit 4M, less than 50M losses guided
* Global inmkt 216M T, recorded
* 9% decr from 237M in 3Q2008
* End of 2008, 37K on Tx in commercial setting, 2300 incr, incr 6%
* # patients incr, rve fell due to f/x, # shipping days
* $ strengthened, 1.50 to 1.3, reduced 15M from f/x
* EBITDA minimal due to natural hedge of Euro expenses
* 813M in 2008 for T almost double
* 557M rpted by ELN, incr 140% YoY
* Rate of growth moderated from 3600 to 2300 in 4Q2008, stabilized
* Incr discont, decr rate of prescribing
* Believe 100K target appr, but likely longer than 2010
* 1 of every 5 or 6 ABCR or quitters on T, reasonable target, profound efficacy, 2/3 decr in relapsed
* US 50% incr YoY, FY2008 421.6M almost double in US
* Ex-US, approved in 40 countries, 16.9K on Tx, 101.7M in qtr almost double, ex-US recorded 37.6M, our share of prift+royalties
* FY2008 in mkt ex-US, 125M to 391.4M in 2008
* More than 48K Tx, 20K at least 1 yr, 10.7K 18M or longer, 4.3K over 2 yrs
* Focus 2009
* Better understanding re PML, those most at risk, better diagnostic tools, and better tools to Tx PML
* As understand better risk/reward in debil disease
* Other pharma prods
* Generic Maxipime,decr from 15.8M to 3.1 in 4Q2008, down 80% FY
* Exactam supply issues, 12% ahead 96.9M FY2008
* EDT, 4Q2008 up 14% 89.2M, EBITDA up 40%+
* Strng revs, incr in shipments
* Cost containment, reduced litigation costs
* Over 20 prods
* Rev can vary based on # of factors, timing of orders, shipment
* EDT FY2008 EBITDA 130M vs 126.7M
* EDT potential for strong growth over next 5 yrs
* Some near end of prod cycle
* More than replaced by robust pipeline
* EDT signif progress in pipeline
* Notable devs, ACOR compl P III and NDA filing for Fampridine SR
* If appr, EDT M/F in Athlone
* J&J submitted paliperidone palmitate from approvable latter, nano, not M/F, but royalties
* MAP compl recruitment re asthma in children P III
* EDT extensive patent estate, imp element
* Jun2008 jury ruled Abraxis infringed nano re Abraxane, 55M aware
* Abraxis challenge ruling
* 2009 move EDT forward, expect EBITDA to decline due to generics or next gen like Abbot’s tri-
* Less than 3% incr SG&A+R&D
* 2009 expect SG&A and R&S 625-675M
* Expect R&D over 50%, fund late stage trials, part AD trials P III
* SG&A decr % of that total
* In 2009 SG&A les sthan 2008 269M
* Rigorously manage costs
* Reduced from 363.1M to 289M in 2 yrs with rev incr 80%
* Incr R&D 2006 to 328Min 2008
* 11 trials in autoimmune, neurodegen
* Adj priorities to adv pipeline
* A few ocmments re liquidity
* Approx 450M cash and incv, next debt maturity end of 2011, no revolving credit
* Cash in ST treasures and ST bank deposits
* Target end 2009 200M, after paying last 50M milestone to Biogen, paid last month
* Very challenging backdrop, look forward w/enthusiasm and optimism
* Reduce cash burn, derisk B/S, progress pipeline
* Carlos Paya
* 1st quarterly call, biopharma pipeline
* Very active on mult fronts
* Tysabri shared w/Biogen, growth cont at moderate rate, 2300 in 4Q2008, 37K on Tx
* Interpr of moderation due to few cases of PML, inbal in risk/benefit of unique features
* 2 reasons expect to accel growth of T, refocus communication on T subst efficacy docs and patients, increase docs comfort to diagnose and treat PML
* Lancet LT data, retro from P III AFFIRM study, 37% free of MS ovcer 2 yrs, 58% free of radiologic
* Incr communications re unique features
* Focus efforts re PML ed
* Clin tudy in Jounral of Am Neurology, plasmapheresis, clear T
* Several initiatives, early stages improve diagn and Tx, make PML manageable side effect and avoidable
* P I/II T in MM
* For CD, in Dec2008 adv in inflamm diseases, impr QoL for anti-TNF failures
* AD programs
* P II data for Bap submitted for peer review
* PET PBI later this qtr
* Manage P III N Am Bap trials
* Fully enrolled APOE4 carriers, cont to enroll non-carriers
* Wyeth good progress ex-US
* Sub-Q in Bap dosing in P II
* Inject weekly, enroll 120 patients
* May add convenience, geo opps
* Active immunization, ACC-001, P II n=240 continues
* Have back-up compounds, AIL
* ELND-005 oral, P II w/Transition, enrolled 240 patients, may move to early AD
* Gamma secretase in P I safety study, have follow-up compounds
* 4 P III Bap, ACC-001, ELND-005 P II
* Early P I addit 5 trials ELND-006, ELND-004 small mol VLA 4 UC, CD, ELND-002 hema malign, pot SBMS
* Very excited novel science, improve lives of patients
* Thank you
* Q&A
* Q1: Corey Davis, Natixis
* First, Carlos, 30 patient AD study in Europe, breakdown carrier and non-carrier, if P II small #s, pot inconclusive.
* A1: Believe no segmentation re carrier status, get back to you re dosing.
* Q2: # stabilized re T adds, is it 177 per 4Q?
* A2: Yes,in that region.
* Q3: What restrictions, new cost containment re moving early pipeline like ELND-005, gamma secretase?
* A3: Really support and sustain, maybe even further that which is core, ELND-005 is, anything neuroregen.
* Q4: Ian Sanderson, Cowen
* Follow-up on Corey’s Q re pipeline. Break out R&D, likely incr in 2009. Second, provide more color on patient enrollment for APOE4 non-carriers, enhanced tactics. Still expect cpmpl in 1H2009.
* A4: KM: SC respond to 1st half, then CP. SC: R&D spend, 40-50M re EDT, 120-140M re immuneTx, rest re Tysabri research and other programs. Large part of incr related to immuneTx advances and enrollment, 4 P III Bap trials. KM: For ELND-005, if have more data review and have opp to make decision re program whether stay in P II or add P III, it is dynamic, use budget to guide us, but dynamic Presume asking for non-carrier enrollment. CP: Did finish carrier enrollment, fact that non-carrier different speed. # non-carrier in clin setting is lower than carrier. Second higher attrition in screening. Re dates, premature to say. Last 2-3M, enh recruitment speed. Closer to end of 1Q2009, say more, # 1 focus.
* Q5: Ian Hunter, Goodbody’s
* Plans for CD franchise re Tysabri w/SF rationalization?
* A5: CP: Net growth in CD not slowed down, very few wks of data, signif effort, proactive re med liaison and med ed. Continue to do that. Addit clarity around PML, then re-engage more aggr.
* Q6: Re guidance, double digit percentage rev growth, low to mid teens, any other ways to cut costs or as efficient as can be? Addit pipeline devs, contained due to cost mgt?
* A6: SC: Double digit means >10%, see where we go, Tysabri big pt of that, see how well reaccel growth. Re costs, continuously look at how to manage. Succ reducing SG&A, look for other reductions. Look at R&D and how structured to see where reduce costs, but reinvest saving in pipeline, adv as quickly as can. CP: Compliment mgt re progress, great opp to be more flexible, nimble, focus on core activities. Deep review, biopharma setting, make appr changes going forward.
* Q7: Hon Lee, Stanford Group
* Color re Tysabri holiday, talked last earnings CC?
* A7: SC: Hard for us to get to firm conclusions re drug holidays. Have a lot of data in US from TOUCH re # infusions, track w/patients, some anecdotal data some drug holidays, better data over time. More diff in EU. CP: Diff to measure, docs have in mind re LT Tx, help to get info.
* Q8: Stopped mkting CD in 4Q2008, contr to sales decline?
* A8: No
* Q9: EBITDA profitability in 2009, give shares?
* A9: SC: Make around rev growth, costs, how manage to get to 200M balance at YE2009. Where end up EBITDA, depends how well reaccel Tysabri sales. Have lots of leverage, 10M new sales, 4M op profit. Shares outstanding 475M basic, maybe 20M more fully diluted.
* Q10: Rich Silver, Barclay’s
* EDT business and generic competition, when expect rev return to 2008 rate w/incr rev from new prods?
* A10: SC: Depends when generic comp arrives, sometimes earlier, sometimes later, in a couple yrs out at same levels or higher. Depends on approval of prods in pipelines and succ of launches.
* Q11: Potential impact re PFE acq of WYE? Impact on Bap.
* A11: Not privy before, but now communicated, work to aggr move forward on Bap, AIP.
* Q12: Bill Tanner, Leerink Swann
* Strategic review, possible to rank order, provide liquidity need. Two most valuable assets, one is Tysabri. Does repr fair value? Any thought re EDT revisit? A lot of chatter, needing shareholder approval?
* A12: KM: Give broad answer, in Jan2009 announced strategic review, hire advisor, multiple goals, given mkt condition lots going on. Lots of activity going on, from ELN persp, enormous progress operationally and adv science, fantastic prospective opps, grow in depth and #. 2 main objs of strat transaction, one, derisk B/S and fin construct, due to mult of sci opps, abundance of opps to move forward. In inetrmed to LT, participate in signif value creation if sci can be progr. From sci PoV, goal to be very focused on what best at. Deep unique sci, deep clin knowledge, want to invest aggr. Some participation commercially. If look at AD, 10x size of MS mkt, 140 countries around world, infrastructure subst, has to be far and wide, avail sooner than later. Pleased w/interest. Keep going thru process, allow umbrella, us, to talk w/# of players, walk thru process w/advisor come back to us, BOD w/options. Lots of parts to your Q, hope positioned way helpful to you.
* Q13: Any initiatives req s/h vote?
* A13: KM: Absolutely, some types of transactions req s/h vote, some don’t. Premature until know options. Like any public company, diff levels of appr reqd.
* Q14: Annie Change, Bryant Garnier
* Tysabri Q, perception of PML risk., mgt re docs. What are you telling them, not just #s but outcomes. What kind of communications re outcome of PML?
* A14: CP: Our group internally, discuss w/Biogen, PML used to be fatal disease, esp w/HIV positive or transplantations. Can remove Tysabri (like other drugs), remove quickly, lead to less mortality. Only 1 of 5 w/PML died. Once remove immunosuppr, could get IRIS, rebound, looking at best mgt. Trying to figure out. Lots of thought going on. Get more aggr, PRP, even though PML lower than label incidence, make PML manageable disease.
* Q15: Jack Gorman, Davy’s
* First, Tysabri in oncology, MM, timelines re study? Re communicating T message and broader message, give color what hear at AAN2009? Broader Q, KM, housekeeping re strat revew, original partnering plan of300-500M superceded?
* A15: KM: SC outlined, everything under one umbrella, frankly easier for us, one process, one of major intents. Other Q more directed to CP.
* CP: Re MM, shared publicly, started in Sep2008, enrolling trial, provide addit timing down the line. #1 focus communication re PML, workw/Biogen, not sure what appr focus. Add to Corey’s P II PIB PET study, trial is ascending dose 3 up to 4 doses, no segmentation re genotype.
* Q16: Vincent Meunier, BNP Paribas
* Tysabri pricing trends US and ROW? Bap recruitment, any idea, potential pace US vs ROW? Guidance 200M cash and inv YE2009, does this include milestone payments apparently paid to Biogen?
* A16: SC: 200M includes 50M paid to Biogen in Jan2009. Pricing ex-US set at launch, doesn’t change. However, f/x can impact, charge in euro, rpt in US. In US 3% price incr beg of 2009. CP: Bap, aggr pursue non-carrier enrollment. Good progress, indiv countries ex-US, P II data, imp re P III, WYE shared at JPM, signif progress, all but 1 country agreed to continue enrollment of P III. Expect signif ramp of ex-US enrollment.
* Q17: Fair if enrollment completed in 2009, 18M Tx, expect launch in 2012?
* A17: Can’t give guidance now, 4 trials, see what strategy when to submit. If only 1, yes, but have 4.
* Q18: Scott Bardo, CS
* One Q is strategy, understand hesitant to comment, board members discussing. What are preferred options, selling more options to raise $, what component to pay off ST debt, what component re M/F for Bap?
* A18: KM: Preferred outcome find minority investor for ELN, if had global comm. I/S, would be attractive, many do, given pipeline. Preferred global player. What do w/cash is multiple things, premature to outline, depends on size and construct of investment. Have ability, unique in industry, to change breadth and depth of pipeline, given dearth of industry pipeline, good things. Drastic shift in Sep2008 given Lehman failure, changed macro view, mkt telling us that, derisk financially, strat also whether biological plants, EDT things to invest. Derisk and give R&D in biopharma and EDT more to invest in pipeline, bring prods forward.
* In concl thank everyone for joining us.
http://www.fool.com/investing/general/2009/02/17/5-stocks-un…
Elan (NYSE: ELN) -- $7.63
Drugmakers are typically portrayed as recession-resistant, given the steady demand for their medicine. Elan is already a giant as a result of Tysabri, treating patients battling multiple sclerosis and Crohn's disease.
Charly Travers recommended the stock to Motley Fool Rule Breakers subscribers two months ago, as a result of the company making major headway in a treatment for Alzheimer's. The Irish drugmaker isn't profitable, but the upside is huge if it lands another blockbuster drug.
Elan (NYSE: ELN) -- $7.63
Drugmakers are typically portrayed as recession-resistant, given the steady demand for their medicine. Elan is already a giant as a result of Tysabri, treating patients battling multiple sclerosis and Crohn's disease.
Charly Travers recommended the stock to Motley Fool Rule Breakers subscribers two months ago, as a result of the company making major headway in a treatment for Alzheimer's. The Irish drugmaker isn't profitable, but the upside is huge if it lands another blockbuster drug.
Antwort auf Beitrag Nr.: 36.599.224 von GuHu1 am 17.02.09 23:29:46Moin in die Runde...Was treibt Ihr so in diesen Zeiten???Gruss Birgit
Was treibt Ihr so in diesen Zeiten???Gruss Birgit
Antwort auf Beitrag Nr.: 36.600.128 von Birgit.Tersteegen am 18.02.09 09:05:43 
und höre dabei
http://www.youtube.com/watch?v=7sei-eEjy4g
wenn ich nen größeren schlitten hätte wäre die berliner waschmaschine dran!
grüße
und höre dabei
http://www.youtube.com/watch?v=7sei-eEjy4g
wenn ich nen größeren schlitten hätte wäre die berliner waschmaschine dran!
grüße
Antwort auf Beitrag Nr.: 36.616.871 von welke91 am 20.02.09 08:41:19Hi Welke schön von Dir zu hören!!
Krise + dieser Winter sind ja echt ´ne Herausforderung---und Elan ist auch im Winterschlaf...lg Birgit
schön von Dir zu hören!!Krise + dieser Winter sind ja echt ´ne Herausforderung---und Elan ist auch im Winterschlaf
...lg Birgit
Antwort auf Beitrag Nr.: 36.616.912 von Birgit.Tersteegen am 20.02.09 08:48:16Some some I murder
some I some I let go
heißt es in dem lied...und so sieht die momentane situation aus...
ihr könnt nur hoffen, dass diese Kriese ;-) nicht zu lang anhält und elan schnellst möglich ihr EDT Geschäft verkaufen können.
Das schafft spielraum gegenüber der passiva...
sonst ist es sehr verhalten, wie elan ihre tysabri umsätze erklären.
warum ist MC nicht so stark nachgefragt und wo kann man mehr generieren und warum tut man es nicht...das sind sätze die eine Press conference beleben doch so gott will sitzt dieser stumme martin noch in 10 jahren auf diesen Stuhl.
fakt ist, pfizer hat nicht umsonst wyeth gekauft...die wollen alzheimer und elan wird so denke ich ausgeschlossen mit einer hübschen summe.
dann kauft biogen den rest.
und ende
third world democracy
some I some I let go
heißt es in dem lied...und so sieht die momentane situation aus...
ihr könnt nur hoffen, dass diese Kriese ;-) nicht zu lang anhält und elan schnellst möglich ihr EDT Geschäft verkaufen können.
Das schafft spielraum gegenüber der passiva...
sonst ist es sehr verhalten, wie elan ihre tysabri umsätze erklären.
warum ist MC nicht so stark nachgefragt und wo kann man mehr generieren und warum tut man es nicht...das sind sätze die eine Press conference beleben doch so gott will sitzt dieser stumme martin noch in 10 jahren auf diesen Stuhl.
fakt ist, pfizer hat nicht umsonst wyeth gekauft...die wollen alzheimer und elan wird so denke ich ausgeschlossen mit einer hübschen summe.
dann kauft biogen den rest.
und ende
third world democracy
Antwort auf Beitrag Nr.: 36.617.041 von welke91 am 20.02.09 09:06:17übrigens den song nicht falsch verstehen,...
das lied handelt von den unglaublichen Tatsachen der Flüchtlinge aus der dritten Welt und wie man mit diesen umgeht.
Wenn ihr die Nachrichten aus Italien verfolgt usw. versteht ihr auch warum ich so einen hass habe auf hiesige Politik.
rühmt man sich gegenüber frankreich für seine integration kann ich nur sagen das diese in deutschland nicht vorhanden ist.
übrigens der schnee hat bei mir auch kein Asyl beantragt.
deshalb wird er abgeschoben
das lied handelt von den unglaublichen Tatsachen der Flüchtlinge aus der dritten Welt und wie man mit diesen umgeht.
Wenn ihr die Nachrichten aus Italien verfolgt usw. versteht ihr auch warum ich so einen hass habe auf hiesige Politik.
rühmt man sich gegenüber frankreich für seine integration kann ich nur sagen das diese in deutschland nicht vorhanden ist.
übrigens der schnee hat bei mir auch kein Asyl beantragt.
deshalb wird er abgeschoben
Antwort auf Beitrag Nr.: 36.617.250 von welke91 am 20.02.09 09:27:45 wenn der dow heute noch mal abrauscht sieht es düüüüster aus.
dax macht es vor.
denke wir verfallen noch ein wenig weiter.
übrigens habt ihr auch gehört, dass die usa einen atomschlag egen nordkorea planen?
in russland werden schiffe versengt...
man in welcher welt leben wir was hat sich denn so schnell so stark geändert.
geld ist doch nicht alles oder?
wenn der dow heute noch mal abrauscht sieht es düüüüster aus.dax macht es vor.
denke wir verfallen noch ein wenig weiter.
übrigens habt ihr auch gehört, dass die usa einen atomschlag egen nordkorea planen?
in russland werden schiffe versengt...
man in welcher welt leben wir was hat sich denn so schnell so stark geändert.
geld ist doch nicht alles oder?
kaufe ein k
versenkt...
versinkt denn alles ins bodenlose?
welche sparten bevorzugt ihr in zukunft? wenn in 1-2 jahren es vielleicht besser werden wird?
grüße gehe weiter schieeeben
versenkt...
versinkt denn alles ins bodenlose?
welche sparten bevorzugt ihr in zukunft? wenn in 1-2 jahren es vielleicht besser werden wird?
grüße gehe weiter schieeeben
Antwort auf Beitrag Nr.: 36.617.348 von welke91 am 20.02.09 09:35:34 bachas prognose für ende märz
dow 6800-6900
dax 3800-3900
dann anstiege im laufe des jahres
dow 6800-6900
dax 3800-3900
dann anstiege im laufe des jahres
Antwort auf Beitrag Nr.: 36.617.348 von welke91 am 20.02.09 09:35:34Das ganze MIESE dieses Systems kommt so richtig zum Vorschein im Moment....
Antwort auf Beitrag Nr.: 36.617.412 von Birgit.Tersteegen am 20.02.09 09:41:51ja genau birgit,
habt ihr gehört, der seehofer will, das die bafin nicht mehr anfragen von unikum wie den steuerzahler bearbeiten darf?
das heißt, dass wenn ihr von einer bank geprellt werdet und die bafin findet heraus, dass die bank tatsächlich scheiße gebaut hat darf oder muss sie es in zukunft verschweigen.
d.h. ihr könnt klagen bis der anwalt umkippt jedoch erreichen werdet ih nix.
damit auch poltiker weiter in ruhe ihren arsch im Aufsichtsrat breitsitzen können.
so weit sind wir...da haben rentner ihre altersvorsogen in "sicheren anlagen" gesteckt und haben nun nichts mehr...
armes deutscheland
habt ihr gehört, der seehofer will, das die bafin nicht mehr anfragen von unikum wie den steuerzahler bearbeiten darf?
das heißt, dass wenn ihr von einer bank geprellt werdet und die bafin findet heraus, dass die bank tatsächlich scheiße gebaut hat darf oder muss sie es in zukunft verschweigen.
d.h. ihr könnt klagen bis der anwalt umkippt jedoch erreichen werdet ih nix.
damit auch poltiker weiter in ruhe ihren arsch im Aufsichtsrat breitsitzen können.
so weit sind wir...da haben rentner ihre altersvorsogen in "sicheren anlagen" gesteckt und haben nun nichts mehr...
armes deutscheland
Antwort auf Beitrag Nr.: 36.617.483 von welke91 am 20.02.09 09:49:20hi,
hre muss sich selbst mit mehr als 1000 mrd. refinanzieren...
das ist schon mal mehr als der 2 Weltkrieg...
so mal als vergleich...
Kindred shares rise on 4Q results, outlook
Kindred Healthcare shares jump on better-than-expected 4th-quarter results, 2009 outlook
KND die haben immer etwas zu tun.
grüße
hre muss sich selbst mit mehr als 1000 mrd. refinanzieren...
das ist schon mal mehr als der 2 Weltkrieg...
so mal als vergleich...
Kindred shares rise on 4Q results, outlook
Kindred Healthcare shares jump on better-than-expected 4th-quarter results, 2009 outlook
KND die haben immer etwas zu tun.
grüße
Antwort auf Beitrag Nr.: 36.627.495 von welke91 am 21.02.09 20:43:451000 mrd sind die nominal werte, refinanzierung erfolgt laut aussagen der hre zu den marktwerten
Elan Announces Further Alignment of Resources
25 February 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
DUBLIN--(BUSINESS WIRE)--Feb. 25, 2009-- Elan Corporation, plc (NYSE: ELN) announced today that, as previously guided, and as part of its ongoing efforts to consistently and rigorously manage its overall cost base and direct additional investment toward its promising and late stage pipeline, it will refine its business operations and functions to realize greater efficiencies and deepen its commitment and focus to key and strategic areas.
The holding company, Elan Corporation, plc, will continue to have two related but distinct operating divisions: Biopharmaceuticals and Elan Drug Technologies.
Specific adjustments include a postponement of biologics manufacturing activities, a strategic redesign and realignment of the R&D organization within the Biopharmaceutical business, and a reduction in related G&A and other support activities. These changes follow the realignment of components of Elan’s commercial organization announced in late 2008.
These adjustments, largely driven by changes in the Biopharmaceuticals business, will result in a reduction in Elan’s global workforce of approximately 230 positions, or 14% of Elan’s workforce. In Ireland, where Elan’s biological manufacturing and related fill finish activities are based, approximately 115 positions will be impacted. A further approximately 115 positions will be affected in the United States, mainly in the areas of research, clinical development, biopharmaceutical development, and related corporate support and administrative services. Elan expects to reassess the opportunity to invest in a biologics manufacturing facility and restart its related fill finish activities after the company has had the opportunity to evaluate the data from the Phase 3 trials of bapineuzumab in Alzheimer’s disease.
Elan expects that the financial benefits of these adjustments, some of which will be re-invested in the advancement of the clinical development of its pipeline, will reduce operating expenses in 2009 by $30-$35 million and by approximately $50 million in a full year. Severance and related charges are expected to be $15 million and will be recorded as a charge in the first half of 2009.
Following these planned changes, Elan reiterates its financial guidance for 2009 and expects revenue to grow by double digit percentages, to be Adjusted EBITDA profitable for the year, and to end the year with cash and investment balances in the region of $200 million.
Elan CEO Kelly Martin said this internal realignment was driven in large part by an assessment of the Biopharmaceuticals division completed by Dr. Carlos V. Paya , who joined Elan as President late last year. The internal business review was conducted in addition to and separately from the previously announced and on-going corporate strategic review process which, should it be successful, may bring additional capabilities to Elan and further augment the company’s improved financial performance and increased revenues reported in 2008.
Mr. Martin said, “As we continue to advance the company, we remain committed to the precise and specific investment in new talent, new technologies and novel therapeutic opportunities in the neuroscience field. This will further strengthen our core business areas that bring the greatest potential value to patients and shareholders, and enable us to invest in our most valuable programs within the Biopharmaceuticals and Elan Drug Technologies businesses.”
Dr. Paya said that following the changes, Elan is well positioned in the biopharmaceutical industry. “We are creating a forward-thinking, flexible, science-based and patient-focused business supported by modest infrastructure,” Dr. Paya said. “This model maximizes our opportunities and leverages our unique innovation, talent, experience and pipeline.”
Dr. Paya said that further progress would enable Elan to leverage a highly focused and cost-advantaged organization, with a foundation to become the world’s leading neuroscience company. Dr. Paya added, “This realignment has been strategically driven and will enable us to further focus on our four key near-and intermediate-term priorities: driving uptake of Tysabri, advancing our Alzheimer’s programs, harnessing the value of our pipeline, and maximizing the growth of EDT.”
http://www.elan.com/News/full.asp?ID=1259794
25 February 2009
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process
DUBLIN--(BUSINESS WIRE)--Feb. 25, 2009-- Elan Corporation, plc (NYSE: ELN) announced today that, as previously guided, and as part of its ongoing efforts to consistently and rigorously manage its overall cost base and direct additional investment toward its promising and late stage pipeline, it will refine its business operations and functions to realize greater efficiencies and deepen its commitment and focus to key and strategic areas.
The holding company, Elan Corporation, plc, will continue to have two related but distinct operating divisions: Biopharmaceuticals and Elan Drug Technologies.
Specific adjustments include a postponement of biologics manufacturing activities, a strategic redesign and realignment of the R&D organization within the Biopharmaceutical business, and a reduction in related G&A and other support activities. These changes follow the realignment of components of Elan’s commercial organization announced in late 2008.
These adjustments, largely driven by changes in the Biopharmaceuticals business, will result in a reduction in Elan’s global workforce of approximately 230 positions, or 14% of Elan’s workforce. In Ireland, where Elan’s biological manufacturing and related fill finish activities are based, approximately 115 positions will be impacted. A further approximately 115 positions will be affected in the United States, mainly in the areas of research, clinical development, biopharmaceutical development, and related corporate support and administrative services. Elan expects to reassess the opportunity to invest in a biologics manufacturing facility and restart its related fill finish activities after the company has had the opportunity to evaluate the data from the Phase 3 trials of bapineuzumab in Alzheimer’s disease.
Elan expects that the financial benefits of these adjustments, some of which will be re-invested in the advancement of the clinical development of its pipeline, will reduce operating expenses in 2009 by $30-$35 million and by approximately $50 million in a full year. Severance and related charges are expected to be $15 million and will be recorded as a charge in the first half of 2009.
Following these planned changes, Elan reiterates its financial guidance for 2009 and expects revenue to grow by double digit percentages, to be Adjusted EBITDA profitable for the year, and to end the year with cash and investment balances in the region of $200 million.
Elan CEO Kelly Martin said this internal realignment was driven in large part by an assessment of the Biopharmaceuticals division completed by Dr. Carlos V. Paya , who joined Elan as President late last year. The internal business review was conducted in addition to and separately from the previously announced and on-going corporate strategic review process which, should it be successful, may bring additional capabilities to Elan and further augment the company’s improved financial performance and increased revenues reported in 2008.
Mr. Martin said, “As we continue to advance the company, we remain committed to the precise and specific investment in new talent, new technologies and novel therapeutic opportunities in the neuroscience field. This will further strengthen our core business areas that bring the greatest potential value to patients and shareholders, and enable us to invest in our most valuable programs within the Biopharmaceuticals and Elan Drug Technologies businesses.”
Dr. Paya said that following the changes, Elan is well positioned in the biopharmaceutical industry. “We are creating a forward-thinking, flexible, science-based and patient-focused business supported by modest infrastructure,” Dr. Paya said. “This model maximizes our opportunities and leverages our unique innovation, talent, experience and pipeline.”
Dr. Paya said that further progress would enable Elan to leverage a highly focused and cost-advantaged organization, with a foundation to become the world’s leading neuroscience company. Dr. Paya added, “This realignment has been strategically driven and will enable us to further focus on our four key near-and intermediate-term priorities: driving uptake of Tysabri, advancing our Alzheimer’s programs, harnessing the value of our pipeline, and maximizing the growth of EDT.”
http://www.elan.com/News/full.asp?ID=1259794
Elan Sees 09 Revenue Growth In Double Digits; Cuts Jobs
Wednesday reiterated its financial guidance for 2009 and expects revenue to grow by double-digit percentages, but said it is cutting 115 jobs in the U.S. and 115 in Ireland as part of its ongoing restructuring program.
The Irish pharmaceutical company also said it expects to be profitable for the year on an adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda, basis, and to end the year with cash and investment balances in the region of $200 million.
These job cuts will result in a 14% reduction in Elan's global workforce, which will, along with other measures, reduce operating expenses in 2009 by $30 million to $35 million and by approximately $50 million in a full year.
Severance and related charges are expected to be $15 million and will be recorded as a charge in the first half of 2009, Elan said.
The company will continue to have two related but distinct operating divisions: Biopharmaceuticals and Elan Drug Technologies.
Analysts say Elan must issue equity, sell part of its business or refinance debt, as its projected cash flows aren't sufficient to cover its $1.1 billion in debt due late 2011, a situation compounded by the global credit crunch.
At 1500 GMT, Elan was down 1.9%, or EUR0.10, at EUR4.88 in Dublin in a buoyant overall market. The stock has lost over 65% of its value over the past 12 months.
Earlier this month, Elan swung to a fourth-quarter net profit, helped by its multiple sclerosis drug Tysabri, but this result was helped by a $236.6 million tax benefit.
It posted a fourth quarter net income of $169.5 million, helped by deferred tax assets, up from a net loss of $83.5 million a year ago.
Revenue rose 32% to $1 billion in 2008, helped by increased sales of Tysabri, as well as contract manufacturing revenues.
Tysabri was in June 2006 approved for use primarily as a monotherapy for relapsing and remitting MS patients by the two regulatory agencies in the U.S. and E.U.
Elan is also engaged in Phase III trials of its Alzheimer's treatment AAB-001, which is another 50/50 joint venture with Wyeth (WYE).
Wednesday reiterated its financial guidance for 2009 and expects revenue to grow by double-digit percentages, but said it is cutting 115 jobs in the U.S. and 115 in Ireland as part of its ongoing restructuring program.
The Irish pharmaceutical company also said it expects to be profitable for the year on an adjusted earnings before interest, taxes, depreciation and amortization, or Ebitda, basis, and to end the year with cash and investment balances in the region of $200 million.
These job cuts will result in a 14% reduction in Elan's global workforce, which will, along with other measures, reduce operating expenses in 2009 by $30 million to $35 million and by approximately $50 million in a full year.
Severance and related charges are expected to be $15 million and will be recorded as a charge in the first half of 2009, Elan said.
The company will continue to have two related but distinct operating divisions: Biopharmaceuticals and Elan Drug Technologies.
Analysts say Elan must issue equity, sell part of its business or refinance debt, as its projected cash flows aren't sufficient to cover its $1.1 billion in debt due late 2011, a situation compounded by the global credit crunch.
At 1500 GMT, Elan was down 1.9%, or EUR0.10, at EUR4.88 in Dublin in a buoyant overall market. The stock has lost over 65% of its value over the past 12 months.
Earlier this month, Elan swung to a fourth-quarter net profit, helped by its multiple sclerosis drug Tysabri, but this result was helped by a $236.6 million tax benefit.
It posted a fourth quarter net income of $169.5 million, helped by deferred tax assets, up from a net loss of $83.5 million a year ago.
Revenue rose 32% to $1 billion in 2008, helped by increased sales of Tysabri, as well as contract manufacturing revenues.
Tysabri was in June 2006 approved for use primarily as a monotherapy for relapsing and remitting MS patients by the two regulatory agencies in the U.S. and E.U.
Elan is also engaged in Phase III trials of its Alzheimer's treatment AAB-001, which is another 50/50 joint venture with Wyeth (WYE).
Irish Independent
Thursday February 26 2009
Irish drug company Elan is to axe 115 jobs in Ireland as part of a reorganisation that will see a total of 230 people employed by the group lose their positions.
The firm has also shelved any immediate plans for the construction of a major new multimillion euro biologics facility in Ireland that would be used for the manufacture of an Alzheimer's treatment that Elan is currently co-developing with drug giant Wyeth.
It's understood that over 90 of the jobs to be lost in Ireland are at Elan's Athlone plant, while the remainder will be shed in Dublin at its biologics planning and operational unit. A further 115 jobs are being cut in San Francisco. The losses will represent about 14pc of Elan's 1,640 workforce. The company currently employs nearly 700 people in Ireland.
Elan's Bapineuzumab Alzheimer's treatment is currently undergoing final clinical testing that will involve about 800 patients. Those trials began last year and are due to be complete in April 2011. Vials of the drug for use in the trial were manufactured at Elan's "fill-finish" facility in Athlone, but the final doses will be packaged there by March or April.
A spokeswoman for the company said Elan deems it to be "prudent" to await the final outcome of those trials before committing to a new manufacturing facility.
Elan retains the rights to manufacture the drug when it becomes commercially available, although Wyeth has the right to manufacture it for the initial roll-out period. A spokeswoman said Elan remains committed to the plant pending the outcome of the drug trials, and that it would be located in Ireland.
Elan said its earnings guidance for 2009 remains unchanged, and that the layoffs will reduce operating expenses this year by between $30m and $35m, and by $50m in a full financial year. Severance payments are expected to be in the region of $15m.
Criticised
Elan said the reorganisation is being made following a reassessment of the company's biopharmaceuticals division that was undertaken by its new chairman, Carlos Paya. Elan has been under pressure from investors who have criticised the board composition.
The company's current revenue stream is dominated by the Tysabri multiple sclerosis treatment that it co-owns with US-based Biogen-Idec. It has sales of almost $1bn (€78m) per annum.
Elan has said it is not ruling out a potential sale of its 50pc stake in Tysabri. A minority stake in the firm could be sold to an outside investor. Shares in Elan closed down 2.6pc in Dublin yesterday at €4.85.
Thursday February 26 2009
Irish drug company Elan is to axe 115 jobs in Ireland as part of a reorganisation that will see a total of 230 people employed by the group lose their positions.
The firm has also shelved any immediate plans for the construction of a major new multimillion euro biologics facility in Ireland that would be used for the manufacture of an Alzheimer's treatment that Elan is currently co-developing with drug giant Wyeth.
It's understood that over 90 of the jobs to be lost in Ireland are at Elan's Athlone plant, while the remainder will be shed in Dublin at its biologics planning and operational unit. A further 115 jobs are being cut in San Francisco. The losses will represent about 14pc of Elan's 1,640 workforce. The company currently employs nearly 700 people in Ireland.
Elan's Bapineuzumab Alzheimer's treatment is currently undergoing final clinical testing that will involve about 800 patients. Those trials began last year and are due to be complete in April 2011. Vials of the drug for use in the trial were manufactured at Elan's "fill-finish" facility in Athlone, but the final doses will be packaged there by March or April.
A spokeswoman for the company said Elan deems it to be "prudent" to await the final outcome of those trials before committing to a new manufacturing facility.
Elan retains the rights to manufacture the drug when it becomes commercially available, although Wyeth has the right to manufacture it for the initial roll-out period. A spokeswoman said Elan remains committed to the plant pending the outcome of the drug trials, and that it would be located in Ireland.
Elan said its earnings guidance for 2009 remains unchanged, and that the layoffs will reduce operating expenses this year by between $30m and $35m, and by $50m in a full financial year. Severance payments are expected to be in the region of $15m.
Criticised
Elan said the reorganisation is being made following a reassessment of the company's biopharmaceuticals division that was undertaken by its new chairman, Carlos Paya. Elan has been under pressure from investors who have criticised the board composition.
The company's current revenue stream is dominated by the Tysabri multiple sclerosis treatment that it co-owns with US-based Biogen-Idec. It has sales of almost $1bn (€78m) per annum.
Elan has said it is not ruling out a potential sale of its 50pc stake in Tysabri. A minority stake in the firm could be sold to an outside investor. Shares in Elan closed down 2.6pc in Dublin yesterday at €4.85.
AAN - the 4 BAPINEUZUMAB Abstracts
[S32.002] Cognitive and Functional Outcomes from a Phase II Trial of Bapineuzumab in Mild to Moderate Alzheimer's Disease
Stephen Salloway, Reisa Sperling, Keith Gregg, Ronald Black, Michael Grundman, Providence, RI, Boston, MA, South San Francisco, CA, Collegeville, PA, San Diego, CA
OBJECTIVE: To evaluate the safety and efficacy of bapineuzumab in mild to moderate Alzheimer's disease (AD). BACKGROUND: Bapineuzumab is a humanized anti-amyloid-beta (A) monoclonal antibody currently in Phase 3 studies in AD. DESIGN/METHODS: This Phase 2a, placebo-controlled, multiple-ascending dose study enrolled 234 patients randomly assigned to intravenous (IV) bapineuzumab or placebo (8:7 ratio). Four dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg) were evaluated. Patients received 6 infusions of bapineuzumab or placebo, 13 weeks apart, with final assessments at week 78. The modified intent-to-treat population (MITT, n=229) included patients who received study drug and had 1 on-treatment efficacy evaluation. The primary efficacy analysis was change from baseline through week 78 in individual dose cohorts comparing bapineuzumab vs. placebo for ADAS-Cog and DAD scales, using a repeated measures analysis that assumed a linear decline over time. Post-hoc analyses removed the assumption of linear decline with time and included ApoE4 carrier status in the model. RESULTS: Demography was similar between groups, including severity (baseline MMSE 20.9 bapineuzumab, 20.7 placebo). Adverse events (AEs) were common (95% bapineuzumab, 90% placebo); mean AEs per patient: 7.5 bapineuzumab, 5.7 placebo. Vasogenic edema, related to dose and ApoE4 allele, occurred in 10% of bapineuzumab-treated patients; additional safety data presented in companion paper. Pre-specified primary efficacy analyses did not achieve statistical significance in the MITT population. Post-hoc analyses showed favorable trends in the MITT population for ADAS-Cog and NTB (p<0.10). Significant treatment differences (p<0.05) were observed on cognitive and functional endpoints (ADAS-Cog, NTB, DAD) in the completer population (all doses, week 78 assessment) as well as the ApoE non-carrier subgroup (ADAS-Cog, NTB and CDR-SOB). Completer analyses in ApoE4 carriers showed non-significant treatment differences favoring bapineuzumab for ADAS-Cog and DAD scales. CONCLUSIONS/RELEVANCE: The Phase 2 results support continued development of bapineuzumab for the treatment of AD. Supported by: Elan Pharmaceuticals and Wyeth Research.
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 4:00 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
[
[P03.098] Effect of Bapineuzumab on MRI Measures of Cerebral Volume Change in Patients with Alzheimer's Disease
Nick C. Fox, Charles DeCarli, Ronald Black, Michael Grundman, London, United Kingdom, Sacramento, CA, Collegeville, PA, San Diego, CA
OBJECTIVE: To determine the effect of bapineuzumab on MRI measures of volume change in patients with mild to moderate Alzheimer's disease (AD). BACKGROUND: Bapineuzumab is a humanized monoclonal antibody designed to target the free N-terminus of the amyloid-beta peptide (A). DESIGN/METHODS: This Phase 2a, placebo-controlled, multiple-ascending dose study enrolled 234 patients randomly assigned to intravenous (IV) bapineuzumab or placebo (8:7 ratio). Four dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg) were evaluated. Patients received 6 infusions of bapineuzumab or placebo, 13 weeks apart. MRI scans were conducted using a standardized protocol at screening, Week 6, and every 13 weeks thereafter until Week 71. Brain volume and ventricular volume change were assessed by brain boundary shift integral (BBSI) and ventricular boundary shift integral (VBSI). Results for the MITT group were analysed using a repeated measures model without assumption of linearity, adjusted for brain volume and MMSE at baseline, and ApoE4 status. RESULTS: Of 234 patients enrolled, 219 had MRI data available for analysis. Overall, there was no statistically significant treatment difference for change in MRI parameters between patients treated with bapineuzumab (n=116) and placebo (n=103). In ApoE4 carriers, there was no difference in brain volume, however, an increase in ventricular volume was observed with bapineuzumab (n=70) compared with placebo (n=72; mean difference: 2.6 cc; 95% CI: 0.2 to 5.0 cc; p=0.037). Non-carriers of the ApoE4 allele treated with bapineuzumb (n=46) had less brain volume decline compared to non-carriers treated with placebo (n=31) without a significant difference in ventricular volume. The mean difference in brain volume between the groups was 10.7 cc; 95% CI: 3.4 to 18.0 cc; p=0.004. CONCLUSIONS/RELEVANCE: Although no differences on MRI were observed overall, non-carriers of ApoE4 treated with bapineuzumab had significantly less brain loss over 18 months compared to placebo. Further study is warranted. Supported by: Elan Pharmaceuticals and Wyeth Research
Category - Aging and Dementia - Imaging
Tuesday, April 28, 2009 4:00 PM
Poster Session III: Aging and Dementia: Imaging I (4:00 PM-7:00 PM)
[S32.001] Risk Factors and Clinical Course Associated with Vasogenic Edema in a Phase II Trial of Bapineuzumab
Reisa A. Sperling, Stephen Salloway, Nick C. Fox, Jerome Barackos, Kristen Morris, Gordon Francis, Ronald S. Black, Michael Grundman, Bapineuzemab 201 Clinical Trial Investigators, Boston, MA, Providence, RI, London, United Kingdom, Collegeville, PA, San Diego, CA, San Francisco, CA
OBJECTIVE: To characterize the risk factors and clinical course associated with vasogenic edema in a Phase II Alzheimer's disease (AD) anti-amyloid passive immunotherapy trial. BACKGROUND: Bapineuzumab (BAP) is a humanized anti-amyloid-beta (A) monoclonal antibody undergoing investigation as a treatment for AD. In the Phase I study, 3 subjects developed MRI abnormalities consistent with vasogenic edema (VE) in the highest dose (5mg/kg) cohort. DESIGN/METHODS: In this Phase IIa study, subjects were randomized (8:7) to IV BAP or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). MRI scans were obtained 6 weeks after each infusion. RESULTS: Twelve/124 (9.7%) subjects treated with BAP, compared to 0/110 on placebo (p<0.001) developed transient MR signal abnormalities on FLAIR sequences, most prominently in parietal, frontal, and occipital white matter. Gryal swelling was seen in some cases, and microhemorrhage was detected in 4/12 subjects. VE occurred in 11/60 BAP patients treated at higher doses (1-2mg/kg) compared to 1/64 at lower doses (0.15-0.5mg/kg; p<0.01). Ten/74 (13.5%) BAP-treated ApoE4 carriers developed VE compared to 2/47 (4.3%) non-carriers (genotype unknown on 3 subjects). Ten/12 VE cases were detected on routine MRI monitoring. Six cases were asymptomatic; 4 had mild transient symptoms, including lethargy, confusion, headache and/or visual disturbances. Two subjects had clinical symptoms prompting off-protocol MRI; one was treated with IV steroids. CSF studies were generally normal, but two cases had elevated WBC (8 and 19 WBC) and increased protein (259 and 337mg/dL). VE resolved on follow-up MRI within 3 months in most subjects. Six subjects were subsequently re-dosed at a lower dose (0.5mg/kg) and had no recurrence of VE. CONCLUSIONS/RELEVANCE: VE appears to be dose-related and reversible during treatment with passive anti-amyloid immunotherapy. Although the pathophysiology of VE remains to be fully elucidated, the association with the ApoE4 allele suggests that VE may be related to vascular amyloid deposition. Supported by: Elan and Wyeth Pharmaceuticals
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 3:45 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
[S32.005] Safety Profile of Bapineuzumab in a Phase II Trial of Mild-to-Moderate Alzheimer's Disease (AD)
Lawrence S. Honig, Sid Gilman, Kristen Morris, Ronald Black, Michael Grundman, Gordon Francis, New York, NY, Ann Arbor, MI, Collegeville, PA, San Diego, CA, South San Francisco, CA
OBJECTIVE: Evaluation of safety and efficacy of bapineuzumab treatment in mild-to-moderate AD. BACKGROUND: Immunization to A42 in transgenic mice models of Alzheimer's Disease (AD) results in decreased amyloid burden and improved function. Bapineuzumab is a humanized mouse monoclonal antibody to A42 peptide currently in phase 3 studies in AD. DESIGN/METHODS: This phase 2a, randomized double-blind placebo-controlled study had a safety population of 234 patients, 55% female, mean age 69 years, MMSE 20.8, and duration of AD 3.6 years. Treatment with bapineuzumab or placebo (8:7 ratio) consisted of IV infusion every 13 weeks in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg vs. placebo), for a total of 6 treatments. Safety data are reported as pooled bapineuzumab groups(B) compared to placebo(P). RESULTS: Primary efficacy endpoints (ADAS-Cog and DAD) did not achieve statistical significance (full data in companion paper). AEs occurred in 94%B and 90%P, with 7.5B and 5.7P mean events per patient, numbers unrelated to dose or apoE4 carrier status. AEs that were >5% and 2-fold higher for B were vasogenic edema (VE), back pain, anxiety, paranoia, vomiting, hypertension, weight loss, skin laceration, gait disturbance, and muscle spasm. Four patients died (3.2%B;0%P), but the deaths were all considered unrelated to treatment. The proportions of AEs that were mild/moderate/severe were 66%/28%/6%B and 72%/25%/3.5%P. Percentage dropouts for all causes were 26%B versus 21%P, and for AE 6%B versus 3%P. The most common SAEs were VE (4.0%B;0%P), DVT (3.2%B;0%P), dehydration (2.4%B;0.9%P) and seizures (2.4%B;0%P). VE occurred in 12 cases (10%B;0%P), but was asymptomatic in 6. VE is related to dose and apoE4 carrier status. No hypersensitivity reactions, B-specific antibodies, or intergroup laboratory value differences were detected. CONCLUSIONS/RELEVANCE: Bapineuzumab safety profile supports further study of this drug in phase 3 with monitoring for adverse events. Supported by: Elan Pharmaceuticals and Wyeth Research.
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 4:45 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
[S32.002] Cognitive and Functional Outcomes from a Phase II Trial of Bapineuzumab in Mild to Moderate Alzheimer's Disease
Stephen Salloway, Reisa Sperling, Keith Gregg, Ronald Black, Michael Grundman, Providence, RI, Boston, MA, South San Francisco, CA, Collegeville, PA, San Diego, CA
OBJECTIVE: To evaluate the safety and efficacy of bapineuzumab in mild to moderate Alzheimer's disease (AD). BACKGROUND: Bapineuzumab is a humanized anti-amyloid-beta (A) monoclonal antibody currently in Phase 3 studies in AD. DESIGN/METHODS: This Phase 2a, placebo-controlled, multiple-ascending dose study enrolled 234 patients randomly assigned to intravenous (IV) bapineuzumab or placebo (8:7 ratio). Four dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg) were evaluated. Patients received 6 infusions of bapineuzumab or placebo, 13 weeks apart, with final assessments at week 78. The modified intent-to-treat population (MITT, n=229) included patients who received study drug and had 1 on-treatment efficacy evaluation. The primary efficacy analysis was change from baseline through week 78 in individual dose cohorts comparing bapineuzumab vs. placebo for ADAS-Cog and DAD scales, using a repeated measures analysis that assumed a linear decline over time. Post-hoc analyses removed the assumption of linear decline with time and included ApoE4 carrier status in the model. RESULTS: Demography was similar between groups, including severity (baseline MMSE 20.9 bapineuzumab, 20.7 placebo). Adverse events (AEs) were common (95% bapineuzumab, 90% placebo); mean AEs per patient: 7.5 bapineuzumab, 5.7 placebo. Vasogenic edema, related to dose and ApoE4 allele, occurred in 10% of bapineuzumab-treated patients; additional safety data presented in companion paper. Pre-specified primary efficacy analyses did not achieve statistical significance in the MITT population. Post-hoc analyses showed favorable trends in the MITT population for ADAS-Cog and NTB (p<0.10). Significant treatment differences (p<0.05) were observed on cognitive and functional endpoints (ADAS-Cog, NTB, DAD) in the completer population (all doses, week 78 assessment) as well as the ApoE non-carrier subgroup (ADAS-Cog, NTB and CDR-SOB). Completer analyses in ApoE4 carriers showed non-significant treatment differences favoring bapineuzumab for ADAS-Cog and DAD scales. CONCLUSIONS/RELEVANCE: The Phase 2 results support continued development of bapineuzumab for the treatment of AD. Supported by: Elan Pharmaceuticals and Wyeth Research.
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 4:00 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
[
[P03.098] Effect of Bapineuzumab on MRI Measures of Cerebral Volume Change in Patients with Alzheimer's Disease
Nick C. Fox, Charles DeCarli, Ronald Black, Michael Grundman, London, United Kingdom, Sacramento, CA, Collegeville, PA, San Diego, CA
OBJECTIVE: To determine the effect of bapineuzumab on MRI measures of volume change in patients with mild to moderate Alzheimer's disease (AD). BACKGROUND: Bapineuzumab is a humanized monoclonal antibody designed to target the free N-terminus of the amyloid-beta peptide (A). DESIGN/METHODS: This Phase 2a, placebo-controlled, multiple-ascending dose study enrolled 234 patients randomly assigned to intravenous (IV) bapineuzumab or placebo (8:7 ratio). Four dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg) were evaluated. Patients received 6 infusions of bapineuzumab or placebo, 13 weeks apart. MRI scans were conducted using a standardized protocol at screening, Week 6, and every 13 weeks thereafter until Week 71. Brain volume and ventricular volume change were assessed by brain boundary shift integral (BBSI) and ventricular boundary shift integral (VBSI). Results for the MITT group were analysed using a repeated measures model without assumption of linearity, adjusted for brain volume and MMSE at baseline, and ApoE4 status. RESULTS: Of 234 patients enrolled, 219 had MRI data available for analysis. Overall, there was no statistically significant treatment difference for change in MRI parameters between patients treated with bapineuzumab (n=116) and placebo (n=103). In ApoE4 carriers, there was no difference in brain volume, however, an increase in ventricular volume was observed with bapineuzumab (n=70) compared with placebo (n=72; mean difference: 2.6 cc; 95% CI: 0.2 to 5.0 cc; p=0.037). Non-carriers of the ApoE4 allele treated with bapineuzumb (n=46) had less brain volume decline compared to non-carriers treated with placebo (n=31) without a significant difference in ventricular volume. The mean difference in brain volume between the groups was 10.7 cc; 95% CI: 3.4 to 18.0 cc; p=0.004. CONCLUSIONS/RELEVANCE: Although no differences on MRI were observed overall, non-carriers of ApoE4 treated with bapineuzumab had significantly less brain loss over 18 months compared to placebo. Further study is warranted. Supported by: Elan Pharmaceuticals and Wyeth Research
Category - Aging and Dementia - Imaging
Tuesday, April 28, 2009 4:00 PM
Poster Session III: Aging and Dementia: Imaging I (4:00 PM-7:00 PM)
[S32.001] Risk Factors and Clinical Course Associated with Vasogenic Edema in a Phase II Trial of Bapineuzumab
Reisa A. Sperling, Stephen Salloway, Nick C. Fox, Jerome Barackos, Kristen Morris, Gordon Francis, Ronald S. Black, Michael Grundman, Bapineuzemab 201 Clinical Trial Investigators, Boston, MA, Providence, RI, London, United Kingdom, Collegeville, PA, San Diego, CA, San Francisco, CA
OBJECTIVE: To characterize the risk factors and clinical course associated with vasogenic edema in a Phase II Alzheimer's disease (AD) anti-amyloid passive immunotherapy trial. BACKGROUND: Bapineuzumab (BAP) is a humanized anti-amyloid-beta (A) monoclonal antibody undergoing investigation as a treatment for AD. In the Phase I study, 3 subjects developed MRI abnormalities consistent with vasogenic edema (VE) in the highest dose (5mg/kg) cohort. DESIGN/METHODS: In this Phase IIa study, subjects were randomized (8:7) to IV BAP or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). MRI scans were obtained 6 weeks after each infusion. RESULTS: Twelve/124 (9.7%) subjects treated with BAP, compared to 0/110 on placebo (p<0.001) developed transient MR signal abnormalities on FLAIR sequences, most prominently in parietal, frontal, and occipital white matter. Gryal swelling was seen in some cases, and microhemorrhage was detected in 4/12 subjects. VE occurred in 11/60 BAP patients treated at higher doses (1-2mg/kg) compared to 1/64 at lower doses (0.15-0.5mg/kg; p<0.01). Ten/74 (13.5%) BAP-treated ApoE4 carriers developed VE compared to 2/47 (4.3%) non-carriers (genotype unknown on 3 subjects). Ten/12 VE cases were detected on routine MRI monitoring. Six cases were asymptomatic; 4 had mild transient symptoms, including lethargy, confusion, headache and/or visual disturbances. Two subjects had clinical symptoms prompting off-protocol MRI; one was treated with IV steroids. CSF studies were generally normal, but two cases had elevated WBC (8 and 19 WBC) and increased protein (259 and 337mg/dL). VE resolved on follow-up MRI within 3 months in most subjects. Six subjects were subsequently re-dosed at a lower dose (0.5mg/kg) and had no recurrence of VE. CONCLUSIONS/RELEVANCE: VE appears to be dose-related and reversible during treatment with passive anti-amyloid immunotherapy. Although the pathophysiology of VE remains to be fully elucidated, the association with the ApoE4 allele suggests that VE may be related to vascular amyloid deposition. Supported by: Elan and Wyeth Pharmaceuticals
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 3:45 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
[S32.005] Safety Profile of Bapineuzumab in a Phase II Trial of Mild-to-Moderate Alzheimer's Disease (AD)
Lawrence S. Honig, Sid Gilman, Kristen Morris, Ronald Black, Michael Grundman, Gordon Francis, New York, NY, Ann Arbor, MI, Collegeville, PA, San Diego, CA, South San Francisco, CA
OBJECTIVE: Evaluation of safety and efficacy of bapineuzumab treatment in mild-to-moderate AD. BACKGROUND: Immunization to A42 in transgenic mice models of Alzheimer's Disease (AD) results in decreased amyloid burden and improved function. Bapineuzumab is a humanized mouse monoclonal antibody to A42 peptide currently in phase 3 studies in AD. DESIGN/METHODS: This phase 2a, randomized double-blind placebo-controlled study had a safety population of 234 patients, 55% female, mean age 69 years, MMSE 20.8, and duration of AD 3.6 years. Treatment with bapineuzumab or placebo (8:7 ratio) consisted of IV infusion every 13 weeks in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg vs. placebo), for a total of 6 treatments. Safety data are reported as pooled bapineuzumab groups(B) compared to placebo(P). RESULTS: Primary efficacy endpoints (ADAS-Cog and DAD) did not achieve statistical significance (full data in companion paper). AEs occurred in 94%B and 90%P, with 7.5B and 5.7P mean events per patient, numbers unrelated to dose or apoE4 carrier status. AEs that were >5% and 2-fold higher for B were vasogenic edema (VE), back pain, anxiety, paranoia, vomiting, hypertension, weight loss, skin laceration, gait disturbance, and muscle spasm. Four patients died (3.2%B;0%P), but the deaths were all considered unrelated to treatment. The proportions of AEs that were mild/moderate/severe were 66%/28%/6%B and 72%/25%/3.5%P. Percentage dropouts for all causes were 26%B versus 21%P, and for AE 6%B versus 3%P. The most common SAEs were VE (4.0%B;0%P), DVT (3.2%B;0%P), dehydration (2.4%B;0.9%P) and seizures (2.4%B;0%P). VE occurred in 12 cases (10%B;0%P), but was asymptomatic in 6. VE is related to dose and apoE4 carrier status. No hypersensitivity reactions, B-specific antibodies, or intergroup laboratory value differences were detected. CONCLUSIONS/RELEVANCE: Bapineuzumab safety profile supports further study of this drug in phase 3 with monitoring for adverse events. Supported by: Elan Pharmaceuticals and Wyeth Research.
Category - Aging and Dementia - Clinical
Wednesday, April 29, 2009 4:45 PM
Scientific Sessions: Aging and Dementia: Treatment (3:45 PM-5:00 PM)
Antwort auf Beitrag Nr.: 36.656.497 von Birgit.Tersteegen am 26.02.09 10:20:37Und was bedeuten die fett markierten Sätze als Prognose ?
Wie wahrscheinlich ist denn jetzt die Wirksamkeit von Bapineuzumab ?
Dank im Voraus
Wie wahrscheinlich ist denn jetzt die Wirksamkeit von Bapineuzumab ?
Dank im Voraus
Antwort auf Beitrag Nr.: 36.657.100 von moneyseeker am 26.02.09 11:28:07WISSEN werden wir das erst 2010---aber die Ergebnisse werte ich positiv.
dito
http://www.aerztezeitung.de/medizin/?sid=533182" target="_blank" rel="nofollow ugc noopener">http://www.aerztezeitung.de/medizin/?sid=533182
Ärzte Zeitung, 25.02.2009 05:00
Antikörper läuten Wandel in der MS-Therapie ein
Ärzte Zeitung, 25.02.2009 05:00
Antikörper läuten Wandel in der MS-Therapie ein
Also im Beitrag steht
"
In kaum einem anderen neurologischen Bereich verändert sich die Therapie derart rasch, für keine andere neurologische Krankheit werden derzeit mehr Medikamente klinisch geprüft und bald marktreif sein wie für MS
"
Toll - aber nicht für Tysabri und Elan.
Trotz Tysabri scheinen sie einfach nicht wirklich profitabel werden zu wollen/können. Der CEO war der reinste Lügner & Stümper oder saboteur?. Und all das ist in einem positiven Börsenumfeld passiert.
Jetzt kommt die Mega Krise und u.a. mit Kürzungen im Gesundheitsbreich laut Obama. Abgesehen davon wirds bald wohl keine Dollars mehr wie bisher geben. Inflation bzw. Abwertung drohen.
Bapineuzumab wir erst 2010 VIELLEICHT eine Erfolg.
Bis dahin kann wie bisher immer geschehen viel negatives passieren oder (fälschlicherweise) geschrieben werden. Und bisher immer mit "Erfolg".
Leider kein Investment für die kommende Zeit.
Hat mich ca. 90.000 gekostet. Hab ein halbes Jahr nicht Elan angeguckt. Jetzt ist Schluß.
Viel Glück den Standhaften
"
In kaum einem anderen neurologischen Bereich verändert sich die Therapie derart rasch, für keine andere neurologische Krankheit werden derzeit mehr Medikamente klinisch geprüft und bald marktreif sein wie für MS
"
Toll - aber nicht für Tysabri und Elan.
Trotz Tysabri scheinen sie einfach nicht wirklich profitabel werden zu wollen/können. Der CEO war der reinste Lügner & Stümper oder saboteur?. Und all das ist in einem positiven Börsenumfeld passiert.
Jetzt kommt die Mega Krise und u.a. mit Kürzungen im Gesundheitsbreich laut Obama. Abgesehen davon wirds bald wohl keine Dollars mehr wie bisher geben. Inflation bzw. Abwertung drohen.
Bapineuzumab wir erst 2010 VIELLEICHT eine Erfolg.
Bis dahin kann wie bisher immer geschehen viel negatives passieren oder (fälschlicherweise) geschrieben werden. Und bisher immer mit "Erfolg".
Leider kein Investment für die kommende Zeit.
Hat mich ca. 90.000 gekostet. Hab ein halbes Jahr nicht Elan angeguckt. Jetzt ist Schluß.
Viel Glück den Standhaften
Antwort auf Beitrag Nr.: 36.671.750 von moneyseeker am 27.02.09 21:57:56....bitter! Mach´s gut + Alles Gute!!Gruss! Birgit
Mach´s gut + Alles Gute!!Gruss! Birgit
Antwort auf Beitrag Nr.: 36.672.069 von Birgit.Tersteegen am 27.02.09 22:57:00Danke
Antwort auf Beitrag Nr.: 36.685.113 von moneyseeker am 02.03.09 21:26:39Moneyseeker,
halte ein Auge auf Elan.
Es kommen auch wieder Zeiten,in denen wir hier 20 Kommentare täglich lesen können, spätestens 2010, "vielleicht" wie du schreibst.
Das wäre die Zeit, in der du dein Geld schneller als man jetzt glauben mag zurückholen kannst.
posimist
halte ein Auge auf Elan.
Es kommen auch wieder Zeiten,in denen wir hier 20 Kommentare täglich lesen können, spätestens 2010, "vielleicht" wie du schreibst.
Das wäre die Zeit, in der du dein Geld schneller als man jetzt glauben mag zurückholen kannst.
posimist
Antwort auf Beitrag Nr.: 36.704.509 von posimist am 05.03.09 11:18:17Moneyseeker,halte ein Auge auf Elan.
...Es kommen auch wieder Zeiten,in denen wir hier 20 Kommentare täglich lesen können, spätestens 2010
Das wäre die Zeit, in der du dein Geld schneller als man jetzt glauben mag zurückholen kannst.
........tja, lieber posimist, auch, wenn es zur Zeit sehr hart an der Börse zugeht, ich sehe die möglichen Perspektiven genauso wie du...
...in diesem Sinne uns allen + +
..schöne Grüße, in die Runde...
bernie55
Moneyseeker,halte ein Auge auf Elan....Es kommen auch wieder Zeiten,in denen wir hier 20 Kommentare täglich lesen können, spätestens 2010Das wäre die Zeit, in der du dein Geld schneller als man jetzt glauben mag zurückholen kannst.........tja, lieber posimist, auch, wenn es zur Zeit sehr hart an der Börse zugeht, ich sehe die möglichen Perspektiven genauso wie du...
...in diesem Sinne uns allen
+ + ..schöne Grüße, in die Runde...
bernie55
Antwort auf Beitrag Nr.: 36.714.435 von bernie55 am 06.03.09 12:43:18 Untergang oder Reichtum--das ist hier die Frage....
Und Kelly Martin ist ein LOOSER--das steht mal fest.....
Untergang oder Reichtum--das ist hier die Frage....
Und Kelly Martin ist ein LOOSER--das steht mal fest.....
Perspective from post wtfw. Why it was removed only the original poster knows.
How a broken financial market slows drug discovery
By worldbeggedyoutovoteKerry
Mon Aug 04, 2008 at 07:10:19 AM PDT
This is going to be a hard diary to write because I don't know if I can do justice to what I have just witnessed. As it involves a stock I would normally just post on a stock message board, but I truly believe this is an issue that could affect many of you here as well. There has been a great deal of discussion lately about abusive shorting practices and how naked shorting is undermining the integrity of our markets. It even seems that the SEC is finally prepared to help out their banking buddies by stepping in and temporarily preventing naked shorting of their stocks. Does this surprise us? When the guys who do set up the fixed game get stung because they've left themselves vulnerable of course they will run to the government to keep the monster they created from biting them in the butt. Yet, what about everybody else?...
* WorldbeggedyoutovoteKerry's' diary :: ::
*
Last week I bore witness to an extraordinary event. I can't prove it, nor will likely anybody ever be able to connect the dots completely, but that is the beauty of a well orchestrated short raid, it leaves the victims in the realm of conspiracy mongers. Over 2 days, billions of dollars were wiped off the market cap of a biotech company, Elan Pharmaceuticals, leaving the price of the stock at 70% below where it was trading on July 29th. For biotech investors this kind of fall is unfortunately not an impossibility, but it comes after news of a failed trial or a product withdrawal. In this case neither event occurred, but two rather unusual things happened back to back. Bear with me a bit as I explain some things about this industry.
Typically biotechs announce advancements in their drug programs at big congresses. That's their moment to inform the medical community of how their drug trials are fairing. They also frequently will give some top line news a few weeks prior to the event to build interest. This is what Elan did back in June. They informed the world that their Alzheimer's drug had not met its endpoints in its phase II trial, but had shown statistically significant efficacy in a substantial sub-group and this is why they, with the head nod from the FDA, proceeded to a phase III trial to test the drug further. At the end of July they presented the full data to the world at ICAD, a major Alzheimer's congress. This release was literally billed as the most anticipated results of the decade. From what I heard from those who were there, Dr. Gilman was clear in explaining that the 3 deaths that occurred were not related to the drug and he also explained that the side effects seen were quickly resolved and appeared to be related to the higher dosage which was not chosen as the optimal dose for the phase III testing. Despite this clarification, 3 minutes later Reuters released the headline saying "Deaths and side effects MAR Alzheimer's drug"???
Now for the fun part. This happened after 4 p.m. So the market was closed, but in after hours trading all of a sudden there was a heavy push to unload stock. The volume was such that the stock dropped from $33.75 to $20, the kind of haircut you would expect from a failed trial. In the next two days, by extraordinary coincidence, Elan and its partner Biogen were informed that two patients taking another drug, Tysabri, had tested positive for a rare brain side effect that is mentioned in their black box warning label. Tysabri has a long story in and of itself because it was withdrawn from the market a few years ago, then reinstated with a very controlled patient monitoring program to ensure that these cases are picked up early and minimize the chance of a fatality. The companies and the FDA were expecting a case to eventually show up, but the risk quoted of 1:1000 (quoted in the label) has not been observed and the FDA is very unlikely to do anything because many drugs that treat difficult diseases like MS have a risk/benefit profile. Nothing is risk free. Notwithstanding this, Elan's stock was forced down to $10 by Friday's close. Undoubtedly people sell on news of this nature, however, the part that raises eyebrows is the number of put that were bought in the last few weeks, especially the 30K just before market close and the formal announcement of the PML cases. A conspiracy theorist would put forth that somebody knew in advance of this information and used the giant loopeholes in the market to create greater damage than was warranted. I like how this blog diared the situation:
"Finally, a word on the stock market reaction to the Tysabri "news". It is quite remarkable that the report of the expected PML cases was able to trigger 30% and 50% declines in the stock prices of Biogen Idec and Elan, respectively. Sensational media and scare-mongering analyst reports, some of them fabricated, accompanied short-selling tactics aimed at suggesting rock-bottom valuations. At one point for example, Elan traded down over 75% in relatively light German trading. Also noteworthy was that 5 minutes before the market close and announcement of the PML cases, 30,000 August '08 Elan put options were traded for what must have been an amazing $30M-dollar-in-5-minute gain.
As the financial world is starting to realize, abusive short-selling aimed at destroying the ability of companies to grow, which in the case of biotechs is designed to undermine their ability to fund drug development, is very real. This should be of great concern to the biotech industry, and it is hoped that trade organizations such as BIO seize the opportunity to put pressure on the SEC to address this problem not just for the benefit of a select number of financial companies."
Link to full diary here
He makes the point that drew me to posting this here, rather than preaching to the choir on the stock boards. This affects every one of us in that new molecules that Elan has prepared to develop will now languish while the company tries to claw its way back to the financial health it held pre the meeting. No fundamental has changed since last Monday, they just were ripe for pillaging by the sharks who knew that there wasn't anybody likely to stop them. The SEC will probably take a look at those suspect puts and others that surfaced, but they haven't done a blessed thing yet with other similar situations, and are only now acknowledging there is a problem because their Wall Street buddies are complaining. Alzheimer's and MS are two disease that a great many people will have to deal with. I remember reading here a touching diary of a Kossack caregiver and I was struck by how many of us have had to deal in one way or another with this dreaded disease. If the SEC and our congressional representatives don't address this problem they will be hurting themselves in the end of the day, few of us are blessed with a life free from disease.
Sorry if I was not clear in places, it has been a trying time. I've been here before with this company (and for some it is the 3rd time), but those incidences were understandable, this was different. In this case I honestly believe it only happened because there is truly not a level playing field.
How a broken financial market slows drug discovery
By worldbeggedyoutovoteKerry
Mon Aug 04, 2008 at 07:10:19 AM PDT
This is going to be a hard diary to write because I don't know if I can do justice to what I have just witnessed. As it involves a stock I would normally just post on a stock message board, but I truly believe this is an issue that could affect many of you here as well. There has been a great deal of discussion lately about abusive shorting practices and how naked shorting is undermining the integrity of our markets. It even seems that the SEC is finally prepared to help out their banking buddies by stepping in and temporarily preventing naked shorting of their stocks. Does this surprise us? When the guys who do set up the fixed game get stung because they've left themselves vulnerable of course they will run to the government to keep the monster they created from biting them in the butt. Yet, what about everybody else?...
* WorldbeggedyoutovoteKerry's' diary :: ::
*
Last week I bore witness to an extraordinary event. I can't prove it, nor will likely anybody ever be able to connect the dots completely, but that is the beauty of a well orchestrated short raid, it leaves the victims in the realm of conspiracy mongers. Over 2 days, billions of dollars were wiped off the market cap of a biotech company, Elan Pharmaceuticals, leaving the price of the stock at 70% below where it was trading on July 29th. For biotech investors this kind of fall is unfortunately not an impossibility, but it comes after news of a failed trial or a product withdrawal. In this case neither event occurred, but two rather unusual things happened back to back. Bear with me a bit as I explain some things about this industry.
Typically biotechs announce advancements in their drug programs at big congresses. That's their moment to inform the medical community of how their drug trials are fairing. They also frequently will give some top line news a few weeks prior to the event to build interest. This is what Elan did back in June. They informed the world that their Alzheimer's drug had not met its endpoints in its phase II trial, but had shown statistically significant efficacy in a substantial sub-group and this is why they, with the head nod from the FDA, proceeded to a phase III trial to test the drug further. At the end of July they presented the full data to the world at ICAD, a major Alzheimer's congress. This release was literally billed as the most anticipated results of the decade. From what I heard from those who were there, Dr. Gilman was clear in explaining that the 3 deaths that occurred were not related to the drug and he also explained that the side effects seen were quickly resolved and appeared to be related to the higher dosage which was not chosen as the optimal dose for the phase III testing. Despite this clarification, 3 minutes later Reuters released the headline saying "Deaths and side effects MAR Alzheimer's drug"???
Now for the fun part. This happened after 4 p.m. So the market was closed, but in after hours trading all of a sudden there was a heavy push to unload stock. The volume was such that the stock dropped from $33.75 to $20, the kind of haircut you would expect from a failed trial. In the next two days, by extraordinary coincidence, Elan and its partner Biogen were informed that two patients taking another drug, Tysabri, had tested positive for a rare brain side effect that is mentioned in their black box warning label. Tysabri has a long story in and of itself because it was withdrawn from the market a few years ago, then reinstated with a very controlled patient monitoring program to ensure that these cases are picked up early and minimize the chance of a fatality. The companies and the FDA were expecting a case to eventually show up, but the risk quoted of 1:1000 (quoted in the label) has not been observed and the FDA is very unlikely to do anything because many drugs that treat difficult diseases like MS have a risk/benefit profile. Nothing is risk free. Notwithstanding this, Elan's stock was forced down to $10 by Friday's close. Undoubtedly people sell on news of this nature, however, the part that raises eyebrows is the number of put that were bought in the last few weeks, especially the 30K just before market close and the formal announcement of the PML cases. A conspiracy theorist would put forth that somebody knew in advance of this information and used the giant loopeholes in the market to create greater damage than was warranted. I like how this blog diared the situation:
"Finally, a word on the stock market reaction to the Tysabri "news". It is quite remarkable that the report of the expected PML cases was able to trigger 30% and 50% declines in the stock prices of Biogen Idec and Elan, respectively. Sensational media and scare-mongering analyst reports, some of them fabricated, accompanied short-selling tactics aimed at suggesting rock-bottom valuations. At one point for example, Elan traded down over 75% in relatively light German trading. Also noteworthy was that 5 minutes before the market close and announcement of the PML cases, 30,000 August '08 Elan put options were traded for what must have been an amazing $30M-dollar-in-5-minute gain.
As the financial world is starting to realize, abusive short-selling aimed at destroying the ability of companies to grow, which in the case of biotechs is designed to undermine their ability to fund drug development, is very real. This should be of great concern to the biotech industry, and it is hoped that trade organizations such as BIO seize the opportunity to put pressure on the SEC to address this problem not just for the benefit of a select number of financial companies."
Link to full diary here
He makes the point that drew me to posting this here, rather than preaching to the choir on the stock boards. This affects every one of us in that new molecules that Elan has prepared to develop will now languish while the company tries to claw its way back to the financial health it held pre the meeting. No fundamental has changed since last Monday, they just were ripe for pillaging by the sharks who knew that there wasn't anybody likely to stop them. The SEC will probably take a look at those suspect puts and others that surfaced, but they haven't done a blessed thing yet with other similar situations, and are only now acknowledging there is a problem because their Wall Street buddies are complaining. Alzheimer's and MS are two disease that a great many people will have to deal with. I remember reading here a touching diary of a Kossack caregiver and I was struck by how many of us have had to deal in one way or another with this dreaded disease. If the SEC and our congressional representatives don't address this problem they will be hurting themselves in the end of the day, few of us are blessed with a life free from disease.
Sorry if I was not clear in places, it has been a trying time. I've been here before with this company (and for some it is the 3rd time), but those incidences were understandable, this was different. In this case I honestly believe it only happened because there is truly not a level playing field.
Antwort auf Beitrag Nr.: 36.758.148 von Birgit.Tersteegen am 13.03.09 08:47:19Birgit,
ich habe mir gerade noch mal die jüngsten Aussagen von Dale Schenk in Sachen Alzheimer durchgelesen.
Immerhin:
"We are enrolling patients in Phase 3 clinical trials,
and bapineuzumab has received fast track designation from the U.S. Food and Drug Administration."
Was meinst du, wann erste Resultate durchsickern?
Na ja, wir werden es an den Kursbewegungen bemerken.
posimist
ich habe mir gerade noch mal die jüngsten Aussagen von Dale Schenk in Sachen Alzheimer durchgelesen.
Immerhin:
"We are enrolling patients in Phase 3 clinical trials,
and bapineuzumab has received fast track designation from the U.S. Food and Drug Administration."
Was meinst du, wann erste Resultate durchsickern?
Na ja, wir werden es an den Kursbewegungen bemerken.
posimist
Antwort auf Beitrag Nr.: 34.340.127 von bernie55 am 20.06.08 12:12:13Viel Reisen für den Urlaub für wenig Geld http://www.angebot-thailand.de/Pauschalreisen.htm
Antwort auf Beitrag Nr.: 36.810.555 von posimist am 20.03.09 12:07:15....HI!
Tja,ich vermute wir werden es wirklich nur an den Kursbewegungen sehen...ich hoffe,dass sich in den nächsten Tagen die Ergebnisse der Verhandlungen mit der Citybank zeigen....Schönes WE!
Tja,ich vermute wir werden es wirklich nur an den Kursbewegungen sehen...ich hoffe,dass sich in den nächsten Tagen die Ergebnisse der Verhandlungen mit der Citybank zeigen....Schönes WE!
In 4Q 08, Elan Corporation PLC(NYSE:ELN)recorded q-o-q decline in its top-selling drug; Tysabri, after the report of 5 cases of Progressive Multifocal Leukoencephalopathy (PML; a fatal brain disorder) associated with its use. Although we believe Tysabri will continue to gain market share over the medium term, the reported cases of PML are likely to slowdown the growth of Tysabri’s sales and any further cases will severely impact the drugs future, negatively impacting Elan. Consequently, we hold a conservative outlook for Elan’s growth over the forthcoming year. In addition, the Phase III clinical trial of Bapineuzumab is now being conducted by Pfizer Inc. (Pfizer), as it has recently acquired Wyeth Inc. (Wyeth), which was Elan’s partner in the development of Bapineuzumab. We maintain our cautious outlook for the clinical development of Bapineuzumab based on the disappointing Phase II results and until further details are available from Pfizer. On 13 January 2009, Elan announced the evaluation of strategic alternatives (including the sale of minority stake or strategic partnerships) by hiring Citigroup Global Markets Inc. (Citigroup) as advisor. The strategic alternative is aimed at obtaining access to necessary financial resources and infrastructure to accelerate development and commercialization of Elan’s R&D pipeline, as discussed in our company news alert dated 14 January 2009. Elan’s current cash position can only support its full year R&D spending in FY2009, which demonstrates its current weak cash position. In addition, Elan has approximately US$1.1 bn of debt maturing in FY 2011. Considering the significant repayment liability arising within the next 2 years and the anticipated negative cash flows from operations over the next 2 years, we believe Elan will be in a weaker position while negotiating with potential buyers. Elan continues to focus on the high growth Central Nervous System (CNS) disorder management market, with its anticipated drug; Bapineuzumab. Consequently, we believe Elan is an attractive target for global pharmaceutical majors. However, our primary concern is Elan’s weak bargaining power, which renders the company unable to achieve optimum prices while selling its assets. We believe Elan’s weak cash position may further worsen, resulting in a negative cash balance in FY2012. Although Elan has multiple drugs in various stages of development, we believe the current weakness in cash flows will negatively impact the development of drugs, leading to longer than expected time to be revenue accretive. In light of the above mentioned factors, we hold a weak outlook for revenue growth over the next 2 years. As the company will have to continue to invest in its R&D; given the weak cash position, we expect the company to focus on cost reduction measures, particularly at the Selling, General and Administrative (SG&A) level, which are likely to support margin improvement, going forward. However, we maintain our weak outlook for the company’s future cash position and await further clarity on this matter from Management. Hence, we hold a weak outlook for the ADR.
http://blogs.iirgroup.com/?p=11517
http://blogs.iirgroup.com/?p=11517
hi @ all .....nette Grüsse in die Runde....warum der Kurs wohl so steigt...ob wieder jemand mehr weiss...?? Jeden tag 20% + das einen Monat-----dann könnte Kelly Martin im Amt bleiben...
Gute Nacht!
Creative Disruption
Life Sciences Entrepreneur
Josh Wolfe, Editor Forbes/Wolfe Emerging Tech Report, 03.26.09, 06:00 AM EDT
New ways to understand complex processes, like the workings of tumor cells or the immune system, will lead to areas for drug development.
Dr. Larry Fritz has founded and developed several successful biotechnology companies. His most recent company, Covella Pharmaceuticals, is focused on new mechanistic approaches to inflammatory diseases.
Prior to Covella, Fritz founded Conforma Therapeutics and served as its president and CEO from inception in 1999 through its acquisition by Biogen Idec (nasdaq: BIIB - news - people ) in 2006. Dr. Fritz was also a founder and director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma in conjunction with Biogen Idec's acquisition; Cabrellis was subsequently acquired by Pharmion.
Prior to Conforma, Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corp. (nyse: ELN - news - people ), and Idun Pharmaceuticals, subsequently acquired by Pfizer (nyse: PFE - news - people ). As vice president of research at Athena, his work led to the clinical development of products for multiple sclerosis, Alzheimer's disease and neuromuscular disorders. In addition to his entrepreneurial start-up activities, Fritz also has experience as the CEO of a public biotechnology company.
Following the sale of Conforma in 2006, he served as president and CEO of Anadys Pharmaceuticals (nasdaq: ANDS - news - people ), a Nasdaq-listed company working on viral diseases and oncology. Fritz also serves as a venture partner with Westfield Capital Management. He holds an A.B. degree in Biochemical Sciences from Harvard, an M.S. degree in Physiology from University College London and a Ph.D. in Biophysics from Rockefeller University.
Josh Wolfe: Walk the readers through your background and how you got involved in the life sciences.
Larry Fritz: I'm a scientist by training. I did my undergrad in biochemistry at Harvard and a Ph.D. in biophysics at Rockefeller University. At Rockefeller, I was in a rather small biophysics lab doing neurobiology research, measuring the electrical properties of cells in neurons and muscle. I was interested in aspects of brain function, but I wanted to move in a more biochemical direction instead of just being, as I like to say, "at the back end of an electrode." That is, if you really want to understand brain function, you need to study the system interactions at the molecular level. That was my introduction to molecular biology, and I came out to California in the early 1980s to start looking at problems in neurobiology using emerging molecular tools and techniques.
So you were a really bright young Ph.D. neurophysiologist--a title likely to immediately confuse most people! How did you get involved with start-up companies?
Comment On This Story
I always thought I would go into academics, but at some gut level I got really excited about the biotechnology industry that was emerging at the time. Only a handful of companies like Genentech and Amgen even existed at that point. I decided, rather than take an academic position, I would see if somebody would hire me in the biotech industry, even though I wasn't the typical "type."
Despite the fact that my educational background was a bit unusual, a Bay-area company called California Biotechnology decided to hire me. For a time, I think I was the only card-carrying neurobiologist in the entire biotech industry! While there, I worked on problems in the cardiovascular system and started a small neurobiology group within the company. Around that time, the first molecular hooks into Alzheimer's disease had just been discovered within the academic world, and I formed a collaboration with some academics to explore the prospects.
Through that collaboration, I was introduced to a seed-funding group called Avalon Ventures. We maintained an ongoing discussion, which ultimately led to the founding of my first company, Athena Neurosciences. That is where I first met Larry Bock, and we put Athena together. [Full disclosure: Larry is a partner at my firm, Lux Capital.] I ran R&D for about seven years, we took the company public, and it was a great success story both financially and medically. I'm proud to say that some of the work we did back then has stood the test of time. For instance, we developed a drug called Tysabri, which is the single most effective drug for multiple sclerosis, and we invented that drug from absolute concept.
What led you from Athena to your subsequent start-ups?
Over the course of all our research at Athena, I had gotten quite interested in the simple-minded fundamental question of why cells die in neurodegenerative diseases, such as Alzheimer's and Parkinson's. It turns out that this is not a stupid question, but rather a deep question. Emerging science at the time was trying to understand the process of genetically programmed cell death (called apoptosis), and we wanted to see if we could explore this process and perhaps control it.
We formed Idun Pharmaceuticals in San Diego in 1993, focused partly on degenerative diseases and party on oncology. I ran the science side for about seven years, and it was still an independent private company when I left.
Afterward, I formed a company called Conforma Therapeutics to focus on another fundamental problem in cell biology: protein folding. At Conforma, our research centered on what are called "chaperone proteins," a special class of proteins that assist in the folding of other proteins. In essentially all cancer cells, the key signals that allow these abnormal cells to survive and divide require careful control. What was emerging from the research was the recognition that cancer cells are particularly dependent on signaling molecules, and these require close control by chaperone proteins so that the signaling molecules fold correctly. In forming the company, we took a bet that five years hence, every major pharmaceutical company would have a chaperone proteins group. The company was eventually sold to Biogen Idec.
In the vast expanse of scientific research, how do you decide which discoveries could form the foundation for a successful company?
What has always grabbed my attention is where fundamental new cell biology intersects with opportunities for drug development. The founding of each of these companies was triggered by the emergence of a fundamental new area of molecular and cell biology, where important new processes with broad implications were just being discovered. What I've learned is that if something is important in biology, it usually turns out that it's important in disease as well.
Many of your companies have been based, at least partially, on work spun-out from the prior organization you had just left. Why start from scratch instead of developing products with the resources already at hand?
The reality is that it's fundamentally difficult to start something new and early. The value of a maturing company is really being judged by the later-stage opportunities, and it's hard to bring brand-new things into an ongoing organization. In my experience, it's much easier to start anew.
What exciting areas are you keeping your eye on today?
There are a few potential ideas for companies I've been eying. Most are still very early but could be important in six months' time. In many complex processes, like the workings of tumor cells or the immune system, there are thousands of papers published every year on very specific sub-topics, but it is hard to identify those fundamentally new mechanisms that will lead to truly novel and efficacious therapeutics. However, once in a while, these fundamental understandings emerge, and those are very attractive areas for drug development.
One really interesting example of this was just published in Nature by Genentech's neurobiology group. It relates to the biology of the precursor protein that gives rise to the plaque in Alzheimer's disease. This protein has been known for a long time and is well-studied, but the new results suggest that this protein may have another totally unexpected function that relates directly to the neuronal cell death that characterizes Alzheimer's disease.
What's something you've learned recently that's surprised you or changed your perception about the world?
Something that really hit me recently was the realization of the enormous complexity of the economic systems in the world. I'm obviously not an economist, and prior to this crisis, I had never actually thought about these systems that deeply. As everything was unraveling this past fall, I was finding myself riveted by what I was reading in The Wall Street Journal. I struggled just trying to understand what was happening enough to form an educated opinion! I found that experience both humbling and interesting.
How do you stay humble amid the spotlight of success?
As scientists, we're trained to focus on those things we don't know. It's all I focus on. I think it is important to have that sense of wonder about the world, to realize that there are all of these important things that are out there that we simply do not understand. For a neurobiologist, it's particularly easy to maintain that sense of wonder--who can say that they really understand what's going on in their brain when they bring up a memory or decide to say hello?
We have come a great way in our understanding of areas like physics and biology, but in most of these realms, I believe we're still just scratching the surface.
Josh Wolfe is editor of the Forbes Wolfe Emerging Tech Report. Click here for more of his analysis of the evolving nanotechnology sector.
http://www.forbes.com/2009/03/23/fritz-pfizer-biogen-leaders…
Life Sciences Entrepreneur
Josh Wolfe, Editor Forbes/Wolfe Emerging Tech Report, 03.26.09, 06:00 AM EDT
New ways to understand complex processes, like the workings of tumor cells or the immune system, will lead to areas for drug development.
Dr. Larry Fritz has founded and developed several successful biotechnology companies. His most recent company, Covella Pharmaceuticals, is focused on new mechanistic approaches to inflammatory diseases.
Prior to Covella, Fritz founded Conforma Therapeutics and served as its president and CEO from inception in 1999 through its acquisition by Biogen Idec (nasdaq: BIIB - news - people ) in 2006. Dr. Fritz was also a founder and director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma in conjunction with Biogen Idec's acquisition; Cabrellis was subsequently acquired by Pharmion.
Prior to Conforma, Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corp. (nyse: ELN - news - people ), and Idun Pharmaceuticals, subsequently acquired by Pfizer (nyse: PFE - news - people ). As vice president of research at Athena, his work led to the clinical development of products for multiple sclerosis, Alzheimer's disease and neuromuscular disorders. In addition to his entrepreneurial start-up activities, Fritz also has experience as the CEO of a public biotechnology company.
Following the sale of Conforma in 2006, he served as president and CEO of Anadys Pharmaceuticals (nasdaq: ANDS - news - people ), a Nasdaq-listed company working on viral diseases and oncology. Fritz also serves as a venture partner with Westfield Capital Management. He holds an A.B. degree in Biochemical Sciences from Harvard, an M.S. degree in Physiology from University College London and a Ph.D. in Biophysics from Rockefeller University.
Josh Wolfe: Walk the readers through your background and how you got involved in the life sciences.
Larry Fritz: I'm a scientist by training. I did my undergrad in biochemistry at Harvard and a Ph.D. in biophysics at Rockefeller University. At Rockefeller, I was in a rather small biophysics lab doing neurobiology research, measuring the electrical properties of cells in neurons and muscle. I was interested in aspects of brain function, but I wanted to move in a more biochemical direction instead of just being, as I like to say, "at the back end of an electrode." That is, if you really want to understand brain function, you need to study the system interactions at the molecular level. That was my introduction to molecular biology, and I came out to California in the early 1980s to start looking at problems in neurobiology using emerging molecular tools and techniques.
So you were a really bright young Ph.D. neurophysiologist--a title likely to immediately confuse most people! How did you get involved with start-up companies?
Comment On This Story
I always thought I would go into academics, but at some gut level I got really excited about the biotechnology industry that was emerging at the time. Only a handful of companies like Genentech and Amgen even existed at that point. I decided, rather than take an academic position, I would see if somebody would hire me in the biotech industry, even though I wasn't the typical "type."
Despite the fact that my educational background was a bit unusual, a Bay-area company called California Biotechnology decided to hire me. For a time, I think I was the only card-carrying neurobiologist in the entire biotech industry! While there, I worked on problems in the cardiovascular system and started a small neurobiology group within the company. Around that time, the first molecular hooks into Alzheimer's disease had just been discovered within the academic world, and I formed a collaboration with some academics to explore the prospects.
Through that collaboration, I was introduced to a seed-funding group called Avalon Ventures. We maintained an ongoing discussion, which ultimately led to the founding of my first company, Athena Neurosciences. That is where I first met Larry Bock, and we put Athena together. [Full disclosure: Larry is a partner at my firm, Lux Capital.] I ran R&D for about seven years, we took the company public, and it was a great success story both financially and medically. I'm proud to say that some of the work we did back then has stood the test of time. For instance, we developed a drug called Tysabri, which is the single most effective drug for multiple sclerosis, and we invented that drug from absolute concept.
What led you from Athena to your subsequent start-ups?
Over the course of all our research at Athena, I had gotten quite interested in the simple-minded fundamental question of why cells die in neurodegenerative diseases, such as Alzheimer's and Parkinson's. It turns out that this is not a stupid question, but rather a deep question. Emerging science at the time was trying to understand the process of genetically programmed cell death (called apoptosis), and we wanted to see if we could explore this process and perhaps control it.
We formed Idun Pharmaceuticals in San Diego in 1993, focused partly on degenerative diseases and party on oncology. I ran the science side for about seven years, and it was still an independent private company when I left.
Afterward, I formed a company called Conforma Therapeutics to focus on another fundamental problem in cell biology: protein folding. At Conforma, our research centered on what are called "chaperone proteins," a special class of proteins that assist in the folding of other proteins. In essentially all cancer cells, the key signals that allow these abnormal cells to survive and divide require careful control. What was emerging from the research was the recognition that cancer cells are particularly dependent on signaling molecules, and these require close control by chaperone proteins so that the signaling molecules fold correctly. In forming the company, we took a bet that five years hence, every major pharmaceutical company would have a chaperone proteins group. The company was eventually sold to Biogen Idec.
In the vast expanse of scientific research, how do you decide which discoveries could form the foundation for a successful company?
What has always grabbed my attention is where fundamental new cell biology intersects with opportunities for drug development. The founding of each of these companies was triggered by the emergence of a fundamental new area of molecular and cell biology, where important new processes with broad implications were just being discovered. What I've learned is that if something is important in biology, it usually turns out that it's important in disease as well.
Many of your companies have been based, at least partially, on work spun-out from the prior organization you had just left. Why start from scratch instead of developing products with the resources already at hand?
The reality is that it's fundamentally difficult to start something new and early. The value of a maturing company is really being judged by the later-stage opportunities, and it's hard to bring brand-new things into an ongoing organization. In my experience, it's much easier to start anew.
What exciting areas are you keeping your eye on today?
There are a few potential ideas for companies I've been eying. Most are still very early but could be important in six months' time. In many complex processes, like the workings of tumor cells or the immune system, there are thousands of papers published every year on very specific sub-topics, but it is hard to identify those fundamentally new mechanisms that will lead to truly novel and efficacious therapeutics. However, once in a while, these fundamental understandings emerge, and those are very attractive areas for drug development.
One really interesting example of this was just published in Nature by Genentech's neurobiology group. It relates to the biology of the precursor protein that gives rise to the plaque in Alzheimer's disease. This protein has been known for a long time and is well-studied, but the new results suggest that this protein may have another totally unexpected function that relates directly to the neuronal cell death that characterizes Alzheimer's disease.
What's something you've learned recently that's surprised you or changed your perception about the world?
Something that really hit me recently was the realization of the enormous complexity of the economic systems in the world. I'm obviously not an economist, and prior to this crisis, I had never actually thought about these systems that deeply. As everything was unraveling this past fall, I was finding myself riveted by what I was reading in The Wall Street Journal. I struggled just trying to understand what was happening enough to form an educated opinion! I found that experience both humbling and interesting.
How do you stay humble amid the spotlight of success?
As scientists, we're trained to focus on those things we don't know. It's all I focus on. I think it is important to have that sense of wonder about the world, to realize that there are all of these important things that are out there that we simply do not understand. For a neurobiologist, it's particularly easy to maintain that sense of wonder--who can say that they really understand what's going on in their brain when they bring up a memory or decide to say hello?
We have come a great way in our understanding of areas like physics and biology, but in most of these realms, I believe we're still just scratching the surface.
Josh Wolfe is editor of the Forbes Wolfe Emerging Tech Report. Click here for more of his analysis of the evolving nanotechnology sector.
http://www.forbes.com/2009/03/23/fritz-pfizer-biogen-leaders…
Elan shares jump on fresh talk of Lundbeck bid
LONDON, March 26 (Reuters) - Shares in Irish biotechnology firm Elan jumped 11 percent on Thursday on market talk Denmark's Lundbeck was lining up an imminent bid at 8 euros per shares, dealers said.
Anders Schroll, head of corporate communications at Lundbeck, declined to comment, as did a spokeswoman at Elan (nyse: ELN - news - people ).
Elan hired Citigroup (nyse: C - news - people ) in January to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company, and Lundbeck was tipped soon after by Danish and Irish newspapers as a possible buyer.
Some analysts see the two companies, both with a focus on neurology, as a good strategic fit.
Lundbeck's biggest drug is antidepressant Cipralex, sold in the United States as Lexapro. It faces generic competition for the drug in major markets starting in 2012 as patents run out and Lundbeck has repeatedly said it is looking for deals to boost its post-Cipralex prospects.
Elan shares were 11.3 percent higher at 5.45 euros by 1450 GMT, while Lundbeck was 2.1 percent higher at 98 Danish crowns.
http://www.forbes.com/feeds/afx/2009/03/26/afx6217498.html
LONDON, March 26 (Reuters) - Shares in Irish biotechnology firm Elan jumped 11 percent on Thursday on market talk Denmark's Lundbeck was lining up an imminent bid at 8 euros per shares, dealers said.
Anders Schroll, head of corporate communications at Lundbeck, declined to comment, as did a spokeswoman at Elan (nyse: ELN - news - people ).
Elan hired Citigroup (nyse: C - news - people ) in January to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company, and Lundbeck was tipped soon after by Danish and Irish newspapers as a possible buyer.
Some analysts see the two companies, both with a focus on neurology, as a good strategic fit.
Lundbeck's biggest drug is antidepressant Cipralex, sold in the United States as Lexapro. It faces generic competition for the drug in major markets starting in 2012 as patents run out and Lundbeck has repeatedly said it is looking for deals to boost its post-Cipralex prospects.
Elan shares were 11.3 percent higher at 5.45 euros by 1450 GMT, while Lundbeck was 2.1 percent higher at 98 Danish crowns.
http://www.forbes.com/feeds/afx/2009/03/26/afx6217498.html
Financial Times - Elan Soars on Lundbeck bid talk
http://www.ft.com/cms/s/0/71d95196-1a6e-11de-9f91-0000779fd2…
Elan soars on Lundbeck bid talk
By Miles Johnson
Published: March 27 2009 02:00 | Last updated: March 27 2009 02:00
Shares in Irish biotech company Elan jumped yesterday on rumours that Denmark's Lundbeck was preparing to launch a €8-per-share bid.
Speculation over Elan has been bubbling since the company engaged Citigroup in January to advise it on a strategic review to secure access to fresh funds.
Several options, including a merger or sale, were presented to shareholders, but the board is understood to be only considering such a move as a last resort and would prefer to find a strategic partner, according to people with knowledge of the company. A move by Lundbeck is also considered to be unlikely so soon after it acquired US company Ovation Pharmaceuticals for $900m in February.
Elan, which has a market capitalisation of €2.6bn remains an attractive target due to its multiple sclerosis drug Tysabri and valuable development pipeline including ten late stage clinical trials set for next year.
Elan's Dublin-listed shares rose 15 per cent to €5.64, marking a 41 per cent rise since Tuesday.
An Elan spokeswoman said the company did not comment on market speculation. Lundbeck shares rose 1.5 per cent to DKr97.50.
The Elan talk comes as expectations grow for a round of smaller deals in the European pharma sector - with France's Sanofi-Aventis rumoured to be hot on the acquisition trail. Sanofi-Aventis rose 0.9 per cent to €42.28 while Germany's Merck gained 1.3 per cent to €66.08.
Swiss drugmaker Roche said it had effectively completed its $46bn takeover of US biotechnology house Genentech.
The Basel-based company holds 93 per cent of Genentech shares following its tender offer and plans to squeeze out the remaining shareholders by the end of the first half. Roche shares fell 1.4 per cent to SFr146.70.
In the wider market, European shares skirted in and out of negative territory. The pan-European FTSE Eurofirst 300 eventually closed higher by 0.2 per cent at 745.33.
Copyright The Financial Times Limited 2009
http://www.ft.com/cms/s/0/71d95196-1a6e-11de-9f91-0000779fd2…
Elan soars on Lundbeck bid talk
By Miles Johnson
Published: March 27 2009 02:00 | Last updated: March 27 2009 02:00
Shares in Irish biotech company Elan jumped yesterday on rumours that Denmark's Lundbeck was preparing to launch a €8-per-share bid.
Speculation over Elan has been bubbling since the company engaged Citigroup in January to advise it on a strategic review to secure access to fresh funds.
Several options, including a merger or sale, were presented to shareholders, but the board is understood to be only considering such a move as a last resort and would prefer to find a strategic partner, according to people with knowledge of the company. A move by Lundbeck is also considered to be unlikely so soon after it acquired US company Ovation Pharmaceuticals for $900m in February.
Elan, which has a market capitalisation of €2.6bn remains an attractive target due to its multiple sclerosis drug Tysabri and valuable development pipeline including ten late stage clinical trials set for next year.
Elan's Dublin-listed shares rose 15 per cent to €5.64, marking a 41 per cent rise since Tuesday.
An Elan spokeswoman said the company did not comment on market speculation. Lundbeck shares rose 1.5 per cent to DKr97.50.
The Elan talk comes as expectations grow for a round of smaller deals in the European pharma sector - with France's Sanofi-Aventis rumoured to be hot on the acquisition trail. Sanofi-Aventis rose 0.9 per cent to €42.28 while Germany's Merck gained 1.3 per cent to €66.08.
Swiss drugmaker Roche said it had effectively completed its $46bn takeover of US biotechnology house Genentech.
The Basel-based company holds 93 per cent of Genentech shares following its tender offer and plans to squeeze out the remaining shareholders by the end of the first half. Roche shares fell 1.4 per cent to SFr146.70.
In the wider market, European shares skirted in and out of negative territory. The pan-European FTSE Eurofirst 300 eventually closed higher by 0.2 per cent at 745.33.
Copyright The Financial Times Limited 2009
Elan beendet einen Arm des Bap-trials wegen Nebenwirkungen bei der 2.0 mg-Dosis...
Q&A—Bapineuzumab Phase 3 Protocol Amendment ----- From Elan's Website
http://www.elan.com/Images/IRWebsiteQA_tcm3-22318.pdf
Q&A—Bapineuzumab Phase 3 Protocol Amendment
Elan President Carlos Paya, MD, PhD
Note: This Q&A is intended to address additional questions investors may have concerning the announcement made by Elan and Wyeth, on April 2, that we plan to amend the bapineuzumab Phase 3 clinical study protocols. That announcement may be read here.
Q. What is changing in the bapineuzumab Phase 3 clinical trial?
Dr. Paya: Effective immediately, we are discontinuing the highest of three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in patients with mild to moderate Alzheimer’s disease who do not carry the Apolipoprotein E4 (ApoE4) allele—the "non-carrier" bapineuzumab study.
Q. Why are Elan and Wyeth making this change?
Dr. Paya: We are making this change in concurrence with the independent Safety Monitoring Committee overseeing the study, following its review of vasogenic edema (VE) in the ongoing Phase 3 clinical program.
Q. What did the independent Safety Monitoring Committee determine?
Dr. Paya: The independent Safety Monitoring Committee (SMC) reviewed unblinded data in the non-carrier studies that made it clear that continued development of the highest dose was not advisable.
Q. Is this a safety-based decision?
Dr. Paya: Yes. The decision to remove the 2.0 mg/kg (the highest) dose from development reduces potential risk of harm to patients.
Q. What are the other doses in the non-carrier study? Are there safety issues with these?
Dr. Paya: The other doses in the non-carrier study are .5 mg/kg and 1.0 mg/kg. The Safety Monitoring Committee also reviewed unblinded data from these dose cohorts and does not have concerns about them at this time.
Q. What will happen to the patients who were receiving the 2.0 mg/kg dose?
Dr. Paya: In consultation with the independent Safety Monitoring Committee, Elan and Wyeth plan to amend the study protocols to allow these patients to be reassigned to the 1.0 mg/kg dose.
Q. Will the protocol amendment affect the "carrier trials" in North America or internationally?
Dr. Paya: No. This decision has no impact on two other ongoing studies, which are testing a single 0.5 mg/kg dose of bapineuzumab in patients who carry the ApoE4 allele (carriers). No changes are planned for the carrier studies.
Q. What is Vasogenic Edema?
Dr. Paya: Vasogenic edema (VE) is an accumulation of water in brain tissue, possibly related to changes in blood vessel permeability. VE is most frequently detected on MRI scans in asymptomatic patients exposed to bapineuzumab, but may be associated with symptoms in some patients. In a phase 2 trial of bapineuzumab, VE was observed more frequently in patients who were carriers of the ApoE4 allele and was more likely to occur at higher doses of bapineuzumab. 2
Q. Will this announcement impact enrollment and study completion timing?
Dr. Paya: Elan and Wyeth are currently working on a re-assessment of the projected enrollment
completion of the North American Phase 3 Non-Carrier study. The International studies started
after the North American studies. Patient recruitment is ongoing in these trials. The two non-carrier trials were originally anticipated to enroll approximately 1,250 patients each. With the removal of the 2.0 mg/kg dose group, it is now expected that the studies will each have approximately 1,000 patients for efficacy evaluation. We continue to anticipate that the two carrier trials, which only test the 0.5 mg/kg dose, will enroll approximately 800 patients each; this is unchanged with today’s announcement
Q&A—Bapineuzumab Phase 3 Protocol Amendment ----- From Elan's Website
http://www.elan.com/Images/IRWebsiteQA_tcm3-22318.pdf
Q&A—Bapineuzumab Phase 3 Protocol Amendment
Elan President Carlos Paya, MD, PhD
Note: This Q&A is intended to address additional questions investors may have concerning the announcement made by Elan and Wyeth, on April 2, that we plan to amend the bapineuzumab Phase 3 clinical study protocols. That announcement may be read here.
Q. What is changing in the bapineuzumab Phase 3 clinical trial?
Dr. Paya: Effective immediately, we are discontinuing the highest of three dosing regimens, 2.0 mg/kg, in the two ongoing Phase 3 studies of bapineuzumab in patients with mild to moderate Alzheimer’s disease who do not carry the Apolipoprotein E4 (ApoE4) allele—the "non-carrier" bapineuzumab study.
Q. Why are Elan and Wyeth making this change?
Dr. Paya: We are making this change in concurrence with the independent Safety Monitoring Committee overseeing the study, following its review of vasogenic edema (VE) in the ongoing Phase 3 clinical program.
Q. What did the independent Safety Monitoring Committee determine?
Dr. Paya: The independent Safety Monitoring Committee (SMC) reviewed unblinded data in the non-carrier studies that made it clear that continued development of the highest dose was not advisable.
Q. Is this a safety-based decision?
Dr. Paya: Yes. The decision to remove the 2.0 mg/kg (the highest) dose from development reduces potential risk of harm to patients.
Q. What are the other doses in the non-carrier study? Are there safety issues with these?
Dr. Paya: The other doses in the non-carrier study are .5 mg/kg and 1.0 mg/kg. The Safety Monitoring Committee also reviewed unblinded data from these dose cohorts and does not have concerns about them at this time.
Q. What will happen to the patients who were receiving the 2.0 mg/kg dose?
Dr. Paya: In consultation with the independent Safety Monitoring Committee, Elan and Wyeth plan to amend the study protocols to allow these patients to be reassigned to the 1.0 mg/kg dose.
Q. Will the protocol amendment affect the "carrier trials" in North America or internationally?
Dr. Paya: No. This decision has no impact on two other ongoing studies, which are testing a single 0.5 mg/kg dose of bapineuzumab in patients who carry the ApoE4 allele (carriers). No changes are planned for the carrier studies.
Q. What is Vasogenic Edema?
Dr. Paya: Vasogenic edema (VE) is an accumulation of water in brain tissue, possibly related to changes in blood vessel permeability. VE is most frequently detected on MRI scans in asymptomatic patients exposed to bapineuzumab, but may be associated with symptoms in some patients. In a phase 2 trial of bapineuzumab, VE was observed more frequently in patients who were carriers of the ApoE4 allele and was more likely to occur at higher doses of bapineuzumab. 2
Q. Will this announcement impact enrollment and study completion timing?
Dr. Paya: Elan and Wyeth are currently working on a re-assessment of the projected enrollment
completion of the North American Phase 3 Non-Carrier study. The International studies started
after the North American studies. Patient recruitment is ongoing in these trials. The two non-carrier trials were originally anticipated to enroll approximately 1,250 patients each. With the removal of the 2.0 mg/kg dose group, it is now expected that the studies will each have approximately 1,000 patients for efficacy evaluation. We continue to anticipate that the two carrier trials, which only test the 0.5 mg/kg dose, will enroll approximately 800 patients each; this is unchanged with today’s announcement
Hi ELANIA
für die, die noch nicht kennen: US level2stockquotes
http://www.level2stockquotes.com/level-ii-quotes.html
Antwort auf Beitrag Nr.: 36.926.451 von surga am 06.04.09 14:07:31Hi!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Welcome back!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Liebe Grüsse!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
PS....musss gleich weg aber wir talken demnächst....
Birgit
Welcome back!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Liebe Grüsse!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
PS....musss gleich weg aber wir talken demnächst....
Birgit
OKI DOCKI Bis gleich! WAS MACHT BERNIE & POPPI?
Bis gleich! WAS MACHT BERNIE & POPPI?
Antwort auf Beitrag Nr.: 36.926.545 von Birgit.Tersteegen am 06.04.09 14:20:51........so, da bin ich auch mal wieder im WO Board......
... aber dann auch gleich schon wieder weg......
...einfach mal nur liebe Grüße in die ELAN Runde.....
bernie55
..... aber dann auch gleich schon wieder weg......
...einfach mal nur liebe Grüße in die ELAN Runde.....bernie55
Hi ...mal wieder was zu unserem Schätzchen...
HERE IS YOUR NEWS
4/22/2009 1:00:00 AM (Business Wire)
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc, today reported its first quarter 2009 financial results, highlighted by a 14% increase in revenue to $245.1 million and Adjusted EBITDA losses reduced by 59% to $6.0 million, compared to the first quarter of 2008, and significant advances in the company’s Biopharmaceuticals business.
Elan CEO Kelly Martin said that the company continued advancing its science toward patients, with particular focus on multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Mr. Martin noted that specific progress in the quarter included the continued growth of Tysabri and the advancement of Elan’s Alzheimer’s clinical portfolio.
Commenting on the company’s previously announced strategic review process, Mr. Martin said, “This process is continuing and we remain committed to exploring and objectively assessing all available options that balance the short-, intermediate- and long-term opportunities. We will communicate our progress at the appropriate time.”
Elan executive vice president and chief financial officer Shane Cooke said that the company was pleased with the solid start to the year, noting that Tysabri continues to grow and, with a number of new initiatives, Elan is confident it will see a reacceleration to a stronger growth trend. The improvement in Elan’s operating performance was offset by the inclusion of other net charges associated with the adjustments mainly to the Biopharmaceuticals business announced in February 2009, non-cash tax charges associated with the U.S. business, partially offset by a gain on a legal settlement. As a result, the net loss increased to $102.6 million.
Mr. Cooke added, “For the full year 2009, we remain on target to record double digit revenue growth and to be profitable on an Adjusted EBITDA basis.” Mr. Cooke also emphasized that the goal of Elan’s strategic review was to secure access to financial resources and commercial infrastructure that would enable the company to accelerate the development and commercialization of its extensive pipeline and product portfolio, while maximizing the ability of Elan’s shareholders to participate in the resulting long-term value creation.
To supplement its consolidated financial statements presented on a U.S. GAAP basis, Elan provides readers with EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) and Adjusted EBITDA, non-GAAP measures of operating results. EBITDA is defined as net income or loss plus or minus depreciation and amortization of costs and revenues, provisions for income tax and net interest expense. Adjusted EBITDA is defined as EBITDA plus or minus share-based compensation, other net charges, and net investment gains or losses. EBITDA and Adjusted EBITDA are not presented as, and should not be considered alternative measures of, operating results or cash flows from operations, as determined in accordance with U.S. GAAP. Elan’s management uses EBITDA and Adjusted EBITDA to evaluate the operating performance of Elan and its business and these measures are among the factors considered as a basis for Elan’s planning and forecasting for future periods. Elan believes EBITDA and Adjusted EBITDA are measures of performance used by some investors, equity analysts and others to make informed investment decisions. EBITDA and Adjusted EBITDA are used as analytical indicators of income generated to service debt and to fund capital expenditures. EBITDA and Adjusted EBITDA do not give effect to cash used for interest payments related to debt service requirements and do not reflect funds available for investment in the business of Elan or for other discretionary purposes. EBITDA and Adjusted EBITDA, as defined by Elan and presented in this press release, may not be comparable to similarly titled measures reported by other companies. Reconciliations of EBITDA and Adjusted EBITDA to net loss from continuing operations are set out in the tables above titled, “Non-GAAP Financial Information Reconciliation Schedule.”
(1) Elan’s debt covenants do not require it to maintain or adhere to any specific financial ratios. Consequently, the shareholders’ deficit has no impact on Elan’s ability to comply with its debt covenants.
Overview
Operating Results
For the first quarter of 2009, total revenue increased by 14% to $245.1 million, from $214.7 million for the same period in 2008. Revenue from the Biopharmaceuticals business grew by 28% while revenue from the Elan Drug Technologies (EDT) business decreased by 14%. The increase in revenue from the Biopharmaceuticals business was driven by a strong performance from Tysabri®, more than offsetting reduced sales of Azactam® and Maxipime®. Elan’s recorded sales of Tysabri increased 48% to $158.7 million for the first quarter of 2009, from $107.0 million for the first quarter of 2008, consistent with the 42% growth in global in-market net sales of Tysabri to $227.5 million in the first quarter of 2009. The decrease in revenue from the EDT business was principally due to timing differences of milestone payments earned and customer orders.
For the first quarter of 2009, the gross margin was $116.3 million, compared to $103.9 million for the first quarter of 2008. The increased gross margin was driven by significantly higher sales of Tysabri, which more than offset the loss of gross margin as a result of reduced sales of Azactam, Maxipime and revenues from EDT.
The operating loss before other net charges for the first quarter of 2009 was $35.2 million, a decrease of 17% from $42.6 million for the first quarter of 2008. This improved operating performance was driven by the 14% increase in revenue and the resulting increase in the gross margins. Selling, general and administrative (SG&A) expenses declined by 4% while research and development (R&D) costs increased by 11%.
For the first quarter of 2009, the net loss before tax was $88.6 million, compared to $83.4 million for the first quarter of 2008. This increase was primarily due to higher other net charges and R&D expenses, partially offset by the 14% increase in revenues and lower net investment losses. The increase in other net charges primarily relates to severance and restructuring charges of $22.2 million and non-cash asset impairment charges of $15.4 million, partially offset by a legal settlement gain of $18.0 million related to Elan’s Naprelan® product. These charges relate to the previously announced postponement of Elan’s biologics manufacturing activities, a strategic redesign and realignment of the R&D organization within Elan’s Biopharmaceuticals business, and reduction of related G&A and other support activities.
The provision for income taxes was $14.0 million in the first quarter of 2009, compared to $2.1 million in the first quarter of 2008. This follows the recognition of a net deferred tax asset of $236.6 million in the fourth quarter of 2008 related to Elan’s U.S. tax loss carryforwards, due to the recent and projected future profitability of Elan's U.S. operations. The tax charge for the quarter includes a non-cash amortization expense related to that asset as the underlying loss carryforwards are utilized to shelter taxable income in the United States. Elan expects its tax expense in future periods to include similar non-cash amortization expenses.
Adjusted EBITDA
For the first quarter of 2009, Adjusted EBITDA losses were $6.0 million, a decrease of 59% compared to Adjusted EBITDA losses of $14.6 million for the same period of 2008. The improvement principally reflects the 14% increase in revenue and improved operating margins.
A reconciliation of Adjusted EBITDA to net loss, is presented in the table titled, “Unaudited Non-GAAP Financial Information – EBITDA,” included on page 3. Included at Appendix I is a further analysis of the results and Adjusted EBITDA between the Biopharmaceuticals and EDT businesses.
Total Revenue
For the first quarter of 2009, total revenue increased 14% to $245.1 million from $214.7 million for the same period of 2008, primarily driven by the strong growth of Tysabri. Revenue from the Biopharmaceuticals business increased by 28% while revenue from the EDT business decreased by 14%. Revenue is analyzed below between revenue from the Biopharmaceuticals and EDT business units.
Revenue from the Biopharmaceuticals business
For the first quarter of 2009, revenue from the Biopharmaceuticals business increased by 28% to $185.4 million from $145.3 million for the first quarter of 2008. The increase was primarily driven by strong growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime.
Tysabri
Global in-market net sales of Tysabri can be analyzed as follows:
For the first quarter of 2009, Tysabri in-market net sales increased by 42% to $227.5 million from $159.7 million for the same period of 2008. The increase reflects strong patient demand across global markets. At the end of March 2009, approximately 40,000 patients were on therapy worldwide, including approximately 20,800 commercial patients in the United States and approximately 18,500 commercial patients in the ROW, representing an increase of 6% over the approximately 37,600 patients who were on therapy at the end of December 2008.
Cumulatively, in the post-marketing setting approximately 52,000 patients have been treated with Tysabri as of the end of March 2009. Of those patients, approximately 24,900 have received at least one year of Tysabri therapy, approximately 14,400 patients have received at least 18 months of Tysabri therapy, and 6,800 patients have received at least 24 months of Tysabri therapy. In the post marketing setting, there have been six confirmed cases of progressive multifocal leukoencephalopathy (PML) in Tysabri-treated MS patients.
Tysabri was developed and is being marketed in collaboration with Biogen Idec Inc. (Biogen Idec). In general, subject to certain limitations imposed by the parties, Elan shares with Biogen Idec most of the development and commercialization costs for Tysabri. Biogen Idec is responsible for manufacturing the product. In the United States, Elan purchases Tysabri from Biogen Idec and is responsible for distribution. Consequently, Elan records as revenue the net sales of Tysabri in the U.S. market. Elan purchases product from Biogen Idec at a price that includes the cost of manufacturing, plus Biogen Idec’s gross margin on Tysabri, and this cost, together with royalties payable to other third parties, is included in cost of sales.
Outside of the United States, Biogen Idec is responsible for distribution and Elan records as revenue its share of the profit or loss on these sales of Tysabri, plus Elan’s directly-incurred expenses on these sales.
As a result of the continuing strong growth in Tysabri sales, in January 2009, Elan made an optional payment of $50.0 million to Biogen Idec in order to maintain an approximate 50% share of Tysabri for annual global in-market net sales of Tysabri that are in excess of $1.1 billion. This payment has been capitalized as an intangible asset and is being amortized on a straight-line basis over approximately 11 years. There are no further milestone payments required for Elan to retain its approximate 50% profit share.
Tysabri – U.S.
In the U.S. market, Elan recorded net sales of $116.0 million for the first quarter of 2009, an increase of 34% over net sales of $86.3 million in the same period of 2008. Almost all of these sales are for the MS indication.
At the end of March 2009, approximately 20,800 patients were on commercial therapy, which represents an increase of 3% over the approximately 20,200 since the end of December 2008 and 36% since the end of March last year.
Tysabri – ROW
In the ROW market, Biogen Idec is responsible for distribution and Elan records as revenue its share of the profit or loss on ROW sales of Tysabri, plus Elan’s directly-incurred expenses on these sales. As a result, in the ROW market, Elan recorded net revenue of $42.7 million for the first quarter of 2009, compared to $20.7 million for the first quarter of 2008, an increase of 106%. Elan’s net Tysabri ROW revenue is calculated as follows:
At the end of March 2009, approximately 18,500 patients, principally in the European Union (EU), were on commercial therapy, an increase of 9% over the approximately 16,900 who were on therapy at the end of December 2008 and 81% over the end of March last year.
Other Biopharmaceuticals products
Azactam revenue decreased 29% to $17.2 million for the first quarter of 2009, compared to $24.2 million for the same period of 2008. The decrease was principally due to supply shortages, which are expected to be resolved by mid-year. Azactam lost its patent exclusivity in October 2005 and its future sales are expected to be negatively impacted by generic competition. However, no generic form of Azactam has been approved to date.
Maxipime revenue decreased 50% to $5.0 million for the first quarter of 2009 from $10.1 million for the first quarter of 2008. The decrease was principally due to generic competition. The first generic cefepime hydrochloride was launched in June 2007, and additional generic forms of Maxipime have since been launched.
Prialt revenue was $4.1 million for the first quarter of 2009, compared to $3.8 million for the same period of 2008, an increase of 8%. The increase was primarily due to higher demand for the product.
Revenue from the EDT business
For the first quarter of 2009, revenue from the EDT business decreased by 14% to $59.7 million from $69.4 million for the first quarter of 2008.
Manufacturing revenue and royalties comprise revenue earned from products manufactured for clients and royalties earned principally on sales by clients of products that incorporate Elan’s technologies. Except as noted above, no other product accounted for more than 10% of total manufacturing revenue and royalties for the first quarter of 2009 or 2008. For the first quarter of 2009, of the total of $57.5 million (2008: $62.0 million) in manufacturing revenue and royalties, 43% (2008: 42%) consisted of royalties received on products that were not manufactured by Elan.
An additional analysis of the results between the Biopharmaceuticals and EDT businesses are set out in Appendix I. For the first quarter of 2009, Adjusted EBITDA from the EDT business decreased by $4.1 million to $20.7 million from $24.8 million for the same period of 2008. The first quarter of 2008 benefitted from milestones associated with the approval of Luvox CR® and Zanaflex® achieving $105 million in cumulative sales. EDT revenues, and their impact on Adjusted EBITDA, vary from quarter to quarter based on a number of factors including the timing of customer orders and contractual in-market sales hurdles for royalties.
Potential generic competitors have challenged the existing patent protection for several of the products from which Elan earns manufacturing revenue and royalties. Elan and its clients defend the parties’ intellectual property rights vigorously. However, if these challenges are successful, Elan’s manufacturing revenue and royalties will be materially and adversely affected.
Operating Expenses
Selling, general and administrative
Although revenues increased by 14% in the first quarter of 2009, SG&A expenses decreased by 4% to $71.0 million from $74.0 million for the same period of 2008. The decrease principally reflects reduced litigation expenses, along with continued cost control. SG&A expense for the three months ended March 31, 2009 and 2008 can be analyzed as follows:
The SG&A expenses related to the Tysabri ROW sales are reflected in the Tysabri ROW revenue as previously described on page 9.
Research and development
For the first quarter of 2009, R&D expenses increased 11% to $80.5 million from $72.5 million for the same period of 2008. The increase was primarily due to increased expenses associated with the progression of Elan’s Alzheimer’s disease programs, including the Phase 3 clinical trials of bapineuzumab.
Other net charges
Other net charges for the three months ended March 31, 2009 and 2008 were as follows:
For the first quarter of 2009, other net charges of $19.6 million primarily consist of severance and restructuring charges of $22.2 million and non-cash asset impairment charges of $15.4 million, partially offset by a legal settlement gain of $18.0 million. The severance and restructuring charges and asset impairment charges were principally associated with the postponement of Elan’s biologics manufacturing activities, the strategic redesign and realignment of the R&D organization within Elan’s Biopharmaceuticals business, and reduction of related support activities. These adjustments resulted in a reduction in Elan’s global workforce of approximately 230 positions, or 14% of its total workforce.
The legal settlement gain of $18.0 million relates to an agreement with Watson Pharmaceuticals, Inc. (Watson) to settle litigation with respect to Watson’s marketing of a generic version of Naprelan. As part of the settlement, Watson stipulated that Elan’s patent at issue is valid and enforceable and that Watson’s generic formulations of Naprelan infringed Elan’s patent. In connection with the settlement, Elan received $18.0 million from Watson in March 2009.
Net interest and investment losses
For the first quarter of 2009, net interest and investment losses decreased to $33.8 million from $37.8 million for the first quarter of 2008. This decrease was primarily due to net investment losses of $3.3 million in the first quarter of 2008, mainly related to investment impairments.
Movement in Shareholders’ Deficit
Elan’s debt covenants do not require it to maintain or adhere to any specific financial ratios. Consequently, the shareholders’ deficit has no impact on Elan’s ability to comply with its debt covenants.
Research and Development Update
During the course of 2009, Elan’s goal is to continue its progress throughout its R&D programs, including Alzheimer’s disease, Parkinson’s disease, MS and other neurodegenerative areas.
Alzheimer’s disease and other neurodegenerative diseases
Elan is focused on further enhancing its breakthrough basic and clinical research in Alzheimer’s disease. With bapineuzumab (AAB-001, a monoclonal antibody targeted against beta amyloid peptide), Elan and
Wyeth have discontinued the highest of three doses, 2.0 mg/kg, in the two ongoing Phase 3 studies in patients with mild to moderate Alzheimer’s disease who do not carry the Apolipoprotein E4 (ApoE4) allele (non-carriers). ApoE4 is a known genetic risk factor for development of Alzheimer’s disease. The decision was made in concurrence with the study’s independent Safety Monitoring Committee, following its review of vasogenic edema in the ongoing Phase 3 clinical program. The 0.5 mg/kg and 1.0 mg/kg doses in these two trials will continue as planned. Enrollment in these two trials is ongoing.
A paper published in Current Alzheimer’s Research, 2009, Vol. 6 No. 2 indicates that 4.6 years after immunization with AN 1792 (synthetic amyloid-Beta peptide), a sub-group of patients defined as antibody responders in the Phase 2a study, had evidence of low but detectable, sustained anti-AN1792 antibody titers. [AN1792 Study was discontinued in 2002 when 6% of patients developed meningoencephalitis] These patients demonstrated significantly reduced functional decline compared to patients who had received placebo during the initial phase of the study. Though this long-term follow-up data is limited and must be assessed cautiously, we believe that the data support the hypothesis that ABeta immunotherapy has the potential for long-term functional benefits.
On February 9, 2009, Elan and Biogen Idec announced the publication of new efficacy data on Tysabri in the March 2009 issue of The Lancet Neurology. Results of a retrospective analysis of data from the Phase 3 AFFIRM trial indicate that five-times as many multiple sclerosis patients taking Tysabri were free from disease activity versus placebo in the overall patient population. Results showed that two years after beginning treatment with Tysabri, 37 % of patients remained free of disease activity (as defined by absence of relapses, new MRI lesions or disability progression), compared to 7% of placebo-treated patients.
...mal wieder was zu unserem Schätzchen...HERE IS YOUR NEWS
4/22/2009 1:00:00 AM (Business Wire)
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc, today reported its first quarter 2009 financial results, highlighted by a 14% increase in revenue to $245.1 million and Adjusted EBITDA losses reduced by 59% to $6.0 million, compared to the first quarter of 2008, and significant advances in the company’s Biopharmaceuticals business.
Elan CEO Kelly Martin said that the company continued advancing its science toward patients, with particular focus on multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Mr. Martin noted that specific progress in the quarter included the continued growth of Tysabri and the advancement of Elan’s Alzheimer’s clinical portfolio.
Commenting on the company’s previously announced strategic review process, Mr. Martin said, “This process is continuing and we remain committed to exploring and objectively assessing all available options that balance the short-, intermediate- and long-term opportunities. We will communicate our progress at the appropriate time.”
Elan executive vice president and chief financial officer Shane Cooke said that the company was pleased with the solid start to the year, noting that Tysabri continues to grow and, with a number of new initiatives, Elan is confident it will see a reacceleration to a stronger growth trend. The improvement in Elan’s operating performance was offset by the inclusion of other net charges associated with the adjustments mainly to the Biopharmaceuticals business announced in February 2009, non-cash tax charges associated with the U.S. business, partially offset by a gain on a legal settlement. As a result, the net loss increased to $102.6 million.
Mr. Cooke added, “For the full year 2009, we remain on target to record double digit revenue growth and to be profitable on an Adjusted EBITDA basis.” Mr. Cooke also emphasized that the goal of Elan’s strategic review was to secure access to financial resources and commercial infrastructure that would enable the company to accelerate the development and commercialization of its extensive pipeline and product portfolio, while maximizing the ability of Elan’s shareholders to participate in the resulting long-term value creation.
To supplement its consolidated financial statements presented on a U.S. GAAP basis, Elan provides readers with EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) and Adjusted EBITDA, non-GAAP measures of operating results. EBITDA is defined as net income or loss plus or minus depreciation and amortization of costs and revenues, provisions for income tax and net interest expense. Adjusted EBITDA is defined as EBITDA plus or minus share-based compensation, other net charges, and net investment gains or losses. EBITDA and Adjusted EBITDA are not presented as, and should not be considered alternative measures of, operating results or cash flows from operations, as determined in accordance with U.S. GAAP. Elan’s management uses EBITDA and Adjusted EBITDA to evaluate the operating performance of Elan and its business and these measures are among the factors considered as a basis for Elan’s planning and forecasting for future periods. Elan believes EBITDA and Adjusted EBITDA are measures of performance used by some investors, equity analysts and others to make informed investment decisions. EBITDA and Adjusted EBITDA are used as analytical indicators of income generated to service debt and to fund capital expenditures. EBITDA and Adjusted EBITDA do not give effect to cash used for interest payments related to debt service requirements and do not reflect funds available for investment in the business of Elan or for other discretionary purposes. EBITDA and Adjusted EBITDA, as defined by Elan and presented in this press release, may not be comparable to similarly titled measures reported by other companies. Reconciliations of EBITDA and Adjusted EBITDA to net loss from continuing operations are set out in the tables above titled, “Non-GAAP Financial Information Reconciliation Schedule.”
(1) Elan’s debt covenants do not require it to maintain or adhere to any specific financial ratios. Consequently, the shareholders’ deficit has no impact on Elan’s ability to comply with its debt covenants.
Overview
Operating Results
For the first quarter of 2009, total revenue increased by 14% to $245.1 million, from $214.7 million for the same period in 2008. Revenue from the Biopharmaceuticals business grew by 28% while revenue from the Elan Drug Technologies (EDT) business decreased by 14%. The increase in revenue from the Biopharmaceuticals business was driven by a strong performance from Tysabri®, more than offsetting reduced sales of Azactam® and Maxipime®. Elan’s recorded sales of Tysabri increased 48% to $158.7 million for the first quarter of 2009, from $107.0 million for the first quarter of 2008, consistent with the 42% growth in global in-market net sales of Tysabri to $227.5 million in the first quarter of 2009. The decrease in revenue from the EDT business was principally due to timing differences of milestone payments earned and customer orders.
For the first quarter of 2009, the gross margin was $116.3 million, compared to $103.9 million for the first quarter of 2008. The increased gross margin was driven by significantly higher sales of Tysabri, which more than offset the loss of gross margin as a result of reduced sales of Azactam, Maxipime and revenues from EDT.
The operating loss before other net charges for the first quarter of 2009 was $35.2 million, a decrease of 17% from $42.6 million for the first quarter of 2008. This improved operating performance was driven by the 14% increase in revenue and the resulting increase in the gross margins. Selling, general and administrative (SG&A) expenses declined by 4% while research and development (R&D) costs increased by 11%.
For the first quarter of 2009, the net loss before tax was $88.6 million, compared to $83.4 million for the first quarter of 2008. This increase was primarily due to higher other net charges and R&D expenses, partially offset by the 14% increase in revenues and lower net investment losses. The increase in other net charges primarily relates to severance and restructuring charges of $22.2 million and non-cash asset impairment charges of $15.4 million, partially offset by a legal settlement gain of $18.0 million related to Elan’s Naprelan® product. These charges relate to the previously announced postponement of Elan’s biologics manufacturing activities, a strategic redesign and realignment of the R&D organization within Elan’s Biopharmaceuticals business, and reduction of related G&A and other support activities.
The provision for income taxes was $14.0 million in the first quarter of 2009, compared to $2.1 million in the first quarter of 2008. This follows the recognition of a net deferred tax asset of $236.6 million in the fourth quarter of 2008 related to Elan’s U.S. tax loss carryforwards, due to the recent and projected future profitability of Elan's U.S. operations. The tax charge for the quarter includes a non-cash amortization expense related to that asset as the underlying loss carryforwards are utilized to shelter taxable income in the United States. Elan expects its tax expense in future periods to include similar non-cash amortization expenses.
Adjusted EBITDA
For the first quarter of 2009, Adjusted EBITDA losses were $6.0 million, a decrease of 59% compared to Adjusted EBITDA losses of $14.6 million for the same period of 2008. The improvement principally reflects the 14% increase in revenue and improved operating margins.
A reconciliation of Adjusted EBITDA to net loss, is presented in the table titled, “Unaudited Non-GAAP Financial Information – EBITDA,” included on page 3. Included at Appendix I is a further analysis of the results and Adjusted EBITDA between the Biopharmaceuticals and EDT businesses.
Total Revenue
For the first quarter of 2009, total revenue increased 14% to $245.1 million from $214.7 million for the same period of 2008, primarily driven by the strong growth of Tysabri. Revenue from the Biopharmaceuticals business increased by 28% while revenue from the EDT business decreased by 14%. Revenue is analyzed below between revenue from the Biopharmaceuticals and EDT business units.
Revenue from the Biopharmaceuticals business
For the first quarter of 2009, revenue from the Biopharmaceuticals business increased by 28% to $185.4 million from $145.3 million for the first quarter of 2008. The increase was primarily driven by strong growth in Tysabri sales, which more than compensated for reduced sales of Azactam and Maxipime.
Tysabri
Global in-market net sales of Tysabri can be analyzed as follows:
For the first quarter of 2009, Tysabri in-market net sales increased by 42% to $227.5 million from $159.7 million for the same period of 2008. The increase reflects strong patient demand across global markets. At the end of March 2009, approximately 40,000 patients were on therapy worldwide, including approximately 20,800 commercial patients in the United States and approximately 18,500 commercial patients in the ROW, representing an increase of 6% over the approximately 37,600 patients who were on therapy at the end of December 2008.
Cumulatively, in the post-marketing setting approximately 52,000 patients have been treated with Tysabri as of the end of March 2009. Of those patients, approximately 24,900 have received at least one year of Tysabri therapy, approximately 14,400 patients have received at least 18 months of Tysabri therapy, and 6,800 patients have received at least 24 months of Tysabri therapy. In the post marketing setting, there have been six confirmed cases of progressive multifocal leukoencephalopathy (PML) in Tysabri-treated MS patients.
Tysabri was developed and is being marketed in collaboration with Biogen Idec Inc. (Biogen Idec). In general, subject to certain limitations imposed by the parties, Elan shares with Biogen Idec most of the development and commercialization costs for Tysabri. Biogen Idec is responsible for manufacturing the product. In the United States, Elan purchases Tysabri from Biogen Idec and is responsible for distribution. Consequently, Elan records as revenue the net sales of Tysabri in the U.S. market. Elan purchases product from Biogen Idec at a price that includes the cost of manufacturing, plus Biogen Idec’s gross margin on Tysabri, and this cost, together with royalties payable to other third parties, is included in cost of sales.
Outside of the United States, Biogen Idec is responsible for distribution and Elan records as revenue its share of the profit or loss on these sales of Tysabri, plus Elan’s directly-incurred expenses on these sales.
As a result of the continuing strong growth in Tysabri sales, in January 2009, Elan made an optional payment of $50.0 million to Biogen Idec in order to maintain an approximate 50% share of Tysabri for annual global in-market net sales of Tysabri that are in excess of $1.1 billion. This payment has been capitalized as an intangible asset and is being amortized on a straight-line basis over approximately 11 years. There are no further milestone payments required for Elan to retain its approximate 50% profit share.
Tysabri – U.S.
In the U.S. market, Elan recorded net sales of $116.0 million for the first quarter of 2009, an increase of 34% over net sales of $86.3 million in the same period of 2008. Almost all of these sales are for the MS indication.
At the end of March 2009, approximately 20,800 patients were on commercial therapy, which represents an increase of 3% over the approximately 20,200 since the end of December 2008 and 36% since the end of March last year.
Tysabri – ROW
In the ROW market, Biogen Idec is responsible for distribution and Elan records as revenue its share of the profit or loss on ROW sales of Tysabri, plus Elan’s directly-incurred expenses on these sales. As a result, in the ROW market, Elan recorded net revenue of $42.7 million for the first quarter of 2009, compared to $20.7 million for the first quarter of 2008, an increase of 106%. Elan’s net Tysabri ROW revenue is calculated as follows:
At the end of March 2009, approximately 18,500 patients, principally in the European Union (EU), were on commercial therapy, an increase of 9% over the approximately 16,900 who were on therapy at the end of December 2008 and 81% over the end of March last year.
Other Biopharmaceuticals products
Azactam revenue decreased 29% to $17.2 million for the first quarter of 2009, compared to $24.2 million for the same period of 2008. The decrease was principally due to supply shortages, which are expected to be resolved by mid-year. Azactam lost its patent exclusivity in October 2005 and its future sales are expected to be negatively impacted by generic competition. However, no generic form of Azactam has been approved to date.
Maxipime revenue decreased 50% to $5.0 million for the first quarter of 2009 from $10.1 million for the first quarter of 2008. The decrease was principally due to generic competition. The first generic cefepime hydrochloride was launched in June 2007, and additional generic forms of Maxipime have since been launched.
Prialt revenue was $4.1 million for the first quarter of 2009, compared to $3.8 million for the same period of 2008, an increase of 8%. The increase was primarily due to higher demand for the product.
Revenue from the EDT business
For the first quarter of 2009, revenue from the EDT business decreased by 14% to $59.7 million from $69.4 million for the first quarter of 2008.
Manufacturing revenue and royalties comprise revenue earned from products manufactured for clients and royalties earned principally on sales by clients of products that incorporate Elan’s technologies. Except as noted above, no other product accounted for more than 10% of total manufacturing revenue and royalties for the first quarter of 2009 or 2008. For the first quarter of 2009, of the total of $57.5 million (2008: $62.0 million) in manufacturing revenue and royalties, 43% (2008: 42%) consisted of royalties received on products that were not manufactured by Elan.
An additional analysis of the results between the Biopharmaceuticals and EDT businesses are set out in Appendix I. For the first quarter of 2009, Adjusted EBITDA from the EDT business decreased by $4.1 million to $20.7 million from $24.8 million for the same period of 2008. The first quarter of 2008 benefitted from milestones associated with the approval of Luvox CR® and Zanaflex® achieving $105 million in cumulative sales. EDT revenues, and their impact on Adjusted EBITDA, vary from quarter to quarter based on a number of factors including the timing of customer orders and contractual in-market sales hurdles for royalties.
Potential generic competitors have challenged the existing patent protection for several of the products from which Elan earns manufacturing revenue and royalties. Elan and its clients defend the parties’ intellectual property rights vigorously. However, if these challenges are successful, Elan’s manufacturing revenue and royalties will be materially and adversely affected.
Operating Expenses
Selling, general and administrative
Although revenues increased by 14% in the first quarter of 2009, SG&A expenses decreased by 4% to $71.0 million from $74.0 million for the same period of 2008. The decrease principally reflects reduced litigation expenses, along with continued cost control. SG&A expense for the three months ended March 31, 2009 and 2008 can be analyzed as follows:
The SG&A expenses related to the Tysabri ROW sales are reflected in the Tysabri ROW revenue as previously described on page 9.
Research and development
For the first quarter of 2009, R&D expenses increased 11% to $80.5 million from $72.5 million for the same period of 2008. The increase was primarily due to increased expenses associated with the progression of Elan’s Alzheimer’s disease programs, including the Phase 3 clinical trials of bapineuzumab.
Other net charges
Other net charges for the three months ended March 31, 2009 and 2008 were as follows:
For the first quarter of 2009, other net charges of $19.6 million primarily consist of severance and restructuring charges of $22.2 million and non-cash asset impairment charges of $15.4 million, partially offset by a legal settlement gain of $18.0 million. The severance and restructuring charges and asset impairment charges were principally associated with the postponement of Elan’s biologics manufacturing activities, the strategic redesign and realignment of the R&D organization within Elan’s Biopharmaceuticals business, and reduction of related support activities. These adjustments resulted in a reduction in Elan’s global workforce of approximately 230 positions, or 14% of its total workforce.
The legal settlement gain of $18.0 million relates to an agreement with Watson Pharmaceuticals, Inc. (Watson) to settle litigation with respect to Watson’s marketing of a generic version of Naprelan. As part of the settlement, Watson stipulated that Elan’s patent at issue is valid and enforceable and that Watson’s generic formulations of Naprelan infringed Elan’s patent. In connection with the settlement, Elan received $18.0 million from Watson in March 2009.
Net interest and investment losses
For the first quarter of 2009, net interest and investment losses decreased to $33.8 million from $37.8 million for the first quarter of 2008. This decrease was primarily due to net investment losses of $3.3 million in the first quarter of 2008, mainly related to investment impairments.
Movement in Shareholders’ Deficit
Elan’s debt covenants do not require it to maintain or adhere to any specific financial ratios. Consequently, the shareholders’ deficit has no impact on Elan’s ability to comply with its debt covenants.
Research and Development Update
During the course of 2009, Elan’s goal is to continue its progress throughout its R&D programs, including Alzheimer’s disease, Parkinson’s disease, MS and other neurodegenerative areas.
Alzheimer’s disease and other neurodegenerative diseases
Elan is focused on further enhancing its breakthrough basic and clinical research in Alzheimer’s disease. With bapineuzumab (AAB-001, a monoclonal antibody targeted against beta amyloid peptide), Elan and
Wyeth have discontinued the highest of three doses, 2.0 mg/kg, in the two ongoing Phase 3 studies in patients with mild to moderate Alzheimer’s disease who do not carry the Apolipoprotein E4 (ApoE4) allele (non-carriers). ApoE4 is a known genetic risk factor for development of Alzheimer’s disease. The decision was made in concurrence with the study’s independent Safety Monitoring Committee, following its review of vasogenic edema in the ongoing Phase 3 clinical program. The 0.5 mg/kg and 1.0 mg/kg doses in these two trials will continue as planned. Enrollment in these two trials is ongoing.
A paper published in Current Alzheimer’s Research, 2009, Vol. 6 No. 2 indicates that 4.6 years after immunization with AN 1792 (synthetic amyloid-Beta peptide), a sub-group of patients defined as antibody responders in the Phase 2a study, had evidence of low but detectable, sustained anti-AN1792 antibody titers. [AN1792 Study was discontinued in 2002 when 6% of patients developed meningoencephalitis] These patients demonstrated significantly reduced functional decline compared to patients who had received placebo during the initial phase of the study. Though this long-term follow-up data is limited and must be assessed cautiously, we believe that the data support the hypothesis that ABeta immunotherapy has the potential for long-term functional benefits.
On February 9, 2009, Elan and Biogen Idec announced the publication of new efficacy data on Tysabri in the March 2009 issue of The Lancet Neurology. Results of a retrospective analysis of data from the Phase 3 AFFIRM trial indicate that five-times as many multiple sclerosis patients taking Tysabri were free from disease activity versus placebo in the overall patient population. Results showed that two years after beginning treatment with Tysabri, 37 % of patients remained free of disease activity (as defined by absence of relapses, new MRI lesions or disability progression), compared to 7% of placebo-treated patients.
Hallo Birgit,
am interessantesten fand ich den Bericht am Schluß rund um die Alzheimer Forschung und Entwicklung.
Auch bei vorsichtiger Betrachtungsweise wurde gesagt, dass die Ergebnisse des alten AN1792-Programms den heutigen Ansatz unterstützen. Und das ist gut so.
posimist
am interessantesten fand ich den Bericht am Schluß rund um die Alzheimer Forschung und Entwicklung.
Auch bei vorsichtiger Betrachtungsweise wurde gesagt, dass die Ergebnisse des alten AN1792-Programms den heutigen Ansatz unterstützen. Und das ist gut so.
posimist
Antwort auf Beitrag Nr.: 37.015.482 von posimist am 22.04.09 10:38:59Yepp,stimmt! Netten Gruss! Birgit
Antwort auf Beitrag Nr.: 37.016.372 von Birgit.Tersteegen am 22.04.09 12:22:47Birgit,
lesenswerter Kommentar von Cyberhexe zu Elan
in Depotbesprechung.
posimist
lesenswerter Kommentar von Cyberhexe zu Elan
in Depotbesprechung.
posimist
Antwort auf Beitrag Nr.: 37.037.034 von posimist am 24.04.09 17:47:56Danke Dir...ich habs gelesen + sehe es genauso....!!Ich hoffe,sie kriegen bald die Finanzierung hin...Schönes WE!! Birgit
Antwort auf Beitrag Nr.: 37.037.463 von Birgit.Tersteegen am 24.04.09 18:52:21Hallo Birgit und Posimist,
habe viele Jahre Elan nicht beobachet, bin aber seit einigen Wochen wieder eingestiegen. Hier gibt es ja kaum Diskosionen um die Aktie.
Die News mit der Finanzierung. Könnt Ihr die News einstellen, damit ich sie auch lesen kann?!
Wo ist euer Kursziel in 12 Monaten?
Vielen Dank
Schero
habe viele Jahre Elan nicht beobachet, bin aber seit einigen Wochen wieder eingestiegen. Hier gibt es ja kaum Diskosionen um die Aktie.
Die News mit der Finanzierung. Könnt Ihr die News einstellen, damit ich sie auch lesen kann?!
Wo ist euer Kursziel in 12 Monaten?
Vielen Dank
Schero
Antwort auf Beitrag Nr.: 37.041.993 von Schero am 26.04.09 11:32:06hi Schero,
der Beitrag von Cyberhexe kannst Du in ihrem Thread "Biotechnologiedepot" nachlesen...
Was das Kursziel betrifft,rechne ich mit 20 € im nächsten Jahr falls sie ihre Schulden refinanzieren können und Bapi Phase 3 gut durchsteht......ich halte + stocke ggfs auf!
Netten Gruss! Birgit
der Beitrag von Cyberhexe kannst Du in ihrem Thread "Biotechnologiedepot" nachlesen...
Was das Kursziel betrifft,rechne ich mit 20 € im nächsten Jahr falls sie ihre Schulden refinanzieren können und Bapi Phase 3 gut durchsteht......ich halte + stocke ggfs auf!
Netten Gruss! Birgit
Antwort auf Beitrag Nr.: 37.043.586 von Birgit.Tersteegen am 26.04.09 22:06:56Hallo Birgit,
Ich glaub, Du siehst das Chance-Risikoverhältnis ziemlich gut.
Chancen sind durchaus gegeben. Und wenn BAP Phase 3 gut durchsteht ... wäre die Alzheimer-Medizin einen riesigen Schritt weiter. Wäre sehr schön und auch vorstellbar. Garantieren kann mans aber nicht.
Also, so als rein spekulative Depotbeimischung ist die Aktie durchaus immer noch geeignet. Wär schön, wenn die Chancen bald größer werden würden.
Gruß Henrig
Ich glaub, Du siehst das Chance-Risikoverhältnis ziemlich gut.
Chancen sind durchaus gegeben. Und wenn BAP Phase 3 gut durchsteht ... wäre die Alzheimer-Medizin einen riesigen Schritt weiter. Wäre sehr schön und auch vorstellbar. Garantieren kann mans aber nicht.
Also, so als rein spekulative Depotbeimischung ist die Aktie durchaus immer noch geeignet. Wär schön, wenn die Chancen bald größer werden würden.
Gruß Henrig
Antwort auf Beitrag Nr.: 37.044.037 von Henrig am 27.04.09 08:05:17....das sehe ich auch so!Gruss! Birgit
Gruss! Birgit
Antwort auf Beitrag Nr.: 37.041.993 von Schero am 26.04.09 11:32:06Hallo Schero, hier mal das statement von Cybie.....
...nun, Elan ist tatsächlich, neben Dendreon, meine "Lieblingsaktie" (obwohl man zu Aktien keine sentimentale Beziehung haben sollte!), in welche ich sehr viel Herzblut investiert habe. Wieso? Weil Elan, bestückt mit hervorragenden Wissenschaftlern , das Potential hat, die Geschichte der Pharmaindustrie neu zu schreiben. Kein anderes Unternehmen ist meiner Ansicht nach in der Erforschung von neurodegenerativen Erkrankungen so weit wie dieses (nur) mittelständische Unternehmen - selbst mein (wesentlich grösserer) Arbeitgeber ist um Längen zurück. Jedoch, und dies zieht sich wie ein roter Faden durch die jüngere Geschichte, bin ich mir nicht sicher, in wie weit Elan in der Lage ist, diese wissenschaftlichen Leistungen von R&D in gewinnbringende Produkte umzusetzen. Dies soll jedoch nicht heissen, dass das Management nicht fähig ist, vielmehr habe ich mittlerweile gewisse Zweifel, ob Elans Atem lang genug ist - sprich dessen wirtschaftliche Potenz -, um diese beschwerliche Entwicklung, weil nicht frei von Rückschlägen, ohne finanzkräftigen Partner durchzustehen. Elans Wissenschaftler um Dale Schenk und Dennis Selkoe werden, da bin ich mir ziemlich sicher, irgendwann einmal für den Nobelpreis vorgeschlagen, ob diese dann allerdings noch bei Elan auf der Gehaltsliste stehen, kann man bezweifeln. Die finanziellen Mittel dieser Gesellschaft sind endlich und die durch PML gedämpften Zuwachsraten bei Tysabri, mit dem die Entwicklung der neurodegenerativen Pipeline finanziert werden sollte, geben Anlass zur Sorge. Allerdings habe ich die Hoffnung, dass Elans CEO, der ja bekanntlicherweise aus der Finanzbranche rekrutiert wurde, seine Herkunft beweisen kann und Elan die Mittel auf vernünftige Weise beschafft, die dem Unternehmen ermöglicht, die unbestritten grossartigen Leistungen aus R&D in gewinnbringende Produkte (welche der Menschheit grossen Nutzen bringen!) umzusetzen. Es bleibt überaus spannend. Deine Frage jedoch, wie Elan in 1 bis 2 Jahre aufgestellt sein wird, kann ich ehrlicherweise nicht beantworten.
Grüße
bernie55
...nun, Elan ist tatsächlich, neben Dendreon, meine "Lieblingsaktie" (obwohl man zu Aktien keine sentimentale Beziehung haben sollte!), in welche ich sehr viel Herzblut investiert habe. Wieso? Weil Elan, bestückt mit hervorragenden Wissenschaftlern , das Potential hat, die Geschichte der Pharmaindustrie neu zu schreiben. Kein anderes Unternehmen ist meiner Ansicht nach in der Erforschung von neurodegenerativen Erkrankungen so weit wie dieses (nur) mittelständische Unternehmen - selbst mein (wesentlich grösserer) Arbeitgeber ist um Längen zurück. Jedoch, und dies zieht sich wie ein roter Faden durch die jüngere Geschichte, bin ich mir nicht sicher, in wie weit Elan in der Lage ist, diese wissenschaftlichen Leistungen von R&D in gewinnbringende Produkte umzusetzen. Dies soll jedoch nicht heissen, dass das Management nicht fähig ist, vielmehr habe ich mittlerweile gewisse Zweifel, ob Elans Atem lang genug ist - sprich dessen wirtschaftliche Potenz -, um diese beschwerliche Entwicklung, weil nicht frei von Rückschlägen, ohne finanzkräftigen Partner durchzustehen. Elans Wissenschaftler um Dale Schenk und Dennis Selkoe werden, da bin ich mir ziemlich sicher, irgendwann einmal für den Nobelpreis vorgeschlagen, ob diese dann allerdings noch bei Elan auf der Gehaltsliste stehen, kann man bezweifeln. Die finanziellen Mittel dieser Gesellschaft sind endlich und die durch PML gedämpften Zuwachsraten bei Tysabri, mit dem die Entwicklung der neurodegenerativen Pipeline finanziert werden sollte, geben Anlass zur Sorge. Allerdings habe ich die Hoffnung, dass Elans CEO, der ja bekanntlicherweise aus der Finanzbranche rekrutiert wurde, seine Herkunft beweisen kann und Elan die Mittel auf vernünftige Weise beschafft, die dem Unternehmen ermöglicht, die unbestritten grossartigen Leistungen aus R&D in gewinnbringende Produkte (welche der Menschheit grossen Nutzen bringen!) umzusetzen. Es bleibt überaus spannend. Deine Frage jedoch, wie Elan in 1 bis 2 Jahre aufgestellt sein wird, kann ich ehrlicherweise nicht beantworten.
Grüße
bernie55
Hallo Birgit, Hallo Bernie,
vielen Dank für Euer Posting. Vor allem die von Bernie.
Wie seht Ihr es, wenn Elan Übernommen wird. Kann das passieren?
Ich habe gehört, dass bei Übernahmen von Biotech-Aktien, die Aktinäre nicht 100% davon profitieren. Stimmt das?
Ich kann mir nicht vorstellen, dass die Aktie ganz von der Bildfläche verschwindet, wenn kein Geld mehr da ist, sondern die Wahrscheinlichkeit einer Übernahme wäre wahrscheinlich.
Übrigens welche Marktkapitalisierung hat denn Elan?
Vieln Dank für Antworten.
Schero
vielen Dank für Euer Posting. Vor allem die von Bernie.
Wie seht Ihr es, wenn Elan Übernommen wird. Kann das passieren?
Ich habe gehört, dass bei Übernahmen von Biotech-Aktien, die Aktinäre nicht 100% davon profitieren. Stimmt das?
Ich kann mir nicht vorstellen, dass die Aktie ganz von der Bildfläche verschwindet, wenn kein Geld mehr da ist, sondern die Wahrscheinlichkeit einer Übernahme wäre wahrscheinlich.
Übrigens welche Marktkapitalisierung hat denn Elan?
Vieln Dank für Antworten.
Schero
Das ist doch Balsam für geschundene Elan-Seelen, aber vor allem ganz neue Perspektiven für MS-Patienten:
What we have seen in these MRI data suggest that TYSABRI may have the capacity to repair and possibly restore some of the damaged myelin sheath that protects nerve fibers. Results from this study support the continued investigation of the potential effects of TYSABRI on this process,”
http://www.elan.com/News/full.asp?ID=1281713
Hinsichtlich der zukünftigen Wachstumsrate darf man bei Tysabri vorsichtig optimistisch sein.
weiteres Highlight für 2009:
Eine Zulassung von Acordas Fampridine im 2HJ09 könnte Elans Gewinn- und Verlustrechnung nachhaltig positiv beeinflussen.
What we have seen in these MRI data suggest that TYSABRI may have the capacity to repair and possibly restore some of the damaged myelin sheath that protects nerve fibers. Results from this study support the continued investigation of the potential effects of TYSABRI on this process,”
http://www.elan.com/News/full.asp?ID=1281713
Hinsichtlich der zukünftigen Wachstumsrate darf man bei Tysabri vorsichtig optimistisch sein.
weiteres Highlight für 2009:
Eine Zulassung von Acordas Fampridine im 2HJ09 könnte Elans Gewinn- und Verlustrechnung nachhaltig positiv beeinflussen.
Antwort auf Beitrag Nr.: 37.060.800 von Cyberhexe am 29.04.09 11:41:25schön mal wieder mehr von Dir zu hören.
Antwort auf Beitrag Nr.: 37.060.800 von Cyberhexe am 29.04.09 11:41:25...dann mal den BALSAM " noch schriftlich" ...
DUBLIN, April 29 (Reuters) -
Elan's (ELN.I) Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec (BIIB.O) said on Wednesday, boosting Elan's shares 10 percent.
Data released by the companies at the American Academy of Neurology showed Tysabri promoted the regeneration of the protein coat that protects nerve fibres and whose damage causes the symptoms of multiple sclerosis.
"This provides more evidence that Tysabri may not just slow down the progress of MS but also may be able to reverse the damage caused by the disease," Goodbody analyst Ian Hunter said in a note.
Tysabri, which is given by infusion, is the most effective drug on the market, reducing the relapse rate in patients with multiple sclerosis by 68 percent.
But sales have been crimped because of its link with progressive multifocal leukoencephalopathy, or PML, a potentially deadly brain infection.
Elan's shares have lost almost three-quarters of their value over 12 months due to concerns over the safety of Tysabri, disappointing results from a trial of its experimental Alzheimer's vaccine and uncertainty over its future.
Its stock traded 10 percent higher by 0911 GMT at 4.8 euros, outperforming a 3 percent stronger wider Irish market .ISEQ.
Elan said last week it was seeking a partnership with a big pharmaceutical company, after reporting a 14 percent rise in first-quarter revenue and a wider net loss.
Swiss drugmaker Novartis AG (NOVN.VX) and Germany's Merck KGaA (MRCG.DE) are leading the charge to develop multiple sclerosis drugs that can be taken orally, rather than by infusion or injection. (Reporting by Andras Gergely; Editing by David Cowell)
http://www.reuters.com/article/marketsNews/idINLT86173120090…
DUBLIN, April 29 (Reuters) -
Elan's (ELN.I) Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec (BIIB.O) said on Wednesday, boosting Elan's shares 10 percent.
Data released by the companies at the American Academy of Neurology showed Tysabri promoted the regeneration of the protein coat that protects nerve fibres and whose damage causes the symptoms of multiple sclerosis.
"This provides more evidence that Tysabri may not just slow down the progress of MS but also may be able to reverse the damage caused by the disease," Goodbody analyst Ian Hunter said in a note.
Tysabri, which is given by infusion, is the most effective drug on the market, reducing the relapse rate in patients with multiple sclerosis by 68 percent.
But sales have been crimped because of its link with progressive multifocal leukoencephalopathy, or PML, a potentially deadly brain infection.
Elan's shares have lost almost three-quarters of their value over 12 months due to concerns over the safety of Tysabri, disappointing results from a trial of its experimental Alzheimer's vaccine and uncertainty over its future.
Its stock traded 10 percent higher by 0911 GMT at 4.8 euros, outperforming a 3 percent stronger wider Irish market .ISEQ.
Elan said last week it was seeking a partnership with a big pharmaceutical company, after reporting a 14 percent rise in first-quarter revenue and a wider net loss.
Swiss drugmaker Novartis AG (NOVN.VX) and Germany's Merck KGaA (MRCG.DE) are leading the charge to develop multiple sclerosis drugs that can be taken orally, rather than by infusion or injection. (Reporting by Andras Gergely; Editing by David Cowell)
http://www.reuters.com/article/marketsNews/idINLT86173120090…
Antwort auf Beitrag Nr.: 37.064.110 von bernie55 am 29.04.09 17:05:38Hi Bernie--nice to see you---hab mal gerade wieder 200 Schätzchen gekooft (und übrigens bei Dendreon schnelle 450% gestern realisiert...)---muss leider los--lass mal von Dir hören...lg Birgit
--nice to see you---hab mal gerade wieder 200 Schätzchen gekooft (und übrigens bei Dendreon schnelle 450% gestern realisiert...)---muss leider los--lass mal von Dir hören...lg Birgit
Alzheimers report - mit BAP ....
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.
The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.
In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.
"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."
http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=1…
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources
WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.
The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.
In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.
"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."
http://news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=1…
[b]Medical News Article
Patients With Multiple Sclerosis Treated With TYSABRI Show Overall Improvement In Cognition And Quality Of Life, With Lower Levels Of Fatigue[/b]
Main Category: Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from an ongoing, one-year longitudinal health outcomes study (n=1275) in which patients who received three infusions of TYSABRI® (natalizumab) reported reduced fatigue, as well significant improvements in general and disease-specific measurements of quality of life (QoL) and cognitive function. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The results from this study were presented in two separate posters at the 61st Annual Meeting of the American Academy of Neurology.
"MS is a debilitating disease that significantly reduces the quality of patients' lives. In this study, a majority of patients said they were less tired, thought more clearly, and had a better overall quality of life," said Dr. William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "Data from the pivotal trial has shown that TYSABRI not only results in a significant reduction in relapses, but also showed an improvement in quality of life. These new patient-reported outcomes expand our understanding of the real-world impact of TYSABRI on different aspects of the lives of MS patients."
The ongoing one-year follow-up study will assess health outcomes from patients' perspectives before starting TYSABRI and after the third, sixth, and 12th infusions of TYSABRI, respectively. A majority of the patients in the study are female (78.4%) with mean age of 45.3 years and mean disease duration of 10 years.
Quality of Life Study Results
As early as after the third infusion of TYSABRI, patients reported statistically significant improvement in:
general health-related QoL, as measured by the 12-item Short Form Scale (SF-12), with higher scores indicating better QoL
MS-specific QoL, as measured by the 29-item Multiple Sclerosis Impact Scale (MSIS-29), with lower scores indicating better QoL
Both scales report the physical and psychological aspects of QoL in two summary scores. SF-12 physical component summary (baseline 34.03 vs. 36.02 at the 3rd infusion; p<0.001) and the SF-12 mental component summary score (baseline 43.17 vs. 47.22 at the 3rd infusion; p<0.001) showed statistically significant improvements from baseline.
For the MSIS-29 subscales, there were statistically significant improvements from baseline for both the physical (baseline 48.25 vs. 40.19; p<0.001) and psychological (baseline 43.70 vs. 34.80; p<0.001) impact scores.
The results of the current study are consistent with those reported in clinical trials and an earlier cross-sectional study in which patients reported significant improvements in functional status, disability and overall QoL after three TYSABRI infusions. The cross-sectional study also found that TYSABRI patients who had the disease for less than five years had higher magnitudes of improvement in functional status and overall QoL as compared to patients who had the disease for more than five years. Findings from this study will also be reported in the peer-reviewed journal The Patient: Patient-Centered Outcomes Research later this quarter.
Cognition and Fatigue Study Results
After three infusions of TYSABRI, patients reported both:
improvements in cognitive functioning
lower impact of fatigue on daily functioning
Cognitive functioning was assessed by Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale) with higher scores indicating improved cognition. Impact of fatigue on daily functioning was assessed by short version of Modified Fatigue Impact Scale (MFIS-5) with lower scores indicating lower fatigue.
On average, MOS-Cog scores increased by statistical significance from baseline (baseline score 24.48; 3rd infusion score 26.29, p<0.001) and MFIS scores decreased by statistical significance from baseline (baseline score 12.46; 3 rd infusion score 10.29, p<0.001).
Source:
Shannon Altimari
Biogen Idec
Mary Stutts
Elan
Jonathan Birt
Elan
Patients With Multiple Sclerosis Treated With TYSABRI Show Overall Improvement In Cognition And Quality Of Life, With Lower Levels Of Fatigue[/b]
Main Category: Multiple Sclerosis
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) have announced results from an ongoing, one-year longitudinal health outcomes study (n=1275) in which patients who received three infusions of TYSABRI® (natalizumab) reported reduced fatigue, as well significant improvements in general and disease-specific measurements of quality of life (QoL) and cognitive function. Findings from the study, which was performed in conjunction with HealthCore Inc., a health-outcomes research company, are the first attempt to assess patient experiences with TYSABRI in usual-care settings. The results from this study were presented in two separate posters at the 61st Annual Meeting of the American Academy of Neurology.
"MS is a debilitating disease that significantly reduces the quality of patients' lives. In this study, a majority of patients said they were less tired, thought more clearly, and had a better overall quality of life," said Dr. William Stuart, M.D., medical director of the Multiple Sclerosis Center of Atlanta. "Data from the pivotal trial has shown that TYSABRI not only results in a significant reduction in relapses, but also showed an improvement in quality of life. These new patient-reported outcomes expand our understanding of the real-world impact of TYSABRI on different aspects of the lives of MS patients."
The ongoing one-year follow-up study will assess health outcomes from patients' perspectives before starting TYSABRI and after the third, sixth, and 12th infusions of TYSABRI, respectively. A majority of the patients in the study are female (78.4%) with mean age of 45.3 years and mean disease duration of 10 years.
Quality of Life Study Results
As early as after the third infusion of TYSABRI, patients reported statistically significant improvement in:
general health-related QoL, as measured by the 12-item Short Form Scale (SF-12), with higher scores indicating better QoL
MS-specific QoL, as measured by the 29-item Multiple Sclerosis Impact Scale (MSIS-29), with lower scores indicating better QoL
Both scales report the physical and psychological aspects of QoL in two summary scores. SF-12 physical component summary (baseline 34.03 vs. 36.02 at the 3rd infusion; p<0.001) and the SF-12 mental component summary score (baseline 43.17 vs. 47.22 at the 3rd infusion; p<0.001) showed statistically significant improvements from baseline.
For the MSIS-29 subscales, there were statistically significant improvements from baseline for both the physical (baseline 48.25 vs. 40.19; p<0.001) and psychological (baseline 43.70 vs. 34.80; p<0.001) impact scores.
The results of the current study are consistent with those reported in clinical trials and an earlier cross-sectional study in which patients reported significant improvements in functional status, disability and overall QoL after three TYSABRI infusions. The cross-sectional study also found that TYSABRI patients who had the disease for less than five years had higher magnitudes of improvement in functional status and overall QoL as compared to patients who had the disease for more than five years. Findings from this study will also be reported in the peer-reviewed journal The Patient: Patient-Centered Outcomes Research later this quarter.
Cognition and Fatigue Study Results
After three infusions of TYSABRI, patients reported both:
improvements in cognitive functioning
lower impact of fatigue on daily functioning
Cognitive functioning was assessed by Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale) with higher scores indicating improved cognition. Impact of fatigue on daily functioning was assessed by short version of Modified Fatigue Impact Scale (MFIS-5) with lower scores indicating lower fatigue.
On average, MOS-Cog scores increased by statistical significance from baseline (baseline score 24.48; 3rd infusion score 26.29, p<0.001) and MFIS scores decreased by statistical significance from baseline (baseline score 12.46; 3 rd infusion score 10.29, p<0.001).
Source:
Shannon Altimari
Biogen Idec
Mary Stutts
Elan
Jonathan Birt
Elan
Antwort auf Beitrag Nr.: 37.086.554 von Birgit.Tersteegen am 03.05.09 22:31:01Mein Englich ist sooo schlecht.
Ich wäre jeden Dankbar, wenn jemand in einigen Sätzen, mir verdeutlichen könnte, was der Inhalt des vorherigen Beitags ist.o
Vilen Dank im voraus
Schero
Ich wäre jeden Dankbar, wenn jemand in einigen Sätzen, mir verdeutlichen könnte, was der Inhalt des vorherigen Beitags ist.o
Vilen Dank im voraus
Schero
Antwort auf Beitrag Nr.: 37.089.068 von Schero am 04.05.09 12:53:43....versuchs mal mit http://translate.google.com/translate_t#
Hallo Birgit,
vielen Dank für den Hinweis.
würdest Du auf dem jetzigen Niveau weitere Aktien von Elan kaufen?
schero
vielen Dank für den Hinweis.
würdest Du auf dem jetzigen Niveau weitere Aktien von Elan kaufen?
schero
Antwort auf Beitrag Nr.: 37.089.931 von Schero am 04.05.09 14:55:39Ja! Ich kaufe auch immer mal wieder zu ....Netten Gruss! Birgit
Es gibt Gerüchte,dass Lundbeck einen Anteil an Elan zwischen 15% und 25% für 12$ kaufen will...im Moment steht der Kurs bei 6,25$....wäre also fast eine Verdopplung.......
Antwort auf Beitrag Nr.: 37.090.819 von Birgit.Tersteegen am 04.05.09 16:21:01Aha! Daher lernt unser Baby wieder zu laufen
Gruße Dich Birgit!
Gruße Dich Birgit!
Antwort auf Beitrag Nr.: 37.091.970 von surga am 04.05.09 18:12:20Hi lieber Surga,
ob das ´ne Sucht ist???Habe heute 2x Elan wieder verbilligt.... Mit der Hälfte des Dendreon Gewinns....Gibts bei Dir was Neues??(Gern BM...) Lieben Gruss! Birgit
,ob das ´ne Sucht ist???Habe heute 2x Elan wieder verbilligt....
Mit der Hälfte des Dendreon Gewinns....Gibts bei Dir was Neues??(Gern BM...) Lieben Gruss! Birgit
Antwort auf Beitrag Nr.: 37.092.102 von Birgit.Tersteegen am 04.05.09 18:24:38nix Neues, vielleicht fliege ich wieder runter in kürze
Schön, dass Du bei DNDN realisiert hast, was wir bei unserem Baby verpasst haben.
Ich vermiese Popholz und Bernie, wo sie alle sind?
Schön, dass Du bei DNDN realisiert hast
, was wir bei unserem Baby verpasst haben.Ich vermiese Popholz und Bernie, wo sie alle sind?
Antwort auf Beitrag Nr.: 37.092.140 von surga am 04.05.09 18:28:57Bernie ist selten auf WO (hält aber alle Schätzchen...)----ich schick ihm mal`ne Mail und von Poppi weiss ich nix.War ja auch sehr frustrierend die letzten Wochen...
Antwort auf Beitrag Nr.: 37.092.155 von Birgit.Tersteegen am 04.05.09 18:31:02wenn ELN wieder in Schwung ist, schauen sie wieder vorbei. Ich sehe einige \"NEUE\" wie POSIMIST und SCHERO und ab und zu taucht CYBERHEXE wieder auf. WELLCOME BACK
. Ich sehe einige \"NEUE\" wie POSIMIST und SCHERO und ab und zu taucht CYBERHEXE wieder auf. WELLCOME BACK
Antwort auf Beitrag Nr.: 37.092.155 von Birgit.Tersteegen am 04.05.09 18:31:02ist schon über 20% Plus
Irgendeine News wird wohl kommen...
Antwort auf Beitrag Nr.: 37.092.140 von surga am 04.05.09 18:28:57Hallo Surga,
bin immer mal wieder hier bei Euch, auch wenn ich nicht jedesmal etwas schreibe.
Unser Baby ist halt von einem hohen Niveau runter geholt worden, ohne dass es hierfür einen "echten" Grund gegeben hat, aber das wissen die Longies und somit habe ich mir mein tägliches Kopfschütteln nicht schriftlich im Forum hinterlassen.
Habe keine Aktien verkauft und "kleine" Mengen nachgeordert.
Somit bleibe ich auch weiterhin dabei und warte halt ein paar Jahre länger auf die Ernte.
Ich habe Zeit.
Dendreon sorgt auch bei mir im Depot für ein dunkles Grün, ist aber in Verhältnis zu Elan nur eine kleine Position.
bin immer mal wieder hier bei Euch, auch wenn ich nicht jedesmal etwas schreibe.
Unser Baby ist halt von einem hohen Niveau runter geholt worden, ohne dass es hierfür einen "echten" Grund gegeben hat, aber das wissen die Longies und somit habe ich mir mein tägliches Kopfschütteln nicht schriftlich im Forum hinterlassen.
Habe keine Aktien verkauft und "kleine" Mengen nachgeordert.
Somit bleibe ich auch weiterhin dabei und warte halt ein paar Jahre länger auf die Ernte.
Ich habe Zeit.
Dendreon sorgt auch bei mir im Depot für ein dunkles Grün, ist aber in Verhältnis zu Elan nur eine kleine Position.
Antwort auf Beitrag Nr.: 37.092.925 von Poppholz am 04.05.09 19:51:33schön von Dir wieder zu lesen
Bei DNDN kann ich leider nicht mit feiern, schon längst verkauft.
ELN habe ich immer noch, jedoch nicht nachgekauft, immer noch im gleichen alten Stand.
Bei DNDN kann ich leider nicht mit feiern, schon längst verkauft.
ELN habe ich immer noch, jedoch nicht nachgekauft, immer noch im gleichen alten Stand.
na,jungs--dann sind wir ja noch alle vereint (eben im Moment eher in "Stille")Bin gespannt was uns Elan die nächsten Tage so bietet
)Bin gespannt was uns Elan die nächsten Tage so bietet
Hallo alle zusammen, ja ich bin der neue stolze Elan-Aktien Besitzer. Ich beobachte Elan schon seit einigen Jahren.
Habe bei USD 5,88 einige Tausend gekauft und bei 6,10 wieder einige Tausend nachgekauft. Heute wollte ich wieder einiges kaufen. Jedoch ist mir leider (Gott sei Dank) der Kurs hoch geeilt. Na ja. Vielleicht kommt der Kurs ja wieder etwas runter und dann würde ich wieder einige nachkaufen. Das weiß man bei Elan eben nicht so. Sie ist sehr volatil. Ich kaufe Elan eher langfristig und bin von dem Wert überzeugt. Ich denke, dass wir sogar USD 30 oder 60 in den nächsten 2-3 Jahren sehen. Auf jeden Fall wünsche ich unlück.
Schero
Habe bei USD 5,88 einige Tausend gekauft und bei 6,10 wieder einige Tausend nachgekauft. Heute wollte ich wieder einiges kaufen. Jedoch ist mir leider (Gott sei Dank) der Kurs hoch geeilt. Na ja. Vielleicht kommt der Kurs ja wieder etwas runter und dann würde ich wieder einige nachkaufen. Das weiß man bei Elan eben nicht so. Sie ist sehr volatil. Ich kaufe Elan eher langfristig und bin von dem Wert überzeugt. Ich denke, dass wir sogar USD 30 oder 60 in den nächsten 2-3 Jahren sehen. Auf jeden Fall wünsche ich unlück.
Schero
Antwort auf Beitrag Nr.: 37.095.048 von Schero am 05.05.09 00:14:44... sollte heißen. Auf jeden Fall wünsche ich uns viel Glück.
Antwort auf Beitrag Nr.: 37.095.048 von Schero am 05.05.09 00:14:44na dann WILLKOMMEN IM CLUB!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Netten Gruss--mitten in der Nacht
WILLKOMMEN IM CLUB!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Netten Gruss--mitten in der Nacht
Antwort auf Beitrag Nr.: 37.092.273 von Birgit.Tersteegen am 04.05.09 18:44:58Irgendeine News wird wohl kommen...
YEAH,bernie55 wieder mal im WO....
Grüße euch alle von Birgit, über Poppie, surga, Cybie bis hin zu " unseren " Neuen.....
..aktuell " on watching "......
deshalb........hier ein kleines Video von Vern Beachy nach seiner 31sten TY-Infusion ...
http://www.youtube.com/watch?v=93II812cyrc
YEAH,bernie55 wieder mal im WO....
Grüße euch alle von Birgit, über Poppie, surga, Cybie bis hin zu " unseren " Neuen.....
..aktuell " on watching "......
deshalb........hier ein kleines Video von Vern Beachy nach seiner 31sten TY-Infusion ...
http://www.youtube.com/watch?v=93II812cyrc
Antwort auf Beitrag Nr.: 37.095.586 von bernie55 am 05.05.09 08:11:39Danke für das Video.
Super Erfahrung. Wenn 98% der Patienten das auch so wiedergeben könne. Ja dann, Elan Richtung USD 1.000,--
Ach was 30 reichen auch.
Super Erfahrung. Wenn 98% der Patienten das auch so wiedergeben könne. Ja dann, Elan Richtung USD 1.000,--
Ach was 30 reichen auch.
Antwort auf Beitrag Nr.: 37.095.586 von bernie55 am 05.05.09 08:11:39
Elan surges on renewed takeover speculation
Shares in Irish pharmaceutical company Elan rose by as much as 17 per cent in Dublin this morning on renewed market speculation that Danish drugmaker Lundbeck will make a bid.
Elan soared as much as 76 cents to €5.33 euros, the steepest gain since March 27th.
The stock gained 68 cents to €5.25 as of 9.35am in Dublin. Citigroup has been advising the company since January on options including a merger or sale.
Elan would prefer a partnership with another drugmaker, chief executive officer Kelly Martin said April 22nd.
The shares gained 15 per cent March 26th, also on speculation of a Lundbeck offer. Elan’s American depositary receipts jumped 20 per cent in New York trading yesterday, when the Dublin market was closed.
“The Lundbeck rumour was in the market yesterday, and this has come up before,” said Ian Hunter, an analyst at Goodbody Stockbrokers in Dublin.
“The synergies from a Danish company buying Elan, I just don’t know. The financials don’t make sense either. We can’t see where the fit is.”
Niamh Lyons and Jonathan Birt, external spokespeople for Elan, and Mads Kronborg, a spokesman for Copenhagen-based Lundbeck, didn’t immediately return calls or e-mails seeking comment.
http://www.irishtimes.com/newspaper/breaking/2009/0505/break…
Shares in Irish pharmaceutical company Elan rose by as much as 17 per cent in Dublin this morning on renewed market speculation that Danish drugmaker Lundbeck will make a bid.
Elan soared as much as 76 cents to €5.33 euros, the steepest gain since March 27th.
The stock gained 68 cents to €5.25 as of 9.35am in Dublin. Citigroup has been advising the company since January on options including a merger or sale.
Elan would prefer a partnership with another drugmaker, chief executive officer Kelly Martin said April 22nd.
The shares gained 15 per cent March 26th, also on speculation of a Lundbeck offer. Elan’s American depositary receipts jumped 20 per cent in New York trading yesterday, when the Dublin market was closed.
“The Lundbeck rumour was in the market yesterday, and this has come up before,” said Ian Hunter, an analyst at Goodbody Stockbrokers in Dublin.
“The synergies from a Danish company buying Elan, I just don’t know. The financials don’t make sense either. We can’t see where the fit is.”
Niamh Lyons and Jonathan Birt, external spokespeople for Elan, and Mads Kronborg, a spokesman for Copenhagen-based Lundbeck, didn’t immediately return calls or e-mails seeking comment.
http://www.irishtimes.com/newspaper/breaking/2009/0505/break…
...sieht gut aus :http://www.elanexcellence.com/
Antwort auf Beitrag Nr.: 37.104.670 von Birgit.Tersteegen am 06.05.09 08:35:48HAllo midanand,
kann mir jemand sagen warum die Aktie wieder am sinken ist??
Bis bald
kann mir jemand sagen warum die Aktie wieder am sinken ist??
Bis bald
Antwort auf Beitrag Nr.: 37.110.602 von Schero am 06.05.09 17:19:13...weil noch keine Neuigkeiten in bezug auf die Schuldenreduzierung veröffentlicht worden sind....die Citigroup ist ja von Elan beauftragt worden,alle Möglichkeiten zu eruieren....Alles wartet auf die Ergebnisse...
Antwort auf Beitrag Nr.: 37.110.602 von Schero am 06.05.09 17:19:13Hallo,
wenn Du ELAN schon seit Jahren beobachtest, dann sind Dir die "Kursschwankungen" bei der Aktie ja bekannt.
Der Kurs der Aktie hat nicht unbedingt etwas mit der "tatsächlichen" Situation des Unternehmens etwas gemein.
wenn Du ELAN schon seit Jahren beobachtest, dann sind Dir die "Kursschwankungen" bei der Aktie ja bekannt.
Der Kurs der Aktie hat nicht unbedingt etwas mit der "tatsächlichen" Situation des Unternehmens etwas gemein.
Antwort auf Beitrag Nr.: 37.113.779 von Poppholz am 06.05.09 22:23:35....wohl war....:mad wir denken an WTF(--What the fuck)-week....im Juli letzten Jahres
wir denken an WTF(--What the fuck)-week....im Juli letzten Jahres
Antwort auf Beitrag Nr.: 37.114.344 von Birgit.Tersteegen am 06.05.09 23:43:30meinte :wohl WAHR...(sorry:yawn
Antwort auf Beitrag Nr.: 37.114.344 von Birgit.Tersteegen am 06.05.09 23:43:30Na, das gehtdoch.
Ist ja doll. Die Wallsreet geht runter und under Schnuggel geht wieder ab.
Gute Nachtruhe an alle Aktionäre.
Ist ja doll. Die Wallsreet geht runter und under Schnuggel geht wieder ab.
Gute Nachtruhe an alle Aktionäre.
Antwort auf Beitrag Nr.: 37.124.834 von Schero am 07.05.09 22:54:25SCHNUGGEL ist jetzt der Name unseres (missratenen)Schätzchens bis wir wieder bei 20€ stehen----mein Vorschlag an die Elan-Altaktionäre---seid Ihr einverstanden????????????????? Schlaft gut!
Antwort auf Beitrag Nr.: 37.125.200 von Birgit.Tersteegen am 07.05.09 23:28:53Du weißt doch, dass wir mit allen Deinen Vorschlägen einverstanden sind, liebe Birgit.
Antwort auf Beitrag Nr.: 37.126.196 von Poppholz am 08.05.09 08:54:45!
!
Antwort auf Beitrag Nr.: 37.126.196 von Poppholz am 08.05.09 08:54:45Du weißt doch, dass wir mit allen Deinen Vorschlägen einverstanden sind, liebe Birgit.
SCHNUGGEL ist jetzt der Name unseres (missratenen)Schätzchens bis wir wieder bei 20€ stehen
..genau, wir kennen doch dein" Demokratur"verständnis...
SCHNUGGEL ist jetzt der Name unseres (missratenen)Schätzchens bis wir wieder bei 20€ stehen
..genau, wir kennen doch dein" Demokratur"verständnis...
hier gehts auch bald los
Antwort auf Beitrag Nr.: 37.127.685 von [KERN]Codex am 08.05.09 11:36:30wir sind auf jeden Fall dabei.
Wie auch schon beim letzten Mal.
Wie auch schon beim letzten Mal.
Antwort auf Beitrag Nr.: 37.128.478 von Poppholz am 08.05.09 12:43:36Dieser MC ADAMS könnte sich auch bald zur unser Schnuggel äußern. Die Frage ist nur auch so negativ. Oder gerade deshalb positiv. 
Dendreon sell (McAdams Wright Ragen Inc.)
Rating-Update:
Seattle (aktiencheck.de AG) - Die Analysten von McAdams Wright Ragen stufen die Aktie von Dendreon (ISIN US24823Q1076/ WKN 615606) von "hold" auf "sell" zurück. Das Kursziel werde bei 16 USD gesehen. (08.05.2009/ac/a/u)
Analyse-Datum: 08.05.2009
Analyst: McAdams Wright Ragen Inc.
Rating des Analysten: sell
Dendreon sell (McAdams Wright Ragen Inc.)
Rating-Update:
Seattle (aktiencheck.de AG) - Die Analysten von McAdams Wright Ragen stufen die Aktie von Dendreon (ISIN US24823Q1076/ WKN 615606) von "hold" auf "sell" zurück. Das Kursziel werde bei 16 USD gesehen. (08.05.2009/ac/a/u)
Analyse-Datum: 08.05.2009
Analyst: McAdams Wright Ragen Inc.
Rating des Analysten: sell
Antwort auf Beitrag Nr.: 37.125.200 von Birgit.Tersteegen am 07.05.09 23:28:53Ja, bis dahin versteckt sich der SCHNUGGEL unter d.. 
Hallo zusammen,
kann mir jemand einen Grund nennen warum man in ELAN investieren sollte!
Wie sieht es mit dem Cash per Share aus, steht evtl. eine Kapitalmaßnahme an oder evtl. auch ein Rev. Splitt!!!!
Gruß
quickclick
kann mir jemand einen Grund nennen warum man in ELAN investieren sollte!
Wie sieht es mit dem Cash per Share aus, steht evtl. eine Kapitalmaßnahme an oder evtl. auch ein Rev. Splitt!!!!
Gruß
quickclick
HBO series now online. here is the link of segment with Elan and Dale Schenk
http://www.hbo.com/alzheimers/supplementary-inflammation-the…
http://www.hbo.com/alzheimers/supplementary-inflammation-the…
WIE UNSER SCHNUGGEL NACH DEM GENERAL MEETING WOHL REAGIERT??
Rebel Shareholders Prepare For battle At Elan Meeting - Sunday Times Irish Edition - Business Section
Rebel American shareholders at Elan, Ireland’s biggest pharmaceutical company, are preparing to propose alternative directors to the board, writes Tom Lyons.
Sources say Jack Schuler, a 1% shareholder at Elan, has sounded out support among shareholders for running independent candidates. Elan has yet to announce the date of its annual meeting. Schuler, former president of Abbott Laboratories, is believed to be waiting until the meeting is called before revealing his hand.
Schuler, who has set up a website called Fixelan.com, declined to comment last week. Larry Feinberg, president of Oracle Investment Management, which owns 1% of Elan, has repeatedly said he is supportive of a shake-up of the Elan board, which he claims is lacking in pharmaceutical experience.
Matt Strobeck, a partner at Westfield Capital Management, a 4% shareholder in Elan, is the third member of the rebel group considering challenging its existing board. Elan must hold its general meeting by the end of August. Elan has held the meeting in May for the past three years but will not do so this year.
Kelly Martin, Elan’s chief executive, is currently working on finding a new strategic investor in the group. Pfizer and Lundbeck, a Danish pharmaceutical company, have been reported to be considering investing. Elan declined to say which of its directors would be up for re-election. “The resolutions for the AGM will be sent out in due course”, it said.
Elan has already moved to address criticism of its board’s pharmaceutical experience. It has set up a commercial committee of the board led by Bill Rohn, former chief operating officer of Biogen. This is not seen as enough by the rebels, who have criticised Elan for having five Irish directors without direct pharmaceutical experience.
Cheers,
MarkyP
(apologies for any typos, I had to type this out as it's not available in the on-line edition)
Rebel Shareholders Prepare For battle At Elan Meeting - Sunday Times Irish Edition - Business Section
Rebel American shareholders at Elan, Ireland’s biggest pharmaceutical company, are preparing to propose alternative directors to the board, writes Tom Lyons.
Sources say Jack Schuler, a 1% shareholder at Elan, has sounded out support among shareholders for running independent candidates. Elan has yet to announce the date of its annual meeting. Schuler, former president of Abbott Laboratories, is believed to be waiting until the meeting is called before revealing his hand.
Schuler, who has set up a website called Fixelan.com, declined to comment last week. Larry Feinberg, president of Oracle Investment Management, which owns 1% of Elan, has repeatedly said he is supportive of a shake-up of the Elan board, which he claims is lacking in pharmaceutical experience.
Matt Strobeck, a partner at Westfield Capital Management, a 4% shareholder in Elan, is the third member of the rebel group considering challenging its existing board. Elan must hold its general meeting by the end of August. Elan has held the meeting in May for the past three years but will not do so this year.
Kelly Martin, Elan’s chief executive, is currently working on finding a new strategic investor in the group. Pfizer and Lundbeck, a Danish pharmaceutical company, have been reported to be considering investing. Elan declined to say which of its directors would be up for re-election. “The resolutions for the AGM will be sent out in due course”, it said.
Elan has already moved to address criticism of its board’s pharmaceutical experience. It has set up a commercial committee of the board led by Bill Rohn, former chief operating officer of Biogen. This is not seen as enough by the rebels, who have criticised Elan for having five Irish directors without direct pharmaceutical experience.
Cheers,
MarkyP
(apologies for any typos, I had to type this out as it's not available in the on-line edition)
Goodbody
EDT client quarterly results reveal little
Two small biotech companies, with whom Elan's EDT Division is collaborating, yesterday reported Q109 results. Jazz Pharmaceuticals reported a mixed set of numbers with revenue 16% behind expectations but the loss per share 40% less than expected. Of relevance to Elan, the company's once-daily formulation of Luvox (treats social anxiety disorder and obsessive compulsive disorder), recorded revenue of $3.6m. Elan not only receives a royalty on the SODAS drug delivery platform used in the drug (Luvox CR), but also manufactures the drug for Jazz. MAP Pharmaceuticals reported sales 265% ahead of market expectations (single digit numbers) and a loss per share 36% less than expected. Elan is working with MAPP (which in turn is developing the drug in association with AstraZeneca) to produce a pediatric form of budesonide for the treatment of asthma, incorporating Elan's NanoCrystal drug delivery technology. A Phase III trial completed enrolment in September 2008. There was no mention of progress in the drug's development in the results release other than that it was contributing to R&D costs.
Both programmes are small in EDT's overall drug development and commercialisation programme, but every little helps.
...Kleinvieh macht auch Mist....
http://www.investorvillage.com/smbd.asp?mb=160&mn=349079&pt=…
EDT client quarterly results reveal little
Two small biotech companies, with whom Elan's EDT Division is collaborating, yesterday reported Q109 results. Jazz Pharmaceuticals reported a mixed set of numbers with revenue 16% behind expectations but the loss per share 40% less than expected. Of relevance to Elan, the company's once-daily formulation of Luvox (treats social anxiety disorder and obsessive compulsive disorder), recorded revenue of $3.6m. Elan not only receives a royalty on the SODAS drug delivery platform used in the drug (Luvox CR), but also manufactures the drug for Jazz. MAP Pharmaceuticals reported sales 265% ahead of market expectations (single digit numbers) and a loss per share 36% less than expected. Elan is working with MAPP (which in turn is developing the drug in association with AstraZeneca) to produce a pediatric form of budesonide for the treatment of asthma, incorporating Elan's NanoCrystal drug delivery technology. A Phase III trial completed enrolment in September 2008. There was no mention of progress in the drug's development in the results release other than that it was contributing to R&D costs.
Both programmes are small in EDT's overall drug development and commercialisation programme, but every little helps.
...Kleinvieh macht auch Mist....
http://www.investorvillage.com/smbd.asp?mb=160&mn=349079&pt=…
Elan
There has been only one case of PML in the US among 20k patients (plus possibly another few k dropouts). These patients have probably averaged more than 12 months exposure, with the majority approaching 2 yrs. Remember, Tysabri was launched in the US first. Also, did this patient even have MS, and was the PML T related?
Rate of PML in the US is probably not far off just 1 in 30k patient yrs. I bet this is not far off the average for the general MS population who are not on Tysabri. Time for FDA action perhaps.
In the post-marketing setting only and since the reintroduction of TYSABRI in July 2006, approximately
• 24,900 patients have received at least one year of TYSABRI therapy,
• 14,400 patients have received at least 18 months of TYSABRI therapy,
• 6,800 patients have received at least 24 months of TYSABRI therapy.
As of the end of March 2009:
• Approximately 40,000 patients were on TYSABRI therapy worldwide; of these:
• In the U.S., approximately 20,800 patients were on TYSABRI therapy
commercially;
• In the rest of world, approximately 18,500 patients were on TYSABRI therapy
commercially; and
• In global clinical trials, approximately 600 patients were on TYSABRI therapy.
Progressive multifocal leukoencephalopathy (PML):
In the period between the reintroduction and approval of TYSABRI in July 2006 and May 8, 2009, the following cases of PML have been confirmed:
April 15, 2009 31 months MS Ex-US
February 5, 2009 12 months MS Ex-US
December 10, 2008 26 months MS Ex-US
October 29, 2008 14 doses MS US
July 31, 2008 14 months MS Ex-US
July 30, 2008 17 months MS Ex-US
http://www.investorvillage.com/smbd.asp?mb=160&mn=349082&pt=…
There has been only one case of PML in the US among 20k patients (plus possibly another few k dropouts). These patients have probably averaged more than 12 months exposure, with the majority approaching 2 yrs. Remember, Tysabri was launched in the US first. Also, did this patient even have MS, and was the PML T related?
Rate of PML in the US is probably not far off just 1 in 30k patient yrs. I bet this is not far off the average for the general MS population who are not on Tysabri. Time for FDA action perhaps.
In the post-marketing setting only and since the reintroduction of TYSABRI in July 2006, approximately
• 24,900 patients have received at least one year of TYSABRI therapy,
• 14,400 patients have received at least 18 months of TYSABRI therapy,
• 6,800 patients have received at least 24 months of TYSABRI therapy.
As of the end of March 2009:
• Approximately 40,000 patients were on TYSABRI therapy worldwide; of these:
• In the U.S., approximately 20,800 patients were on TYSABRI therapy
commercially;
• In the rest of world, approximately 18,500 patients were on TYSABRI therapy
commercially; and
• In global clinical trials, approximately 600 patients were on TYSABRI therapy.
Progressive multifocal leukoencephalopathy (PML):
In the period between the reintroduction and approval of TYSABRI in July 2006 and May 8, 2009, the following cases of PML have been confirmed:
April 15, 2009 31 months MS Ex-US
February 5, 2009 12 months MS Ex-US
December 10, 2008 26 months MS Ex-US
October 29, 2008 14 doses MS US
July 31, 2008 14 months MS Ex-US
July 30, 2008 17 months MS Ex-US
http://www.investorvillage.com/smbd.asp?mb=160&mn=349082&pt=…
Ja Hallo, gibt es überhaupt noch Schnuggel-Aktionäre???
Unser Schnuggel geht ab und niemand schreibt darüber.
Na hoffentlich geht es so weiter. Eher langsam als zu schell.
Unser Schnuggel geht ab und niemand schreibt darüber.
Na hoffentlich geht es so weiter. Eher langsam als zu schell.
Antwort auf Beitrag Nr.: 37.149.038 von Schero am 11.05.09 22:02:33hi Schero;
....es gibt uns--und freuen tun wir uns auch--aber wenn der Kurs schon mal bei 25€ stand und ohne "Lageveränderung " dann bei 4€ landet (und viele tausend Stücke im Depot"schlummern"),bricht mann bei der Kurserholung von 4€ auf 5,50€ nicht mehr in Freudentänzen aus.... Nette Grüsse!
....es gibt uns--und freuen tun wir uns auch--aber wenn der Kurs schon mal bei 25€ stand und ohne "Lageveränderung " dann bei 4€ landet (und viele tausend Stücke im Depot"schlummern"),bricht mann bei der Kurserholung von 4€ auf 5,50€ nicht mehr in Freudentänzen aus....
Nette Grüsse!
Antwort auf Beitrag Nr.: 37.149.530 von Birgit.Tersteegen am 11.05.09 22:54:56Ah ja, Ich vestehe.
Du hast Recht.
Ich glaube und Hoffe, dass der Kurs wieder dahin kommt.
Gute Nacht.
Du hast Recht.
Ich glaube und Hoffe, dass der Kurs wieder dahin kommt.
Gute Nacht.
Experimental drug at MSU may help Alzheimer's patient
May 11, 2009
It seems contradictory, but Barb Loudon can clearly recall a key moment when she realized she was losing her memory.
As usual, she asked her husband, Ted, if he wanted her to pack him a lunch for work the next day.
He said he did.
"I turned right around and headed to the bedroom and said, 'Do you need a lunch tomorrow?' " she said.
"He said, 'You just asked me that,' and I said, 'I did?' I was shocked," she said.
The Loudons, who live in Delhi Township, took a proactive approach to Barb's memory loss. They got a diagnosis of probable Alzheimer's after a trip to the Mayo Clinic in Rochester, Minn., in 2005. They also have visited a holistic doctor in the Chicago area.
Barb takes two drugs, supplements and an antidepressant to help her cope.
When the Loudons learned that a Michigan State University professor was participating in a clinical trial of a new drug that developers hope could slow the progression of the disease, they were eager to sign up.
"In the beginning, it was, very selfishly, for me," said Barb, now 67. "But when we got into the study, when we got accepted, I said to Ted, 'This is not only for me. This is for everybody who has Alzheimer's and who might get Alzheimer's.' "
The drug is called Bapineuzumab, or Bapi for short, co-developed by two drug companies, Elan and Wyeth.
Dr. Andrea Bozoki, assistant professor of neurology at MSU, is responsible for the trial site at MSU. She said she's excited about the possibilities.
"It provides a way for my patients to gain access to, and possibly benefit from, medications that do not yet have FDA approval," Bozoki said.
"Whether the drug turns out, ultimately, to be the thing or not, it is a morale booster and provides people with optimism or hope and a reason to keep going and doing things day to day."
Drug or placebo?
Clinical trials help researchers determine whether a drug is safe and effective. Across the Bapi trial, 60 percent of participants will get the drug and 40 percent will get a placebo. Neither doctors nor patients know who gets what.
The Bapi trial, which will involve more than 2,000 people at 200 sites across the country, started in January 2008. MSU's trial has been active since last May and is expected to enroll new participants through the summer.
After the Loudons' trip to the Mayo Clinic, Barb started taking two Alzheimer's drugs: Aricept and Namenda. They're exactly half of the drugs currently available to treat the symptoms of the disease. The other two are Exelon and Razadyne.
None slows the disease's progression, Bozoki said.
"As long as you take them, you have a 5 to 10 percent boost from where you were without it," Bozoki said.
"But [with these drugs] your baseline keeps dropping."
Bapineuzumab is a substance known as a monoclonal antibody. Researchers hope it will reduce the beta amyloid plaques, or protein deposits, that are believed to cause Alzheimer's, thus slowing the progression of the disease.
When the Loudons joined the study, Barb took blood tests, had an MRI scan of her brain and participated in cognitive tests to see if she qualified and to set a baseline for her abilities.
Every three months, she gets an infusion of the drug, followed in a few weeks by another MRI. The MRIs are for the patient's safety, since some people have developed a potentially dangerous swelling of the brain after receiving higher doses of Bapineuzumab. The MRIs also will be used to look for a decrease in the rate of brain atrophy that is typical of Alzheimer's.
Coping with disease
Ever since Barb and Ted started noticing her symptoms 10 years or so ago, progress of the disease has been slow. Barb retired from work as an adjunct professor, teaching writing and business English at Lansing Community College because of her increasing forgetfulness, but she has found ways to cope.
"If I'm going to bake something, I've learned to place everything on one counter, then place it on another counter when it's been used," she said. That way, she knows every ingredient has been added to the recipe.
She had given up reading - once a favorite pastime - but has been enjoying Readers Digest condensed books again in recent weeks.
"I don't know if it's being in the study or not," she said. "But I am reading again."
Ted said both he and Barb are happy for the opportunity to help researchers.
"Our hope is that we could certainly provide some help to others along the way," he said. "We didn't have high hopes for ourselves, but we're hopeful that something would be found that would be more toward a cure."
http://www.lansingstatejournal.com/article/20090511/NEWS01/9…
May 11, 2009
It seems contradictory, but Barb Loudon can clearly recall a key moment when she realized she was losing her memory.
As usual, she asked her husband, Ted, if he wanted her to pack him a lunch for work the next day.
He said he did.
"I turned right around and headed to the bedroom and said, 'Do you need a lunch tomorrow?' " she said.
"He said, 'You just asked me that,' and I said, 'I did?' I was shocked," she said.
The Loudons, who live in Delhi Township, took a proactive approach to Barb's memory loss. They got a diagnosis of probable Alzheimer's after a trip to the Mayo Clinic in Rochester, Minn., in 2005. They also have visited a holistic doctor in the Chicago area.
Barb takes two drugs, supplements and an antidepressant to help her cope.
When the Loudons learned that a Michigan State University professor was participating in a clinical trial of a new drug that developers hope could slow the progression of the disease, they were eager to sign up.
"In the beginning, it was, very selfishly, for me," said Barb, now 67. "But when we got into the study, when we got accepted, I said to Ted, 'This is not only for me. This is for everybody who has Alzheimer's and who might get Alzheimer's.' "
The drug is called Bapineuzumab, or Bapi
for short, co-developed by two drug companies, Elan and Wyeth.Dr. Andrea Bozoki, assistant professor of neurology at MSU, is responsible for the trial site at MSU. She said she's excited about the possibilities.
"It provides a way for my patients to gain access to, and possibly benefit from, medications that do not yet have FDA approval," Bozoki said.
"Whether the drug turns out, ultimately, to be the thing or not, it is a morale booster and provides people with optimism or hope and a reason to keep going and doing things day to day."
Drug or placebo?
Clinical trials help researchers determine whether a drug is safe and effective. Across the Bapi trial, 60 percent of participants will get the drug and 40 percent will get a placebo. Neither doctors nor patients know who gets what.
The Bapi trial, which will involve more than 2,000 people at 200 sites across the country, started in January 2008. MSU's trial has been active since last May and is expected to enroll new participants through the summer.
After the Loudons' trip to the Mayo Clinic, Barb started taking two Alzheimer's drugs: Aricept and Namenda. They're exactly half of the drugs currently available to treat the symptoms of the disease. The other two are Exelon and Razadyne.
None slows the disease's progression, Bozoki said.
"As long as you take them, you have a 5 to 10 percent boost from where you were without it," Bozoki said.
"But [with these drugs] your baseline keeps dropping."
Bapineuzumab is a substance known as a monoclonal antibody. Researchers hope it will reduce the beta amyloid plaques, or protein deposits, that are believed to cause Alzheimer's, thus slowing the progression of the disease.
When the Loudons joined the study, Barb took blood tests, had an MRI scan of her brain and participated in cognitive tests to see if she qualified and to set a baseline for her abilities.
Every three months, she gets an infusion of the drug, followed in a few weeks by another MRI. The MRIs are for the patient's safety, since some people have developed a potentially dangerous swelling of the brain after receiving higher doses of Bapineuzumab. The MRIs also will be used to look for a decrease in the rate of brain atrophy that is typical of Alzheimer's.
Coping with disease
Ever since Barb and Ted started noticing her symptoms 10 years or so ago, progress of the disease has been slow. Barb retired from work as an adjunct professor, teaching writing and business English at Lansing Community College because of her increasing forgetfulness, but she has found ways to cope.
"If I'm going to bake something, I've learned to place everything on one counter, then place it on another counter when it's been used," she said. That way, she knows every ingredient has been added to the recipe.
She had given up reading - once a favorite pastime - but has been enjoying Readers Digest condensed books again in recent weeks.
"I don't know if it's being in the study or not," she said. "But I am reading again."
Ted said both he and Barb are happy for the opportunity to help researchers.
"Our hope is that we could certainly provide some help to others along the way," he said. "We didn't have high hopes for ourselves, but we're hopeful that something would be found that would be more toward a cure."
http://www.lansingstatejournal.com/article/20090511/NEWS01/9…
Antwort auf Beitrag Nr.: 37.149.530 von Birgit.Tersteegen am 11.05.09 22:54:56ruhig Blutt, Birgit
Unser Schnuggel wird schon schaukeln.
Bernie, schon, dass Du wieder fleißig bist
Unser Schnuggel wird schon schaukeln.
Bernie, schon, dass Du wieder fleißig bist
Antwort auf Beitrag Nr.: 37.151.061 von surga am 12.05.09 09:48:16 bin ja voll cool!!Jetzt muss nur noch Kelly die Schulden managen + dann werden wir alle REICH....
bin ja voll cool!!Jetzt muss nur noch Kelly die Schulden managen + dann werden wir alle REICH....
Antwort auf Beitrag Nr.: 37.137.018 von quickclick am 09.05.09 16:37:58===== "ELN for beginners?"
AS A WHOLE:
Elan can be broken into 2 divisions: Biopharmaceuticals and Elan Drug Technologies (EDT)
REVENUES:
Biopharm includes the following approved drugs: Tysabri, Azactam, Maxipime, Prialt, and some royalty income.
EDT produces manufacturing and royalty revenues from a number of products.
In 1Q09 EDT produced $59.7M revenue and biopharm $185.7 revenue as a whole, $158.7M from Tysabri alone. So Tysabri (frequently referred to as Ty) accounts for 85% of biopharm revenue and 65% of all Elan revenue. Needless to say, it's the 8th grader in Elan's toddler sandbox.
TYSABRI:
Tysabri has an interesting history. It was originally approved in November 2004 for the treatment of MS. After a few deaths attributed to PML brought on by the use of Tysabri, it was pulled from the market in March 2005. After implementing a rigorous prescription/distribution plan called TOUCH, Tysabri was reintroduced to the market in July of 2006.
Tysabri was initially expected to be a runaway blockbuster. During the initial Tysabri launch (5 months), about 5K patients were dosed, and another 25K were scheduled to be dosed, before it was pulled. The second time around, with concerns of PML reducing prescription rates and complicated TOUCH program, it took almost two years to get to that 30K mark. Simonig keeps a nice patient count chart updated; Here's the latest (http://www.investorvillage.com/iv2/smbd.asp?mb=160&mn=343161…
For awhile it looked like PML might not pop up, but that changed on July 31, 2008 when 2 post marketing cases were confirmed. Since then, another 4 cases have been confirmed. Longtimelong keeps a nice PML chart updated; Here's the latest (http://www.investorvillage.com/iv2/smbd.asp?mb=160&mn=343568…
Tysabri is also approved as a treatment for Crohn's disease, but it is not actively marketed for this indication.
Tysabri sales are currently not meeting expectations. This shortfall in projected revenue is having a definite and material effect on Elan, but I'll get to that later.
THE TYSABRI PIPELINE
It's believed that Tysabri could be effective against a number of other diseases. I don't know much about them or the prospects, but Multiple Myeloma is mentioned on Elan's pipeline page (http://www.elan.com/research_development/Pipeline_Products/)… You'll have to ask others or do more research if you want to know more.
ALZHEIMER'S DISEASE
Speaking of the pipeline page, the top portion is devoted to AD. Elan has a number of therapies in clinical and pre-clinical trials. The most advanced, and most important/relevant to Elan's current share price, is bapineuzumab (frequently referred to as bapi or bap).
Bap is being developed in partnership with Wyeth. Elan is currently running two PIII trials in the US; One for patients who are APOE4+ (carriers) and one for patients who are APOE4- (non-carriers). Wyeth is running two mirror trials in the EU.
Results from bap's PII trial were presented at ICAD on July 29th, 2008. The accompanying slide show can be seen here (http://library.corporate-ir.net/library/88/883/88326/items/3… You can read through posts by nangasimon for an informed positive interpretation. If you want to hear a more negative slant, you might try reading my posts on the topic.
THE STOCK PRICE:
ELN dropped from $34-$37 pre-ICAD to $19-$22 post-ICAD. Two days later (July 31st), those first two pesky PML cases popped up which crashed ELN to the $10-$12 range. Financing/cash flow/debt issues, brought on primarily by failing to meet Tysabri revenue projections, have caused ELN to fall further into the $5-$7 range. Elan is currently exploring strategic options in an attempt to raise cash. It was hoped that they could sell EDT in order to raise about a billion bucks or so, but it's now believed that they'll be selling a 20% stake in the company in order to raise the cash.
WHY WE WAIT
Short-term, we're waiting for the outcome of the strategic review.
Mid-term, we're waiting for neurologists to accept that the benefits of Tysabri FAR outweigh the risks, and to begin prescribing Ty accordingly.
Early long-term, we're waiting for results from the first bap trial (carrier/US), for which enrollment was completed in Dec 2008. It's an 18 month trial, so we're looking at 3Q10 there.
Long-term, we're waiting for the results from the second bap trial (non-carrier/US), which is currently enrolling. It's expected/hoped that enrollment will complete by the end of 2009, putting 18 month results in 3Q11.
There's plenty more to the story, but those are the highlights/lowdarks IMO.
For more info, this might help.
http://www.tixx.com/elan.htm
Hope that helps,
AS A WHOLE:
Elan can be broken into 2 divisions: Biopharmaceuticals and Elan Drug Technologies (EDT)
REVENUES:
Biopharm includes the following approved drugs: Tysabri, Azactam, Maxipime, Prialt, and some royalty income.
EDT produces manufacturing and royalty revenues from a number of products.
In 1Q09 EDT produced $59.7M revenue and biopharm $185.7 revenue as a whole, $158.7M from Tysabri alone. So Tysabri (frequently referred to as Ty) accounts for 85% of biopharm revenue and 65% of all Elan revenue. Needless to say, it's the 8th grader in Elan's toddler sandbox.
TYSABRI:
Tysabri has an interesting history. It was originally approved in November 2004 for the treatment of MS. After a few deaths attributed to PML brought on by the use of Tysabri, it was pulled from the market in March 2005. After implementing a rigorous prescription/distribution plan called TOUCH, Tysabri was reintroduced to the market in July of 2006.
Tysabri was initially expected to be a runaway blockbuster. During the initial Tysabri launch (5 months), about 5K patients were dosed, and another 25K were scheduled to be dosed, before it was pulled. The second time around, with concerns of PML reducing prescription rates and complicated TOUCH program, it took almost two years to get to that 30K mark. Simonig keeps a nice patient count chart updated; Here's the latest (http://www.investorvillage.com/iv2/smbd.asp?mb=160&mn=343161…
For awhile it looked like PML might not pop up, but that changed on July 31, 2008 when 2 post marketing cases were confirmed. Since then, another 4 cases have been confirmed. Longtimelong keeps a nice PML chart updated; Here's the latest (http://www.investorvillage.com/iv2/smbd.asp?mb=160&mn=343568…
Tysabri is also approved as a treatment for Crohn's disease, but it is not actively marketed for this indication.
Tysabri sales are currently not meeting expectations. This shortfall in projected revenue is having a definite and material effect on Elan, but I'll get to that later.
THE TYSABRI PIPELINE
It's believed that Tysabri could be effective against a number of other diseases. I don't know much about them or the prospects, but Multiple Myeloma is mentioned on Elan's pipeline page (http://www.elan.com/research_development/Pipeline_Products/)… You'll have to ask others or do more research if you want to know more.
ALZHEIMER'S DISEASE
Speaking of the pipeline page, the top portion is devoted to AD. Elan has a number of therapies in clinical and pre-clinical trials. The most advanced, and most important/relevant to Elan's current share price, is bapineuzumab (frequently referred to as bapi or bap).
Bap is being developed in partnership with Wyeth. Elan is currently running two PIII trials in the US; One for patients who are APOE4+ (carriers) and one for patients who are APOE4- (non-carriers). Wyeth is running two mirror trials in the EU.
Results from bap's PII trial were presented at ICAD on July 29th, 2008. The accompanying slide show can be seen here (http://library.corporate-ir.net/library/88/883/88326/items/3… You can read through posts by nangasimon for an informed positive interpretation. If you want to hear a more negative slant, you might try reading my posts on the topic.
THE STOCK PRICE:
ELN dropped from $34-$37 pre-ICAD to $19-$22 post-ICAD. Two days later (July 31st), those first two pesky PML cases popped up which crashed ELN to the $10-$12 range. Financing/cash flow/debt issues, brought on primarily by failing to meet Tysabri revenue projections, have caused ELN to fall further into the $5-$7 range. Elan is currently exploring strategic options in an attempt to raise cash. It was hoped that they could sell EDT in order to raise about a billion bucks or so, but it's now believed that they'll be selling a 20% stake in the company in order to raise the cash.
WHY WE WAIT
Short-term, we're waiting for the outcome of the strategic review.
Mid-term, we're waiting for neurologists to accept that the benefits of Tysabri FAR outweigh the risks, and to begin prescribing Ty accordingly.
Early long-term, we're waiting for results from the first bap trial (carrier/US), for which enrollment was completed in Dec 2008. It's an 18 month trial, so we're looking at 3Q10 there.
Long-term, we're waiting for the results from the second bap trial (non-carrier/US), which is currently enrolling. It's expected/hoped that enrollment will complete by the end of 2009, putting 18 month results in 3Q11.
There's plenty more to the story, but those are the highlights/lowdarks IMO.
For more info, this might help.
http://www.tixx.com/elan.htm
Hope that helps,
..kein Lundbeck Deal mit Elan..
Lundbeck CFO: Elan not an acquisition option now
Wed May 13, 2009 6:11am EDT
COPENHAGEN, May 13 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO) would not be able to buy Irish biotech company Elan (ELN.I) in current market conditions, Lundbeck's Chief Financial Officer Anders Gotzsche said on Wednesday.
In March, shares in Elan jumped on what dealers said was market talk Lundbeck was lining up a bid. The two firms at the time declined to comment.
Elan shares rose again this month as traders cited renewed talk Lundbeck was planning a bid.
"I don't see that, at this point in time, it would be possible to borrow the money needed to buy a company the size of Elan," Gotzsche told Reuters.
Elan hired Citigroup in January to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company, and Lundbeck was tipped soon after by Danish and Irish newspapers as a possible buyer.
Elan shares were down 5.1 percent at 4.9975 euros at 1009 GMT, underperforming the DJ Stoxx Healthcare sector index .SCDP, which was up 3 percent, while Lundbeck shares were up 6.5 percent. (Editing by Will Waterman)
http://www.reuters.com/article/rbssHealthcareNews/idUSDKT002…
Lundbeck CFO: Elan not an acquisition option now
Wed May 13, 2009 6:11am EDT
COPENHAGEN, May 13 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO) would not be able to buy Irish biotech company Elan (ELN.I) in current market conditions, Lundbeck's Chief Financial Officer Anders Gotzsche said on Wednesday.
In March, shares in Elan jumped on what dealers said was market talk Lundbeck was lining up a bid. The two firms at the time declined to comment.
Elan shares rose again this month as traders cited renewed talk Lundbeck was planning a bid.
"I don't see that, at this point in time, it would be possible to borrow the money needed to buy a company the size of Elan," Gotzsche told Reuters.
Elan hired Citigroup in January to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company, and Lundbeck was tipped soon after by Danish and Irish newspapers as a possible buyer.
Elan shares were down 5.1 percent at 4.9975 euros at 1009 GMT, underperforming the DJ Stoxx Healthcare sector index .SCDP, which was up 3 percent, while Lundbeck shares were up 6.5 percent. (Editing by Will Waterman)
http://www.reuters.com/article/rbssHealthcareNews/idUSDKT002…
Was ist eigentlich gemeint, wenn man über Verkauf von Elan Spricht?
Was passiert dann mit Elan? Geht die AG ganz in dem Käufer über?
Was heißt das für die Aktionäre?
Was passiert, wenn Elan in den nächsten Monaten keinen Investor findet? Kann das die Insolvenz mit sich führen?
Ich denke nicht, aber wäre für einige Antworten Dankbar.
Schero
Was passiert dann mit Elan? Geht die AG ganz in dem Käufer über?
Was heißt das für die Aktionäre?
Was passiert, wenn Elan in den nächsten Monaten keinen Investor findet? Kann das die Insolvenz mit sich führen?
Ich denke nicht, aber wäre für einige Antworten Dankbar.
Schero
Davy
Improvement in Tysabri run-rate
Barry Gallagher
Closing Price $6.63
Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
At an investor conference yesterday (May 18th), Biogen Idec said that 200 Tysabri net new TYSABRI patients per week on average were added worldwide in both March and April of 2009.
This run-rate of over 200 per week in March and April is an improvement on the Q1 average which was 167 net new Tysabri patients.
This is positive for Elan and shows that Biogen's initiatives are working. It supports the thesis that product acceleration can be a near-term catalyst.
http://www.investorvillage.com/smbd.asp?mb=160&mn=350955&pt=…
Improvement in Tysabri run-rate
Barry Gallagher
Closing Price $6.63
Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
At an investor conference yesterday (May 18th), Biogen Idec said that 200 Tysabri net new TYSABRI patients per week on average were added worldwide in both March and April of 2009.
This run-rate of over 200 per week in March and April is an improvement on the Q1 average which was 167 net new Tysabri patients.
This is positive for Elan and shows that Biogen's initiatives are working. It supports the thesis that product acceleration can be a near-term catalyst.
http://www.investorvillage.com/smbd.asp?mb=160&mn=350955&pt=…
Antwort auf Beitrag Nr.: 37.207.482 von bernie55 am 19.05.09 12:45:42Hi Bernie,
wie geht es Dir so?
wie geht es Dir so?
Antwort auf Beitrag Nr.: 37.212.521 von surga am 19.05.09 20:29:48....MIR geht´s gut--aber MICH fragt ja wieder keiner...
Liebe Grüsse in die Runde.... Birgit
Liebe Grüsse in die Runde....
Birgit
Antwort auf Beitrag Nr.: 37.212.548 von Birgit.Tersteegen am 19.05.09 20:32:57Schön Birgit, freut mich zu lesen, dass Dir gut geht
Bald kommt die "Sonne"
Birgit, weil Bernie so selten sich zeigte, sollten wir ihn doch "Beachtung" schenken
Sonst verschwindet er wieder, dass wäre sehr schade
Bald kommt die "Sonne"
Birgit, weil Bernie so selten sich zeigte, sollten wir ihn doch "Beachtung" schenken
Sonst verschwindet er wieder, dass wäre sehr schade
Antwort auf Beitrag Nr.: 37.212.656 von surga am 19.05.09 20:42:31...locker bleiben, surga....
...leider muss ich feststellen, dass die Beiträge des ELAN - IV Boards aktuell nicht mehr einzulesen sind...
....wollen die doch tatsächlich " money " dafür haben ???
Pick a Payment Plan
Less than 30 cents per day.
Monthly - $8.99 (recurring fee)
Less than 20 cents per day. Best value!
Yearly - $71.88 (recurring fee)
...also, dann schauen wir mal, wie , wo und wann wir Infos bekommen....
LG bernie55
...locker bleiben, surga.......leider muss ich feststellen, dass die Beiträge des ELAN - IV Boards aktuell nicht mehr einzulesen sind...
....wollen die doch tatsächlich " money " dafür haben ???
Pick a Payment Plan
Less than 30 cents per day.
Monthly - $8.99 (recurring fee)
Less than 20 cents per day. Best value!
Yearly - $71.88 (recurring fee)
...also, dann schauen wir mal, wie , wo und wann wir Infos bekommen....
LG bernie55
Antwort auf Beitrag Nr.: 37.219.257 von bernie55 am 20.05.09 15:25:29...nein Bernie--Du musst nur zahlen wenn Du Premium Mitglied sein willst--als"normales" Mitglied musst Du Dich nur mit Password anmelden....Gruss!Birgit
z.b. von heute aus dem IV-Board
GREAT Tysabri article in Chicago Tribune
http://www.chicagotribune.com/news/local/chicago/chi-ms-trea…
chicagotribune.com
Balancing drug's risk, rewards
MS patients welcome close monitoring of Tysabri use
By Robert Mitchum
Tribune reporter
May 20, 2009
The drug was like a life preserver, as Daisy Roque describes it, the first effective ally she had found in her battle against multiple sclerosis.
But when Tysabri was taken from the market in 2005 due to the appearance of a rare but deadly side effect, that preserver was pulled away from Roque, leaving her back in the thrall of the disease's progressive damage.
"It was devastating," said Roque, 35, of Crystal Lake. "It was saying 'you can't do this,' even though the drug is so wonderful, even though it was two years of having my life back."
But after the development of a unique monitoring system that allows doctors -- and Tysabri's manufacturer -- to keep close watch on every single U.S. user of the drug, it was allowed to return to market. Now, in light of encouraging results from that monitoring system presented last month, Tysabri may serve as a model for how hazardous drugs could be used safely in treating serious chronic illnesses.
"We're rethinking this whole thing," said Dr. Anthony Reder, a neurologist at the University of Chicago Medical Center. "MS actually is a pretty bad disease; your brain's being destroyed. So maybe we should try to treat it with drugs that are a little dangerous."
Multiple sclerosis, a disease in which the body's immune defense mistakenly attacks its own nervous system, afflicts 400,000 people in the United States, according to the National Multiple Sclerosis Society. As a protein called myelin, which insulates neurons and allows them to rapidly communicate signals, is degraded by the body's defenses, patients can develop problems walking and moving, blindness, fatigue and even paralysis.
Tysabri was designed by drug company Biogen Idec to prevent immune cells from crossing the blood-brain barrier, the body's protective wall around the nervous system. Infused once every four weeks, the drug was shown in clinical trials to reduce the number of "flare-ups" -- attacks of serious symptoms that usually lead to hospitalization -- experienced by MS patients.
Roque, who was a subject in the clinical trial, said she would have two or three flare-ups each year on other MS medications, losing vision or balance and putting her in the hospital for days at a time. But even though the clinical study was "blind," meaning neither she nor her doctor knew whether she was being given Tysabri or a placebo, she could tell the difference right away.
"During the two years, not one exacerbation," Roque said. "I pretty much knew I was on it."
But shortly after the encouraging trial led to accelerated approval by the Food and Drug Administration, an alarming statistic came to light. Three patients taking Tysabri in the clinical trial contracted progressive multifocal leukoencephalopathy, or PML, a deadly brain disease with no known treatment.
Though the disease appeared in only 1 in 1,000 patients given Tysabri, that number was high enough for the drug company to immediately suspend its sale. Over the next year, as many MS patients and doctors argued that the benefits of the drug were still worth the risk, Biogen and the FDA came up with a compromise: Every person prescribed Tysabri would be followed in a national database and closely screened for early signs of PML. If any worrisome symptoms arose, the drug would be stopped immediately and flushed from the patient's system.
Since Tysabri's return to the market in late 2006, the monitoring system has followed more than 50,000 patients taking the drug. And though cases of PML continue to appear -- a sixth case was announced last month -- the disease has been detected earlier in patients, leading to only one death. Carmen Bozic, vice president/global head of drug safety and risk management at Biogen Idec, said that data presented by the company last month at a neurology meeting indicated a lower risk of PML than previously thought, closer to 1 in 10,000 patients.
But even that risk is enough for doctors to use extreme care in how they prescribe Tysabri to patients. The drug is recommended as a second-line defense, only used after other MS drugs prove ineffective, said Dr. Bruce Cohen, director of the multiple sclerosis program at Northwestern Memorial Hospital. Even then, the decision about taking Tysabri is difficult for patients after they hear about its potential side effects, Cohen said.
"About half of the people we offer the drug to decide not to take it, because of concern over risk of PML," Cohen said. "This drug carries a black box warning, and it deserves to: PML is a very real and anticipated part of this drug's risk profile. It's a rare risk, but nonetheless it's a legitimate one."
For Deborah Burroughs, 54, of Elwood, that decision was not easy. Diagnosed with MS in 1981, she had tried basically every medication designed to treat the disease, with varying results. When her doctor told her about the risks associated with Tysabri, Burroughs and her family decided the possible benefits outweighed the potential danger.
"I thought, 'What's the difference? I'll go for it,' " Burroughs said.
Now, although Burroughs still can't play baseball with her son as she used to, she can appreciate the ability to accomplish smaller things that had become impossible: walking through the backyard, cleaning the house or even thinking of the right word when she's having a conversation.
"I would give an A-plus compared to before," Burroughs said. "I really felt like there was no hope before, but now I'm just so thankful."
rmitchum@tribune.com
Copyright © 2009, Chicago Tribune
z.b. von heute aus dem IV-Board
GREAT Tysabri article in Chicago Tribune
http://www.chicagotribune.com/news/local/chicago/chi-ms-trea…
chicagotribune.com
Balancing drug's risk, rewards
MS patients welcome close monitoring of Tysabri use
By Robert Mitchum
Tribune reporter
May 20, 2009
The drug was like a life preserver, as Daisy Roque describes it, the first effective ally she had found in her battle against multiple sclerosis.
But when Tysabri was taken from the market in 2005 due to the appearance of a rare but deadly side effect, that preserver was pulled away from Roque, leaving her back in the thrall of the disease's progressive damage.
"It was devastating," said Roque, 35, of Crystal Lake. "It was saying 'you can't do this,' even though the drug is so wonderful, even though it was two years of having my life back."
But after the development of a unique monitoring system that allows doctors -- and Tysabri's manufacturer -- to keep close watch on every single U.S. user of the drug, it was allowed to return to market. Now, in light of encouraging results from that monitoring system presented last month, Tysabri may serve as a model for how hazardous drugs could be used safely in treating serious chronic illnesses.
"We're rethinking this whole thing," said Dr. Anthony Reder, a neurologist at the University of Chicago Medical Center. "MS actually is a pretty bad disease; your brain's being destroyed. So maybe we should try to treat it with drugs that are a little dangerous."
Multiple sclerosis, a disease in which the body's immune defense mistakenly attacks its own nervous system, afflicts 400,000 people in the United States, according to the National Multiple Sclerosis Society. As a protein called myelin, which insulates neurons and allows them to rapidly communicate signals, is degraded by the body's defenses, patients can develop problems walking and moving, blindness, fatigue and even paralysis.
Tysabri was designed by drug company Biogen Idec to prevent immune cells from crossing the blood-brain barrier, the body's protective wall around the nervous system. Infused once every four weeks, the drug was shown in clinical trials to reduce the number of "flare-ups" -- attacks of serious symptoms that usually lead to hospitalization -- experienced by MS patients.
Roque, who was a subject in the clinical trial, said she would have two or three flare-ups each year on other MS medications, losing vision or balance and putting her in the hospital for days at a time. But even though the clinical study was "blind," meaning neither she nor her doctor knew whether she was being given Tysabri or a placebo, she could tell the difference right away.
"During the two years, not one exacerbation," Roque said. "I pretty much knew I was on it."
But shortly after the encouraging trial led to accelerated approval by the Food and Drug Administration, an alarming statistic came to light. Three patients taking Tysabri in the clinical trial contracted progressive multifocal leukoencephalopathy, or PML, a deadly brain disease with no known treatment.
Though the disease appeared in only 1 in 1,000 patients given Tysabri, that number was high enough for the drug company to immediately suspend its sale. Over the next year, as many MS patients and doctors argued that the benefits of the drug were still worth the risk, Biogen and the FDA came up with a compromise: Every person prescribed Tysabri would be followed in a national database and closely screened for early signs of PML. If any worrisome symptoms arose, the drug would be stopped immediately and flushed from the patient's system.
Since Tysabri's return to the market in late 2006, the monitoring system has followed more than 50,000 patients taking the drug. And though cases of PML continue to appear -- a sixth case was announced last month -- the disease has been detected earlier in patients, leading to only one death. Carmen Bozic, vice president/global head of drug safety and risk management at Biogen Idec, said that data presented by the company last month at a neurology meeting indicated a lower risk of PML than previously thought, closer to 1 in 10,000 patients.
But even that risk is enough for doctors to use extreme care in how they prescribe Tysabri to patients. The drug is recommended as a second-line defense, only used after other MS drugs prove ineffective, said Dr. Bruce Cohen, director of the multiple sclerosis program at Northwestern Memorial Hospital. Even then, the decision about taking Tysabri is difficult for patients after they hear about its potential side effects, Cohen said.
"About half of the people we offer the drug to decide not to take it, because of concern over risk of PML," Cohen said. "This drug carries a black box warning, and it deserves to: PML is a very real and anticipated part of this drug's risk profile. It's a rare risk, but nonetheless it's a legitimate one."
For Deborah Burroughs, 54, of Elwood, that decision was not easy. Diagnosed with MS in 1981, she had tried basically every medication designed to treat the disease, with varying results. When her doctor told her about the risks associated with Tysabri, Burroughs and her family decided the possible benefits outweighed the potential danger.
"I thought, 'What's the difference? I'll go for it,' " Burroughs said.
Now, although Burroughs still can't play baseball with her son as she used to, she can appreciate the ability to accomplish smaller things that had become impossible: walking through the backyard, cleaning the house or even thinking of the right word when she's having a conversation.
"I would give an A-plus compared to before," Burroughs said. "I really felt like there was no hope before, but now I'm just so thankful."
rmitchum@tribune.com
Copyright © 2009, Chicago Tribune
Antwort auf Beitrag Nr.: 37.219.681 von Birgit.Tersteegen am 20.05.09 15:55:18..nein Bernie--Du musst nur zahlen wenn Du Premium Mitglied sein willst--als"normales" Mitglied musst Du Dich nur mit Password anmelden....Gruss!Birgit
THX..werde mich dann bald anmelden....
.....normal ey....
THX..werde mich dann bald anmelden....
.....normal ey....
Einloggen nur gegen cash. :O
Antwort auf Beitrag Nr.: 37.220.333 von Huges am 20.05.09 16:52:20...bei mir nicht! Ich bin aber schon von Beginn an beim IV-Board (kostenlos) angemeldet.Vielleicht ist es für Neue anders?
Davy
Price $7.04 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Eli Lilly has moved a second product candidate for Alzheimer’s Disease (AD) into
Phase III trials, this time a monoclonal antibody that acts as a passive
immunotherapeutic like Bapineuzumab. Solantezumab, previously known as
LY2062430, will begin enrolling patients this month in two global trials. Some
2,000 patients will be enrolled in total, and treatment for each patient will last 18
months. Although the scale of the Bapineuzumab programme is larger (3,700
patients), it is across four trials segmented by ApoE4 status. There is no indication
that Lilly will segment the trials by genotype.
Solantezumab’s approach is broadly similar to Bapineuzumab in that it seeks to
remove beta amyloid from the brain. Its mechanism, however, is different in that it
binds to the mid-section of the peptide, whereas Bapineuzumab binds to the Nterminal
portion. Lilly decided to pursue a short Phase II programme that analysed
safety and amyloid levels only, and the product was found to be well tolerated
with no evidence of edema, microhaemhorrages or inflammation. However, there
is no indication on the efficacy of the product so far even as it enters expensive
Phase III trials.
This is Lilly’s second AD candidate to reach Phase III trials. LY450139 began
enrolling 2,600 patients for its two pivotal trials in April 2008. This product works
very differently in that it is a gamma secretase inhibitor, designed to disrupt the
amyloid formation process itself. Elan has a co-promote option on this product
should it reach approval.
http://www.investorvillage.com/smbd.asp?mb=160&mn=351691&pt=…
Price $7.04 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Eli Lilly has moved a second product candidate for Alzheimer’s Disease (AD) into
Phase III trials, this time a monoclonal antibody that acts as a passive
immunotherapeutic like Bapineuzumab. Solantezumab, previously known as
LY2062430, will begin enrolling patients this month in two global trials. Some
2,000 patients will be enrolled in total, and treatment for each patient will last 18
months. Although the scale of the Bapineuzumab programme is larger (3,700
patients), it is across four trials segmented by ApoE4 status. There is no indication
that Lilly will segment the trials by genotype.
Solantezumab’s approach is broadly similar to Bapineuzumab in that it seeks to
remove beta amyloid from the brain. Its mechanism, however, is different in that it
binds to the mid-section of the peptide, whereas Bapineuzumab binds to the Nterminal
portion. Lilly decided to pursue a short Phase II programme that analysed
safety and amyloid levels only, and the product was found to be well tolerated
with no evidence of edema, microhaemhorrages or inflammation. However, there
is no indication on the efficacy of the product so far even as it enters expensive
Phase III trials.
This is Lilly’s second AD candidate to reach Phase III trials. LY450139 began
enrolling 2,600 patients for its two pivotal trials in April 2008. This product works
very differently in that it is a gamma secretase inhibitor, designed to disrupt the
amyloid formation process itself. Elan has a co-promote option on this product
should it reach approval.
http://www.investorvillage.com/smbd.asp?mb=160&mn=351691&pt=…
Antwort auf Beitrag Nr.: 37.275.414 von Huges am 28.05.09 19:13:07....wurd´auch mal Zeit! Danke für den Fund!
Antwort auf Beitrag Nr.: 37.223.740 von Birgit.Tersteegen am 20.05.09 23:13:25für frauen gratis
bernie
nenne dich halt barby
bernie
nenne dich halt barby
Antwort auf Beitrag Nr.: 37.275.730 von Bachalor am 28.05.09 19:44:16
Ein Novartis-Manager wird eingestellt:
Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
http://finance.yahoo.com/news/Renee-P-Tannenbaum-PharmD-bw-1…
Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
http://finance.yahoo.com/news/Renee-P-Tannenbaum-PharmD-bw-1…
After Hours Last: 8,42 $
After Hours HIgh: 8,65 &
Bristol-Myers in talks to buy Elan stake
http://www.marketwatch.com/story/bristol-myers-reportedly-in…
Montag geht die Post ab.
After Hours HIgh: 8,65 &
Bristol-Myers in talks to buy Elan stake
http://www.marketwatch.com/story/bristol-myers-reportedly-in…
Montag geht die Post ab.
Antwort auf Beitrag Nr.: 37.288.404 von Huges am 30.05.09 14:11:58thanks,gut dass Du hier aufpasst wo wir Oldies schon ein bisschen die Lust verloren hatten....
Whole WSJ Article
Elan in Talks to Sell Stake to Bristol-Myers
Article
By DANA CIMILLUCA, JEANNE WHALEN and MATTHEW KARNITSCHNIG
Irish biotech firm Elan Corp. is in late-stage talks to sell a minority stake to Bristol-Myers Squibb Co., a deal that could be a precursor to a full takeover of Elan, people familiar with the matter said.
Bristol-Myers is one of two serious contenders for a stake in Elan that could also come with board representation and an ability to take control of the company later on, one of the people said. A deal could be reached as early as next week, though the talks could also break down. It is unclear who else is in contention and what the terms of any deal might be. Elan has a market value of roughly $3.3 billion.
The Dublin-based company, facing pressure from unhappy shareholders, in January said it hired Citigroup Inc. to help conduct a strategic review. At the time, Elan said it needed a partner with the cash and infrastructure to help it develop and market drugs. Chief Executive Kelly Martin later said that the company's preferred outcome would be to sell a minority stake to a drug company large enough to help Elan boost its global sales.
A spokeswoman for Elan declined to comment, as did a spokesman for Bristol Myers.
U.S. shares of Elan, which traded as high as $60 earlier this decade, rose nearly 4.0% to $6.98 Friday afternoon on the New York Stock Exchange.
Elan derives most of its sales from the multiple sclerosis drug Tysabri, which it markets with Biogen Idec Inc. of the U.S. Elan is also developing a closely watched drug for Alzheimer's disease with Wyeth, which recently struck a deal to be acquired by Pfizer Inc. Because of its ties to Biogen, bankers have said that anyone who does a deal with Elan would be in a strong position to ultimately buy the Cambridge, Mass., company as well.
Biogen has tried unsuccessfully to sell itself under pressure from activist shareholder Carl Icahn. Mr. Icahn has renewed his campaign against the company's management, which could lead to another sale process, bankers say.
A deal for Elan would be the latest in wave of pharmaceutical deals driven by the desire of bigger, more established players like Bristol to acquire innovative firms that can help them replenish their pipelines of drugs under development.
Any deal with Elan or Biogen would be risky, given investor concerns about the prospects for their drugs. Both companies' shares fell sharply last summer after Tysabri was linked to cases of a deadly brain infection. Elan was also hurt by questions surrounding the efficacy of the Alzheimer's drug.
Some Elan shareholders, frustrated with the company's performance and an expense structure they say is bloated, have called for Mr. Martin's ouster and a shakeup of the board. Mr. Martin and the board have defended their performance and said they've taken steps to cut costs.
Some of the dissident shareholders have also expressed opposition to doing any deal now, which they say would amount to selling stock at a depressed price.
Write to Dana Cimilluca at dana.cimilluca@wsj.com, Jeanne Whalen at jeanne.whalen@wsj.com and Matthew Karnitschnig at matthew
Whole WSJ Article
Elan in Talks to Sell Stake to Bristol-Myers
Article
By DANA CIMILLUCA, JEANNE WHALEN and MATTHEW KARNITSCHNIG
Irish biotech firm Elan Corp. is in late-stage talks to sell a minority stake to Bristol-Myers Squibb Co., a deal that could be a precursor to a full takeover of Elan, people familiar with the matter said.
Bristol-Myers is one of two serious contenders for a stake in Elan that could also come with board representation and an ability to take control of the company later on, one of the people said. A deal could be reached as early as next week, though the talks could also break down. It is unclear who else is in contention and what the terms of any deal might be. Elan has a market value of roughly $3.3 billion.
The Dublin-based company, facing pressure from unhappy shareholders, in January said it hired Citigroup Inc. to help conduct a strategic review. At the time, Elan said it needed a partner with the cash and infrastructure to help it develop and market drugs. Chief Executive Kelly Martin later said that the company's preferred outcome would be to sell a minority stake to a drug company large enough to help Elan boost its global sales.
A spokeswoman for Elan declined to comment, as did a spokesman for Bristol Myers.
U.S. shares of Elan, which traded as high as $60 earlier this decade, rose nearly 4.0% to $6.98 Friday afternoon on the New York Stock Exchange.
Elan derives most of its sales from the multiple sclerosis drug Tysabri, which it markets with Biogen Idec Inc. of the U.S. Elan is also developing a closely watched drug for Alzheimer's disease with Wyeth, which recently struck a deal to be acquired by Pfizer Inc. Because of its ties to Biogen, bankers have said that anyone who does a deal with Elan would be in a strong position to ultimately buy the Cambridge, Mass., company as well.
Biogen has tried unsuccessfully to sell itself under pressure from activist shareholder Carl Icahn. Mr. Icahn has renewed his campaign against the company's management, which could lead to another sale process, bankers say.
A deal for Elan would be the latest in wave of pharmaceutical deals driven by the desire of bigger, more established players like Bristol to acquire innovative firms that can help them replenish their pipelines of drugs under development.
Any deal with Elan or Biogen would be risky, given investor concerns about the prospects for their drugs. Both companies' shares fell sharply last summer after Tysabri was linked to cases of a deadly brain infection. Elan was also hurt by questions surrounding the efficacy of the Alzheimer's drug.
Some Elan shareholders, frustrated with the company's performance and an expense structure they say is bloated, have called for Mr. Martin's ouster and a shakeup of the board. Mr. Martin and the board have defended their performance and said they've taken steps to cut costs.
Some of the dissident shareholders have also expressed opposition to doing any deal now, which they say would amount to selling stock at a depressed price.
Write to Dana Cimilluca at dana.cimilluca@wsj.com, Jeanne Whalen at jeanne.whalen@wsj.com and Matthew Karnitschnig at matthew
Antwort auf Beitrag Nr.: 37.288.446 von Birgit.Tersteegen am 30.05.09 14:31:45thanks,gut dass Du hier aufpasst wo wir Oldies schon ein bisschen die Lust verloren hatten....
aber aber birgit, du weißt doch gut ding braucht weile!
aber aber birgit, du weißt doch gut ding braucht weile!
Antwort auf Beitrag Nr.: 37.290.343 von GuHu1 am 31.05.09 11:57:13
Das sind ja dolle Nachrichten.
Unser Schnuggel wird jetzt aber richtig abgehe.
Erfreulich für mich ist, dass ich in den letzten 4-5 Wochen immer wieder dazu gekauft haben. Nun sitze ich auf einen Berg von "Gold" (hoffentlich).
Bin jetzt so euphorich, dass ich vor 50-60 USD keines verkaufen will.
Ich habe die ADR`s am NASDAQ gekauft. Würdet Ihr mir raten die in richtigen Aktien (EURO) umzuwandeln??
Das sind ja dolle Nachrichten.
Unser Schnuggel wird jetzt aber richtig abgehe.
Erfreulich für mich ist, dass ich in den letzten 4-5 Wochen immer wieder dazu gekauft haben. Nun sitze ich auf einen Berg von "Gold" (hoffentlich).
Bin jetzt so euphorich, dass ich vor 50-60 USD keines verkaufen will.
Ich habe die ADR`s am NASDAQ gekauft. Würdet Ihr mir raten die in richtigen Aktien (EURO) umzuwandeln??
Subset Data from Two Randomized Phase 3 Trials Show TYSABRI Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF Therapy
http://finance.yahoo.com/news/Subset-Data-from-Two-bw-153924…
http://finance.yahoo.com/news/Subset-Data-from-Two-bw-153924…
Antwort auf Beitrag Nr.: 37.290.555 von Schero am 31.05.09 13:00:51Hi Schero,
ich habe sie auch in Dollar und in Euro ....und behalte sie auch bis mind.35Dollar in beiden Währungen...
----nach netten Tagen am Fluss muss ich mich mal wieder bei unsrerem Schnuggel einlesen....bis später!
ich habe sie auch in Dollar und in Euro ....und behalte sie auch bis mind.35Dollar in beiden Währungen...
----nach netten Tagen am Fluss muss ich mich mal wieder bei unsrerem Schnuggel einlesen....bis später!
Kennt ihr das Posting auf Yahoo...Was this just a Scam?
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Meinungen hierzu???
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks…
Meinungen hierzu???
Antwort auf Beitrag Nr.: 37.294.709 von Uptick08 am 01.06.09 12:56:06....nee-keine Ahnung---wir werden es aber später am Kursverlauf sehen...
Antwort auf Beitrag Nr.: 37.294.865 von Birgit.Tersteegen am 01.06.09 13:18:54Hi Birgit.
Kennt ihr das Posting auf Yahoo...Was this just a Scam?
Der Text ist zweideutig. Was meinen die damit?
Ob ADR oder Aktie hängt doch von dem Umrechnungskurs ab oder?!
Kennt ihr das Posting auf Yahoo...Was this just a Scam?
Der Text ist zweideutig. Was meinen die damit?
Ob ADR oder Aktie hängt doch von dem Umrechnungskurs ab oder?!
Antwort auf Beitrag Nr.: 37.298.421 von Schero am 01.06.09 21:33:18Der Text stellt in Frage,ob es tatsächlich Beteiligungsgespräche gibt.
....klar hängt der Kurs in Euro vom Umrechnungskure €/$ ab...oder was ist Deine Frage??
Gruss! Birgit
....klar hängt der Kurs in Euro vom Umrechnungskure €/$ ab...
oder was ist Deine Frage??Gruss! Birgit
Monday, June 1, 2009 Irishtimes.com
Bristol-Myers may purchase stake in Elan
BRISTOL-MYERS Squibb is reportedly negotiating to purchase a stake in Elan as the Irish-listed drug developer tries to shore up its finances.
A source close to the deal confirmed yesterday that talks were ongoing, but neither company would confirm this last night. Both Elan and Bristol-Myers, which has close to $8 billion in cash, said they did not comment on “rumour and speculation”.
Bristol-Myers Squibb is the second Elan suitor to be named within the past few months, with Dutch firm Lundbeck emerging as a potential bidder in March.
In January, Elan said it had engaged Citigroup to look at ways to support the firm’s finances, which are under pressure as it tries to finance expensive Alzheimer’s drug trials and repay more than $1 billion due in 2011.
Bristol-Myers Squibb chief executive James Cornelius has made no secret of his desire to do deals in the sector, while his counterpart in Elan has said the firm’s preferred option is a partnership with another drug company that would include the sale of a stake of up to 25 per cent. In February, the firm said “everything is on the table”.
Partnership deals coupled with the taking of minority stakes are not unusual in the sector. Pfizer, the world’s largest drugmaker, is acquiring Wyeth for $65 billion, while Merck Co is spending about $44 billion to buy rival Schering-Plough.
Bristol-Myers in early March formed a group of top managers to pursue deals and drug development.
If Elan does not complete a deal soon, it could run out of money before its Alzheimer’s trials are complete. The firm reported a first-quarter loss of $102.6 million this year, a 20 per cent increase from 2008. Sales of its multiple sclerosis drug Tysabri, which is marketed with Biogen Idec, rose 44 per cent over the same period, but have failed to reach the potential expected by many investors. Biogen has admitted that it will be “difficult” to achieve forecasts of 100,000 patients by 2010.
The reinvigoration of Tysabri sales has been a focus for the firm this year. Yesterday, Elan and Biogen issued positive guidance on the use of the drug for treating Crohn’s disease, noting it had improved the quality of life of some patients who are traditionally difficult to treat.
Elan’s shares were trading at €5.30 on Friday, having fallen almost 70 per cent from levels reached a year ago.
Bristol-Myers may purchase stake in Elan
BRISTOL-MYERS Squibb is reportedly negotiating to purchase a stake in Elan as the Irish-listed drug developer tries to shore up its finances.
A source close to the deal confirmed yesterday that talks were ongoing, but neither company would confirm this last night. Both Elan and Bristol-Myers, which has close to $8 billion in cash, said they did not comment on “rumour and speculation”.
Bristol-Myers Squibb is the second Elan suitor to be named within the past few months, with Dutch firm Lundbeck emerging as a potential bidder in March.
In January, Elan said it had engaged Citigroup to look at ways to support the firm’s finances, which are under pressure as it tries to finance expensive Alzheimer’s drug trials and repay more than $1 billion due in 2011.
Bristol-Myers Squibb chief executive James Cornelius has made no secret of his desire to do deals in the sector, while his counterpart in Elan has said the firm’s preferred option is a partnership with another drug company that would include the sale of a stake of up to 25 per cent. In February, the firm said “everything is on the table”.
Partnership deals coupled with the taking of minority stakes are not unusual in the sector. Pfizer, the world’s largest drugmaker, is acquiring Wyeth for $65 billion, while Merck Co is spending about $44 billion to buy rival Schering-Plough.
Bristol-Myers in early March formed a group of top managers to pursue deals and drug development.
If Elan does not complete a deal soon, it could run out of money before its Alzheimer’s trials are complete. The firm reported a first-quarter loss of $102.6 million this year, a 20 per cent increase from 2008. Sales of its multiple sclerosis drug Tysabri, which is marketed with Biogen Idec, rose 44 per cent over the same period, but have failed to reach the potential expected by many investors. Biogen has admitted that it will be “difficult” to achieve forecasts of 100,000 patients by 2010.
The reinvigoration of Tysabri sales has been a focus for the firm this year. Yesterday, Elan and Biogen issued positive guidance on the use of the drug for treating Crohn’s disease, noting it had improved the quality of life of some patients who are traditionally difficult to treat.
Elan’s shares were trading at €5.30 on Friday, having fallen almost 70 per cent from levels reached a year ago.
Antwort auf Beitrag Nr.: 37.298.644 von Birgit.Tersteegen am 01.06.09 22:01:25Ich habe Elan bei $ 5,80 gekauft. Damals war der €-Kurs 1,30. Nun haben wir einen Kurs von ca. 1,40, d. h. wenn ich an der Nasdaq verkaufen würde, hätte ich ca. 7% miese gemacht. Verkaufe ich aber in €, hätte ich 7% extra-Plus. Vorausgesetzt der Kurs bleibt gleich. Daher ist es in meinem Fall nicht unerheblich wo ich verkaufe.
Warum nimmt Elan keine Kapitalerhöhung vor? Siehe Premiere: hat 500 Mio. besorgt.
Warum nimmt Elan keine Kapitalerhöhung vor? Siehe Premiere: hat 500 Mio. besorgt.
Antwort auf Beitrag Nr.: 37.301.331 von Schero am 02.06.09 12:37:31? habe ich nicht verstanden dieses Zahlenspiel.
http://www.hemscott.com/news/comment-archive/item.do?id=7014…
Bristol & Elan would make sense from both sides
Several media sources have reported that Bristol-Myers Squibb may take a minority stake in Elan, which could lead to a full acquisition of the Irish company. We believe a partnership would make sense from both sides. Ever since Bristol lost the acquisition battle for ImClone to Lilly in late 2008, we believe it has been looking to aggressively expand its pipeline and marketed products through midsize acquisitions. Elan fits Bristol's needs with marketed drugs, primarily multiple sclerosis drug Tysabri, and a robust pipeline including Alzheimer's drug bapineuzumab. Also, we don't think Bristol would have any concerns that Elan's important drugs are already partnered with other companies, as Bristol uses a similar strategy with several of its late-stage drugs, including Onglyza, dapaglifozin, and apixaban.
Elan announced earlier in the year that it was looking for strategic alternatives to continue to fund itself adequately, including an outright sale of the company. We believe Elan is open to offers from Bristol and other pharmaceutical companies at the right price.
If the Elan rumours materialise, they would reinforce our merger and acquisition analysis from earlier in the year. In February, we published a list of our top biotech takeout targets, and Elan was the number-one candidate. We believe Elan's strong pipeline and currently marketed drugs along with a weak financial position make the company a prime target for Big Pharma.
Bristol & Elan would make sense from both sides
Several media sources have reported that Bristol-Myers Squibb may take a minority stake in Elan, which could lead to a full acquisition of the Irish company. We believe a partnership would make sense from both sides. Ever since Bristol lost the acquisition battle for ImClone to Lilly in late 2008, we believe it has been looking to aggressively expand its pipeline and marketed products through midsize acquisitions. Elan fits Bristol's needs with marketed drugs, primarily multiple sclerosis drug Tysabri, and a robust pipeline including Alzheimer's drug bapineuzumab. Also, we don't think Bristol would have any concerns that Elan's important drugs are already partnered with other companies, as Bristol uses a similar strategy with several of its late-stage drugs, including Onglyza, dapaglifozin, and apixaban.
Elan announced earlier in the year that it was looking for strategic alternatives to continue to fund itself adequately, including an outright sale of the company. We believe Elan is open to offers from Bristol and other pharmaceutical companies at the right price.
If the Elan rumours materialise, they would reinforce our merger and acquisition analysis from earlier in the year. In February, we published a list of our top biotech takeout targets, and Elan was the number-one candidate. We believe Elan's strong pipeline and currently marketed drugs along with a weak financial position make the company a prime target for Big Pharma.
Antwort auf Beitrag Nr.: 37.303.382 von Huges am 02.06.09 16:34:38Vor einigen Minuten ist der Kurs plötzlich um 6% gesunken. Weiss jemand warum?
Antwort auf Beitrag Nr.: 37.306.182 von Schero am 02.06.09 21:45:50Ja,weil Reuters eine "Quelle" zitierte,nach der die Gespräche mit Bristol Myers über das Anfangsstadium nicht hinausgekommen seien....
Reuters sind blöd + mögen uns nicht....
heisst also nichts...
Reuters sind blöd + mögen uns nicht....
heisst also nichts...
Antwort auf Beitrag Nr.: 37.306.837 von Birgit.Tersteegen am 02.06.09 22:56:34"We will not comment on the strategic review process until it's completed," Mary Stutts
http://www.cnbc.com/id/31069747/site/14081545
Irish drugmaker Elan and Bristol-Myers Squibb held strategic discussions last month, but they broke down in the early stages, a source familiar with the matter said Tuesday.
"The talks were in the early stages, and never got down to price" of a potential transaction between the two drugmakers, said the source, who asked not to be named.
Another source last weekend said Bristol-Myers had been negotiating for a minority stake in Elan, which markets fast-growing multiple sclerosis drug Tysabri with U.S. biotechnology company Biogen
Elan is also developing a high-profile experimental drug for Alzheimer's disease in partnership with Wyeth [WYE 45.00 0.31 (+0.69%) ], which analysts said might have helped draw Bristol-Myers' interest. But the source Tuesday said discussions never got far enough to focus on a potential minority stake in Elan.
"The discussions were very early on when information (about the talks) was leaked out," the source said, adding that a second suitor for Elan had appeared by that point.
The source said it was unclear whether talks between Elan and Bristol-Myers could resume at a later date. Another source said Tuesday that the talks were complicated by price and Elan's drug partnerships, suggesting they were further along.
Elan and Bristol-Myers declined to comment on the matter.
In January, Elan hired Citigroup to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company. Elan has been under pressure from investors critical of Chief Executive Kelly Martin's leadership and the state of the biotech company, which is burning through cash at a rapid rate.
"We will not comment on the strategic review process until it's completed," Mary Stutts, Elan's senior vice president of corporate relations, said Tuesday. "We're not going to comment about it until a deal is actually done."
http://www.cnbc.com/id/31069747/site/14081545
Irish drugmaker Elan and Bristol-Myers Squibb held strategic discussions last month, but they broke down in the early stages, a source familiar with the matter said Tuesday.
"The talks were in the early stages, and never got down to price" of a potential transaction between the two drugmakers, said the source, who asked not to be named.
Another source last weekend said Bristol-Myers had been negotiating for a minority stake in Elan, which markets fast-growing multiple sclerosis drug Tysabri with U.S. biotechnology company Biogen
Elan is also developing a high-profile experimental drug for Alzheimer's disease in partnership with Wyeth [WYE 45.00 0.31 (+0.69%) ], which analysts said might have helped draw Bristol-Myers' interest. But the source Tuesday said discussions never got far enough to focus on a potential minority stake in Elan.
"The discussions were very early on when information (about the talks) was leaked out," the source said, adding that a second suitor for Elan had appeared by that point.
The source said it was unclear whether talks between Elan and Bristol-Myers could resume at a later date. Another source said Tuesday that the talks were complicated by price and Elan's drug partnerships, suggesting they were further along.
Elan and Bristol-Myers declined to comment on the matter.
In January, Elan hired Citigroup to conduct a strategic review of its business, which it said at the time could lead to a sale or merger of the company. Elan has been under pressure from investors critical of Chief Executive Kelly Martin's leadership and the state of the biotech company, which is burning through cash at a rapid rate.
"We will not comment on the strategic review process until it's completed," Mary Stutts, Elan's senior vice president of corporate relations, said Tuesday. "We're not going to comment about it until a deal is actually done."
Ireland's Elan running out of partnership options
Wed Jun 3, 2009 9:39am EDT
http://www.reuters.com/article/marketsNews/idINL340582200906…
Auszüge aus dem Artikel:
Elan, which is also co-developing experimental Alzheimer's drug Bapineuzumab with Wyeth (WYE.N), has 1.15 billion euros ($1.6 billion) worth of debt due in November 2011 and is burning through cash at a rapid rate.
Bristol-Myers was reported to be negotiating for a minority stake in Elan, but another source said the talks were complicated by price and Elan's drug partnerships.
"The difficulty is what are you going to gain for a 20 percent stake in Elan?" Hunter said.
"It's 20 percent of a 50 percent share of Tysabri and of Bapinuzamab which still has the risk of coming through Phase III trials to markets."
Analysts say 500 million euros would be enough for Elan to roll over its debt and if a strategic partnership is not forthcoming, the drugmaker could raise the equity itself or combine such a move with selling some of its pipeline.
...The sale of its share in Tysabri to Biogen....
....sell its profit-generating drug delivery business
...a partnership is still the preferred choice.
"If they don't find a trade investor at a reasonable price, then the risk is the market is going to say if there is no one in the industry willing to invest in Elan, then why should a regular investor?"
Wed Jun 3, 2009 9:39am EDT
http://www.reuters.com/article/marketsNews/idINL340582200906…
Auszüge aus dem Artikel:
Elan, which is also co-developing experimental Alzheimer's drug Bapineuzumab with Wyeth (WYE.N), has 1.15 billion euros ($1.6 billion) worth of debt due in November 2011 and is burning through cash at a rapid rate.
Bristol-Myers was reported to be negotiating for a minority stake in Elan, but another source said the talks were complicated by price and Elan's drug partnerships.
"The difficulty is what are you going to gain for a 20 percent stake in Elan?" Hunter said.
"It's 20 percent of a 50 percent share of Tysabri and of Bapinuzamab which still has the risk of coming through Phase III trials to markets."
Analysts say 500 million euros would be enough for Elan to roll over its debt and if a strategic partnership is not forthcoming, the drugmaker could raise the equity itself or combine such a move with selling some of its pipeline.
...The sale of its share in Tysabri to Biogen....
....sell its profit-generating drug delivery business
...a partnership is still the preferred choice.
"If they don't find a trade investor at a reasonable price, then the risk is the market is going to say if there is no one in the industry willing to invest in Elan, then why should a regular investor?"
Elan to Present at Goldman Sachs 30th Annual Global Healthcare Conference
*On Wednesday June 3, 2009, 9:00 am EDT
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) today announced that it will present at
the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time and 2:30 p.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
http://finance.yahoo.com/news/Elan-to-Present-at-Goldman-bw-…
*On Wednesday June 3, 2009, 9:00 am EDT
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) today announced that it will present at
the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time and 2:30 p.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
http://finance.yahoo.com/news/Elan-to-Present-at-Goldman-bw-…
Jetzt wird in den USA der Kurs wieder nach oben gezockt! 
Antwort auf Beitrag Nr.: 37.314.892 von Huges am 03.06.09 21:51:44
The pop in trading started at 4:59 pm. The last high trades were at 7.94 (700 shares) and 7.89 (1000 shares) at 5:15, but since then it has dropped back to 7.65 (as of 5:43 pm). Total volume since the pop at 4:59 pm is 47,100 shares.
After Hours
Last: $ 7.50
After Hours
High: $ 8
After Hours
Volume: 95,881
After Hours
Low: $ 7.3135
The pop in trading started at 4:59 pm. The last high trades were at 7.94 (700 shares) and 7.89 (1000 shares) at 5:15, but since then it has dropped back to 7.65 (as of 5:43 pm). Total volume since the pop at 4:59 pm is 47,100 shares.
After Hours
Last: $ 7.50
After Hours
High: $ 8
After Hours
Volume: 95,881
After Hours
Low: $ 7.3135
Davy
Icahn may have succeeded in proxy battle at BIIB......YEPPP
Jack Gorman
Price $7.45 Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
--------------------------------------------------------------------------------
At what was by all accounts a very lively AGM, some reports suggest that Carl Icahn may have succeeded in winning two seats on the board of BIIB. After heated discussion between activists and the existing board, there was an unexpected recess in the meeting followed by a statement by BIIB saying that it was still tabulating votes and that a result could take another few days. Icahn claimed he had won two seats — whatever the actual result, it looks to be much closer than last year's battle when he secured approximately 25% support.
We still contend that this increased pressure on BIIB management can only be positive for Tysabri. If it is confirmed that Icahn obtained two board seats. This 'foot in the door' might then allow him to pursue his objective of breaking up BIIB, and any subsequent corporate transaction could potentially allow Elan to crystallise value on Tysabri, through a sale or renegotiation of its stake. At the very least, his continued presence will ensure that BIIB strives to improve operating performance. Given that Tysabri is one of BIIB's key sources of growth, this is also positive for the product.
..wenn dem so wäre, dass ICAHN nun mehr Einfluss auf das Management von BIIB hat, dann kann das nur gut für ELAN sein...
..also, ich hätte nicht gedacht, dass ich ICAHN mal Sympathie entgegenbringen könnte...
Icahn may have succeeded in proxy battle at BIIB......YEPPP
Jack Gorman
Price $7.45 Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
--------------------------------------------------------------------------------
At what was by all accounts a very lively AGM, some reports suggest that Carl Icahn may have succeeded in winning two seats on the board of BIIB. After heated discussion between activists and the existing board, there was an unexpected recess in the meeting followed by a statement by BIIB saying that it was still tabulating votes and that a result could take another few days. Icahn claimed he had won two seats — whatever the actual result, it looks to be much closer than last year's battle when he secured approximately 25% support.
We still contend that this increased pressure on BIIB management can only be positive for Tysabri. If it is confirmed that Icahn obtained two board seats. This 'foot in the door' might then allow him to pursue his objective of breaking up BIIB, and any subsequent corporate transaction could potentially allow Elan to crystallise value on Tysabri, through a sale or renegotiation of its stake. At the very least, his continued presence will ensure that BIIB strives to improve operating performance. Given that Tysabri is one of BIIB's key sources of growth, this is also positive for the product.
..wenn dem so wäre, dass ICAHN nun mehr Einfluss auf das Management von BIIB hat, dann kann das nur gut für ELAN sein...
..also, ich hätte nicht gedacht, dass ich ICAHN mal Sympathie entgegenbringen könnte...
Antwort auf Beitrag Nr.: 37.317.027 von bernie55 am 04.06.09 10:14:38....das ist auf alle Fälle GUT! Spannende Zeiten voraus mit unserem (ungeliebten!:madSchnuggel.....
Schnuggel.....
Antwort auf Beitrag Nr.: 37.317.027 von bernie55 am 04.06.09 10:14:38ergänzende Info
NCB Biogen Icahns re Elan future
Yesterday was a day of high drama at BiogenIdec which saw the company call a recess
at its AGM to allow shareholders more time to vote, which in turn prompted activist
investor Carl Icahn to file a lawsuit to try and close voting.
• It would appear that Icahn has been successful in placing two of his four nominees on
the BiogenIdec board at his second year of trying, however the final result is not
expected to be confirmed until later this month. Icahn chances received a boost last
month when a leading investor advisory group recommended his two nominees who it
now seems were successful in gaining support for board representation.
• Last year, Icahn was unsuccessful in proposing three nominees to the board following
dissatisfaction with the manner in which the attempt to find a buyer for BiogenIdec was
undertaken in 2007. Icahn controls a 5.6% interest in BiogenIdec and previously offered
$23bn for the company in October 2007.
• Icahn’s two representatives on the thirteen person BiogenIdec board are expected to
push for the company to be split into two separate entities - one focusing on oncology
and the other on neurology (which would include Tysabri). A revisiting of the sale
process for BiogenIdec may also be a consideration. In such a scenario, any
prospective bidder would have to clarify Elan’s intentions on Tysabri and given the
importance of Tysabri to BiogenIdec’s future growth, the newly shaped board may have
an important role to play in Elan’s ongoing strategic review.
http://www.investorvillage.com/smbd.asp?mb=160&mn=355124&pt=…
NCB Biogen Icahns re Elan future
Yesterday was a day of high drama at BiogenIdec which saw the company call a recess
at its AGM to allow shareholders more time to vote, which in turn prompted activist
investor Carl Icahn to file a lawsuit to try and close voting.
• It would appear that Icahn has been successful in placing two of his four nominees on
the BiogenIdec board at his second year of trying, however the final result is not
expected to be confirmed until later this month. Icahn chances received a boost last
month when a leading investor advisory group recommended his two nominees who it
now seems were successful in gaining support for board representation.
• Last year, Icahn was unsuccessful in proposing three nominees to the board following
dissatisfaction with the manner in which the attempt to find a buyer for BiogenIdec was
undertaken in 2007. Icahn controls a 5.6% interest in BiogenIdec and previously offered
$23bn for the company in October 2007.
• Icahn’s two representatives on the thirteen person BiogenIdec board are expected to
push for the company to be split into two separate entities - one focusing on oncology
and the other on neurology (which would include Tysabri). A revisiting of the sale
process for BiogenIdec may also be a consideration. In such a scenario, any
prospective bidder would have to clarify Elan’s intentions on Tysabri and given the
importance of Tysabri to BiogenIdec’s future growth, the newly shaped board may have
an important role to play in Elan’s ongoing strategic review.
http://www.investorvillage.com/smbd.asp?mb=160&mn=355124&pt=…
Wieder ein Gerücht (siehe untenstehende Meldung), dass Pfizer ein Kaufangebot für ELAN abgeben will.
Aufgrund der Gerüchte in der letzten Zeit hätte sich Elan schon ein wenig mehr nordwärts bewegen können. Wenn ich mir andere Meldungen/Gerüchte bei anderen Unternehmen ansehe, bewegt sich Elan ein kleinwenig träge. Aber solange es aufwärts geht, kann ich grundsätzlich damit gut leben.
Gruß,
d.H.
Source
Url: http://www.mysmartrend.com/briefs.asp?nwdate=20090604&story=…
Kurzurl: http://tinyurl.com/q6s4eu
_______________________
Pfizer May Bid for Elan
By Chip Brian, SmarTrend Analytics Team
Shares of drug maker Elan Corp. (NYSE:ELN) are up over 5% today on rumors that biotech giant Pfizer (NYSE:PFE) may make a bid for the company. Earlier this week, reports surfaced that Bristol-Myers Squibb (NYSE:BMY) was interested in purchasing a stake in Elan which were later refuted in a UBS report and it was subsequently reported that although talks began in April, they never progressed beyond early stages. No official comments have been made.
Aufgrund der Gerüchte in der letzten Zeit hätte sich Elan schon ein wenig mehr nordwärts bewegen können. Wenn ich mir andere Meldungen/Gerüchte bei anderen Unternehmen ansehe, bewegt sich Elan ein kleinwenig träge. Aber solange es aufwärts geht, kann ich grundsätzlich damit gut leben.
Gruß,
d.H.
Source
Url: http://www.mysmartrend.com/briefs.asp?nwdate=20090604&story=…
Kurzurl: http://tinyurl.com/q6s4eu
_______________________
Pfizer May Bid for Elan
By Chip Brian, SmarTrend Analytics Team
Shares of drug maker Elan Corp. (NYSE:ELN) are up over 5% today on rumors that biotech giant Pfizer (NYSE:PFE) may make a bid for the company. Earlier this week, reports surfaced that Bristol-Myers Squibb (NYSE:BMY) was interested in purchasing a stake in Elan which were later refuted in a UBS report and it was subsequently reported that although talks began in April, they never progressed beyond early stages. No official comments have been made.
Antwort auf Beitrag Nr.: 37.321.734 von dasHaendchen am 04.06.09 18:08:42hatten wir das gerücht zu pfizer nicht schon vor ca. 2 monaten?
Also, an Gerüchten ist meistens etwas dran. Irgendwann werden Sie sich einig. Und dann kommt der Kursfeuerwerk.
Unser Schnuggel macht das Rennen.
Unser Schnuggel macht das Rennen.
Antwort auf Beitrag Nr.: 37.324.354 von Schero am 04.06.09 22:27:01bin ich gerne dabei, ich mein ja nur.....
Antwort auf Beitrag Nr.: 37.323.699 von GuHu1 am 04.06.09 21:26:09hatten wir das gerücht zu pfizer nicht schon vor ca. 2 monaten?
.....Gerüchte für eine mögliche Übernahme gab es im März/April mit der Dänischen Firma LUNDBECK...
.....Gerüchte für eine mögliche Übernahme gab es im März/April mit der Dänischen Firma LUNDBECK...
Davy
A foot in the door at BIIB
Jack Gorman
Price $7.82 Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
--------------------------------------------------------------------------------
It has been confirmed that at least one of Carl Icahn's representatives has won a seat on the board of Biogen Idec (BIIB), following a dramatic AGM on June 3rd. The voting on the last new board appointment remains too close to call, so BIIB will rely on its independent inspector of elections to make the final call.
This result is positive for Tysabri and thus for ELN. Even with one board member, Icahn will be an agent of change at BIIB. Tysabri is one of BIIB’s only growth drivers and will be an important factor in any consideration of change or improved performance at the company.
http://www.investorvillage.com/smbd.asp?mb=160&mn=355562&pt=…
A foot in the door at BIIB
Jack Gorman
Price $7.82 Target: $25.00 Issued: 05/08/08
Previous: $31.00 Issued: 18/06/08
--------------------------------------------------------------------------------
It has been confirmed that at least one of Carl Icahn's representatives has won a seat on the board of Biogen Idec (BIIB), following a dramatic AGM on June 3rd. The voting on the last new board appointment remains too close to call, so BIIB will rely on its independent inspector of elections to make the final call.
This result is positive for Tysabri and thus for ELN. Even with one board member, Icahn will be an agent of change at BIIB. Tysabri is one of BIIB’s only growth drivers and will be an important factor in any consideration of change or improved performance at the company.
http://www.investorvillage.com/smbd.asp?mb=160&mn=355562&pt=…
Antwort auf Beitrag Nr.: 37.325.887 von bernie55 am 05.06.09 09:14:13von GuHu1 am 04.06.09 21:26:09
hatten wir das gerücht zu pfizer nicht schon vor ca. 2 monaten?
bernie55 .....Gerüchte für eine mögliche Übernahme gab es im März/April mit der Dänischen Firma LUNDBECK...
..upppss.......im Januar 09 hatte Pfizer mal die Fühler ausgefahren....
....Mannomann....langsam verliere ich als ELANIAC sogar den Überblick .....
hatten wir das gerücht zu pfizer nicht schon vor ca. 2 monaten?
bernie55 .....Gerüchte für eine mögliche Übernahme gab es im März/April mit der Dänischen Firma LUNDBECK...
..upppss.......im Januar 09 hatte Pfizer mal die Fühler ausgefahren....
....Mannomann....langsam verliere ich als ELANIAC sogar den Überblick .....
NCB
Now its Pfizer
In a week that started and now ends with bid speculation, it is Pfizer’s turn to be linked
(again) with a bid for Elan. Pfizer was first rumoured to be interested in Elan back in
January, but this was subsequently refuted by Elan’s management. Later that same
month, Pfizer announced its $68bn deal to acquire Wyeth and market chatter moved to
other potential acquirers (Roche, Lundbeck and most recently Bristol Myers Squibb). A
move by Pfizer on Elan would give the company control over bapineuzumab and the
other Alzheimer’s Disease pipeline candidates that Elan and Wyeth have co-developed.
On this basis a bid for Elan would make sense although the timing may not be to Pfizer
liking as it re-structures following the Wyeth deal. Given the high level of M&A activity
seen in the pharma sector to date in 2009 and the succession of reports linking Elan to
prospective bidders, perhaps time is not on Pfizer’s side?
• Separately, BiogenIdec has confirmed that one of Carl Icahn’s nominees has been
elected to the board following the AGM on Wednesday. There remains one seat to be
confirmed with the company stating that the count was too close to call after the
preliminary tally.
Paraic Quinn +353 1 611 5863 paraic.quinn@ncb
http://www.investorvillage.com/smbd.asp?mb=160&mn=355564&pt=…
Now its Pfizer
In a week that started and now ends with bid speculation, it is Pfizer’s turn to be linked
(again) with a bid for Elan. Pfizer was first rumoured to be interested in Elan back in
January, but this was subsequently refuted by Elan’s management. Later that same
month, Pfizer announced its $68bn deal to acquire Wyeth and market chatter moved to
other potential acquirers (Roche, Lundbeck and most recently Bristol Myers Squibb). A
move by Pfizer on Elan would give the company control over bapineuzumab and the
other Alzheimer’s Disease pipeline candidates that Elan and Wyeth have co-developed.
On this basis a bid for Elan would make sense although the timing may not be to Pfizer
liking as it re-structures following the Wyeth deal. Given the high level of M&A activity
seen in the pharma sector to date in 2009 and the succession of reports linking Elan to
prospective bidders, perhaps time is not on Pfizer’s side?
• Separately, BiogenIdec has confirmed that one of Carl Icahn’s nominees has been
elected to the board following the AGM on Wednesday. There remains one seat to be
confirmed with the company stating that the count was too close to call after the
preliminary tally.
Paraic Quinn +353 1 611 5863 paraic.quinn@ncb
http://www.investorvillage.com/smbd.asp?mb=160&mn=355564&pt=…
Übernahme von ELAN durch PFIZER ????
..dann kann es wirklich nur um BAP gehen...
..Pfizer muss erste Einblicke in die klinischen Phasen bekommen haben und sieht jetzt Bedarf zum Handeln....
..zudem treibt ICAHN die Kommerzialisierung von TYSABRI voran...
ELAN mit mehr oder weniger 2 Blockbustern ( TY + BAP) in der Tasche
Was für ein Angebot wird gemacht ???
..dann kann es wirklich nur um BAP gehen...
..Pfizer muss erste Einblicke in die klinischen Phasen bekommen haben und sieht jetzt Bedarf zum Handeln....
..zudem treibt ICAHN die Kommerzialisierung von TYSABRI voran...
ELAN mit mehr oder weniger 2 Blockbustern ( TY + BAP) in der Tasche
Was für ein Angebot wird gemacht ???
Antwort auf Beitrag Nr.: 37.327.113 von bernie55 am 05.06.09 11:18:27Was für ein Angebot wird gemacht ???
GOODBODY:
At last night's closing price, we estimate that the market is valuing Elan's portion of Bapi at $1.4bn, (total implied value $2.8bn) which may be a little rich for a drug starting Phase III trials and for an acquirer still looking to complete a much larger transaction.
..jetzt bin ich mal gespannt, was auf uns zu kommt..
..KM kann und muss jetzt zeigen, was er als er Moneymanager drauf hat...
..entweder Veräußerung von Aktienanteilen an Pfizer, um Schulden abzubauen.....
oder Übernahme durch Pfizer nicht unter 15 USD, 20 USD oder 25 USD !!!
TIME WILL TELL
GOODBODY:
At last night's closing price, we estimate that the market is valuing Elan's portion of Bapi at $1.4bn, (total implied value $2.8bn) which may be a little rich for a drug starting Phase III trials and for an acquirer still looking to complete a much larger transaction.
..jetzt bin ich mal gespannt, was auf uns zu kommt..
..KM kann und muss jetzt zeigen, was er als er Moneymanager drauf hat...
..entweder Veräußerung von Aktienanteilen an Pfizer, um Schulden abzubauen.....
oder Übernahme durch Pfizer nicht unter 15 USD, 20 USD oder 25 USD !!!
TIME WILL TELL
Antwort auf Beitrag Nr.: 37.327.280 von bernie55 am 05.06.09 11:35:07..entweder Veräußerung von Aktienanteilen an Pfizer, um Schulden abzubauen.....
oder Übernahme durch Pfizer nicht unter 15 USD, 20 USD oder 25 USD!!!
dazu Peadar ‘Og aus dem IV Board
6/5/2009 8:57:13 AM
Jan 2009:
“The drugmaker is a "third of the way through" plans to raise $500 million by licensing out experimental cancer drugs, Martin said.”
You do that and raise $1.2b debt and this company gets to $10b value on the market fairly quickly. Talks of a $4b bid is pure manipulation in my view.
Elan is probably looking for a partner to take 25% or so without passing over control. Bids coming in would be on three different levels.
1. Pay X for 25% without control.
2. Pay X+ for 25% with control.
3. Pay X++ for 25% for more or an outright takeover.
I would be surprised if a company didn’t value Elan at $6b for option 1 above.
That would mean $2b for 25% of $8b ($6b + $2b injected), or $13 a shares for 155m shares.
Float would be 470m current float + 155m new = 625m shares outstanding. 155m share would be roughly 25%.
If the same partner were offered the 500m deal above then you could add $4 a share for the JV.
I think $15 a share would be reasonable for option one.
More expected for other options.
A lot more expected for a take over.
oder Übernahme durch Pfizer nicht unter 15 USD, 20 USD oder 25 USD!!!
dazu Peadar ‘Og aus dem IV Board
6/5/2009 8:57:13 AM
Jan 2009:
“The drugmaker is a "third of the way through" plans to raise $500 million by licensing out experimental cancer drugs, Martin said.”
You do that and raise $1.2b debt and this company gets to $10b value on the market fairly quickly. Talks of a $4b bid is pure manipulation in my view.
Elan is probably looking for a partner to take 25% or so without passing over control. Bids coming in would be on three different levels.
1. Pay X for 25% without control.
2. Pay X+ for 25% with control.
3. Pay X++ for 25% for more or an outright takeover.
I would be surprised if a company didn’t value Elan at $6b for option 1 above.
That would mean $2b for 25% of $8b ($6b + $2b injected), or $13 a shares for 155m shares.
Float would be 470m current float + 155m new = 625m shares outstanding. 155m share would be roughly 25%.
If the same partner were offered the 500m deal above then you could add $4 a share for the JV.
I think $15 a share would be reasonable for option one.
More expected for other options.
A lot more expected for a take over.
Hallo,
gibt es etwas neues über Schnuggel??
gibt es etwas neues über Schnuggel??
Antwort auf Beitrag Nr.: 37.344.723 von Schero am 08.06.09 16:40:52nöööö,leider nicht wirklich---vielleicht übermorgen auf der Goldman Sachs Biotech Konferenz....gruss! Birgit
Antwort auf Beitrag Nr.: 37.325.939 von bernie55 am 05.06.09 09:21:06It has been confirmed that at least one of Carl Icahn's representatives has won a seat on the board of Biogen Idec (BIIB),
..aus 1 mach 2 !!!!!
Goodbodys
Two activist investor nominees added to partner's Board
To complete the Biogen Idec Board election story covered last week, the company announced yesterday that two of activist investor Carl Icahn's nominees secured places on the Board. At the time of the AGM, it was known that one of his nominees had gained a seat, from the pool of four places that were up for election. Previous actions from Mr Icahn would suggest that when he gains a foothold in a company (he owns 5.6% of the stock), he presses for increased efficiencies and improved performance in the existing businesses. This could be a positive for Elan as part of that push might see Biogen Idec increase its efforts in the marketing of Tysabri outside the US.
http://www.investorvillage.com/smbd.asp?mb=160&mn=356990&pt=…
..aus 1 mach 2 !!!!! Goodbodys
Two activist investor nominees added to partner's Board
To complete the Biogen Idec Board election story covered last week, the company announced yesterday that two of activist investor Carl Icahn's nominees secured places on the Board. At the time of the AGM, it was known that one of his nominees had gained a seat, from the pool of four places that were up for election. Previous actions from Mr Icahn would suggest that when he gains a foothold in a company (he owns 5.6% of the stock), he presses for increased efficiencies and improved performance in the existing businesses. This could be a positive for Elan as part of that push might see Biogen Idec increase its efforts in the marketing of Tysabri outside the US.
http://www.investorvillage.com/smbd.asp?mb=160&mn=356990&pt=…
Elan to Present at Goldman Sachs 30th Annual Global Healthcare Conference
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time and 2:30 p.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com , then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) today announced that it will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York, NY, on Wednesday, June 10, 2009, at 7:30 p.m. British Summer Time and 2:30 p.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com , then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
Antwort auf Beitrag Nr.: 37.362.910 von bernie55 am 10.06.09 13:58:56Biogen Idec Confirms Second Icahn Pick Elected to Board of Directors
http://www.xconomy.com/boston/2009/06/09/biogen-idec-confirm…
Robert Buderi 6/9/09
Carl Icahn has landed a one-two punch on Biogen Idec. Today, the Cambridge, MA-based biotech confirmed what the activist investor had proclaimed last week—that two members of Icahn’s board slate have been elected to Biogen’s board of directors. This afternoon, the company acknowledged that Richard Mulligan, a professor of genetics at Harvard Medical School and director of the Harvard Gene Therapy Initiative, had won election to its board. He will be joining fellow Icahn slate member Alex Denner, whose election was confirmed last week by the biotech.
As Xconomy reported in an exclusive interview with Denner and Mulligan last Thursday, Denner appeared to be the runaway winner in last week’s board election, where four director seats were up for grabs on the company’s 13-member board. We cited an Icahn vote-tracking tally that showed Mulligan in third place. But Biogen (NASDAQ: BIIB) only confirmed that Denner and two of its own candidates, Robert Pangia and William Young, had won election. Last week, Biogen said the race for the remaining place was still too close to call.
“We welcome Alexander Denner and Richard Mulligan to the Board and look forward to working with them to build on Biogen Idec’s strong track record of delivering value,” said Bruce R. Ross, Biogen Idec’s chairman, in a statement.
With a two-person toehold on Biogen’s 13-person board, Icahn plans to press an agenda for change at the company. As noted in our story last week, Denner and Mulligan told me that they hoped to focus on five areas at Biogen: shoring up relationships with partners, improving cost structure, strengthening and shoring up the product pipeline, improving strategic direction and focus, and settling litigation issues.
“Our objective is not to put the company up for sale,” Denner told me last week. “It’s to improve shareholder value, improve the pipeline, reinvigorate the culture and research, implement smarter spending, and
improve the relationships between Biogen, Genentech-Roche, and Elan - and potentially to renegotiate a deal with Elan that’s better for the shareholders of both companies.”
...aha...BIIB vielleicht auch dran an ELAN !!???
http://www.xconomy.com/boston/2009/06/09/biogen-idec-confirm…
Robert Buderi 6/9/09
Carl Icahn has landed a one-two punch on Biogen Idec. Today, the Cambridge, MA-based biotech confirmed what the activist investor had proclaimed last week—that two members of Icahn’s board slate have been elected to Biogen’s board of directors. This afternoon, the company acknowledged that Richard Mulligan, a professor of genetics at Harvard Medical School and director of the Harvard Gene Therapy Initiative, had won election to its board. He will be joining fellow Icahn slate member Alex Denner, whose election was confirmed last week by the biotech.
As Xconomy reported in an exclusive interview with Denner and Mulligan last Thursday, Denner appeared to be the runaway winner in last week’s board election, where four director seats were up for grabs on the company’s 13-member board. We cited an Icahn vote-tracking tally that showed Mulligan in third place. But Biogen (NASDAQ: BIIB) only confirmed that Denner and two of its own candidates, Robert Pangia and William Young, had won election. Last week, Biogen said the race for the remaining place was still too close to call.
“We welcome Alexander Denner and Richard Mulligan to the Board and look forward to working with them to build on Biogen Idec’s strong track record of delivering value,” said Bruce R. Ross, Biogen Idec’s chairman, in a statement.
With a two-person toehold on Biogen’s 13-person board, Icahn plans to press an agenda for change at the company. As noted in our story last week, Denner and Mulligan told me that they hoped to focus on five areas at Biogen: shoring up relationships with partners, improving cost structure, strengthening and shoring up the product pipeline, improving strategic direction and focus, and settling litigation issues.
“Our objective is not to put the company up for sale,” Denner told me last week. “It’s to improve shareholder value, improve the pipeline, reinvigorate the culture and research, implement smarter spending, and
improve the relationships between Biogen, Genentech-Roche, and Elan - and potentially to renegotiate a deal with Elan that’s better for the shareholders of both companies.” ...aha...BIIB vielleicht auch dran an ELAN !!???
Antwort auf Beitrag Nr.: 37.363.029 von bernie55 am 10.06.09 14:08:51...oder vielleicht will BIIB " money " für ELAN´S Tysabrirechte ????
Folgender untenstehender Artikel ist ev. von Interesse.
Gruß,
d.H.
______
UPDATE 1-Elan CEO expects strategic deal "in the near term"
LOS ANGELES, June 10 (Reuters) - Elan Corp Plc (ELN.I) (ELN.N) expects to conclude a strategic transaction "in the near term," after talking over the past few months with a number of the global players in pharmaceuticals and big biotechnology, the company's chief executive said on Wednesday.
"A lot of people are interested in talking to us," CEO Kelly Martin said in a web broadcast from a Goldman Sachs healthcare conference.
He declined, however, to comment on whether discussions had broken down with Bristol-Myers Squibb Co (BMY.N), as a source told Reuters last week.
Ireland-based Elan, a co-marketer with Biogen Idec (BIIB.O) of multiple sclerosis drug Tysabri, hired Citigroup in January to conduct a review of the business and said at the time a merger or sale of the company was possible.
Elan, which is also co-developing experimental Alzheimer's drug bapineuzumab with Wyeth (WYE.N), has 1.15 billion euros ($1.6 billion) worth of debt due in November 2011 and is burning through cash at a rapid rate. Pfizer Inc (PFE.N) is in the process of acquiring Wyeth.
By doing a strategic transaction, Martin said Elan is hoping to reduce balance sheet risk and go "a fair long way to fully funding the pipeline through late 2011, 2012."
He also said Elan expects the first pivotal trial results for bapineuzumab in the second half of 2010.
The CEO said Elan still expects to sell its profit-generating drug delivery business, but not until after it concludes a strategic transaction.
Source:
http://www.reuters.com/article/rbssHealthcareNews/idUSN10455…
Gruß,
d.H.
______
UPDATE 1-Elan CEO expects strategic deal "in the near term"
LOS ANGELES, June 10 (Reuters) - Elan Corp Plc (ELN.I) (ELN.N) expects to conclude a strategic transaction "in the near term," after talking over the past few months with a number of the global players in pharmaceuticals and big biotechnology, the company's chief executive said on Wednesday.
"A lot of people are interested in talking to us," CEO Kelly Martin said in a web broadcast from a Goldman Sachs healthcare conference.
He declined, however, to comment on whether discussions had broken down with Bristol-Myers Squibb Co (BMY.N), as a source told Reuters last week.
Ireland-based Elan, a co-marketer with Biogen Idec (BIIB.O) of multiple sclerosis drug Tysabri, hired Citigroup in January to conduct a review of the business and said at the time a merger or sale of the company was possible.
Elan, which is also co-developing experimental Alzheimer's drug bapineuzumab with Wyeth (WYE.N), has 1.15 billion euros ($1.6 billion) worth of debt due in November 2011 and is burning through cash at a rapid rate. Pfizer Inc (PFE.N) is in the process of acquiring Wyeth.
By doing a strategic transaction, Martin said Elan is hoping to reduce balance sheet risk and go "a fair long way to fully funding the pipeline through late 2011, 2012."
He also said Elan expects the first pivotal trial results for bapineuzumab in the second half of 2010.
The CEO said Elan still expects to sell its profit-generating drug delivery business, but not until after it concludes a strategic transaction.
Source:
http://www.reuters.com/article/rbssHealthcareNews/idUSN10455…
Antwort auf Beitrag Nr.: 37.368.800 von dasHaendchen am 11.06.09 01:38:03...tja:könnte,sollte,bald-----kurz:nix Neues.....
Davy
Edging closer to a deal?
Jack Gorman
Closing Price $7.92 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Speaking at a US investor conference last night (June 10th), Elan CEO, Kelly Martin, gave a little more colour on the timeline for the company's strategic review. Elan is in the 'last phase' of assessment, after initially receiving a lot of interest when the review process was begun in January. The CEO hopes that a conclusion will be reached 'in the near term'.
Without being specific, Martin did highlight that a lot of parties are interested in Alzheimer's Disease and neurology, and mid-to-late-stage pipeline products. This is not a very earth-shattering revelation, but plainly it does fit well with the shape of Elan's current pipeline.
He also reiterated the key goals of the review from Elan's perspective: to access more capital and a global commercial infrastructure, and to minimise dilution to current shareholders.
Separately, he also remains very bullish on Tysabri prospects and sees potential for 100,000 patients on this drug within a 3-5 year timeframe.
Edging closer to a deal?
Jack Gorman
Closing Price $7.92 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Speaking at a US investor conference last night (June 10th), Elan CEO, Kelly Martin, gave a little more colour on the timeline for the company's strategic review. Elan is in the 'last phase' of assessment, after initially receiving a lot of interest when the review process was begun in January. The CEO hopes that a conclusion will be reached 'in the near term'.
Without being specific, Martin did highlight that a lot of parties are interested in Alzheimer's Disease and neurology, and mid-to-late-stage pipeline products. This is not a very earth-shattering revelation, but plainly it does fit well with the shape of Elan's current pipeline.
He also reiterated the key goals of the review from Elan's perspective: to access more capital and a global commercial infrastructure, and to minimise dilution to current shareholders.
Separately, he also remains very bullish on Tysabri prospects and sees potential for 100,000 patients on this drug within a 3-5 year timeframe.
Antwort auf Beitrag Nr.: 37.369.704 von Birgit.Tersteegen am 11.06.09 10:03:07Elan is in the 'last phase' of assessment, after initially receiving a lot of interest .....
.....hopes that a conclusion will be reached 'in the near term'...
.....a lot of parties are interested in Alzheimer's Disease and neurology, and mid-to-late-stage pipeline products.
...also, da bin ich wirklich mal gespannt, WIE die Sache abgehandelt und vor allem WER den Deal mit ELAN machen könnte, sollte, müsste, wird.....
PFIZER ?? BIIB ?? WYETH ?? oder ??
.....hopes that a conclusion will be reached 'in the near term'...
.....a lot of parties are interested in Alzheimer's Disease and neurology, and mid-to-late-stage pipeline products.
...also, da bin ich wirklich mal gespannt, WIE die Sache abgehandelt und vor allem WER den Deal mit ELAN machen könnte, sollte, müsste, wird.....
PFIZER ?? BIIB ?? WYETH ?? oder ??
Elan's Tysabri wins prestigious award Thursday, June 11 14:06:50
Tysabri, the multiple sclerosis treatment developed by Ireland's Elan and it US partner, Biogen, has been awarded the French 2009 Prix Galien in the category, "Therapies destined for hospital use".
"It represents a true success for research with a very innovative mechanism of action in MS. It opens the door to a new way of treating MS with an efficacy twice as good as current conventional therapies since it reduces the annual relapse rate by 81pc and the risk of disability progression by 50pc. In some patients, a remission of disease activity has also been noted, or even an improvement of disability," the awards panel said.
Tysabri has clearly changed the way we deal with multiple sclerosis and has improved our patients' quality of life. Now, with 2 years follow-up in France and 3000 patients treated, actual use confirms the product's results since many patients remain with no disease activity nor relapses.
This award is justified and honours neurology and, in particular, neurologists involved in multiple sclerosis," said Professor Jerome De Seze of Strasbourg Regional University Hospital Centre.
...aber so was von " justified ".....
http://www.businessworld.ie/livenews.htm?a=2429830
Antwort auf Beitrag Nr.: 37.371.783 von bernie55 am 11.06.09 13:47:49wenn ELAN übernommen wird, dann hoffentlich nicht unter 16,42 Euro pro Aktie.
Das ist der höchste Kurs, zu dem ich Aktien nachgekauft habe.
Das ist der höchste Kurs, zu dem ich Aktien nachgekauft habe.
Rebel shareholder appointed as non-executive director of Elan
DOMINIC COYLE
Fri, Jun 12, 2009
IRISH BIOTECH group Elan last night announced a boardroom shake-up that will see one of the management’s most vociferous critics become a non-executive director of the company.
Jack Schuler, a former president of Abbott Laboratories, was last night named as one of three people the company proposes to nominate for election to the board at the company’s annual general meeting (agm) next month.
Mr Schuler has been outspoken in his views on the competence of chief executive Kelly Martin and chairman Kyran McLaughlin to maximise the company’s revenues from its key drug, Tysabri, the breakthrough treatment for multiple sclerosis.
He has also voiced concerns about the company’s strategic review under which Citigroup is examining options – including the sale of all or a minority stake in the company – to fund its future development.
Mr Martin said on Wednesday that it was in the “last phases” of the strategic review, although he said it could be a year before a deal was agreed. Speaking at an investor conference hosted by Goldman Sachs, Mr Martin was asked whether a decision would be announced in the next six months to a year. “I don’t want to put a specific time frame, but in the near term we would hope to reach a conclusion. That’s about as specific as I can get.”
Mr Schuler, whose activist investment firm Crabtree Partners owns about 1 per cent of the Irish company, has accused Mr Martin of destroying value in the company.
He also established a website, fixelan.com, as a forum for discontented shareholders and held out the possibility of rebel shareholders nominating their own slate of directors at the agm. The fixelan.com was last night inaccessible.
Elan needs funds to pay for trials of drug candidates, led by its most promising treatment, bapineuzumab for Alzheimer’s disease, and to repay $1.1 billion in debt due in November 2011. The company expects to have about $200 million of cash and investments at the end of the year.
Elan also announced last night that it would nominate Vaughan Bryson, a 32-year veteran of Eli Lilly who has also acted as an adviser in the healthcare industry. They will join another former Eli Lilly executive, Richard Pilnik, who was appointed to the company’s board in May as part of Elan’s commitment to Mr Schuler last February to beef up the commercial focus of the company.
Elan said last night that three current directors would step down at the agm. They are Dennis Selkoe, Ann Maynard Gray and Floyd Bloom.
Dr Selkoe has been an Elan director since 1996 when the company bought Athena Neurosciences – the company whose intellectual property has provided the basis for the most high-profile elements of Elan’s recent drug pipeline. Dr Selkoe, a neurologist, was one of Athena’s founders. He is also professor of neurology and neuroscience at Harvard University. Ms Gray has served on the Elan board since 2001 while Dr Bloom was only appointed to the Elan board in July 2007.
The changes mark a significant shift in emphasis in the Elan boardroom with all three nominees boasting significant industry experience while the departing directors are more closely identified with academia and research. – (Additional reporting, Bloomberg)
© 2009 The Irish Times
DOMINIC COYLE
Fri, Jun 12, 2009
IRISH BIOTECH group Elan last night announced a boardroom shake-up that will see one of the management’s most vociferous critics become a non-executive director of the company.
Jack Schuler, a former president of Abbott Laboratories, was last night named as one of three people the company proposes to nominate for election to the board at the company’s annual general meeting (agm) next month.
Mr Schuler has been outspoken in his views on the competence of chief executive Kelly Martin and chairman Kyran McLaughlin to maximise the company’s revenues from its key drug, Tysabri, the breakthrough treatment for multiple sclerosis.
He has also voiced concerns about the company’s strategic review under which Citigroup is examining options – including the sale of all or a minority stake in the company – to fund its future development.
Mr Martin said on Wednesday that it was in the “last phases” of the strategic review, although he said it could be a year before a deal was agreed. Speaking at an investor conference hosted by Goldman Sachs, Mr Martin was asked whether a decision would be announced in the next six months to a year. “I don’t want to put a specific time frame, but in the near term we would hope to reach a conclusion. That’s about as specific as I can get.”
Mr Schuler, whose activist investment firm Crabtree Partners owns about 1 per cent of the Irish company, has accused Mr Martin of destroying value in the company.
He also established a website, fixelan.com, as a forum for discontented shareholders and held out the possibility of rebel shareholders nominating their own slate of directors at the agm. The fixelan.com was last night inaccessible.
Elan needs funds to pay for trials of drug candidates, led by its most promising treatment, bapineuzumab for Alzheimer’s disease, and to repay $1.1 billion in debt due in November 2011. The company expects to have about $200 million of cash and investments at the end of the year.
Elan also announced last night that it would nominate Vaughan Bryson, a 32-year veteran of Eli Lilly who has also acted as an adviser in the healthcare industry. They will join another former Eli Lilly executive, Richard Pilnik, who was appointed to the company’s board in May as part of Elan’s commitment to Mr Schuler last February to beef up the commercial focus of the company.
Elan said last night that three current directors would step down at the agm. They are Dennis Selkoe, Ann Maynard Gray and Floyd Bloom.
Dr Selkoe has been an Elan director since 1996 when the company bought Athena Neurosciences – the company whose intellectual property has provided the basis for the most high-profile elements of Elan’s recent drug pipeline. Dr Selkoe, a neurologist, was one of Athena’s founders. He is also professor of neurology and neuroscience at Harvard University. Ms Gray has served on the Elan board since 2001 while Dr Bloom was only appointed to the Elan board in July 2007.
The changes mark a significant shift in emphasis in the Elan boardroom with all three nominees boasting significant industry experience while the departing directors are more closely identified with academia and research. – (Additional reporting, Bloomberg)
© 2009 The Irish Times
Hallo Birgit und Andere,
was meisnt Du (Ihr)?
Könnte Elan noch Mal auf 7 USD kommen? Oder die Nachrichtenlage ist so gut, dass das nicht passieren kann
Bitte um Meinungen.
Schero
was meisnt Du (Ihr)?
Könnte Elan noch Mal auf 7 USD kommen? Oder die Nachrichtenlage ist so gut, dass das nicht passieren kann
Bitte um Meinungen.
Schero
Antwort auf Beitrag Nr.: 37.383.432 von Schero am 12.06.09 18:26:59Bei Elan kann jederzeit A L L E S passieren.... --ist nur was für Leute,die die Abwechslung lieben...
--ist nur was für Leute,die die Abwechslung lieben...
Antwort auf Beitrag Nr.: 37.383.432 von Schero am 12.06.09 18:26:59ELAN hält sich leider nicht an "unsere" Prognosen.
Besonders wenn die Nachrichten gut gewesen sind, ist der Kurs oft nach unten gegangen.
Besonders wenn die Nachrichten gut gewesen sind, ist der Kurs oft nach unten gegangen.
Ja, das sieht man heute sooo schöööön. Elan geht wiesder Richtung 7,0. Super
Man schaut Euch mal Dendreon an. Ist absolut stabil. Und was macht der Schnuggel (Du dummes Ding). Schmiert voll ab. WARUM??
Antwort auf Beitrag Nr.: 37.405.597 von Schero am 16.06.09 20:27:52....falsche Frage...es gibt kein "Darum".....
These 5 Underdogs Are No Dogs
By Rich Duprey
June 17, 2009 | Comments (1)
Recs
3
Short-sellers and hedge funds, although sometimes shadowy, are sometimes seen as the smartest investors in the room. They did their homework and will bet their capital against the crowd. It's not the most popular way to go, but the rewards can be quite lucrative.
On Motley Fool CAPS, we've got our own brand of leading analysts who found the chinks in a company's armor and correctly called its fall. "Underdogs" are investors who earned 100 or more CAPS points correctly predicting one or more stocks would underperform the market.
Let's look at some of the recent calls these All-Star investors have made. Yet, just as hedge fund operators don't always go short, we're going to look at recent Underdog picks no matter which way they've called them.
Underdog
Member Rating
Company
CAPS Rating
(out of 5)
Call
tenmiles
100.00
Immucor (Nasdaq: BLUD)
****
Outperform
dwot
99.99
Palm (Nasdaq: PALM)
*
Underperform
BravoBevo
99.99
CDC (Nasdaq: CHINA)
****
Outperform
vanamonde
99.98
Elan (NYSE: ELN)
****
Outperform
AirForceFool
99.98
Research In Motion (Nasdaq: RIMM)
**
Outperform
Not every short sale goes as planned, so it's a risky position to hold. Stock prices can be irrational for longer than you have money to stay in the game. So don't use this as a list of stocks to sell or buy, but rather as the launching pad for further research.
Gute Nacht an alle.
By Rich Duprey
June 17, 2009 | Comments (1)
Recs
3
Short-sellers and hedge funds, although sometimes shadowy, are sometimes seen as the smartest investors in the room. They did their homework and will bet their capital against the crowd. It's not the most popular way to go, but the rewards can be quite lucrative.
On Motley Fool CAPS, we've got our own brand of leading analysts who found the chinks in a company's armor and correctly called its fall. "Underdogs" are investors who earned 100 or more CAPS points correctly predicting one or more stocks would underperform the market.
Let's look at some of the recent calls these All-Star investors have made. Yet, just as hedge fund operators don't always go short, we're going to look at recent Underdog picks no matter which way they've called them.
Underdog
Member Rating
Company
CAPS Rating
(out of 5)
Call
tenmiles
100.00
Immucor (Nasdaq: BLUD)
****
Outperform
dwot
99.99
Palm (Nasdaq: PALM)
*
Underperform
BravoBevo
99.99
CDC (Nasdaq: CHINA)
****
Outperform
vanamonde
99.98
Elan (NYSE: ELN)
****
Outperform
AirForceFool
99.98
Research In Motion (Nasdaq: RIMM)
**
Outperform
Not every short sale goes as planned, so it's a risky position to hold. Stock prices can be irrational for longer than you have money to stay in the game. So don't use this as a list of stocks to sell or buy, but rather as the launching pad for further research.
Gute Nacht an alle.
Antwort auf Beitrag Nr.: 37.415.193 von Schero am 17.06.09 23:03:24Sei nicht traurig,Schero----diese Bewegungen bei Elan haben NICHTS zu sagen-----wenn sie die Finanzierung klären + Bapi hält was es verspricht,sind das hier Traumeinstiegskurse... Elan ist nur was für Anlegher die auf gut geschriebenen Krimis stehen....:O
----diese Bewegungen bei Elan haben NICHTS zu sagen-----wenn sie die Finanzierung klären + Bapi hält was es verspricht,sind das hier Traumeinstiegskurse... Elan ist nur was für Anlegher die auf gut geschriebenen Krimis stehen....:O
Antwort auf Beitrag Nr.: 37.415.402 von Birgit.Tersteegen am 17.06.09 23:51:26Hallo Birgit,
danke für die Worte. Du hast Recht. Ich frage mich nur, ob ich noch einige nachkaufen soll, oder lieber noch warte. Der Kurs kann jederzeit Explodieren. Wenn aber keine Nachrichten kommen, kann der Kurs auch noch nächster Woche weiter sinken.
Was tun. Na, mal schauen.
Gute Nacht.
Schero
danke für die Worte. Du hast Recht. Ich frage mich nur, ob ich noch einige nachkaufen soll, oder lieber noch warte. Der Kurs kann jederzeit Explodieren.
Wenn aber keine Nachrichten kommen, kann der Kurs auch noch nächster Woche weiter sinken. Was tun
. Na, mal schauen.Gute Nacht.
Schero
Antwort auf Beitrag Nr.: 37.423.469 von Schero am 18.06.09 22:54:21....vielleicht in kleineren Tranchen kaufen...
Antwort auf Beitrag Nr.: 37.415.402 von Birgit.Tersteegen am 17.06.09 23:51:26so ist es!
Ich habe so ne gefühl, dass es irgendwann nechste Woche los geht.
Was meint Ihr?
Was meint Ihr?
Sollten sich die PML-Fälle häufen, dann wird der Kurs sehr daran zu "schaffen" haben:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9O…
Von grösster Wichtigkeit wäre nun, dass entsprechende Gegenmassnahmen Wirkung zeigen:
http://clinicaltrials.gov/ct2/show/NCT00746941?term=mefloqui…
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9O…
Von grösster Wichtigkeit wäre nun, dass entsprechende Gegenmassnahmen Wirkung zeigen:
http://clinicaltrials.gov/ct2/show/NCT00746941?term=mefloqui…
Antwort auf Beitrag Nr.: 37.436.425 von Cyberhexe am 21.06.09 19:27:02auf der Liste von Deinem ersten Link sind die akutellsten Fälle mit dem 19. Juni 2009 und dem 10 Juni 2009 angegeben.
Ist dieses so korrekt?
Von denen habe ich bisher noch nichts gehört.
Ist dieses so korrekt?
Von denen habe ich bisher noch nichts gehört.
Antwort auf Beitrag Nr.: 37.436.425 von Cyberhexe am 21.06.09 19:27:02Hallo Cyberhexe,
haben, in den letzten 5 Jahren, schon öfter von Dir gehört.
Warum interessiertest Du Dich für ELAN? Hast Du etwas gewittert?
haben, in den letzten 5 Jahren, schon öfter von Dir gehört.
Warum interessiertest Du Dich für ELAN? Hast Du etwas gewittert?
Antwort auf Beitrag Nr.: 37.438.765 von Poppholz am 22.06.09 11:10:00leider korrekt!Gruss!
Antwort auf Beitrag Nr.: 37.440.011 von Schero am 22.06.09 13:24:20Unser Hexchen ist Elan-Veteranin!Und eine fachlich kompetente dazu...
Hallo an alle.
Elan ist Nachbörslich mit 6% im Minus. Ist das nur ein Zufall, oder gibt es Neuigkeiten negativer Art.
Elan ist Nachbörslich mit 6% im Minus. Ist das nur ein Zufall, oder gibt es Neuigkeiten negativer Art.
Novartis in talks to buy much of Elan: report
* On Sunday June 28, 2009, 6:39 am EDT
DUBLIN (Reuters) - Swiss drugmaker Novartis (VTX:NOVN.VX - News) is in talks to buy parts of Irish peer Elan (ISO:ELN - News), including its flagship multiple sclerosis products and its Alzheimer's disease pipeline, the Sunday Times said.
A spokeswoman for Elan said it did not comment on speculation. A spokesman for Novartis declined to comment.
The Sunday Times said a "well-placed source" confirmed the talks but added the "complexity of the deal made a decision some way off".
Elan, a co-marketer with Biogen Idec (NasdaqGS:BIIB - News) of multiple sclerosis drug Tysabri, hired Citigroup in January to conduct a review of the business and said at the time a merger or sale of the company was possible.
It said on June 10 it expected to conclude a strategic transaction "in the near term", after talking over the past few months with a number of the global players in pharmaceuticals and biotechnology.
Chief Executive Kelly Martin then declined, however, to comment on whether discussions had broken down with Bristol-Myers Squibb Co (BMY - News), as a source had earlier told Reuters.
Analysts say Elan is running out of options for a strategic partnership as earlier market talk of a link-up with companies such as U.S. giant Pfizer Inc (NYSE - PFE - News) or Denmark's Lundbeck (Copenhagen:LUN.CO - News) have all turned out to be unfounded so far.
http://finance.yahoo.com/news/Novartis-in-talks-to-buy-much-…
* On Sunday June 28, 2009, 6:39 am EDT
DUBLIN (Reuters) - Swiss drugmaker Novartis (VTX:NOVN.VX - News) is in talks to buy parts of Irish peer Elan (ISO:ELN - News), including its flagship multiple sclerosis products and its Alzheimer's disease pipeline, the Sunday Times said.
A spokeswoman for Elan said it did not comment on speculation. A spokesman for Novartis declined to comment.
The Sunday Times said a "well-placed source" confirmed the talks but added the "complexity of the deal made a decision some way off".
Elan, a co-marketer with Biogen Idec (NasdaqGS:BIIB - News) of multiple sclerosis drug Tysabri, hired Citigroup in January to conduct a review of the business and said at the time a merger or sale of the company was possible.
It said on June 10 it expected to conclude a strategic transaction "in the near term", after talking over the past few months with a number of the global players in pharmaceuticals and biotechnology.
Chief Executive Kelly Martin then declined, however, to comment on whether discussions had broken down with Bristol-Myers Squibb Co (BMY - News), as a source had earlier told Reuters.
Analysts say Elan is running out of options for a strategic partnership as earlier market talk of a link-up with companies such as U.S. giant Pfizer Inc (NYSE - PFE - News) or Denmark's Lundbeck (Copenhagen:LUN.CO - News) have all turned out to be unfounded so far.
http://finance.yahoo.com/news/Novartis-in-talks-to-buy-much-…
Antwort auf Beitrag Nr.: 37.483.035 von Schero am 28.06.09 21:14:43...werde heute Nachmittag mich mal einlesen;war ein paar Tage weg
Aber wie Bernie (lieben Gruss!:kiss schon schreibt,gibt es neue Gerüchte ,diesmal in Richtung Novartis...
Dies schreibt Creedster aus dem IV Board
Reuters got your attention...now listen!
This is either the 3rd or 4th pharma rumored by the media and "high placed sources" out of Ireland to claim to be in talks to buy all or parts of Elan in the past 5 mos. One day, they will be right!
In the meantime, this article has a very different twist from where we had expected things to go. KM said that they were looking for a strategic partner. Presumably, a company that could fill in the gaps on what Elan is lacking (international presence, large sales force, etc).
Previously, we were looking to sell off EDT to help pay off debt and advance the pipeline (which in AD is SIGNIFICANT!). This article now redirects us to believe that Elan is going to sell off all MS products and AD pipeline???? Are you kidding me? Will Elan return to its founding roots and sell off everything they've worked so hard for in research for over a decade just to continue to hold EDT? If so, it would be a complete 180.
I can't believe that they would agree to sell all MS and AD programs just to pay off debt and keep EDT and (hopefully) their PD programs.
More likely, Elan would sell off some portion of MS and AD programs (such as overseas rights) but I really don't see them selling out at this point. Fidelity has 70+M shares probably with an average around $15, as do many of the other big holders. KM has about 3M shares in options and the vast majority of these are under water. If Elan sees ANYTHING in the AAB studies to give them hope, THEY WON'T SELL THE AD PORTFOLIO COMPLETELY!!!!!
If they do sell the AD portfolio completely, I will sell every share I own and never look back.
I would agree to selling our 50% of Tysabri (or some portion with a royalty) to retire debt and fund the AD pipeline, ORAL tysabri and the PD program.
Novartis may be the one this time and Elan always tries to make shareholders happy before the AGM. I look for definitive news in the next 3 weeks.
Lastly, I believe that KM and the board will agree to the best decision in the end. It's a complex world out there with worldwide recession, ballooning Federal deficits, pressure on pharmas to cut drug costs and pharmas with dwindling pipelines. The intersecting currents are not easy to navigate for ANYONE dealing from a position of relative weakness. Fortunately, debt isn't due for over 2 years and even though we are burning cash, we probably still have something like $300-400M in reserves currently.
Maybe, as some have stated, the longer we wait, the more info Elan obtains about the various programs such as AAB OLE, ELND-005 and others. This info, if good, will allow us to bargain from a much stronger position. If someone were willing to offer $15-20/share it may happen.
Going back to just an EDT program with research? I doubt it.
Should be an interesting few weeks ahead. Hope you enjoy it!
Best to all,
Creedster!
Aber wie Bernie (lieben Gruss!:kiss
schon schreibt,gibt es neue Gerüchte ,diesmal in Richtung Novartis...Dies schreibt Creedster aus dem IV Board
Reuters got your attention...now listen!
This is either the 3rd or 4th pharma rumored by the media and "high placed sources" out of Ireland to claim to be in talks to buy all or parts of Elan in the past 5 mos. One day, they will be right!
In the meantime, this article has a very different twist from where we had expected things to go. KM said that they were looking for a strategic partner. Presumably, a company that could fill in the gaps on what Elan is lacking (international presence, large sales force, etc).
Previously, we were looking to sell off EDT to help pay off debt and advance the pipeline (which in AD is SIGNIFICANT!). This article now redirects us to believe that Elan is going to sell off all MS products and AD pipeline???? Are you kidding me? Will Elan return to its founding roots and sell off everything they've worked so hard for in research for over a decade just to continue to hold EDT? If so, it would be a complete 180.
I can't believe that they would agree to sell all MS and AD programs just to pay off debt and keep EDT and (hopefully) their PD programs.
More likely, Elan would sell off some portion of MS and AD programs (such as overseas rights) but I really don't see them selling out at this point. Fidelity has 70+M shares probably with an average around $15, as do many of the other big holders. KM has about 3M shares in options and the vast majority of these are under water. If Elan sees ANYTHING in the AAB studies to give them hope, THEY WON'T SELL THE AD PORTFOLIO COMPLETELY!!!!!
If they do sell the AD portfolio completely, I will sell every share I own and never look back.
I would agree to selling our 50% of Tysabri (or some portion with a royalty) to retire debt and fund the AD pipeline, ORAL tysabri and the PD program.
Novartis may be the one this time and Elan always tries to make shareholders happy before the AGM. I look for definitive news in the next 3 weeks.
Lastly, I believe that KM and the board will agree to the best decision in the end. It's a complex world out there with worldwide recession, ballooning Federal deficits, pressure on pharmas to cut drug costs and pharmas with dwindling pipelines. The intersecting currents are not easy to navigate for ANYONE dealing from a position of relative weakness. Fortunately, debt isn't due for over 2 years and even though we are burning cash, we probably still have something like $300-400M in reserves currently.
Maybe, as some have stated, the longer we wait, the more info Elan obtains about the various programs such as AAB OLE, ELND-005 and others. This info, if good, will allow us to bargain from a much stronger position. If someone were willing to offer $15-20/share it may happen.
Going back to just an EDT program with research? I doubt it.
Should be an interesting few weeks ahead. Hope you enjoy it!
Best to all,
Creedster!
Antwort auf Beitrag Nr.: 37.483.035 von Schero am 28.06.09 21:14:43....es gab einen 10.PML-Fall...
Davy and Bloxhams: Thanks God we got another rumour to bury the 10th one!
Elan Corp (USc)
ELN US
Novartis the latest rumoured suitor
Jack Gorman
Closing Price $7.36 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Novartis has become the latest big pharma name to be mentioned as a potential suitor for ELN, according to weekend media reports. Whatever about the veracity of this latest rumour, the Swiss pharma giant fits the bill as regards infrastructure, with substantial global commercial operations and an existing neurology portfolio including one of the emerging oral MS treatments, FTY-720. We may get more clarity on the situation at, or before, Elan's AGM, which is being held in Dublin on July 16th.
Separately, a tenth case of PML has been reported in BIIB's latest weekly update. The patient is outside the US and had received 30 doses of Tysabri. Each of the last five patients confirmed with PML had been dosed for at least two years, representing a different profile to the first five, which had ranged from 12-26 doses. There also remains a marked difference in the regional distribution of cases: eight of the ten have been confirmed outside the US, suggesting that the US-based TOUCH programme has been more effective than its European counterparts to date.
With 52,000 patients exposed to Tysabri since re-launch, this implies a crude incidence ratio of approximately 1/5,200. This remains within the 1/1,000 guidelines provided on the product labelling. However, we would continue to highlight the increasing rate of confirmation recently (five in the past two months) as the product nears its third anniversary.
Davy and Bloxhams: Thanks God we got another rumour to bury the 10th one!
Elan Corp (USc)
ELN US
Novartis the latest rumoured suitor
Jack Gorman
Closing Price $7.36 Target: $25.00 Issued: 05/08/08 Previous: $31.00 Issued: 18/06/08
Novartis has become the latest big pharma name to be mentioned as a potential suitor for ELN, according to weekend media reports. Whatever about the veracity of this latest rumour, the Swiss pharma giant fits the bill as regards infrastructure, with substantial global commercial operations and an existing neurology portfolio including one of the emerging oral MS treatments, FTY-720. We may get more clarity on the situation at, or before, Elan's AGM, which is being held in Dublin on July 16th.
Separately, a tenth case of PML has been reported in BIIB's latest weekly update. The patient is outside the US and had received 30 doses of Tysabri. Each of the last five patients confirmed with PML had been dosed for at least two years, representing a different profile to the first five, which had ranged from 12-26 doses. There also remains a marked difference in the regional distribution of cases: eight of the ten have been confirmed outside the US, suggesting that the US-based TOUCH programme has been more effective than its European counterparts to date.
With 52,000 patients exposed to Tysabri since re-launch, this implies a crude incidence ratio of approximately 1/5,200. This remains within the 1/1,000 guidelines provided on the product labelling. However, we would continue to highlight the increasing rate of confirmation recently (five in the past two months) as the product nears its third anniversary.
Hi Birget,
würdest Du jetzt noch nachkaufe?
Bitte begründe.
Vielen Dank
würdest Du jetzt noch nachkaufe?
Bitte begründe.
Vielen Dank
Sorry, Du heißt ja Birit!
Antwort auf Beitrag Nr.: 37.487.415 von Schero am 29.06.09 17:17:17...ich habe mir nach einer intensiven Recherche gerade eben wieder eine Position von 1500 Aktien ins Depot gelegt, wobei diese jedoch unter "high risk" zu verbuchen sind. Und zwar ist die Basisarbeit der Wissenschaftler um Dale Schenk wohl immernoch mit das Beste in der Erforschung neurodegenerativer Erkrankungen, wodurch grösste Begehrlichkeiten bei allen Pharmagrössen geweckt wurden, jedoch scheinen derzeit 2 Horrorszenarien den Kurs zu begrenzen:
1) die sich häufenden PML-Fälle bei der Tysabri-Therapie könnten die prognostizierten Umsatzerwartungen nicht nur gefährden sondern dafür sorgen, dass das Medi vom Markt genommen wird
2) Elan muss bis 2011 2 Kreditlinien refinanzieren und kann dies bis zu diesem Zeitpunkt nicht aus eigener Umsatzstärke heraus vollbringen.
"Elan has $1.76bn in debt with $1.1bn due in 2011 and the balance in 2013 but the company is also looking at this as part of its review."
Sollte die Refinazierung nicht gelingen, könnte die Insolvenz drohen. Allerdings sollte Elan über genügend Aktiva verfügen, um die Finanzierungsprobleme irgendwie zu lösen, zumal der CEO gemäss seiner Herkunft diesbezüglich bereits schon einmal überzeugen konnte.
1) die sich häufenden PML-Fälle bei der Tysabri-Therapie könnten die prognostizierten Umsatzerwartungen nicht nur gefährden sondern dafür sorgen, dass das Medi vom Markt genommen wird
2) Elan muss bis 2011 2 Kreditlinien refinanzieren und kann dies bis zu diesem Zeitpunkt nicht aus eigener Umsatzstärke heraus vollbringen.
"Elan has $1.76bn in debt with $1.1bn due in 2011 and the balance in 2013 but the company is also looking at this as part of its review."
Sollte die Refinazierung nicht gelingen, könnte die Insolvenz drohen. Allerdings sollte Elan über genügend Aktiva verfügen, um die Finanzierungsprobleme irgendwie zu lösen, zumal der CEO gemäss seiner Herkunft diesbezüglich bereits schon einmal überzeugen konnte.
Antwort auf Beitrag Nr.: 37.487.720 von Cyberhexe am 29.06.09 17:58:33Hallo Cyberhexe,
vieln Dank für dein Antwort.
vieln Dank für dein Antwort.
...Hi, schnelle Grüße in die Runde.........hier ein Artikel über BAP....
A trial that may hold promise for Alzheimer's patients-
WESTMINSTER - Just as vividly as she can remember the day she first met the man who would become her husband, Carol Rooney still remembers the day she discovered he was slipping away from her.
"We were at lunch at a restaurant, and I was waiting for Jim to finish filling out the tip so we could get on our way," she said. "I'm waiting for what seems like an eternity, and I walk back to the table, and Jim has writings, numbers all over the bill. He couldn't figure out what the tip was."
That was four years ago. A short time later, Jim Rooney was diagnosed with Alzheimer's Disease. Jim still remembers that day, and the other similar days that followed.
"It really got to me and scared me," he said. "I didn't know what was going on at all. And I just said, 'Man, this is something very different than things that I thought.' There were other things too, but that one just got to me."
With time, Jim's condition got worse. Shortly after he began seeing a neurologist to come up with a plan for treatment, his symptoms seemed beyond treatment. He was losing his ability to construct sentences or remember details throughout his day.
"Jim was down to one word at a time," Carol said. "His memory was getting worse, and he was forgetting everything."
Jim's neurologist, Dr. Joshua Renkin, stopped putting him through tests. Jim's scores for comprehension of basic questions and directions were no longer registering scores on tests for patients with early onset Alzheimer's.
Carol did everything she could to help Jim hold onto what he had left, including rounds of flash cards, computer games, nutrition and exercise.
Then she found an article in the Wall Street Journal that caught her eye. It featured a clinical trial for a drug which aims to remove brain plaque often associated with Alzheimer's. The antibody is called bapineuzumab.
A few months into the trial, something about Jim caught Carol's attention.
"We were coming home and I was in the wrong lane to go to the bank," Carol said. "Jim said to me, 'I thought you said you were going to the bank.' And I said, 'What?' It was the first time he had remembered anything beyond more than a minute."
Doubt was replaced by possibility, and faith. Jim retook Renkin's test, scoring the same score he had during that very first trip to his office two years earlier.
"I've only seen Jim in small snapshots throughout his time with Alzheimer's," Renkin said. "But he seems more verbal, more outgoing, and he's taking more initiative."
In early February, Carol described her husband's in an email she sent as a newstip to 9NEWS:
"The changes in him, since beginning this trial have been nothing less than remarkable! His MMSE (Mini Mental State Exam) score has IMPROVED by two points after the first IV! He is remembering dates, appointments, and things that even I forget about! He is taking initiative around the house, taking on projects, following directions, etc!"
"I would call it a little unusual," said Renkin, who is not associated with the study. "Either they're doing well with medicines, experimental or non-experimental, or they're doing very well with their own life adjustment. Or perhaps there's some other influence that's had benefit [on Jim's condition]."
The clinical trial is a double blind study in which patients are not aware whether they're receiving medicine or placebo. The Rooney family will not know whether Jim is receiving any medicine until the second wave of trials finishes in December 2010.
Regardless of whether Jim is receiving medicine, or it's some other influence that's causing Jim's condition to improve, the Rooneys believes the trial has been an answer to prayer.
"Every day for us is a day that we're thankful for," Carol said. "I can't tell you what tomorrow's going to bring, but I can tell you that today is a blessing for us. We're glad we have each other in life. It's not what we planned, but you take what you can get and you do your best with it."
To learn more about the clinical trial regarding Bapineuzumab and Alzheimer's, visit
http://www.9news.com/news/article.aspx?storyid=118667&catid=…
Antwort auf Beitrag Nr.: 37.487.720 von Cyberhexe am 29.06.09 17:58:33jo hi,
wie ich sehe sieht man nichts oder was?
was bleibt ist doch die frage.
was bleibt wenn novartis the big one kauft.
wenn novartis sich die filetstücke holt.
wie du siehst cyber ht die aktiva von elan nicht die macht sich auf den markt schnell zu veräußern.
hierbei ist doch anzumerken, dass biogen sich auch selbst verkaufen möchte.
ist denn der gedanke so fern, dass novartis tysabri aus der masse herauskauft und biogen übernimmt? oder ist es andersrum, novartis bezahlt biogen etwas für tysabri um biogen damit etwas masse abzukaufen und dadurch etwas attraktiver für die übernahme zu werden scheint.
elan an und für sich enfernt sich jeder anlagelogik.
denen geht das geld aus und im hintergrund rumort es an zerlegung in einzelne teile.
meine frage an die profis wie kann dadurch der anleger profitieren wenn diese firma eben nicht gänzlich geschluckt wird?
die aktienanzahl bleibt doch bestehen also bleibt die bewertung "fast" gleich nur steht dem nun bares gegenüber und nicht die zukünftigen erlöse von derzeit horrenden Mrd. die weit weit weit weit weg sind!
grüße
wie ich sehe sieht man nichts oder was?
was bleibt ist doch die frage.
was bleibt wenn novartis the big one kauft.
wenn novartis sich die filetstücke holt.
wie du siehst cyber ht die aktiva von elan nicht die macht sich auf den markt schnell zu veräußern.
hierbei ist doch anzumerken, dass biogen sich auch selbst verkaufen möchte.
ist denn der gedanke so fern, dass novartis tysabri aus der masse herauskauft und biogen übernimmt? oder ist es andersrum, novartis bezahlt biogen etwas für tysabri um biogen damit etwas masse abzukaufen und dadurch etwas attraktiver für die übernahme zu werden scheint.
elan an und für sich enfernt sich jeder anlagelogik.
denen geht das geld aus und im hintergrund rumort es an zerlegung in einzelne teile.
meine frage an die profis wie kann dadurch der anleger profitieren wenn diese firma eben nicht gänzlich geschluckt wird?
die aktienanzahl bleibt doch bestehen also bleibt die bewertung "fast" gleich nur steht dem nun bares gegenüber und nicht die zukünftigen erlöse von derzeit horrenden Mrd. die weit weit weit weit weg sind!
grüße
Antwort auf Beitrag Nr.: 37.498.775 von welke91 am 01.07.09 10:45:34hi Welke.... Wie gehts Dir?? Netten Gruss! Birgit
Elan müsste UNS eigentlich Schmerzensgeld bezahlen.....:O
Wie gehts Dir?? Netten Gruss! BirgitElan müsste UNS eigentlich Schmerzensgeld bezahlen.....:O
Antwort auf Beitrag Nr.: 37.499.535 von Birgit.Tersteegen am 01.07.09 12:30:50hi birgit,
Stimmung ab Freitag gehts ab in den Urlaub!
weiteres kutz per bm
aber bei BiiB tut sich ja etwas.
Warum kaufen die sich nun bei Acordia ein?
Wird man Tysabri abstoßen? Will man dann Elan in zwei Teile trennen?
EDT und Pharma?
Geht das überhaupt? und wo wird sich der Anleger wiederfinden?
nun schöner ausbrecher heute..viel spaß erstmal !
Stimmung
ab Freitag gehts ab in den Urlaub!weiteres kutz per bm
aber bei BiiB tut sich ja etwas.
Warum kaufen die sich nun bei Acordia ein?
Wird man Tysabri abstoßen? Will man dann Elan in zwei Teile trennen?
EDT und Pharma?
Geht das überhaupt? und wo wird sich der Anleger wiederfinden?
nun schöner ausbrecher heute..viel spaß erstmal !
Finanzen.net
Novartis outperform
von Quelle: Finanzen.net / Aktiencheck.de AG
Dienstag 30. Juni 2009, 15:43 Uhr
Paris (aktiencheck.de AG) - Vincent Meunier, Analyst von Exane BNP Paribas, stuft die Aktie von Novartis (ISIN CH0012005267/ WKN 904278) unverändert mit "outperform" ein und bestätigt das Kursziel von 55 Schweizer Franken.
Nach einem Bericht der "Financial Times" habe Novartis Interesse an einer Übernahme von Elan (Dublin: DRX.IR - Nachrichten) . Dies wäre keine Überraschung. Elan führe derzeit eine strategische Prüfung durch, wobei eine Trennung von bestimmten Unternehmensteilen eine Option darstellen könnte.
Das Alzheimer-Mittel von Elan könnte für Novartis (Virt-X: NOVN.VX - Nachrichten) von Interesse sein, da die Schweizer auf diesem Gebiet bereits tätig seien, keine entsprechenden Kandidaten aber mehr in der Pipeline hätten.
Eine Übernahme wäre für Novartis angesichts eines erwarteten Preises von 2,7 Mrd. USD auch leicht zu finanzieren. Die Auswirkungen auf den Gewinn je Aktie wären leicht negativ.
Vor diesem Hintergrund bewerten die Analysten von Exane BNP Paribas die Aktie von Novartis weiterhin mit dem
Votum "outperform". (Analyse vom 29.06.09) (29.06.2009/ac/a/a)
Analyse-Datum: 29.06.2009
http://de.biz.yahoo.com/30062009/338/novartis-outperform.htm…
Novartis outperform
von Quelle: Finanzen.net / Aktiencheck.de AG
Dienstag 30. Juni 2009, 15:43 Uhr
Paris (aktiencheck.de AG) - Vincent Meunier, Analyst von Exane BNP Paribas, stuft die Aktie von Novartis (ISIN CH0012005267/ WKN 904278) unverändert mit "outperform" ein und bestätigt das Kursziel von 55 Schweizer Franken.
Nach einem Bericht der "Financial Times" habe Novartis Interesse an einer Übernahme von Elan (Dublin: DRX.IR - Nachrichten) . Dies wäre keine Überraschung. Elan führe derzeit eine strategische Prüfung durch, wobei eine Trennung von bestimmten Unternehmensteilen eine Option darstellen könnte.
Das Alzheimer-Mittel von Elan könnte für Novartis (Virt-X: NOVN.VX - Nachrichten) von Interesse sein, da die Schweizer auf diesem Gebiet bereits tätig seien, keine entsprechenden Kandidaten aber mehr in der Pipeline hätten.
Eine Übernahme wäre für Novartis angesichts eines erwarteten Preises von 2,7 Mrd. USD auch leicht zu finanzieren. Die Auswirkungen auf den Gewinn je Aktie wären leicht negativ.
Vor diesem Hintergrund bewerten die Analysten von Exane BNP Paribas die Aktie von Novartis weiterhin mit dem
Votum "outperform". (Analyse vom 29.06.09) (29.06.2009/ac/a/a)
Analyse-Datum: 29.06.2009
http://de.biz.yahoo.com/30062009/338/novartis-outperform.htm…
Davy
BIIB to collaborate with Acorda on Fampridine
Jack Gorman
Closing Price $7.00 Rating: Outperform 30/06/09
No sooner had BIIB announced the termination of CDP323 in Phase II than it revealed a collaboration with Acorda Therapeutics, to develop and commercialise the latter's MS product, Fampridine-SR, outside the US.
The deal is of interest given its links to Elan: FampridineSR is manufactured by its EDT division and incorporates one of EDT’s drug delivery technologies. Fampridine assists MS patients in walking ability, has completed Phase III trials and is currently under review by the FDA in the US.
BIIB will pay a $110m upfront payment to Acorda for Fampridine, and up to $400m in milestone-based payments. Tiered, double-digit royalties will also be paid upon commercialisation. Acorda plans to commercialise the product in the US market.
Acorda will pay Elan 7% of the upfront and milestone payments — representing upfront cash of $7.7m and up to another $28m in milestone payments.
Elan will continue to receive manufacturing and royalty revenue on end-user sales (which we understand to be in the high-teen percentages).
The upfront cash is a modest positive for Elan, and successful US and EU approvals will support our medium-term forecasts for EDT. This deal also increases Elan’s MS links with BIIB, albeit indirectly.
http://www.investorvillage.com/smbd.asp?mb=160&mn=363299&pt=…
BIIB to collaborate with Acorda on Fampridine
Jack Gorman
Closing Price $7.00 Rating: Outperform 30/06/09
No sooner had BIIB announced the termination of CDP323 in Phase II than it revealed a collaboration with Acorda Therapeutics, to develop and commercialise the latter's MS product, Fampridine-SR, outside the US.
The deal is of interest given its links to Elan: FampridineSR is manufactured by its EDT division and incorporates one of EDT’s drug delivery technologies. Fampridine assists MS patients in walking ability, has completed Phase III trials and is currently under review by the FDA in the US.
BIIB will pay a $110m upfront payment to Acorda for Fampridine, and up to $400m in milestone-based payments. Tiered, double-digit royalties will also be paid upon commercialisation. Acorda plans to commercialise the product in the US market.
Acorda will pay Elan 7% of the upfront and milestone payments — representing upfront cash of $7.7m and up to another $28m in milestone payments.
Elan will continue to receive manufacturing and royalty revenue on end-user sales (which we understand to be in the high-teen percentages).
The upfront cash is a modest positive for Elan, and successful US and EU approvals will support our medium-term forecasts for EDT. This deal also increases Elan’s MS links with BIIB, albeit indirectly.
http://www.investorvillage.com/smbd.asp?mb=160&mn=363299&pt=…
Johnson & Johnson pays $1B for Elan stake
J&J invests $1B in Elan for 18 percent stake, buys interest in Alzheimer's candidates
On Thursday July 2, 2009, 8:25 am EDT
NEW BRUNSWICK, N.J. (AP) -- Johnson & Johnson will take an 18.4 percent stake Ireland-based drug developer Elan Corp. with a $1 billion investment.
Johnson & Johnson also is buying Elan Corp.'s stake in its Alzheimer's disease treatment partnership with Wyeth, and rolling it into a new company that will be 49.9 percent owned by Elan.
New Brunswick, N.J.-based Johnson & Johnson plans to commit up to $500 million for development of bapineuzumab, a drug that intended to slow the progression of the disease.
The Alzheimer's division has four drug candidates in clinical or preclinical testing.
http://finance.yahoo.com/news/Johnson-amp-Johnson-pays-1B-ap…
J&J invests $1B in Elan for 18 percent stake, buys interest in Alzheimer's candidates
On Thursday July 2, 2009, 8:25 am EDT
NEW BRUNSWICK, N.J. (AP) -- Johnson & Johnson will take an 18.4 percent stake Ireland-based drug developer Elan Corp. with a $1 billion investment.
Johnson & Johnson also is buying Elan Corp.'s stake in its Alzheimer's disease treatment partnership with Wyeth, and rolling it into a new company that will be 49.9 percent owned by Elan.
New Brunswick, N.J.-based Johnson & Johnson plans to commit up to $500 million for development of bapineuzumab, a drug that intended to slow the progression of the disease.
The Alzheimer's division has four drug candidates in clinical or preclinical testing.
http://finance.yahoo.com/news/Johnson-amp-Johnson-pays-1B-ap…
market pulse
Jul 2, 2009, 8:02 a.m. EST
J&J to invest $1.5 bln in Elan in Alzheimer's deal
By Steve Goldstein
LONDON (MarketWatch) -- Johnson & Johnson /quotes/comstock/13*!jnj/quotes/nls/jnj (JNJ 56.70, -0.37, -0.65%) has reached a deal in which the drug giant will take over Wyeth's /quotes/comstock/13*!wye/quotes/nls/wye (WYE 44.38, -0.99, -2.18%) venture with Elan /quotes/comstock/13*!eln/quotes/nls/eln (ELN 8.42, +1.42, +20.29%) on Alzheimer's and also invest $1 billion in the Irish company, to give J&J an 18.4% stake. Johnson & Johnson, through its affiliate, will assume and continue Elan's activities with Wyeth and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds. Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth. Upon closing, the transaction will have an estimated dilutive impact of two to three cents on Johnson & Johnson 2009 adjusted earnings per share.
http://www.marketwatch.com/story/jj-to-invest-15-bln-in-elan…
Jul 2, 2009, 8:02 a.m. EST
J&J to invest $1.5 bln in Elan in Alzheimer's deal
By Steve Goldstein
LONDON (MarketWatch) -- Johnson & Johnson /quotes/comstock/13*!jnj/quotes/nls/jnj (JNJ 56.70, -0.37, -0.65%) has reached a deal in which the drug giant will take over Wyeth's /quotes/comstock/13*!wye/quotes/nls/wye (WYE 44.38, -0.99, -2.18%) venture with Elan /quotes/comstock/13*!eln/quotes/nls/eln (ELN 8.42, +1.42, +20.29%) on Alzheimer's and also invest $1 billion in the Irish company, to give J&J an 18.4% stake. Johnson & Johnson, through its affiliate, will assume and continue Elan's activities with Wyeth and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds. Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth. Upon closing, the transaction will have an estimated dilutive impact of two to three cents on Johnson & Johnson 2009 adjusted earnings per share.
http://www.marketwatch.com/story/jj-to-invest-15-bln-in-elan…
vorbörslich ist unser Baby bereits bei $9,50 gewesen, fällt aber jetzt wieder ein wenig.
Aktuell stehen wir bei $8,38.
Mal schauen was passiert, wenn die Pforten um 15:30 Uhr geöffnet werden.
Aktuell stehen wir bei $8,38.
Mal schauen was passiert, wenn die Pforten um 15:30 Uhr geöffnet werden.
Antwort auf Beitrag Nr.: 37.487.720 von Cyberhexe am 29.06.09 17:58:332) Elan muss bis 2011 2 Kreditlinien refinanzieren und kann dies bis zu diesem Zeitpunkt nicht aus eigener Umsatzstärke heraus vollbringen.
...ein Horrorszenario hat sich nun, hoffentlich nachhaltig, erledigt, weshalb demnächst zweistellige Kurse wieder möglich sein sollten.
...ein Horrorszenario hat sich nun, hoffentlich nachhaltig, erledigt, weshalb demnächst zweistellige Kurse wieder möglich sein sollten.
Antwort auf Beitrag Nr.: 37.487.720 von Cyberhexe am 29.06.09 17:58:33Gratuliere, da bist Du ja "gerade noch" rechtzeitig in "Deine" alte Truppe zurück gekommen.
AUF REUTERS:
J&J buys $1 billion Elan stake, gains Alzheimer's R&D
Thu Jul 2, 2009 8:45am EDT
LONDON (Reuters) - Johnson & Johnson is to take over most of Elan Corp's Alzheimer's research and invest $1 billion in new Elan equity in exchange for an 18.4 percent stake in the Irish drugmaker, the companies said on Thursday.
The deal marks the end of a strategic review by Elan and its adviser, Citigroup, following pressure from investors for change at the group, which has been burning through cash at a rapid rate.
J&J will initially commit up to $500 million to develop and commercialize bapineuzumab, Elan's experimental Alzheimer's treatment, and will continue Elan's existing activities with Wyeth under their Alzheimer's immunotherapy program.
Wyeth is in the process of being acquired by Pfizer.
In exchange, Elan will get a 49.9 percent equity interest in a newly formed J&J company that will acquire the Alzheimer's program.
The program includes several experimental compounds, of which the most advanced is bapineuzumab, which is viewed by analysts as a risky but potentially lucrative product.
Researchers said last summer that a Phase II trial showed it helped some patients with a certain genetic profile, but raised the risk of potentially serious side effects in the brain.
J&J said the transaction would dilute its adjusted earnings in 2009 by between 2 and 3 cents a share. Shares in Elan leapt 30 percent in Dublin.
(Reporting by Ben Hirschler; editing by Simon Jessop)
http://www.reuters.com/article/businessNews/idUSTRE5612N0200…
J&J buys $1 billion Elan stake, gains Alzheimer's R&D
Thu Jul 2, 2009 8:45am EDT
LONDON (Reuters) - Johnson & Johnson is to take over most of Elan Corp's Alzheimer's research and invest $1 billion in new Elan equity in exchange for an 18.4 percent stake in the Irish drugmaker, the companies said on Thursday.
The deal marks the end of a strategic review by Elan and its adviser, Citigroup, following pressure from investors for change at the group, which has been burning through cash at a rapid rate.
J&J will initially commit up to $500 million to develop and commercialize bapineuzumab, Elan's experimental Alzheimer's treatment, and will continue Elan's existing activities with Wyeth under their Alzheimer's immunotherapy program.
Wyeth is in the process of being acquired by Pfizer.
In exchange, Elan will get a 49.9 percent equity interest in a newly formed J&J company that will acquire the Alzheimer's program.
The program includes several experimental compounds, of which the most advanced is bapineuzumab, which is viewed by analysts as a risky but potentially lucrative product.
Researchers said last summer that a Phase II trial showed it helped some patients with a certain genetic profile, but raised the risk of potentially serious side effects in the brain.
J&J said the transaction would dilute its adjusted earnings in 2009 by between 2 and 3 cents a share. Shares in Elan leapt 30 percent in Dublin.
(Reporting by Ben Hirschler; editing by Simon Jessop)
http://www.reuters.com/article/businessNews/idUSTRE5612N0200…
$8,25 ist vorbörslich erst einmal der Boden gewesen.
Aktuell bewegen wir uns um die $8,50.
Aktuell bewegen wir uns um die $8,50.
Antwort auf Beitrag Nr.: 37.507.657 von Poppholz am 02.07.09 15:10:56hi glückwunsch,
aber mehr als 30 % gain dürften erstmal nicht drin sein.
wie immer good news abverkauf oder kennen wir etwas anderes um dann an einen dienstag oder so einfach mal schnell zu steigen.
finanzierung dürfte damit geglückt sein und ist sehr vorteilhaft. man verschafft sich luft.
das ist wohl momentan die optimalste lösung gewesen.
aber das hier ist schon sehr merkwürdig:
based drug developer Elan Corp. with a $1 billion investment. The news sent Elan's shares soaring in premarket activity.
Related QuotesSymbol Price Change
ELN 7.00 0.00
JNJ 57.07 0.00
Johnson & Johnson also is buying Elan Corp.'s stake in its Alzheimer's disease treatment partnership with Wyeth, and rolling it into a new Johnson & Johnson company that will be 49.9 percent owned by Elan. The partnership develops drugs intended to engage the patient's immune system to fight the brain-destroying disease.
Johnson & Johnson is buying 107.3 million newly issued American Depositary Receipts at $9.32 each, which represents a 33 percent premium from Wednesday's closing price. In premarket trading, Elan's U.S. shares surged $1.36, or 19.4 percent, to $8.36.
Elan's Alzheimer's program has four drug candidates in clinical or preclinical testing. Johnson & Johnson will gain all rights to drugs developed by the program, and it plans to commit up to $500 million for development of bapineuzumab, a drug that intended to slow the progression of mild to moderate Alzheimer's disease. Current drugs treat the symptoms of the disease but don't slow the advance of the damage it causes.
Last summer, Elan and Wyeth reported promising early results from a mid stage study of bapineuzumab, but full results were somewhat disappointing. The drug appeared to be ineffective for patients who had a gene that is found in about half of Alzheimer's patients and makes the disease more severe. The drug is in late stage testing now.
Elan will get 49.9 percent of the profits from the company, and royalty payments on sales. It said the deal will allow it to become profitable by the end of 2010, and reduce its debt by about 70 percent to about $400 million. The company said it held discussions with 30 companies before reaching an agreement with Johnson & Johnson.
phu. ist wohl doch nicht so toll. oder was?!
ich denke nicht außer bap wird blockbuster.
momentan steht das aber in den sternen.
dann aber auch erst dann sind meiner ansicht nach kurse von 16 $ geeignet.
bitte nicht schlagen!
aber mehr als 30 % gain dürften erstmal nicht drin sein.
wie immer good news abverkauf oder kennen wir etwas anderes um dann an einen dienstag oder so einfach mal schnell zu steigen.
finanzierung dürfte damit geglückt sein und ist sehr vorteilhaft. man verschafft sich luft.
das ist wohl momentan die optimalste lösung gewesen.
aber das hier ist schon sehr merkwürdig:
based drug developer Elan Corp. with a $1 billion investment. The news sent Elan's shares soaring in premarket activity.
Related QuotesSymbol Price Change
ELN 7.00 0.00
JNJ 57.07 0.00
Johnson & Johnson also is buying Elan Corp.'s stake in its Alzheimer's disease treatment partnership with Wyeth, and rolling it into a new Johnson & Johnson company that will be 49.9 percent owned by Elan. The partnership develops drugs intended to engage the patient's immune system to fight the brain-destroying disease.
Johnson & Johnson is buying 107.3 million newly issued American Depositary Receipts at $9.32 each, which represents a 33 percent premium from Wednesday's closing price. In premarket trading, Elan's U.S. shares surged $1.36, or 19.4 percent, to $8.36.
Elan's Alzheimer's program has four drug candidates in clinical or preclinical testing. Johnson & Johnson will gain all rights to drugs developed by the program, and it plans to commit up to $500 million for development of bapineuzumab, a drug that intended to slow the progression of mild to moderate Alzheimer's disease. Current drugs treat the symptoms of the disease but don't slow the advance of the damage it causes.
Last summer, Elan and Wyeth reported promising early results from a mid stage study of bapineuzumab, but full results were somewhat disappointing. The drug appeared to be ineffective for patients who had a gene that is found in about half of Alzheimer's patients and makes the disease more severe. The drug is in late stage testing now.
Elan will get 49.9 percent of the profits from the company, and royalty payments on sales. It said the deal will allow it to become profitable by the end of 2010, and reduce its debt by about 70 percent to about $400 million. The company said it held discussions with 30 companies before reaching an agreement with Johnson & Johnson.
phu. ist wohl doch nicht so toll. oder was?!
ich denke nicht außer bap wird blockbuster.
momentan steht das aber in den sternen.
dann aber auch erst dann sind meiner ansicht nach kurse von 16 $ geeignet.
bitte nicht schlagen!
Antwort auf Beitrag Nr.: 37.507.638 von Poppholz am 02.07.09 15:08:14@ ELANITES
...tja, sehe diese Aktion ebenfalls als aktuell wichtigsten Schritt für das wirtschaftliche " Überleben " von ELAN....
......und wenn man ehrlich ist, Konzessionsentscheidungen gehören zum Über(leben) einfach dazu ........
...tja, sehe diese Aktion ebenfalls als aktuell wichtigsten Schritt für das wirtschaftliche " Überleben " von ELAN....
......und wenn man ehrlich ist, Konzessionsentscheidungen gehören zum Über(leben) einfach dazu ........
Johnson & Johnson zahlt 1 Mrd. Dollar für Elan-Beteiligung
02.07.2009
aktiencheck.de
New Brunswick (aktiencheck.de AG) - Die amerikanische Johnson & Johnson (ISIN US4781601046 / WKN 853260) gab am Donnerstag bekannt, dass er sich mit über 18 Prozent an dem irischen Pharmakonzern Elan Corp. plc (ISIN IE0003072950 / WKN 903801) beteiligen wird.
Den Angaben zufolge haben beide Unternehmen ein definitives Abkommen unterzeichnet, in dessen Rahmen Johnson & Johnson über eine neu gegründete Gesellschaft nahezu sämtliche Assets und Rechte im Zusammenhang mit dem Alzheimer's Immunotherapy Program (AIP Program) von Elan übernimmt. Zusätzlich wird der US-Konzern 1 Mrd. Dollar in Elan investieren, im Gegenzug für neu ausgegebene American Depositary Receipts (ADRs) von Elan, die wiederum einer Beteiligung von 18,4 Prozent an dem irischen Pharmakonzern entsprechen.
Bei dem AIP Program handelt es sich um Elans Beteiligung an einer Zusammenarbeit mit dem US-Pharmakonzern Wyeth (ISIN US9830241009 / WKN 850229).
Die Transaktion wird voraussichtlich im zweiten Halbjahr 2009 abgeschlossen, hieß es.
Die Aktie von Johnson & Johnson notierte zuletzt bei 57,07 Dollar.
(02.07.2009/ac/n/a)
http://www.aktiencheck.de/artikel/news-Ausland-1933967.html
02.07.2009
aktiencheck.de
New Brunswick (aktiencheck.de AG) - Die amerikanische Johnson & Johnson (ISIN US4781601046 / WKN 853260) gab am Donnerstag bekannt, dass er sich mit über 18 Prozent an dem irischen Pharmakonzern Elan Corp. plc (ISIN IE0003072950 / WKN 903801) beteiligen wird.
Den Angaben zufolge haben beide Unternehmen ein definitives Abkommen unterzeichnet, in dessen Rahmen Johnson & Johnson über eine neu gegründete Gesellschaft nahezu sämtliche Assets und Rechte im Zusammenhang mit dem Alzheimer's Immunotherapy Program (AIP Program) von Elan übernimmt. Zusätzlich wird der US-Konzern 1 Mrd. Dollar in Elan investieren, im Gegenzug für neu ausgegebene American Depositary Receipts (ADRs) von Elan, die wiederum einer Beteiligung von 18,4 Prozent an dem irischen Pharmakonzern entsprechen.
Bei dem AIP Program handelt es sich um Elans Beteiligung an einer Zusammenarbeit mit dem US-Pharmakonzern Wyeth (ISIN US9830241009 / WKN 850229).
Die Transaktion wird voraussichtlich im zweiten Halbjahr 2009 abgeschlossen, hieß es.
Die Aktie von Johnson & Johnson notierte zuletzt bei 57,07 Dollar.
(02.07.2009/ac/n/a)
http://www.aktiencheck.de/artikel/news-Ausland-1933967.html
Tja ihr Lieben...ich bin froh dass die Verschuldung im Griff ist;es bedeutet für mich auch dass BAP erfolgreich sein wird----ABER,unser Management ist in meinen Augen eine Versagerriege.....diesen Deal hätten sie VIEL früher machen müssen um auch uns als Aktionäre zu würdigen....KELLY MUST GO!!!!Ansonsten auf die 100$!!!LG Birgit
DOODAH IST-WIE IMMER-GUUUUT
The good and the bad....
Here are some of my thoughts in the immediate aftermath of this J&J deal announcement....
• With the $1B cash infusion combined with drastically lower future R&D expense, that omnipresent debt overhang shouldn’t be overhanging anymore. Yay! (GOOD)
• So we’re giving up another half of the remaining half of the program that was the primary reason I invested in Elan? Boooo…. (BAD)
• Remember how we feared that Pfizer would, at best, run the whole danged BAP show without regard for Elan’s feelings or, at worse, actively sabotage BAP in favor of its own ALZ programs? Can’t readily do that now with big pharma J&J at BAP’s corner. (GOOD)
• What if, as a partner, J&J proves to be more BIIB-like than Wyeth-like? (BAD)
• Now that the expensive ALZ trial expenses would be pretty much taken care of by J&J, Elan can focus funds on other potentially promising programs. (GOOD)
• What’s in Elan’s pipeline that’s more promising than its ALZ immuno program? (BAD…maybe)
• Now we don’t have to sell EDT! Yay! (GOOD)
• And we still have Prialt! (HA HA HA HA HA HA….)
• This J&J deal pretty much ensures Elan will survive as an ongoing entity for the foreseeable future. (GOOD)
• With 50% of troubled Tysabri, a tad less than 25% of uncertain BAP, and a bunch of early-stage projects that may or may not pan out years from now, what exactly does that surviving company look like? (UH…I’LL GET BACK TO YOU)
So now that the most compelling factor of my Elan investment has been diluted to a smidgeon, why not just sell my shares and get on with life? (WHAT? AND LEAVE MY FELLOW LONG-TIME LONGS – THE CREEDSTERS AND THE LOVESJOHNDORYS AND THE DOYLES AND THE HUNTSMAN[N]S AND THE LIPOSGHOSTS AND THE GOODTOREADTHIS’S ETAL – TO CONTINUE THIS NEVER-ENDING JOURNEY WITHOUT ME????? HELL NO. And besides….investing in Elan builds character. If not wealth. Yet. Hopefully.)
The good and the bad....
Here are some of my thoughts in the immediate aftermath of this J&J deal announcement....
• With the $1B cash infusion combined with drastically lower future R&D expense, that omnipresent debt overhang shouldn’t be overhanging anymore. Yay! (GOOD)
• So we’re giving up another half of the remaining half of the program that was the primary reason I invested in Elan? Boooo…. (BAD)
• Remember how we feared that Pfizer would, at best, run the whole danged BAP show without regard for Elan’s feelings or, at worse, actively sabotage BAP in favor of its own ALZ programs? Can’t readily do that now with big pharma J&J at BAP’s corner. (GOOD)
• What if, as a partner, J&J proves to be more BIIB-like than Wyeth-like? (BAD)
• Now that the expensive ALZ trial expenses would be pretty much taken care of by J&J, Elan can focus funds on other potentially promising programs. (GOOD)
• What’s in Elan’s pipeline that’s more promising than its ALZ immuno program? (BAD…maybe)
• Now we don’t have to sell EDT! Yay! (GOOD)
• And we still have Prialt! (HA HA HA HA HA HA….)
• This J&J deal pretty much ensures Elan will survive as an ongoing entity for the foreseeable future. (GOOD)
• With 50% of troubled Tysabri, a tad less than 25% of uncertain BAP, and a bunch of early-stage projects that may or may not pan out years from now, what exactly does that surviving company look like? (UH…I’LL GET BACK TO YOU)
So now that the most compelling factor of my Elan investment has been diluted to a smidgeon, why not just sell my shares and get on with life? (WHAT? AND LEAVE MY FELLOW LONG-TIME LONGS – THE CREEDSTERS AND THE LOVESJOHNDORYS AND THE DOYLES AND THE HUNTSMAN[N]S AND THE LIPOSGHOSTS AND THE GOODTOREADTHIS’S ETAL – TO CONTINUE THIS NEVER-ENDING JOURNEY WITHOUT ME????? HELL NO. And besides….investing in Elan builds character. If not wealth. Yet. Hopefully.)
von Stockhound4 aus dem IV-Board
What We Really Got Today
We got 1.0 Billion$ in cash and the ability to significantly reduce debt and associated interest costs.
We got the next 500 Million$ in Bapineuzumab R&D costs paid for us by J&J which we can put back into our pocket to help pay off debt or we can reinvest into other projects/products.
We have a global partner that is the largest Health Care company in the world that has money, muscle and a vested interest.
We got 49.9% of the new company that holds the rights to 50% of the profits to the drug when it is commercialized. In essence we are getting 25% of the total profits of the drug that has been billed as possibly the biggest of all times in sales and most likely profits. Does anyone know what 25% of say 10 Billion is with little to no cost???
We got royalties on the drug that as Shane said are tiered and the percent of those royalties has not yet been disclosed.
We get to keep all other Alz products with the exception of AAB-001 IV, Sub Q and ACC-001.
What We Really Got Today
We got 1.0 Billion$ in cash and the ability to significantly reduce debt and associated interest costs.
We got the next 500 Million$ in Bapineuzumab R&D costs paid for us by J&J which we can put back into our pocket to help pay off debt or we can reinvest into other projects/products.
We have a global partner that is the largest Health Care company in the world that has money, muscle and a vested interest.
We got 49.9% of the new company that holds the rights to 50% of the profits to the drug when it is commercialized. In essence we are getting 25% of the total profits of the drug that has been billed as possibly the biggest of all times in sales and most likely profits. Does anyone know what 25% of say 10 Billion is with little to no cost???
We got royalties on the drug that as Shane said are tiered and the percent of those royalties has not yet been disclosed.
We get to keep all other Alz products with the exception of AAB-001 IV, Sub Q and ACC-001.
Hier Elan offiziell
http://www.elan.com/news/print_full.asp?ID=1304171" target="_blank" rel="nofollow ugc noopener">http://www.elan.com/news/print_full.asp?ID=1304171
Elan Corporation
Pharmaceutical company
7/2/2009 13:22 ET
Site Map | Contact Us | Search:
2 July 2009
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
NEW BRUNSWICK, New Jersey and DUBLIN, July 2 /PRNewswire/ --
- First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline
- Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company. In addition, Johnson & Johnson, through its affiliate, will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan's outstanding ordinary shares.
The AIP Program represents Elan's interest in a collaboration with Wyeth to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease.
Johnson & Johnson, through its affiliate, will assume and continue Elan's activities with Wyeth under the AIP Program and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds. The agreement provides for additional funding obligations of the parties if needed.
In consideration for the transfer of these rights and assets, Elan will receive a 49.9% equity interest in the newly formed Johnson & Johnson company that will acquire the AIP Program. Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth.
The AIP Program includes multiple compounds being evaluated for slowing the progression of Alzheimer's disease. The lead compound (bapineuzumab), administered intravenously once every three months, is currently in Phase 3 clinical trials. A subcutaneous formulation, administered once a week, is currently in Phase 2 trials. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development.
In the U.S. alone, as many as 5.3 million people are living with Alzheimer's disease. The direct and indirect costs of this and other dementias to payers, including government programs, amount to more than $148 billion annually, according to the Alzheimer's Association.
"Alzheimer's disease is a significant unmet need in aging populations globally," said Sheri McCoy, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "Johnson & Johnson's development capabilities, commercial experience and global reach will provide the foundation to accelerate the AIP Program development, and increase its potential availability for patients globally."
Elan Chief Executive Officer, Kelly Martin, believes that this transaction positively impacts Elan and patients globally. "This transaction will leverage Elan's unique scientific and clinical work and leadership in bringing treatments to market that potentially slow the progression of Alzheimer's disease. The Elan commitment to scientific innovation and patients remains absolute and we will continue to build upon and expand our leadership in the fields of neuroscience and immunology."
Husseini Manji, M.D., Global Therapeutic Head, Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, added: "This transaction will be a key component in achieving our vision to develop treatments that target underlying disease biology, thereby helping to prevent some of society's most devastating illnesses. We expect to focus our resources on bringing the AIP Program to fruition as quickly as possible because of its potential to slow the progression of Alzheimer's disease."
Dale Schenk, PhD, Executive Vice President and Chief Scientific Officer for Elan provided a perspective that "After twenty years of following the science and advancing this technology into the latest stages of clinical development, it is our responsibility to ensure that this therapy, upon further clinical and regulatory progress, may be made available to the broadest range of patients globally. The capabilities of Johnson & Johnson will help in achieving that goal."
Upon closing, the transaction will have an estimated dilutive impact of $0.02 to $0.03 on Johnson & Johnson 2009 adjusted earnings per share. The companies anticipate concluding the transaction in the second half of 2009.
The boards of directors of both Johnson & Johnson and Elan have each approved the transaction, which represents the culmination of an in-depth strategic review by Elan. The transaction is conditioned on clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
Elan will host an analyst call at 8:00 a.m. EDT today. This call will be simultaneously webcast over the Internet and will be available to investors, members of the news media and the general public. The event can be accessed by visiting Elan's website at www.elan.com and clicking on the Investor Relations section, then on the event icon.
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day throughout the world.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs. Elan shares trade on the New York, London and Dublin Stock Exchanges. The gross assets attributable to the AIP Program in the audited consolidated accounts of Elan as at 31 December, 2008 were US$63.1 million. Costs (losses) associated with the AIP Program in respect of the year ended 31 December, 2008 were approximately US$113 million. For additional information about the company, please visit http://www.elan.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's and Elan Corporation, plc's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the transaction, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign healthcare reforms and government laws and regulations; and trends toward healthcare cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008, and Elan Corporation, plc's Annual Report on Form 20-F for the fiscal year ended December 31, 2008, as well as other subsequent filings. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.elan.com, or on request from Johnson & Johnson or Elan Corporation, plc. Neither Johnson & Johnson nor Elan Corporation, plc undertakes to update any forward-looking statements as a result of new information or future events or developments.)
http://www.elan.com/news/print_full.asp?ID=1304171" target="_blank" rel="nofollow ugc noopener">http://www.elan.com/news/print_full.asp?ID=1304171
Elan Corporation
Pharmaceutical company
7/2/2009 13:22 ET
Site Map | Contact Us | Search:
2 July 2009
Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment
NEW BRUNSWICK, New Jersey and DUBLIN, July 2 /PRNewswire/ --
- First-in-Class Alzheimer's Treatments Expand Existing J&J Neuroscience Pipeline
- Johnson & Johnson Equity Investment Provides Financial Flexibility for Elan
Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company. In addition, Johnson & Johnson, through its affiliate, will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan's outstanding ordinary shares.
The AIP Program represents Elan's interest in a collaboration with Wyeth to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease.
Johnson & Johnson, through its affiliate, will assume and continue Elan's activities with Wyeth under the AIP Program and will initially commit up to $500 million to continue the development and launch activities of bapineuzumab, a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, as well as other compounds. The agreement provides for additional funding obligations of the parties if needed.
In consideration for the transfer of these rights and assets, Elan will receive a 49.9% equity interest in the newly formed Johnson & Johnson company that will acquire the AIP Program. Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth.
The AIP Program includes multiple compounds being evaluated for slowing the progression of Alzheimer's disease. The lead compound (bapineuzumab), administered intravenously once every three months, is currently in Phase 3 clinical trials. A subcutaneous formulation, administered once a week, is currently in Phase 2 trials. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development.
In the U.S. alone, as many as 5.3 million people are living with Alzheimer's disease. The direct and indirect costs of this and other dementias to payers, including government programs, amount to more than $148 billion annually, according to the Alzheimer's Association.
"Alzheimer's disease is a significant unmet need in aging populations globally," said Sheri McCoy, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "Johnson & Johnson's development capabilities, commercial experience and global reach will provide the foundation to accelerate the AIP Program development, and increase its potential availability for patients globally."
Elan Chief Executive Officer, Kelly Martin, believes that this transaction positively impacts Elan and patients globally. "This transaction will leverage Elan's unique scientific and clinical work and leadership in bringing treatments to market that potentially slow the progression of Alzheimer's disease. The Elan commitment to scientific innovation and patients remains absolute and we will continue to build upon and expand our leadership in the fields of neuroscience and immunology."
Husseini Manji, M.D., Global Therapeutic Head, Neuroscience, Johnson & Johnson Pharmaceutical Research & Development, added: "This transaction will be a key component in achieving our vision to develop treatments that target underlying disease biology, thereby helping to prevent some of society's most devastating illnesses. We expect to focus our resources on bringing the AIP Program to fruition as quickly as possible because of its potential to slow the progression of Alzheimer's disease."
Dale Schenk, PhD, Executive Vice President and Chief Scientific Officer for Elan provided a perspective that "After twenty years of following the science and advancing this technology into the latest stages of clinical development, it is our responsibility to ensure that this therapy, upon further clinical and regulatory progress, may be made available to the broadest range of patients globally. The capabilities of Johnson & Johnson will help in achieving that goal."
Upon closing, the transaction will have an estimated dilutive impact of $0.02 to $0.03 on Johnson & Johnson 2009 adjusted earnings per share. The companies anticipate concluding the transaction in the second half of 2009.
The boards of directors of both Johnson & Johnson and Elan have each approved the transaction, which represents the culmination of an in-depth strategic review by Elan. The transaction is conditioned on clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
Elan will host an analyst call at 8:00 a.m. EDT today. This call will be simultaneously webcast over the Internet and will be available to investors, members of the news media and the general public. The event can be accessed by visiting Elan's website at www.elan.com and clicking on the Investor Relations section, then on the event icon.
About Johnson & Johnson
Caring for the world, one person at a time ... inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day throughout the world.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs. Elan shares trade on the New York, London and Dublin Stock Exchanges. The gross assets attributable to the AIP Program in the audited consolidated accounts of Elan as at 31 December, 2008 were US$63.1 million. Costs (losses) associated with the AIP Program in respect of the year ended 31 December, 2008 were approximately US$113 million. For additional information about the company, please visit http://www.elan.com.
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's and Elan Corporation, plc's expectations and projections. Risks and uncertainties include the satisfaction of closing conditions for the transaction, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign healthcare reforms and government laws and regulations; and trends toward healthcare cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 28, 2008, and Elan Corporation, plc's Annual Report on Form 20-F for the fiscal year ended December 31, 2008, as well as other subsequent filings. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.elan.com, or on request from Johnson & Johnson or Elan Corporation, plc. Neither Johnson & Johnson nor Elan Corporation, plc undertakes to update any forward-looking statements as a result of new information or future events or developments.)
Davy
ELN US
Cashflow and commercial benefits from J&J agreement can transform Elan's profile
Jack Gorman
Closing Price $7.60 Rating: Outperform 30/06/09
Elan's agreement with J&J brings to a successful end its six-month-long strategic review process. The quality and scale of this new partner, coupled with the cash infusions into Elan and the new AD entity, transform Elan's financial profile. It will also allow it to accelerate and strengthen its neurology R&D base. We reiterate our 'outperform' rating.
J&J's $1bn equity funding in Elan reduces forecast 2009 net debt by 64%. It provides another independent validation of its science base in Alzheimer’s Disease, and provides access to a global commercial infrastructure from a top-quality partner.
For a total $1.5bn commitment from J&J, Elan has broadly ceded half of its financial interest in the AIP programme (comprising Bapineuzumab and ACC-001). However, it retains additional royalty upside as products are commercialised.
Crucially, Elan also plans to retain its core research infrastructure and personnel. We understand that it will be mainly clinical development staff who will transfer to the new AIP entity. This will be an important factor to monitor given the primacy of Elan's research capability in discovering its Tysabri and AD assets.
Our forecast pre-tax losses for 2009 and 2010 are reduced by 5% (to $251m) and 78% (to $43m) respectively. Elan will generate modest cash next year on these forecasts. Loss per share falls to 62c (from 65c) for this year and to 21c (from 58c) in 2010.
We have assumed that the deal closes in mid-Q4. There will be operating cost savings of an estimated $110m in 2010, as J&J pre-funds the AIP programme instead. We also assume that Elan retires some of its 2011 fixed-rate debt — though we would note that we have no insight as yet on how Elan plans to restructure its debt profile.
Our rating is driven by the fact that Elan can be profitable and cashflow positive at a much faster pace than previously anticipated. The financial risk is also substantially reduced. Although it has had to cede part of its AD portfolio, the quality of its partners here (J&J and Pfizer/Wyeth) should allow the assets to gain maximum commercial exposure.
ELN US
Cashflow and commercial benefits from J&J agreement can transform Elan's profile
Jack Gorman
Closing Price $7.60 Rating: Outperform 30/06/09
Elan's agreement with J&J brings to a successful end its six-month-long strategic review process. The quality and scale of this new partner, coupled with the cash infusions into Elan and the new AD entity, transform Elan's financial profile. It will also allow it to accelerate and strengthen its neurology R&D base. We reiterate our 'outperform' rating.
J&J's $1bn equity funding in Elan reduces forecast 2009 net debt by 64%. It provides another independent validation of its science base in Alzheimer’s Disease, and provides access to a global commercial infrastructure from a top-quality partner.
For a total $1.5bn commitment from J&J, Elan has broadly ceded half of its financial interest in the AIP programme (comprising Bapineuzumab and ACC-001). However, it retains additional royalty upside as products are commercialised.
Crucially, Elan also plans to retain its core research infrastructure and personnel. We understand that it will be mainly clinical development staff who will transfer to the new AIP entity. This will be an important factor to monitor given the primacy of Elan's research capability in discovering its Tysabri and AD assets.
Our forecast pre-tax losses for 2009 and 2010 are reduced by 5% (to $251m) and 78% (to $43m) respectively. Elan will generate modest cash next year on these forecasts. Loss per share falls to 62c (from 65c) for this year and to 21c (from 58c) in 2010.
We have assumed that the deal closes in mid-Q4. There will be operating cost savings of an estimated $110m in 2010, as J&J pre-funds the AIP programme instead. We also assume that Elan retires some of its 2011 fixed-rate debt — though we would note that we have no insight as yet on how Elan plans to restructure its debt profile.
Our rating is driven by the fact that Elan can be profitable and cashflow positive at a much faster pace than previously anticipated. The financial risk is also substantially reduced. Although it has had to cede part of its AD portfolio, the quality of its partners here (J&J and Pfizer/Wyeth) should allow the assets to gain maximum commercial exposure.
Antwort auf Beitrag Nr.: 37.514.588 von Birgit.Tersteegen am 03.07.09 14:33:27mittelfristiges kursziel?
Antwort auf Beitrag Nr.: 37.515.339 von GuHu1 am 03.07.09 16:29:24.....?????-----30$ nächstes Jahr....??!
Elan takeover more likely after Johnsons deal
Damien Conover, 03/07/09 16:45
Elan and Johnson & Johnson's stake deal has made an outright acquisition of our top ranked biotech takeover candidate more plausible
Johnson & Johnson is taking a major stake in Elan Corp in order to gain access to the latter firm's Alzheimer's programme and leading drug bapineuzumab. The deal looks favourable to both companies. While we don't expect the transaction to greatly change our fair value estimate for J&J, we are reviewing the assumptions in our Elan model, which could result in a change to our fair value estimate for that firm.
Under the terms of the transaction, J&J will take a 50.1% ownership in Elan's Alzheimer's programme and an 18.4% ownership in the remaining part of Elan that excludes the Alzheimer's programme. In return, Elan will receive a $1 billion equity investment and a $500 million commitment to fund development and marketing of Alzheimer's drug bapineuzumab. The deal doesn't surprise us, as we had ranked Elan as the top biotech takeover candidate at the beginning of the year. While the deal is not a full acquisition, it supports our thesis that Elan can bring value to a larger pharmaceutical company.
We believe the joint venture helps both companies. J&J expands its reach into neuroscience with access to one of the most promising Alzheimer's drugs, bapineuzumab, as well as several earlier-stage Alzheimer's drugs. Also, it gains exposure to the multiple sclerosis market through Elan's drug Tysabri.
Elan gains needed funding, as it was burning cash and was facing major debt redemptions over the next couple of years. By joining forces with J&J, bapineuzumab gains credibility that could boost its approval chances. Further, Elan retains some of the upside to its Alzheimer's platform by holding on to 49.9% of the newly-formed joint venture. Our only concern is whether the company gave up too much potential upside for its potentially highly lucrative Alzheimer's franchise in exchange for near-term liquidity help. The deal also limits the number of potential Elan suitors to Johnson & Johnson, although an outright acquisition has become more plausible.
Damien Conover, CFA is a senior Morningstar stock analyst based in the United States.
http://www.hemscott.com/news/comment-archive/item.do?id=7174…
Damien Conover, 03/07/09 16:45
Elan and Johnson & Johnson's stake deal has made an outright acquisition of our top ranked biotech takeover candidate more plausible
Johnson & Johnson is taking a major stake in Elan Corp in order to gain access to the latter firm's Alzheimer's programme and leading drug bapineuzumab. The deal looks favourable to both companies. While we don't expect the transaction to greatly change our fair value estimate for J&J, we are reviewing the assumptions in our Elan model, which could result in a change to our fair value estimate for that firm.
Under the terms of the transaction, J&J will take a 50.1% ownership in Elan's Alzheimer's programme and an 18.4% ownership in the remaining part of Elan that excludes the Alzheimer's programme. In return, Elan will receive a $1 billion equity investment and a $500 million commitment to fund development and marketing of Alzheimer's drug bapineuzumab. The deal doesn't surprise us, as we had ranked Elan as the top biotech takeover candidate at the beginning of the year. While the deal is not a full acquisition, it supports our thesis that Elan can bring value to a larger pharmaceutical company.
We believe the joint venture helps both companies. J&J expands its reach into neuroscience with access to one of the most promising Alzheimer's drugs, bapineuzumab, as well as several earlier-stage Alzheimer's drugs. Also, it gains exposure to the multiple sclerosis market through Elan's drug Tysabri.
Elan gains needed funding, as it was burning cash and was facing major debt redemptions over the next couple of years. By joining forces with J&J, bapineuzumab gains credibility that could boost its approval chances. Further, Elan retains some of the upside to its Alzheimer's platform by holding on to 49.9% of the newly-formed joint venture. Our only concern is whether the company gave up too much potential upside for its potentially highly lucrative Alzheimer's franchise in exchange for near-term liquidity help. The deal also limits the number of potential Elan suitors to Johnson & Johnson, although an outright acquisition has become more plausible.
Damien Conover, CFA is a senior Morningstar stock analyst based in the United States.
http://www.hemscott.com/news/comment-archive/item.do?id=7174…
Hallo an alle.
Was fehlt denn noch? Warum steigt der Kurs nicht schneller?
Das sind doch sehr positive Nachrichten.
Bitte um Meinung!
Was fehlt denn noch? Warum steigt der Kurs nicht schneller?
Das sind doch sehr positive Nachrichten.
Bitte um Meinung!
Antwort auf Beitrag Nr.: 37.523.786 von Schero am 06.07.09 14:13:02Was fehlt denn noch? Warum steigt der Kurs nicht schneller?
Das sind doch sehr positive Nachrichten.
...das sind positive Nachrichten, da der drohende Kollaps 2011 abgewendet ist. Kurzfristig erwarte ich, dass die Aktie zumindest den von JNJ bezahlten Preis für die KE erreicht. Mittelfristig wird der Kurs von weiteren Ereignissen beeinflusst, die da wären:
- PML-Häufigkeit unter Tysabri und damit verbunden dessen Penetration
- Behandlungsmöglichkeit von PML (Mefloquin ? --> http://www.clinicaltrials.gov/ct2/show/NCT00746941?term=pml&… )
- p2-Daten zu ELND005 (Alzheimer)
-Zulassungsentscheidung der FDA zu Acordas Fampridine-SR (MS: Gehvermögen) PDUFA: 22.10.2009
-Ausgang des Rechtsstreit mit Abraxis um Lizenzzahlungen zu Abraxane
-weitere Kontrakte von EDT
-IND zu Parkinson (entry into man)
etc.
Das sind doch sehr positive Nachrichten.
...das sind positive Nachrichten, da der drohende Kollaps 2011 abgewendet ist. Kurzfristig erwarte ich, dass die Aktie zumindest den von JNJ bezahlten Preis für die KE erreicht. Mittelfristig wird der Kurs von weiteren Ereignissen beeinflusst, die da wären:
- PML-Häufigkeit unter Tysabri und damit verbunden dessen Penetration
- Behandlungsmöglichkeit von PML (Mefloquin ? --> http://www.clinicaltrials.gov/ct2/show/NCT00746941?term=pml&… )
- p2-Daten zu ELND005 (Alzheimer)
-Zulassungsentscheidung der FDA zu Acordas Fampridine-SR (MS: Gehvermögen) PDUFA: 22.10.2009
-Ausgang des Rechtsstreit mit Abraxis um Lizenzzahlungen zu Abraxane
-weitere Kontrakte von EDT
-IND zu Parkinson (entry into man)
etc.
Antwort auf Beitrag Nr.: 37.525.772 von Cyberhexe am 06.07.09 18:15:21Hallo Cyberhexe,
vielen Dank für deine Antwort.
... zumindest den von JNJ bezahlten Preis für die KE erreicht.
Welsche Aktienkurs wäre das?
Bis bald
Schero
vielen Dank für deine Antwort.
... zumindest den von JNJ bezahlten Preis für die KE erreicht.
Welsche Aktienkurs wäre das?
Bis bald
Schero
Antwort auf Beitrag Nr.: 37.527.701 von Schero am 06.07.09 23:31:28etwas über 9 $.
....nun große Offensive ??!!!??
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting
AIP Pharmacoeconomic and Sociological Analyses
Poster P1-204: Estimating Health-Related Quality of Life for Unique Dependence Levels in Patients with Alzheimer's Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-212: Estimated Dependence Scale Scores Based on Clinical Dementia Rating - Sum of
Boxes Scores in Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's
Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-180: Relationship between Patient Dependence on others and Caregiver Burden in Alzheimer's Disease (AD)
Sunday, July 12, 12:30 - 2:30 PM
Podium presentation: Use of a claims database to estimate AD severity and costs by severity
level
Monday, July 13, 10:30 - 12:30 PM
Poster P2-066: Web-Based Application to Estimate and Project the Burden of Alzheimer's
Disease and Evaluate the Impact of Potential Interventions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-071: Increased Risk of Serious Co-Morbidities in a Cohort of AD Patients Compared
to a Similar Non-AD Cohort
Monday, July 13, 12:30 - 2:30 PM
Poster P3-113: Hip Fracture Risk and Subsequent Mortality among Alzheimer's Disease Patients
in the United Kingdom, 1988-2007
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-221: Predicting Costs of Care for Unique Dependence Levels in Patients with Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of Bapineuzumab
Poster P3-246: Pharmacokinetics and Pharmacodynamics of Bapineuzumab Following Multiple
Intravenous Infusions in Patients with Mild-to-Moderate Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of ELND005 (AZD-103)
Poster P2-082: Oral Amyloid Anti-Aggregating Agent ELND005 is Measurable in CSF and
Brain of Healthy Adult Men
Monday, July 13, 12:30 - 3:00 PM
Poster P2-082: Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence
Estimates with Variable Operationalized Definitions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-225: Characterization of Inositol Transporters as a Method for Drug Delivery to the
CNS
Monday, July 13, 12:30 - 3:00 PM
Poster P3-245: A Sensitive Assay Measuring the Binding of Amyloid Beta Monomers to
Aggregates Reveals the Potential of ELND005 (scylloinositol) to Reduce and Reverse Amyloid
Accumulation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-258: The effect of scyllo-inositol derivatives on β-amyloid peptide aggregation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-279: Scyllo-Inositol (ELND005) Ameliorates Amyloid Pathology in an Aggressive
Mouse Model of Alzheimer's Disease
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-286: Biophysical Characterization of Scyllo-Inositol-Aβ Interactions
Tuesday, July 14, 12:30 - 3:00 PM
Poster P4-193: Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8
Mice Following Treatment with Scyllo-Inositol (ELND005)
Wednesday, July 15, 12:30 - 3:00 PM
Poster P4-354: ELND005 (scyllo-inositol), the β-Amyloid Anti-Aggregation Therapeutic,
Demonstrates Robust Brain Uptake in Rats Following Oral Administration
Wednesday, July 15, 12:30 - 3:00 PM
Presentations of Gamma Secretase Inhibitors (or other Elan Research)
Poster P1-035: Pharmacokinetic and pharmacodynamic Analysis of a Novel Gamma Secretase
Inhibitor in a Non-Transgenic A-Beta Mouse Efficacy Model
Sunday, Jul 12, 2009, 12:30 - 3:00 PM
http://finance.yahoo.com/news/Elan-to-Showcase-Its-bw-164258…
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting
AIP Pharmacoeconomic and Sociological Analyses
Poster P1-204: Estimating Health-Related Quality of Life for Unique Dependence Levels in Patients with Alzheimer's Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-212: Estimated Dependence Scale Scores Based on Clinical Dementia Rating - Sum of
Boxes Scores in Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's
Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-180: Relationship between Patient Dependence on others and Caregiver Burden in Alzheimer's Disease (AD)
Sunday, July 12, 12:30 - 2:30 PM
Podium presentation: Use of a claims database to estimate AD severity and costs by severity
level
Monday, July 13, 10:30 - 12:30 PM
Poster P2-066: Web-Based Application to Estimate and Project the Burden of Alzheimer's
Disease and Evaluate the Impact of Potential Interventions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-071: Increased Risk of Serious Co-Morbidities in a Cohort of AD Patients Compared
to a Similar Non-AD Cohort
Monday, July 13, 12:30 - 2:30 PM
Poster P3-113: Hip Fracture Risk and Subsequent Mortality among Alzheimer's Disease Patients
in the United Kingdom, 1988-2007
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-221: Predicting Costs of Care for Unique Dependence Levels in Patients with Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of Bapineuzumab
Poster P3-246: Pharmacokinetics and Pharmacodynamics of Bapineuzumab Following Multiple
Intravenous Infusions in Patients with Mild-to-Moderate Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of ELND005 (AZD-103)
Poster P2-082: Oral Amyloid Anti-Aggregating Agent ELND005 is Measurable in CSF and
Brain of Healthy Adult Men
Monday, July 13, 12:30 - 3:00 PM
Poster P2-082: Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence
Estimates with Variable Operationalized Definitions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-225: Characterization of Inositol Transporters as a Method for Drug Delivery to the
CNS
Monday, July 13, 12:30 - 3:00 PM
Poster P3-245: A Sensitive Assay Measuring the Binding of Amyloid Beta Monomers to
Aggregates Reveals the Potential of ELND005 (scylloinositol) to Reduce and Reverse Amyloid
Accumulation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-258: The effect of scyllo-inositol derivatives on β-amyloid peptide aggregation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-279: Scyllo-Inositol (ELND005) Ameliorates Amyloid Pathology in an Aggressive
Mouse Model of Alzheimer's Disease
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-286: Biophysical Characterization of Scyllo-Inositol-Aβ Interactions
Tuesday, July 14, 12:30 - 3:00 PM
Poster P4-193: Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8
Mice Following Treatment with Scyllo-Inositol (ELND005)
Wednesday, July 15, 12:30 - 3:00 PM
Poster P4-354: ELND005 (scyllo-inositol), the β-Amyloid Anti-Aggregation Therapeutic,
Demonstrates Robust Brain Uptake in Rats Following Oral Administration
Wednesday, July 15, 12:30 - 3:00 PM
Presentations of Gamma Secretase Inhibitors (or other Elan Research)
Poster P1-035: Pharmacokinetic and pharmacodynamic Analysis of a Novel Gamma Secretase
Inhibitor in a Non-Transgenic A-Beta Mouse Efficacy Model
Sunday, Jul 12, 2009, 12:30 - 3:00 PM
http://finance.yahoo.com/news/Elan-to-Showcase-Its-bw-164258…
Antwort auf Beitrag Nr.: 37.533.449 von bernie55 am 08.07.09 15:11:53yepp!
..wieder eine Anwendung, die ELAN sich patentieren lässt...
United States Patent Application 20090175951
Kind Code A1
LIVERSIDGE; Elaine ; et al. July 9, 2009
--------------------------------------------------------------------------------
NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS
Abstract
Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H…
United States Patent Application 20090175951
Kind Code A1
LIVERSIDGE; Elaine ; et al. July 9, 2009
--------------------------------------------------------------------------------
NANOPARTICULATE COMPOSITIONS OF IMMUNOSUPPRESSIVE AGENTS
Abstract
Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or exposure to non-physiological pH conditions.
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H…
Antwort auf Beitrag Nr.: 37.527.701 von Schero am 06.07.09 23:31:28... zumindest den von JNJ bezahlten Preis für die KE erreicht.
Welsche Aktienkurs wäre das?
JNJ likes ELN for $9.32
Welsche Aktienkurs wäre das?
JNJ likes ELN for $9.32
Elan über 6 EUR einsteigen (Hanseatischer Börsendienst)
Hamburg (aktiencheck.de AG) - Die Experten vom "Hanseatischen Börsendienst" empfehlen im Rahmen ihrer Neuempfehlung bei der Aktie von Elan (ISIN US2841312083/ WKN 871331) erst dann einzusteigen, wenn der Kurs über 6 EUR steigt.
Das irische Unternehmen habe jüngst davon profitiert, dass Johnson & Johnson angekündigt habe, sich für einen Anteil von 18,4% mit 1 Mrd. USD an Elan zu beteiligen. Der Aktienkurs sei in Dublin in der Spitze um 40% auf 6,71 Euro nach oben geschossen. Teil der Vereinbarungen der beiden Unternehmen sei auch gewesen, dass sich Johnson & Johnson um die Entwicklung der Elan-Präparate gegen die Alzheimer-Krankheit kümmere. Dank des Anti-Alzheimer-Wirkstoffes Bapineuzumab verfüge Elan über eine der mit am weitesten entwickelten Substanzen gegen dieses Leiden.
Doch dies habe das Unternehmen nicht davor geschützt, an den Rand des Abgrunds zu rutschen. Denn die Forschung sei teuer und hürdenreich und wenn es Elan nicht geschafft hätte, eine neue Geldquelle aufzutreiben, dann wären die Barmittel und Investments bis zum Ende des Jahres auf 200 Mio. Dollar gesunken. Weil die Iren jedoch bis November 2011 Verbindlichkeiten im Volumen von 1,1 Mrd. Dollar zurückzahlen müssten, sei dies existenzbedrohend gewesen. Auch die kürzlich vorgenommene Entlassung von 14% der Belegschaft habe den Ernst der Lage gezeigt.
Diese vielen Schwierigkeiten hätten sich natürlich auf die Notierung der Aktie ausgewirkt. Im vergangenen Jahr habe diese sehr leiden müssen. Mit dem neuen starken Partner an der Seite könnte es nun mittel- und langfristig aber wieder aufwärts gehen. Dies sei zumindest dann der Fall, wenn das bei der Bekanntgabe des Deals gegebene Versprechen eingehalten werde. Danach wolle man 2010 in die Gewinnzone vorstoßen und die Schulden bis auf 400 Mio. Dollar abbauen.
Wie alleine schon der Blick auf den äußerst volatilen Chart zeige, sei diese Empfehlung aber äußerst spekulativ.
Die Experten vom "Hanseatischen Börsendienst" raten bei der Aktie von Elan erst dann einzusteigen, wenn den Notierungen der Sprung über die Marke von 6 EUR gelingt. Denn dann würde sich die charttechnische Ausgangslage deutlich verbessern. (Ausgabe 14 vom 08.07.2009) (10.07.2009/ac/a/a)
Analyse-Datum: 10.07.2009
Warum warten bis € 6,-- erreicht ist, wenn man auch vorher bereits einsteigen kann??
Vor einigen Tagen war der Kurs über € 6,-- gewesen. Die Leute die da eingestiegen sind, sind nun dick im Minus. Oder was meint Ihr?
Schero
Hamburg (aktiencheck.de AG) - Die Experten vom "Hanseatischen Börsendienst" empfehlen im Rahmen ihrer Neuempfehlung bei der Aktie von Elan (ISIN US2841312083/ WKN 871331) erst dann einzusteigen, wenn der Kurs über 6 EUR steigt.
Das irische Unternehmen habe jüngst davon profitiert, dass Johnson & Johnson angekündigt habe, sich für einen Anteil von 18,4% mit 1 Mrd. USD an Elan zu beteiligen. Der Aktienkurs sei in Dublin in der Spitze um 40% auf 6,71 Euro nach oben geschossen. Teil der Vereinbarungen der beiden Unternehmen sei auch gewesen, dass sich Johnson & Johnson um die Entwicklung der Elan-Präparate gegen die Alzheimer-Krankheit kümmere. Dank des Anti-Alzheimer-Wirkstoffes Bapineuzumab verfüge Elan über eine der mit am weitesten entwickelten Substanzen gegen dieses Leiden.
Doch dies habe das Unternehmen nicht davor geschützt, an den Rand des Abgrunds zu rutschen. Denn die Forschung sei teuer und hürdenreich und wenn es Elan nicht geschafft hätte, eine neue Geldquelle aufzutreiben, dann wären die Barmittel und Investments bis zum Ende des Jahres auf 200 Mio. Dollar gesunken. Weil die Iren jedoch bis November 2011 Verbindlichkeiten im Volumen von 1,1 Mrd. Dollar zurückzahlen müssten, sei dies existenzbedrohend gewesen. Auch die kürzlich vorgenommene Entlassung von 14% der Belegschaft habe den Ernst der Lage gezeigt.
Diese vielen Schwierigkeiten hätten sich natürlich auf die Notierung der Aktie ausgewirkt. Im vergangenen Jahr habe diese sehr leiden müssen. Mit dem neuen starken Partner an der Seite könnte es nun mittel- und langfristig aber wieder aufwärts gehen. Dies sei zumindest dann der Fall, wenn das bei der Bekanntgabe des Deals gegebene Versprechen eingehalten werde. Danach wolle man 2010 in die Gewinnzone vorstoßen und die Schulden bis auf 400 Mio. Dollar abbauen.
Wie alleine schon der Blick auf den äußerst volatilen Chart zeige, sei diese Empfehlung aber äußerst spekulativ.
Die Experten vom "Hanseatischen Börsendienst" raten bei der Aktie von Elan erst dann einzusteigen, wenn den Notierungen der Sprung über die Marke von 6 EUR gelingt. Denn dann würde sich die charttechnische Ausgangslage deutlich verbessern. (Ausgabe 14 vom 08.07.2009) (10.07.2009/ac/a/a)
Analyse-Datum: 10.07.2009
Warum warten bis € 6,-- erreicht ist, wenn man auch vorher bereits einsteigen kann??
Vor einigen Tagen war der Kurs über € 6,-- gewesen. Die Leute die da eingestiegen sind, sind nun dick im Minus. Oder was meint Ihr?
Schero
ANALysten eben---ALLES QUARK! So billig wie möglich einsteigen--ich stocke evtl.motgen auch noch mal auf....
Aber Elan hat eine neue Website--und die sieht GUT aus!!!
New Website
How's this for a new website!
http://elan.com/
Aber Elan hat eine neue Website--und die sieht GUT aus!!!
New Website
How's this for a new website!
http://elan.com/
Msg 367045 of 367082 at 7/12/2009 10:18:21 AM by
RJMCBEAR
The week ahead
Next week will give us ample opportunity to get this stock rolling again. We are presenting 18 papers on our AIP programs at ICAD I believe on Tuesday and Wednesday afternoons. We are also presenting 3 posters with Transition on ELND005. Then there is our PD program as well as our partnered program with Lilly. On Tuesday we here from our new partner JNJ. Maybe we will get some royalty information. Biogen reports on Thursday so new TY numbers will be heard and hopefully some positive slant on PML for a change. Hey Biogen how is that test for JCV coming along? I also hope to get a Multiple Myeloma Cancer trial update. Then there is Elan's AGM as well on Thursday followed by Elan's second quarter CC next Tuesday. Let's hope the upgrades start pouring in by the end of the month. I don't see a better opportunity in the near future for positive price action than right now. I almost forgot to mention that this will be the third Friday of the month as well.(Option Ex) Perfect Storm? We sure do deserve it. Hope Springs Eternal!
RJMCBEAR
The week ahead
Next week will give us ample opportunity to get this stock rolling again. We are presenting 18 papers on our AIP programs at ICAD I believe on Tuesday and Wednesday afternoons. We are also presenting 3 posters with Transition on ELND005. Then there is our PD program as well as our partnered program with Lilly. On Tuesday we here from our new partner JNJ. Maybe we will get some royalty information. Biogen reports on Thursday so new TY numbers will be heard and hopefully some positive slant on PML for a change. Hey Biogen how is that test for JCV coming along? I also hope to get a Multiple Myeloma Cancer trial update. Then there is Elan's AGM as well on Thursday followed by Elan's second quarter CC next Tuesday. Let's hope the upgrades start pouring in by the end of the month. I don't see a better opportunity in the near future for positive price action than right now. I almost forgot to mention that this will be the third Friday of the month as well.(Option Ex) Perfect Storm? We sure do deserve it. Hope Springs Eternal!
Antwort auf Beitrag Nr.: 37.557.885 von Birgit.Tersteegen am 12.07.09 22:38:38http://finance.yahoo.com/news/Elan-to-Showcase-Its-bw-164258…
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting
AIP Pharmacoeconomic and Sociological Analyses
Poster P1-204: Estimating Health-Related Quality of Life for Unique Dependence Levels in Patients with Alzheimer's Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-212: Estimated Dependence Scale Scores Based on Clinical Dementia Rating - Sum of
Boxes Scores in Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's
Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-180: Relationship between Patient Dependence on others and Caregiver Burden in Alzheimer's Disease (AD)
Sunday, July 12, 12:30 - 2:30 PM
Podium presentation: Use of a claims database to estimate AD severity and costs by severity
level
Monday, July 13, 10:30 - 12:30 PM
Poster P2-066: Web-Based Application to Estimate and Project the Burden of Alzheimer's
Disease and Evaluate the Impact of Potential Interventions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-071: Increased Risk of Serious Co-Morbidities in a Cohort of AD Patients Compared
to a Similar Non-AD Cohort
Monday, July 13, 12:30 - 2:30 PM
Poster P3-113: Hip Fracture Risk and Subsequent Mortality among Alzheimer's Disease Patients
in the United Kingdom, 1988-2007
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-221: Predicting Costs of Care for Unique Dependence Levels in Patients with Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of Bapineuzumab
Poster P3-246: Pharmacokinetics and Pharmacodynamics of Bapineuzumab Following Multiple
Intravenous Infusions in Patients with Mild-to-Moderate Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of ELND005 (AZD-103)
Poster P2-082: Oral Amyloid Anti-Aggregating Agent ELND005 is Measurable in CSF and
Brain of Healthy Adult Men
Monday, July 13, 12:30 - 3:00 PM
Poster P2-082: Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence
Estimates with Variable Operationalized Definitions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-225: Characterization of Inositol Transporters as a Method for Drug Delivery to the
CNS
Monday, July 13, 12:30 - 3:00 PM
Poster P3-245: A Sensitive Assay Measuring the Binding of Amyloid Beta Monomers to
Aggregates Reveals the Potential of ELND005 (scylloinositol) to Reduce and Reverse Amyloid
Accumulation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-258: The effect of scyllo-inositol derivatives on β-amyloid peptide aggregation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-279: Scyllo-Inositol (ELND005) Ameliorates Amyloid Pathology in an Aggressive
Mouse Model of Alzheimer's Disease
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-286: Biophysical Characterization of Scyllo-Inositol-Aβ Interactions
Tuesday, July 14, 12:30 - 3:00 PM
Poster P4-193: Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8
Mice Following Treatment with Scyllo-Inositol (ELND005)
Wednesday, July 15, 12:30 - 3:00 PM
Poster P4-354: ELND005 (scyllo-inositol), the β-Amyloid Anti-Aggregation Therapeutic,
Demonstrates Robust Brain Uptake in Rats Following Oral Administration
Wednesday, July 15, 12:30 - 3:00 PM
Presentations of Gamma Secretase Inhibitors (or other Elan Research)
Poster P1-035: Pharmacokinetic and pharmacodynamic Analysis of a Novel Gamma Secretase
Inhibitor in a Non-Transgenic A-Beta Mouse Efficacy Model
Sunday, Jul 12, 2009, 12:30 - 3:00 PM
Elan to Showcase Its Leadership in Alzheimer's Disease at Upcoming International Meeting
AIP Pharmacoeconomic and Sociological Analyses
Poster P1-204: Estimating Health-Related Quality of Life for Unique Dependence Levels in Patients with Alzheimer's Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-212: Estimated Dependence Scale Scores Based on Clinical Dementia Rating - Sum of
Boxes Scores in Patients with Mild Cognitive Impairment or Mild to Moderate Alzheimer's
Disease
Sunday, July 12, 12:30 - 2:30 PM
Poster P1-180: Relationship between Patient Dependence on others and Caregiver Burden in Alzheimer's Disease (AD)
Sunday, July 12, 12:30 - 2:30 PM
Podium presentation: Use of a claims database to estimate AD severity and costs by severity
level
Monday, July 13, 10:30 - 12:30 PM
Poster P2-066: Web-Based Application to Estimate and Project the Burden of Alzheimer's
Disease and Evaluate the Impact of Potential Interventions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-071: Increased Risk of Serious Co-Morbidities in a Cohort of AD Patients Compared
to a Similar Non-AD Cohort
Monday, July 13, 12:30 - 2:30 PM
Poster P3-113: Hip Fracture Risk and Subsequent Mortality among Alzheimer's Disease Patients
in the United Kingdom, 1988-2007
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-221: Predicting Costs of Care for Unique Dependence Levels in Patients with Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of Bapineuzumab
Poster P3-246: Pharmacokinetics and Pharmacodynamics of Bapineuzumab Following Multiple
Intravenous Infusions in Patients with Mild-to-Moderate Alzheimer's Disease
Tuesday, July 14, 12:30 - 2:30 PM
Presentations of ELND005 (AZD-103)
Poster P2-082: Oral Amyloid Anti-Aggregating Agent ELND005 is Measurable in CSF and
Brain of Healthy Adult Men
Monday, July 13, 12:30 - 3:00 PM
Poster P2-082: Defining Mild Cognitive Impairment: Disparity of Incidence and Prevalence
Estimates with Variable Operationalized Definitions
Monday, July 13, 12:30 - 2:30 PM
Poster P2-225: Characterization of Inositol Transporters as a Method for Drug Delivery to the
CNS
Monday, July 13, 12:30 - 3:00 PM
Poster P3-245: A Sensitive Assay Measuring the Binding of Amyloid Beta Monomers to
Aggregates Reveals the Potential of ELND005 (scylloinositol) to Reduce and Reverse Amyloid
Accumulation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-258: The effect of scyllo-inositol derivatives on β-amyloid peptide aggregation
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-279: Scyllo-Inositol (ELND005) Ameliorates Amyloid Pathology in an Aggressive
Mouse Model of Alzheimer's Disease
Tuesday, July 14, 12:30 - 3:00 PM
Poster P3-286: Biophysical Characterization of Scyllo-Inositol-Aβ Interactions
Tuesday, July 14, 12:30 - 3:00 PM
Poster P4-193: Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8
Mice Following Treatment with Scyllo-Inositol (ELND005)
Wednesday, July 15, 12:30 - 3:00 PM
Poster P4-354: ELND005 (scyllo-inositol), the β-Amyloid Anti-Aggregation Therapeutic,
Demonstrates Robust Brain Uptake in Rats Following Oral Administration
Wednesday, July 15, 12:30 - 3:00 PM
Presentations of Gamma Secretase Inhibitors (or other Elan Research)
Poster P1-035: Pharmacokinetic and pharmacodynamic Analysis of a Novel Gamma Secretase
Inhibitor in a Non-Transgenic A-Beta Mouse Efficacy Model
Sunday, Jul 12, 2009, 12:30 - 3:00 PM
Msg 367097 of 367145 at 7/12/2009 5:44:56 PM by
snugpharma
Snug's mining on New Elan Website come up with nugget......
Elan and Wyeth are also initiating open-label extension studies that provide active drug to subjects who complete 18 months in the initial Phase 3 trials. The first open label extension study is scheduled to be activated in North America in July 2009................so far so good.......snug
Neurodegenerative diseases
Bapineuzumab (AAB-001)
Elan, with our collaborator Wyeth, has implemented a broad clinical program evaluating bapineuzumab that includes four Phase 3 trials and is intended to enroll more than 3700 patients. Completing enrollment for the Phase 3 program is a critical objective for Elan in 2009, and the company has made a significant investment in patient service and professional support.
Elan and Wyeth announced the decision to initiate a Phase 3 clinical program for bapineuzumab in May 2007. The move to Phase 3 was based on the seriousness of Alzheimer’s disease and what Elan and Wyeth learned from their immunotherapy programs, including a review of data from the then-ongoing Phase 2 clinical trial.
Detailed results from the companies’ 18-month Phase 2 study of bapineuzumab in patients with mild to moderate Alzheimer’s disease were presented at the International Conference on Alzheimer’s Disease in July 2008. In the study, bapineuzumab appeared to have an acceptable safety profile with potential efficacy signals observed in post-hoc analyses in patients with mild to moderate Alzheimer’s disease. Potential efficacy signals were seen at a range of doses without a clear dose response. The study did not attain statistical significance on the pre-specified efficacy endpoints in the overall study population.
Elan believes that the safety and efficacy findings from this Phase 2 trial of bapineuzumab in patients with mild to moderate Alzheimer’s disease support the design of the ongoing global Phase 3 program.
The Phase 3 program encompasses studies being conducted at approximately 400 sites in North America, Europe, Latin America, Asia and Africa. In December 2007, Elan and Wyeth announced that the first patient had been dosed in the studies taking place in North America. International studies, conducted by Wyeth, began enrolling patients in June 2008.
The Phase 3 program includes four randomized, double-blind, placebo-controlled studies across the two subpopulations of patients with and without an ApoE4 genotype who have mild to moderate AD. The treatment duration for each patient will be 18 months, with patients planned to be distributed between North America and the international studies. All studies have co-primary efficacy end points — one cognitive and one functional. In addition, this trial program will also include sophisticated imaging and biomarker sub-studies to attempt to further elucidate the clinical profile of bapineuzumab. Elan and Wyeth are also initiating open-label extension studies that provide active drug to subjects who complete 18 months in the initial Phase 3 trials. The first open label extension study is scheduled to be activated in North America in July 2009.
snugpharma
Snug's mining on New Elan Website come up with nugget......
Elan and Wyeth are also initiating open-label extension studies that provide active drug to subjects who complete 18 months in the initial Phase 3 trials. The first open label extension study is scheduled to be activated in North America in July 2009................so far so good.......snug
Neurodegenerative diseases
Bapineuzumab (AAB-001)
Elan, with our collaborator Wyeth, has implemented a broad clinical program evaluating bapineuzumab that includes four Phase 3 trials and is intended to enroll more than 3700 patients. Completing enrollment for the Phase 3 program is a critical objective for Elan in 2009, and the company has made a significant investment in patient service and professional support.
Elan and Wyeth announced the decision to initiate a Phase 3 clinical program for bapineuzumab in May 2007. The move to Phase 3 was based on the seriousness of Alzheimer’s disease and what Elan and Wyeth learned from their immunotherapy programs, including a review of data from the then-ongoing Phase 2 clinical trial.
Detailed results from the companies’ 18-month Phase 2 study of bapineuzumab in patients with mild to moderate Alzheimer’s disease were presented at the International Conference on Alzheimer’s Disease in July 2008. In the study, bapineuzumab appeared to have an acceptable safety profile with potential efficacy signals observed in post-hoc analyses in patients with mild to moderate Alzheimer’s disease. Potential efficacy signals were seen at a range of doses without a clear dose response. The study did not attain statistical significance on the pre-specified efficacy endpoints in the overall study population.
Elan believes that the safety and efficacy findings from this Phase 2 trial of bapineuzumab in patients with mild to moderate Alzheimer’s disease support the design of the ongoing global Phase 3 program.
The Phase 3 program encompasses studies being conducted at approximately 400 sites in North America, Europe, Latin America, Asia and Africa. In December 2007, Elan and Wyeth announced that the first patient had been dosed in the studies taking place in North America. International studies, conducted by Wyeth, began enrolling patients in June 2008.
The Phase 3 program includes four randomized, double-blind, placebo-controlled studies across the two subpopulations of patients with and without an ApoE4 genotype who have mild to moderate AD. The treatment duration for each patient will be 18 months, with patients planned to be distributed between North America and the international studies. All studies have co-primary efficacy end points — one cognitive and one functional. In addition, this trial program will also include sophisticated imaging and biomarker sub-studies to attempt to further elucidate the clinical profile of bapineuzumab. Elan and Wyeth are also initiating open-label extension studies that provide active drug to subjects who complete 18 months in the initial Phase 3 trials. The first open label extension study is scheduled to be activated in North America in July 2009.
....und 400 ST. für 4,88 sind meine...
Antwort auf Beitrag Nr.: 37.558.586 von Birgit.Tersteegen am 13.07.09 09:11:14Hallo Birgit,
sind die heute gekauften Aktien in deinem Depot eigentlich gesondert aufgeführt ???
Nicht, dass es einen Kuddelmuddel mit deinem alten Aktienbestand gibt....
Grüße
bernie55
Hallo Birgit,sind die heute gekauften Aktien in deinem Depot eigentlich gesondert aufgeführt ???
Nicht, dass es einen Kuddelmuddel mit deinem alten Aktienbestand gibt....
Grüße
bernie55
Antwort auf Beitrag Nr.: 37.559.481 von bernie55 am 13.07.09 11:03:45...moin!
Nee,aber ich denke die Bank müsste das haben..... gruss!B.
Nee,aber ich denke die Bank müsste das haben.....
gruss!B.
6:35AM Elan and Transition Therapeutics announce phase 1 data showing ELND005 achieves desired concentrations in brain tissue and cerebrospinal fluid (ELN)
Co and Transition Therapeutics (TTHI) presented Phase 1 data demonstrating that treatment with ELND005 (scyllo-inositol formerly known as AZD-103), achieves desired concentrations in human brain tissue and cerebrospinal fluid when given orally. Preclinical data also were presented showing that ELND005 administration is associated with preservation of choline acetyltransferase (ChAT), reflecting preservation of nerve cells that are critical to memory function in the brain. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer's disease. These results were presented at the 2009 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2009) in Vienna, Austria. Concentrations of ELND005 in cerebrospinal fluid were measured directly, while brain tissue concentrations were measured non-invasively using a novel magnetic resonance spectroscopy technique and were determined to be within the range associated with efficacy in previous animal studies that employed a transgenic animal model of Alzheimer's Disease.
http://finance.yahoo.com/marketupdate/inplay#eln
Co and Transition Therapeutics (TTHI) presented Phase 1 data demonstrating that treatment with ELND005 (scyllo-inositol formerly known as AZD-103), achieves desired concentrations in human brain tissue and cerebrospinal fluid when given orally. Preclinical data also were presented showing that ELND005 administration is associated with preservation of choline acetyltransferase (ChAT), reflecting preservation of nerve cells that are critical to memory function in the brain. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer's disease. These results were presented at the 2009 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2009) in Vienna, Austria. Concentrations of ELND005 in cerebrospinal fluid were measured directly, while brain tissue concentrations were measured non-invasively using a novel magnetic resonance spectroscopy technique and were determined to be within the range associated with efficacy in previous animal studies that employed a transgenic animal model of Alzheimer's Disease.
http://finance.yahoo.com/marketupdate/inplay#eln
Antwort auf Beitrag Nr.: 37.560.397 von Birgit.Tersteegen am 13.07.09 13:10:19Meine Aktieneinkäufe ab 2009 haben den Zusatz > VG mit AbgSt.
Meine Aktieneinkäufe vor 2009 haben den Zusatz > VG ohne AbgSt.
Meine Aktieneinkäufe vor 2009 haben den Zusatz > VG ohne AbgSt.
Antwort auf Beitrag Nr.: 37.560.397 von Birgit.Tersteegen am 13.07.09 13:10:19Nee,aber ich denke die Bank müsste das haben....
Banken......die müssten das haben ????
..seit wann vertrauen wir denn Banken ???
..du bekommst doch einen Depotauszug...
....da muss doch drin stehen, dass du Aktien hast , die unter VG mit bzw. ohne Abgabesteuer fallen......
..die können doch nicht alle Aktienkäufe in einen Topf schmeißen.....
Banken......die müssten das haben ????
..seit wann vertrauen wir denn Banken ???
..du bekommst doch einen Depotauszug...
....da muss doch drin stehen, dass du Aktien hast , die unter VG mit bzw. ohne Abgabesteuer fallen......
..die können doch nicht alle Aktienkäufe in einen Topf schmeißen.....
Antwort auf Beitrag Nr.: 37.560.571 von bernie55 am 13.07.09 13:32:27.....ergänzend zur NEWS des heutigen Tages....
http://www.finanznachrichten.de/nachrichten-2009-07/14404892…
13.07.2009 12:31
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ: TTHI) today presented Phase 1 data demonstrating that treatment with ELND005 (scyllo-inositol formerly known as AZD-103), achieves desired concentrations in human brain tissue and cerebrospinal fluid when given orally. Preclinical data also were presented showing that ELND005 administration is associated with preservation of choline acetyltransferase (ChAT), reflecting preservation of nerve cells that are critical to memory function in the brain. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer’s disease. These results were presented at the 2009 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2009) in Vienna, Austria.
In a poster entitled, ”Oral Amyloid Anti-aggregating Agent ELND005 is Measurable in CSF and Brain of Healthy Adult Men,” the researchers describe results of a Phase 1 study in which eight healthy adults each received 2,000 mg of ELND005 twice a day for 10 days. Concentrations of ELND005 in cerebrospinal fluid were measured directly, while brain tissue concentrations were measured non-invasively using a novel magnetic resonance spectroscopy technique and were determined to be within the range associated with efficacy in previous animal studies that employed a transgenic animal model of Alzheimer’s Disease. ELND005 was well tolerated by these study participants with no severe, serious, or treatment-limiting adverse events observed.
”Achieving a clinically beneficial concentration of drug in brain tissue and cerebrospinal fluid has presented a significant hurdle to other drugs investigated to treat Alzheimer’s Disease, so this is an important proof of concept for us,” said Elan president Carlos V. Paya, MD, PhD. ”We look forward to completing and reporting results from our ongoing Phase 2 study of ELND005 in patients with mild to moderate Alzheimer's disease, which completed enrollment in October 2008.”
In a second poster, entitled ”Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8 Mice Following Treatment with Scyllo-Inositol (ELND005),” Dr. JoAnne McLaurin and colleagues from the University of Toronto analyzed levels of the enzyme Choline Acetyltransferase (ChAT) in an animal model of Alzheimer’s disease. As in humans, these Alzheimer’s animal models exhibit damage to nerve cells in a region of the brain called the ”basal forebrain” that use the neurotransmitter acetylcholine to transmit nerve impulses critical to memory functions to other nerve cells in a brain region important for memory function called the hippocampus. Animals treated with ELND005 exhibited significantly more ChAT levels compared to untreated animals.
”There is evidence that amyloid plaque formation drives the decline in memory and cognition associated with Alzheimer’s disease,” said JoAnne McLaurin, PhD, professor at the University of Toronto’s Centre for Research in Neurodegenerative Diseases. ”Although more research is necessary, the findings presented today suggest that ELND005 may have the ability to prevent the loss of ChAT that results from damage to cholinergic neurons in the brain, thereby potentially protecting against cognitive decline in individuals with Alzheimer’s disease.”
”We have conducted a robust preclinical and Phase 1 research program of ELND005 that has demonstrated that the drug is able to cross the blood-brain barrier, which should allow it to target the disaggregation of amyloid beta in the brain,” said Dr. Tony Cruz, chairman and chief executive officer of Transition.
In 2006, Elan and Transition entered into an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer’s disease and other indications.
About ELND005 (AZD-103)
ELND005 is an orally-administered therapeutic agent that has received fast track designation from the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate Alzheimer’s disease. Fast track designation can facilitate development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
ELND005 is currently in a Phase 2 clinical study, which completed enrollment in October 2008. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 340 patients with mild to moderate Alzheimer’s disease. The planned treatment period for each patient is approximately 18 months.
http://www.finanznachrichten.de/nachrichten-2009-07/14404892…
13.07.2009 12:31
Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics Inc. (TSX: TTH, NASDAQ: TTHI) today presented Phase 1 data demonstrating that treatment with ELND005 (scyllo-inositol formerly known as AZD-103), achieves desired concentrations in human brain tissue and cerebrospinal fluid when given orally. Preclinical data also were presented showing that ELND005 administration is associated with preservation of choline acetyltransferase (ChAT), reflecting preservation of nerve cells that are critical to memory function in the brain. ELND005 is an orally-administered drug candidate in Phase 2 trials for the treatment of mild to moderate Alzheimer’s disease. These results were presented at the 2009 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2009) in Vienna, Austria.
In a poster entitled, ”Oral Amyloid Anti-aggregating Agent ELND005 is Measurable in CSF and Brain of Healthy Adult Men,” the researchers describe results of a Phase 1 study in which eight healthy adults each received 2,000 mg of ELND005 twice a day for 10 days. Concentrations of ELND005 in cerebrospinal fluid were measured directly, while brain tissue concentrations were measured non-invasively using a novel magnetic resonance spectroscopy technique and were determined to be within the range associated with efficacy in previous animal studies that employed a transgenic animal model of Alzheimer’s Disease. ELND005 was well tolerated by these study participants with no severe, serious, or treatment-limiting adverse events observed.
”Achieving a clinically beneficial concentration of drug in brain tissue and cerebrospinal fluid has presented a significant hurdle to other drugs investigated to treat Alzheimer’s Disease, so this is an important proof of concept for us,” said Elan president Carlos V. Paya, MD, PhD. ”We look forward to completing and reporting results from our ongoing Phase 2 study of ELND005 in patients with mild to moderate Alzheimer's disease, which completed enrollment in October 2008.”
In a second poster, entitled ”Quantification of Cholinergic Degradation and Adult Neurogenesis in TgCRND8 Mice Following Treatment with Scyllo-Inositol (ELND005),” Dr. JoAnne McLaurin and colleagues from the University of Toronto analyzed levels of the enzyme Choline Acetyltransferase (ChAT) in an animal model of Alzheimer’s disease. As in humans, these Alzheimer’s animal models exhibit damage to nerve cells in a region of the brain called the ”basal forebrain” that use the neurotransmitter acetylcholine to transmit nerve impulses critical to memory functions to other nerve cells in a brain region important for memory function called the hippocampus. Animals treated with ELND005 exhibited significantly more ChAT levels compared to untreated animals.
”There is evidence that amyloid plaque formation drives the decline in memory and cognition associated with Alzheimer’s disease,” said JoAnne McLaurin, PhD, professor at the University of Toronto’s Centre for Research in Neurodegenerative Diseases. ”Although more research is necessary, the findings presented today suggest that ELND005 may have the ability to prevent the loss of ChAT that results from damage to cholinergic neurons in the brain, thereby potentially protecting against cognitive decline in individuals with Alzheimer’s disease.”
”We have conducted a robust preclinical and Phase 1 research program of ELND005 that has demonstrated that the drug is able to cross the blood-brain barrier, which should allow it to target the disaggregation of amyloid beta in the brain,” said Dr. Tony Cruz, chairman and chief executive officer of Transition.
In 2006, Elan and Transition entered into an exclusive, worldwide collaboration agreement for the joint development and commercialization of ELND005 for the treatment of Alzheimer’s disease and other indications.
About ELND005 (AZD-103)
ELND005 is an orally-administered therapeutic agent that has received fast track designation from the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate Alzheimer’s disease. Fast track designation can facilitate development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
ELND005 is currently in a Phase 2 clinical study, which completed enrollment in October 2008. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 340 patients with mild to moderate Alzheimer’s disease. The planned treatment period for each patient is approximately 18 months.
Antwort auf Beitrag Nr.: 37.560.687 von bernie55 am 13.07.09 13:51:14..jetzt auch auf der neuen Homepage von ELAN...
http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-pressr…
http://newsroom.elan.com/phoenix.zhtml?c=88326&p=irol-pressr…
Ich verstehe das nicht,
warum steigt der Kurs nicht, obwohl der Markt soo bullisch ist.
Habe so eben in USA noch 1.000 stück nachgekauft.
Es muss doch bald soweit sein. Oder?
warum steigt der Kurs nicht, obwohl der Markt soo bullisch ist.
Habe so eben in USA noch 1.000 stück nachgekauft.
Es muss doch bald soweit sein. Oder?
Antwort auf Beitrag Nr.: 37.563.890 von Schero am 13.07.09 20:21:48Dem Management wird wohl nicht mehr vertraut----bin gespannt auf die Aktionärsversammlung am Donnerstag....
Antwort auf Beitrag Nr.: 37.560.621 von bernie55 am 13.07.09 13:40:00....lt Auskunft der DAB kein Problem....sie differenzieren das beim Verkauf....
Antwort auf Beitrag Nr.: 37.564.157 von Birgit.Tersteegen am 13.07.09 20:57:12Warum nicht? Das Geschäft mit J&J ist unter Dach und Fach.
Ja nun, das große sagen hat doch jetzt J&J.
Ja nun, das große sagen hat doch jetzt J&J.
Antwort auf Beitrag Nr.: 37.564.453 von Schero am 13.07.09 21:42:09na ja--wenn sie weiter Geld verbrennen + die gute Pipeline nicht vermarkten können...
Antwort auf Beitrag Nr.: 37.564.200 von Birgit.Tersteegen am 13.07.09 21:04:03..lt Auskunft der DAB kein Problem....sie differenzieren das beim Verkauf....
....die Hauptsache ist ,dass Du es hinterher differenzieren kannst...
LG
bernie55
....die Hauptsache ist ,dass Du es hinterher differenzieren kannst...
LG
bernie55
Antwort auf Beitrag Nr.: 37.565.672 von bernie55 am 14.07.09 08:01:04...wenn nicht,nehme ich eben bapi--dann wird´s doch wohl gehen....
Davy
Elan Corp (USc)
ELN US
ELND005 data presented; US Senate backs 12-year exclusivity for biotech products
Jack Gorman
Price $6.76 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
As we noted late last week, ELND005 is one of the more advanced AD drugs outside Elan's AIP programme, and is scheduled to complete Phase II by mid-2010. Phase I data presented at ICAD points to both its bioavailability (crossing the blood-brain barrier to deliver desired concentrations of drug) and its potential mechanism of action (it preserves levels of an enzyme that helps transmit nerve impulses critical to memory function in the brain). This is very encouraging ahead of Phase II data.
Separately, a proposal has been passed in the US Senate that provides for a minimum of 12 years of data exclusivity for biotech drugs, before generics can be introduced. While this measure must still pass through the House, this preliminary result is positive for the biotech industry as it provides lengthy protection for its own IP against generics
Elan Corp (USc)
ELN US
ELND005 data presented; US Senate backs 12-year exclusivity for biotech products
Jack Gorman
Price $6.76 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
As we noted late last week, ELND005 is one of the more advanced AD drugs outside Elan's AIP programme, and is scheduled to complete Phase II by mid-2010. Phase I data presented at ICAD points to both its bioavailability (crossing the blood-brain barrier to deliver desired concentrations of drug) and its potential mechanism of action (it preserves levels of an enzyme that helps transmit nerve impulses critical to memory function in the brain). This is very encouraging ahead of Phase II data.
Separately, a proposal has been passed in the US Senate that provides for a minimum of 12 years of data exclusivity for biotech drugs, before generics can be introduced. While this measure must still pass through the House, this preliminary result is positive for the biotech industry as it provides lengthy protection for its own IP against generics
... verstehe nicnt.
Was nützen die "Outperformer" Ratings, wenn nicht gekauft wird.
Was nützen die "Outperformer" Ratings, wenn nicht gekauft wird.
Antwort auf Beitrag Nr.: 37.569.520 von Schero am 14.07.09 15:36:53....Du bist eben noch nicht lange Elanier....deshalb fragst Du noch...wird schon!! Gruss!B.
wird schon!! Gruss!B.
Antwort auf Beitrag Nr.: 37.569.520 von Schero am 14.07.09 15:36:53Msg 367647 of 367647 at 7/14/2009 11:22:38 AM by
Elanianian
It has simply GOT to be this
The JNJ deal is a good one for ELN. Limits upside, but certainly supports loss to downside. Stability. Strong partner. All that stuff.
PP drug from JNJ looks to be approved in less than a month. More good news.
JNJ makes excellent comments about BAP, and says due dillegence on Phase 2 shows excellent promise.
JNJ deal with Cougar was announced in mid-May, and closed July 9. Therefore look for JNJ deal with ELN to close late August. Done.
Debt issue hangover GOING AWAY.
Support for their key drug of promise (Bap), where a big brother is gonna pay for it all, and use its power and influence to usher it through to the market.
ELND-005 - excellent news about phase one results on both safety and effectiveness in doing what its supposed to do.
Tysabri - maybe some temporary lost traction due to recent PML cases; however, in two weeks the weekly PML updates go away, and 3 year anniversary means restrictions may be lifted off marketing, and sales can begin to accelarate.
ICAD going on now - shows who the leader is in Alz therapies.
All the press about JNJ deal is POSITIVE. All say the same thing... "Limits upside but secures the company's future"
All this good stuff going on, and pps continues to drop like a rock.
This is SO F**KED UP, it can only mean this...
It is the MARKET saying, "We don't care what you do ELN - until you get rid of that horseshit CEO, we are going to continue to punish you".
I cannot think of any other reason for us to be traded this way.
If Martin is sacked at AGM and pps shoots up, I guess we'll know if this theory has any merit.
Elanianian
It has simply GOT to be this
The JNJ deal is a good one for ELN. Limits upside, but certainly supports loss to downside. Stability. Strong partner. All that stuff.
PP drug from JNJ looks to be approved in less than a month. More good news.
JNJ makes excellent comments about BAP, and says due dillegence on Phase 2 shows excellent promise.
JNJ deal with Cougar was announced in mid-May, and closed July 9. Therefore look for JNJ deal with ELN to close late August. Done.
Debt issue hangover GOING AWAY.
Support for their key drug of promise (Bap), where a big brother is gonna pay for it all, and use its power and influence to usher it through to the market.
ELND-005 - excellent news about phase one results on both safety and effectiveness in doing what its supposed to do.
Tysabri - maybe some temporary lost traction due to recent PML cases; however, in two weeks the weekly PML updates go away, and 3 year anniversary means restrictions may be lifted off marketing, and sales can begin to accelarate.
ICAD going on now - shows who the leader is in Alz therapies.
All the press about JNJ deal is POSITIVE. All say the same thing... "Limits upside but secures the company's future"
All this good stuff going on, and pps continues to drop like a rock.
This is SO F**KED UP, it can only mean this...
It is the MARKET saying, "We don't care what you do ELN - until you get rid of that horseshit CEO, we are going to continue to punish you".
I cannot think of any other reason for us to be traded this way.
If Martin is sacked at AGM and pps shoots up, I guess we'll know if this theory has any merit.
Antwort auf Beitrag Nr.: 37.569.520 von Schero am 14.07.09 15:36:53Msg 367652 of 367653 at 7/14/2009 11:33:42 AM by
upanddownpuppet
Stock price is a bad joke
After JNJ deal closes Elan would be valued at 3.8 billion.
Cash on hand almost washes the 400mill in debt left over
Elan's AIP was valued at 750mill by JNJ
EDT is valued at 1.4 billion by independent parties
Athlone plant is valued at 500 million, that makes it
2.65 billion.
So we have Tysabri that sells a billion per year, AZactam that bring in 100 million and no generic in sight(not worth it to a generic company)
Prialt( Joke)
LLY Alz drug in phase three
TTHI drug in phase 2
All other intellectual property, phase one and preclinical compounds
Plant in Gainsville GA
all that is valued at 1.2 billion. Give me a break, Tysabri alone should be valued at around 3 billion.
I guess KM and KMcL are valued at about minus 4 billion.
upanddownpuppet
Stock price is a bad joke
After JNJ deal closes Elan would be valued at 3.8 billion.
Cash on hand almost washes the 400mill in debt left over
Elan's AIP was valued at 750mill by JNJ
EDT is valued at 1.4 billion by independent parties
Athlone plant is valued at 500 million, that makes it
2.65 billion.
So we have Tysabri that sells a billion per year, AZactam that bring in 100 million and no generic in sight(not worth it to a generic company)
Prialt( Joke)
LLY Alz drug in phase three
TTHI drug in phase 2
All other intellectual property, phase one and preclinical compounds
Plant in Gainsville GA
all that is valued at 1.2 billion. Give me a break, Tysabri alone should be valued at around 3 billion.
I guess KM and KMcL are valued at about minus 4 billion.
Antwort auf Beitrag Nr.: 37.570.723 von Birgit.Tersteegen am 14.07.09 17:41:34Es ist der Markt sagt, "Wir tun nichts, was Sie tun ELN - bis Sie loswerden, dass horseshit CEO, werden wir Sie weiterhin zu bestrafen".
Hi Birgit, soll das heißen, wenn der COE gefeuert wird, ist der Weg nach oben frei?
Wann kann er gefeuert werden? Vielleicht morgen, auf die HV?
LG
Schero
Hi Birgit, soll das heißen, wenn der COE gefeuert wird, ist der Weg nach oben frei?
Wann kann er gefeuert werden? Vielleicht morgen, auf die HV?
LG
Schero
Antwort auf Beitrag Nr.: 37.570.998 von Schero am 14.07.09 18:13:49gute Frage...ich glaube, dass ein anderer CEO das Vertrauen grosser Investoren wieder gewinnen könnte angesichts der Pipeline,die Elan hat....aber ich befürchte,dass auf der AGM am Donnerstag es nicht soweit kommt...
Antwort auf Beitrag Nr.: 37.571.362 von Birgit.Tersteegen am 14.07.09 19:00:47ich grüße Dich Birgit
sieht noch nicht viel versprechend aus, unser ELAN
Antwort auf Beitrag Nr.: 37.570.671 von Birgit.Tersteegen am 14.07.09 17:36:10JNJ makes excellent comments about BAP, and says due dillegence on Phase 2 shows excellent promise
...das sollte doch wirklich mal als vielversprechend interpretiert werden....
...das sollte doch wirklich mal als vielversprechend interpretiert werden....
A mid-stage study of the Elan-Wyeth amyloid-blocker did not show a statistically significant benefit, although some subsets of patients did better. Patients were at higher risk for a vasogenic edema, a buildup of fluid in the brain.
Was meinen die damit?
Ist das Medikament von Elan jetzt doch nicht so gut?
http://www.forbes.com/2009/07/14/dimebon-medivation-alzheime…
Wäre für Antworten dankbar.
Schero
Was meinen die damit?
Ist das Medikament von Elan jetzt doch nicht so gut?
http://www.forbes.com/2009/07/14/dimebon-medivation-alzheime…
Wäre für Antworten dankbar.
Schero
Big numbers - 261.5 per week - and likely more recently
3400 new net additions over 13 weeks is 261.5 per week. That’s a big number folks, and massive in terms of the current share price.
As an aside, the numbers are even more impressive if the net adds were 200 pw for Apr and May as suggested. That would mean massive additions during June.
1st qtr = 39,300 commercial patients.
“At the end of March 2009, approximately 40,000 patients were on therapy worldwide, including approximately 20,800 commercial patients in the United States and approximately 18,500 commercial patients in the ROW”
1st qtr = 42,700 commercial patients.
“As of the end of June 2009, approximately 43,300 patients were on commercial and clinical TYSABRI therapy worldwide. According to data available as of the end of June 2009:
* In the U.S., approximately 22,000 patients were on TYSABRI therapy commercially;
* In the rest of world, approximately 20,700 patients were on TYSABRI therapy commercially; and,
“
Peadar ‘Og
3400 new net additions over 13 weeks is 261.5 per week. That’s a big number folks, and massive in terms of the current share price.
As an aside, the numbers are even more impressive if the net adds were 200 pw for Apr and May as suggested. That would mean massive additions during June.
1st qtr = 39,300 commercial patients.
“At the end of March 2009, approximately 40,000 patients were on therapy worldwide, including approximately 20,800 commercial patients in the United States and approximately 18,500 commercial patients in the ROW”
1st qtr = 42,700 commercial patients.
“As of the end of June 2009, approximately 43,300 patients were on commercial and clinical TYSABRI therapy worldwide. According to data available as of the end of June 2009:
* In the U.S., approximately 22,000 patients were on TYSABRI therapy commercially;
* In the rest of world, approximately 20,700 patients were on TYSABRI therapy commercially; and,
“
Peadar ‘Og
Updated WSJ Article 2nd UPDATE: Elan's CEO: J&J Deal Will Help Stabilize Shares
DUBLIN (Dow Jones)--Elan Corp. (ELN) Chief Executive Kelly Martin Thursday said the Irish drug firm's recent $1.5 billion deal with U.S. company Johnson & Johnson (JNJ) will help bring stability to its share price.
"It's very hard to run a company when you have that kind of volatility," Martin said. "We hope it will drive out a fair amount of volatility from the stock."
Elan Chairman Kyran McLaughlin added: "We've de-risked the company... the board and I are optimistic that we're at a turning point now. Being a profitable company in 2010 will have a dramatic effect on the share price."
As part of the deal announced earlier this month, Johnson & Johnson will acquire the assets and rights of Elan's Alzheimer's program and invest $1 billion in Elan in exchange for new American depositary receipts of the Irish firm, representing 18.4% of its outstanding ordinary shares.
Johnson & Johnson will assume and continue Elan's 50-50 joint venture Alzheimer's program with U.S. firm Wyeth (WYE) and will initially commit up to $500 million toward the development and launch of Alzheimer's treatment bapineuzumab, or AAB-001.
Investors liked the confident management statements. At 1105 GMT, Elan shares were up 1.8% at EUR4.98 on the Irish Stock Exchange. The stock has plummeted from EUR21.40 this time last year.
"The share price ran a bit ahead of events last year," McLauglin told Dow Jones Newswires after the company's annual general meeting. McLaughlin said he was surprised the shares didn't react more positively to the Johnson & Johnson deal, but management said that in the short term it was ambitious to expect the stock to reach last year's peak.
Also Thursday, Chief Executive Martin said patient uptake of the Irish pharmaceutical company's blockbuster multiple sclerosis drug Tysabri is accelerating, despite recent cases of the brain disease PML, or progressive multifocal leukoencephalopathy.
He told company's AGM: "It's been three years since we launched Tysabri in the U.S. We have more patient experiences and more clinical advances... and we learn more about how to apply this therapy."
Elan said Tysabri - a joint venture with U.S. firm Biogen Idec (BIIB) - will be a $1 billion drug. It still expects a target of 100,000 patients, but didn't disclose a target date.
Ten patients have so far contracted PML. The company said it now better understands how to manage the disease and detect it before it is full blown. Around 54,000 people are currently taking Tysabri; Biogen Idec will update the market on patient numbers later Thursday.
Chief Financial Officer Shane Cooke said the company isn't looking to immediately sell its Elan Drug Technologies unit and instead hopes to grow the business.
Martin said the company is looking at small acquisitions, particularly in the EDT area if the opportunity arises.
Separately, Elan's management said the company isn't looking at further job losses in Ireland and, Martin added, is more likely to make selective additions to staff after the Johnson & Johnson deal is completed.
DUBLIN (Dow Jones)--Elan Corp. (ELN) Chief Executive Kelly Martin Thursday said the Irish drug firm's recent $1.5 billion deal with U.S. company Johnson & Johnson (JNJ) will help bring stability to its share price.
"It's very hard to run a company when you have that kind of volatility," Martin said. "We hope it will drive out a fair amount of volatility from the stock."
Elan Chairman Kyran McLaughlin added: "We've de-risked the company... the board and I are optimistic that we're at a turning point now. Being a profitable company in 2010 will have a dramatic effect on the share price."
As part of the deal announced earlier this month, Johnson & Johnson will acquire the assets and rights of Elan's Alzheimer's program and invest $1 billion in Elan in exchange for new American depositary receipts of the Irish firm, representing 18.4% of its outstanding ordinary shares.
Johnson & Johnson will assume and continue Elan's 50-50 joint venture Alzheimer's program with U.S. firm Wyeth (WYE) and will initially commit up to $500 million toward the development and launch of Alzheimer's treatment bapineuzumab, or AAB-001.
Investors liked the confident management statements. At 1105 GMT, Elan shares were up 1.8% at EUR4.98 on the Irish Stock Exchange. The stock has plummeted from EUR21.40 this time last year.
"The share price ran a bit ahead of events last year," McLauglin told Dow Jones Newswires after the company's annual general meeting. McLaughlin said he was surprised the shares didn't react more positively to the Johnson & Johnson deal, but management said that in the short term it was ambitious to expect the stock to reach last year's peak.
Also Thursday, Chief Executive Martin said patient uptake of the Irish pharmaceutical company's blockbuster multiple sclerosis drug Tysabri is accelerating, despite recent cases of the brain disease PML, or progressive multifocal leukoencephalopathy.
He told company's AGM: "It's been three years since we launched Tysabri in the U.S. We have more patient experiences and more clinical advances... and we learn more about how to apply this therapy."
Elan said Tysabri - a joint venture with U.S. firm Biogen Idec (BIIB) - will be a $1 billion drug. It still expects a target of 100,000 patients, but didn't disclose a target date.
Ten patients have so far contracted PML. The company said it now better understands how to manage the disease and detect it before it is full blown. Around 54,000 people are currently taking Tysabri; Biogen Idec will update the market on patient numbers later Thursday.
Chief Financial Officer Shane Cooke said the company isn't looking to immediately sell its Elan Drug Technologies unit and instead hopes to grow the business.
Martin said the company is looking at small acquisitions, particularly in the EDT area if the opportunity arises.
Separately, Elan's management said the company isn't looking at further job losses in Ireland and, Martin added, is more likely to make selective additions to staff after the Johnson & Johnson deal is completed.
Antwort auf Beitrag Nr.: 37.584.948 von Birgit.Tersteegen am 16.07.09 13:38:39..das liest sich doch ganz gut....
...ergänzend noch dazu von BIIB...
Total revenues were $1.1 billion, an increase of 10% from $1.0 billion in the second quarter of 2008. The increase was driven primarily by the continued growth of TYSABRI (natalizumab) revenues, which were up 27% over the prior year to $188 million for the quarter, and AVONEX® (interferon beta-1a) sales, which increased 12% over the prior year to $591 million for the quarter.
..das liest sich doch ganz gut.......ergänzend noch dazu von BIIB...
Total revenues were $1.1 billion, an increase of 10% from $1.0 billion in the second quarter of 2008. The increase was driven primarily by the continued growth of TYSABRI (natalizumab) revenues, which were up 27% over the prior year to $188 million for the quarter, and AVONEX® (interferon beta-1a) sales, which increased 12% over the prior year to $591 million for the quarter.
Antwort auf Beitrag Nr.: 37.585.172 von bernie55 am 16.07.09 14:05:23..ach ja.....----irgendwann werden wir alle reich.....
----irgendwann werden wir alle reich.....
Antwort auf Beitrag Nr.: 37.585.190 von Birgit.Tersteegen am 16.07.09 14:08:00..ach ja.....
??????????????????????????????
irgendwann werden wir alle reich.
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
??????????????????????????????
irgendwann werden wir alle reich.
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Antwort auf Beitrag Nr.: 37.585.190 von Birgit.Tersteegen am 16.07.09 14:08:00Wer will den hier reich werden....... wir sind doch hier nicht im Spielcasino aber gegen 100% vom aktuellen Niveau hätte ich auch nichts.....
Gruß
quickclick
aber gegen 100% vom aktuellen Niveau hätte ich auch nichts.....Gruß
quickclick
Na also, jetzt ist endlich die Zeit für unser Schnuggel gekommen.
Diesen lächerlichen Kurs in den letzten Tagen sehen wir hoffentlich nie wieder.
Diesen lächerlichen Kurs in den letzten Tagen sehen wir hoffentlich nie wieder.
Antwort auf Beitrag Nr.: 37.587.236 von quickclick am 16.07.09 17:56:46also 400% müssen es schon sein....in 2 Jahren...
And Icahn is a BIIB investor who recently won a couple of seats on the company's board of directors.
Tysabri is an injectable drug that helps cut the frequency and severity of MS flare-ups. But recently, some analysts and investors have expressed concern about Tysabri's prospects because of a pickup in the number of reported cases of a very rare, potentially fatal side effect. The company responded by giving weekly updates on PML reports, but today BIIB said it'll stop doing that next week. The company pulled the drug off the market after the condition known as PML first cropped up, but later got FDA permission to bring it back to the market three years ago.
I covered the meeting of the FDA panel that considered whether to recommend Tysabri's return. Nearly all of these advisory committee meetings can be extremely dense and dull. It's not uncommon to see several people nodding off in the middle of the meeting. But the Tysabri affair was emotional and, at times, powerful and moving. A few of the MS patients who testified were crying, begging the panel to let the drug come back. Despite the known risk of death, they believed the benefits were too strong.
Read all the Pharma's Market Blogs here
Doctors have become more vigilant about PML and they now know how to quickly flush the drug out of the patient's system and get them out of danger. Since Tysabri has come back to market there have been 10 known PML cases, but only one of them was fatal. Experts think that the longer a patient is on Tysabri, the greater the chances are of getting PML, so they expect the number of cases to continue to pile up in coming months. On the conference call, analysts say execs indicated they're looking at treatment alternatives like possibly taking a Tysabri break and they're trying to figure out why most of the new cases are occurring overseas.
Because there'd been some analyst chatter about the acceleration of PML cases causing a slowdown in Tysabri sales, many were surprised today to see BIIB report that the number of patients on Tysabri is actually growing, sales are climbing and the rate at which new patients are going on the drug is picking up as well. The company now says that Tysabri is on track to become a billion-dollar blockbuster. Still, some analysts are cautious and don't think Tysabri is out of the woods yet.
I hope the apparent turnaround for the franchise will encourage Biogen Idec's CEO Jim Mullen to get back out there. He used to regularly give us an interview, but I don't think he's been on CNBC since 2007.
Carl, can you help?
Elan und JuJ werden das Kind schon schaukeln!!
Trotzdem müsste der Kurs bei ca. 11 USD liegen.
Tysabri is an injectable drug that helps cut the frequency and severity of MS flare-ups. But recently, some analysts and investors have expressed concern about Tysabri's prospects because of a pickup in the number of reported cases of a very rare, potentially fatal side effect. The company responded by giving weekly updates on PML reports, but today BIIB said it'll stop doing that next week. The company pulled the drug off the market after the condition known as PML first cropped up, but later got FDA permission to bring it back to the market three years ago.
I covered the meeting of the FDA panel that considered whether to recommend Tysabri's return. Nearly all of these advisory committee meetings can be extremely dense and dull. It's not uncommon to see several people nodding off in the middle of the meeting. But the Tysabri affair was emotional and, at times, powerful and moving. A few of the MS patients who testified were crying, begging the panel to let the drug come back. Despite the known risk of death, they believed the benefits were too strong.
Read all the Pharma's Market Blogs here
Doctors have become more vigilant about PML and they now know how to quickly flush the drug out of the patient's system and get them out of danger. Since Tysabri has come back to market there have been 10 known PML cases, but only one of them was fatal. Experts think that the longer a patient is on Tysabri, the greater the chances are of getting PML, so they expect the number of cases to continue to pile up in coming months. On the conference call, analysts say execs indicated they're looking at treatment alternatives like possibly taking a Tysabri break and they're trying to figure out why most of the new cases are occurring overseas.
Because there'd been some analyst chatter about the acceleration of PML cases causing a slowdown in Tysabri sales, many were surprised today to see BIIB report that the number of patients on Tysabri is actually growing, sales are climbing and the rate at which new patients are going on the drug is picking up as well. The company now says that Tysabri is on track to become a billion-dollar blockbuster. Still, some analysts are cautious and don't think Tysabri is out of the woods yet.
I hope the apparent turnaround for the franchise will encourage Biogen Idec's CEO Jim Mullen to get back out there. He used to regularly give us an interview, but I don't think he's been on CNBC since 2007.
Carl, can you help?
Elan und JuJ werden das Kind schon schaukeln!!
Trotzdem müsste der Kurs bei ca. 11 USD liegen.
Hier ein spannendes Interview mit unserem irischen Dickkopf.....
Irish Times interview with Kelly Martin
DOMINIC COYLETHE FRIDAY INTERVIEW/Kelly Martin, Elan chief executive: BRINGING ONE life-changing drug to market is testimony enough for most people. Bringing a second close to the same point is a remarkable achievement for an Irish company in the ultra-competitive world of modern pharmaceuticals.
But, having guided one of Ireland’s most volatile companies to a point where its medium-term financial outlook is secure, Elan chief executive Kelly Martin is still a long way from resting on his laurels.
For him, the deal gives Elan the flexibility to chase a range of new opportunities in different approaches to addressing Alzheimer’s disease and other neurological conditions that are among the biggest areas of unmet need in medical science.
“We have the flexibility to chase new streams in Alzheimer’s disease and other areas. If we had kept all of the Alzheimer’s Immunotherapy Programme (AIP), or our half, it would have crowded out everything,” he says.
“The trick for Elan with this transaction is do we have enough runway, enough stability and now enough headroom to build out the vision that was there when they [former executives Donal Geaney and Tom Lynch] bought Athena Neuroscience and I think we do.”
Already the company has invested in a new technology initially developed by a company in Stanford in the US and Martin says it is likely to add a further three technologies to the Alzheimer’s programme in the next year or so.
“Our goal in Alzheimer’s disease is to be the leading company in the world from the RD point of view,” he says.
But that has not stopped rumblings in the background from Elan’s famously opinionated army of small shareholders. While market analysts viewed the Johnson Johnson deal as a coup for Elan, with most of the risk associated with the most advanced Alzheimer’s programme transferring to the US giant, the Elan message boards were talking of selling the family silver.
The chatter does not worry Martin. Since coming in to take over the company in 2003, his expertise and appetite for the job have been questioned continually.
Talking to him in his offices against the backdrop of the emerging new Lansdowne Road stadium in the Grand Canal Dock area of Dublin, he is more interested in looking forward at what the company can achieve. But he is still very satisfied with the Johnson Johnson agreement – one that would certainly draw favourable comment from his former employers in Merrill Lynch.
“We own half of a new company with JJ and, on the other side will ultimately be Pfizer. From a shareholder point of view, we say that if the immunotherapeutic assets work, the upside is so big that the return to our shareholders will be very significant.
“Elan has 25 per cent of the return on this technology, with the largest pharmaceutical company in the world marketing it and the largest healthcare company. I say that’s a great outcome.
“We didn’t give it away but we took the risk down drastically for us. This drug will either be the largest asset in our portfolio or it won’t work, there is no in between.”
In light of the financial commitments that continued development of the AIP programme would have involved, Martin feels holding on to its previous control was unsustainable.“This asset is too big for any one company – even Pfizer or JJ. It will take the full resources, if it is successful, of both Pfizer and JJ to optimise this asset around the world.
Among other things, the cash freed up by the deal will allow the company to concentrate on areas that were struggling for attention. Apart from the Alzheimer’s pipeline that Martin intends to stock up in the next year, there is also Elan’s drug technology business based in Athlone.
“EDT is a critical piece of the company. We would like to invest some more into EDT,” he says.
He defends the decision last year to look at “monetising” the division. “The whole rationale of monetising EDT was to give them acces to capital. That is still an issue. We can do a little bit incrementally but we cannot fundamentally shift the business unless we have more cash.”
That could mean seeking outside partners or possibly even a partial IPO. Martin is open to options but he insists that Elan wants to retain control of the business.
“EDT is a long-term part of Elan; the question is can we give them acces to capital on their own and, if we can do that in a way we retain control but they invest in it, we will do that. We want to grow it, to add products and add jobs.”
Of course, the jewel in the crown of Elan’s current, commercialised portfolio is multiple sclerosis therapy Tysabri.
Martin believes the drug is a winner now and into the future if for no other reason than its efficacy means there will always be demand from patients – two-thirds of whom, he says, see their condition worsening depsite other treatments.
“The challenge with Tysabri is now understanding and managing PML [progressive multifocal leukoencephalopathy].” The brain disease, initially thought fatal in most cases saw the drug pulled from shelves just months after its launch only forit to return after further medical investigation and hearings by the regulator, the Food and Drug Administration that featured strong patient advocacy.
He believes the market in Europe for Tysabri is bigger than previously beleived. Sales growth here has been steronger than the US in the past year, in part because of the lack of alternative treatments. However, he says growth in the US is starting to pick up, a view reinforced by strong sales figures published yesterday by Biogen Idec, its US partner in the Tysabri programme.
“The combination [of the US and European markets] is growing at a rate that we think people will find very acceptable.”
Despite the drug’s rollercoaster ride, he has no regrets about the company’s approach, especialy in withdrawing it when PML first emerged in patients.
“We did not put our patients in harm’s way which you just funadmentally cannot do. I mean our stock got killed. But I would make the same decision a thousand times in a row, it was a hard decision but it was a right decision.”
So how did a New Jersey bank executive with some distant Irish roots end up heading a company like Elan.
Like many things in business, it was more an element of chance and timing than any preplanned strategy.
Martin had spent his whole working life – nearly 22 years – with Merrill Lynch. Having started as a bond trader, he ended up working in areas as diverse as sales and information technology, always with the US group.
Along the way, he got to manage business that came within the remit of Merrill and, ultimately, he decided that this was a path he would prefer to pursue rather than continuing to build on his reputation within the bank as a troubleshooter who could fix problems within units of a business.
It was his luck – or not, some might say – to run into a consultant he knew from his time at Merrill but who had also been engaged by Elan as it struggled to emerge from the turmoil surrounding the company over a failed Alzheimer’s trial and accounting issues in the wake of the Enron scandal.
“It was a big decision. I had absolutely no knowledge of the industry but it was a chance to use the skills I had picked up in organising other businesses and to see if I could take on a challenge like this.”
The consultant through whom he had heard of the job assurred him he couldn’t go wrong. In many quarters, the company was not expected to survive. If he failed to resuce it, he would attract little blame. But succeed and the upside was considerable.
“I consider I am very lucky after workling all my life in one business to get a chance like this to make a go at another,” says Martin.
So is it time now to move on as some would suggest?
“Everyone is entitled to their opinion but my opinion is I’m not finished doing what we need to do,” says Martin.
“It’s hard being a CEO and I think you have got to stay within yourself. I’m not the scientist or the clinician. What we have is world class differentiated science. What it has to do with me is that you need a business platform to let them [the scientisits] succeed.
“We are not finished doing what we have intended to do. When I feel we are finished I will move on.
‘‘I am not interested in hanging around for the title or the profile. But I don’t think that is today and I don’t think it is any time in the near future. there are too many other things to do.”
ON THE RECORD
Name: Kelly Martin.
Age: 50.
Position: chief executive of listed Irish biotech group Elan.
Family: married to Elizabeth with five children, aged between nine and 18.
Career: Graduated from Princeton University with a degree in politics and economics before joining Merrill Lynch on an intern programme.
He spent more than 20 years with the US investment bank, earning a reputation as a troubleshooter and quick learner in areas as diverse as fixed income, equity sales and information technology.
In 2003, he left Merrill and, shortly after, took over as chief executive of Elan.
Something that won’t surprise: He finds managing Elan a full-time job.
Something that might surprise: When he does get a break, he enjoys freshwater fishing or the occasional ski break.
Irish Times interview with Kelly Martin
DOMINIC COYLETHE FRIDAY INTERVIEW/Kelly Martin, Elan chief executive: BRINGING ONE life-changing drug to market is testimony enough for most people. Bringing a second close to the same point is a remarkable achievement for an Irish company in the ultra-competitive world of modern pharmaceuticals.
But, having guided one of Ireland’s most volatile companies to a point where its medium-term financial outlook is secure, Elan chief executive Kelly Martin is still a long way from resting on his laurels.
For him, the deal gives Elan the flexibility to chase a range of new opportunities in different approaches to addressing Alzheimer’s disease and other neurological conditions that are among the biggest areas of unmet need in medical science.
“We have the flexibility to chase new streams in Alzheimer’s disease and other areas. If we had kept all of the Alzheimer’s Immunotherapy Programme (AIP), or our half, it would have crowded out everything,” he says.
“The trick for Elan with this transaction is do we have enough runway, enough stability and now enough headroom to build out the vision that was there when they [former executives Donal Geaney and Tom Lynch] bought Athena Neuroscience and I think we do.”
Already the company has invested in a new technology initially developed by a company in Stanford in the US and Martin says it is likely to add a further three technologies to the Alzheimer’s programme in the next year or so.
“Our goal in Alzheimer’s disease is to be the leading company in the world from the RD point of view,” he says.
But that has not stopped rumblings in the background from Elan’s famously opinionated army of small shareholders. While market analysts viewed the Johnson Johnson deal as a coup for Elan, with most of the risk associated with the most advanced Alzheimer’s programme transferring to the US giant, the Elan message boards were talking of selling the family silver.
The chatter does not worry Martin. Since coming in to take over the company in 2003, his expertise and appetite for the job have been questioned continually.
Talking to him in his offices against the backdrop of the emerging new Lansdowne Road stadium in the Grand Canal Dock area of Dublin, he is more interested in looking forward at what the company can achieve. But he is still very satisfied with the Johnson Johnson agreement – one that would certainly draw favourable comment from his former employers in Merrill Lynch.
“We own half of a new company with JJ and, on the other side will ultimately be Pfizer. From a shareholder point of view, we say that if the immunotherapeutic assets work, the upside is so big that the return to our shareholders will be very significant.
“Elan has 25 per cent of the return on this technology, with the largest pharmaceutical company in the world marketing it and the largest healthcare company. I say that’s a great outcome.
“We didn’t give it away but we took the risk down drastically for us. This drug will either be the largest asset in our portfolio or it won’t work, there is no in between.”
In light of the financial commitments that continued development of the AIP programme would have involved, Martin feels holding on to its previous control was unsustainable.“This asset is too big for any one company – even Pfizer or JJ. It will take the full resources, if it is successful, of both Pfizer and JJ to optimise this asset around the world.
Among other things, the cash freed up by the deal will allow the company to concentrate on areas that were struggling for attention. Apart from the Alzheimer’s pipeline that Martin intends to stock up in the next year, there is also Elan’s drug technology business based in Athlone.
“EDT is a critical piece of the company. We would like to invest some more into EDT,” he says.
He defends the decision last year to look at “monetising” the division. “The whole rationale of monetising EDT was to give them acces to capital. That is still an issue. We can do a little bit incrementally but we cannot fundamentally shift the business unless we have more cash.”
That could mean seeking outside partners or possibly even a partial IPO. Martin is open to options but he insists that Elan wants to retain control of the business.
“EDT is a long-term part of Elan; the question is can we give them acces to capital on their own and, if we can do that in a way we retain control but they invest in it, we will do that. We want to grow it, to add products and add jobs.”
Of course, the jewel in the crown of Elan’s current, commercialised portfolio is multiple sclerosis therapy Tysabri.
Martin believes the drug is a winner now and into the future if for no other reason than its efficacy means there will always be demand from patients – two-thirds of whom, he says, see their condition worsening depsite other treatments.
“The challenge with Tysabri is now understanding and managing PML [progressive multifocal leukoencephalopathy].” The brain disease, initially thought fatal in most cases saw the drug pulled from shelves just months after its launch only forit to return after further medical investigation and hearings by the regulator, the Food and Drug Administration that featured strong patient advocacy.
He believes the market in Europe for Tysabri is bigger than previously beleived. Sales growth here has been steronger than the US in the past year, in part because of the lack of alternative treatments. However, he says growth in the US is starting to pick up, a view reinforced by strong sales figures published yesterday by Biogen Idec, its US partner in the Tysabri programme.
“The combination [of the US and European markets] is growing at a rate that we think people will find very acceptable.”
Despite the drug’s rollercoaster ride, he has no regrets about the company’s approach, especialy in withdrawing it when PML first emerged in patients.
“We did not put our patients in harm’s way which you just funadmentally cannot do. I mean our stock got killed. But I would make the same decision a thousand times in a row, it was a hard decision but it was a right decision.”
So how did a New Jersey bank executive with some distant Irish roots end up heading a company like Elan.
Like many things in business, it was more an element of chance and timing than any preplanned strategy.
Martin had spent his whole working life – nearly 22 years – with Merrill Lynch. Having started as a bond trader, he ended up working in areas as diverse as sales and information technology, always with the US group.
Along the way, he got to manage business that came within the remit of Merrill and, ultimately, he decided that this was a path he would prefer to pursue rather than continuing to build on his reputation within the bank as a troubleshooter who could fix problems within units of a business.
It was his luck – or not, some might say – to run into a consultant he knew from his time at Merrill but who had also been engaged by Elan as it struggled to emerge from the turmoil surrounding the company over a failed Alzheimer’s trial and accounting issues in the wake of the Enron scandal.
“It was a big decision. I had absolutely no knowledge of the industry but it was a chance to use the skills I had picked up in organising other businesses and to see if I could take on a challenge like this.”
The consultant through whom he had heard of the job assurred him he couldn’t go wrong. In many quarters, the company was not expected to survive. If he failed to resuce it, he would attract little blame. But succeed and the upside was considerable.
“I consider I am very lucky after workling all my life in one business to get a chance like this to make a go at another,” says Martin.
So is it time now to move on as some would suggest?
“Everyone is entitled to their opinion but my opinion is I’m not finished doing what we need to do,” says Martin.
“It’s hard being a CEO and I think you have got to stay within yourself. I’m not the scientist or the clinician. What we have is world class differentiated science. What it has to do with me is that you need a business platform to let them [the scientisits] succeed.
“We are not finished doing what we have intended to do. When I feel we are finished I will move on.
‘‘I am not interested in hanging around for the title or the profile. But I don’t think that is today and I don’t think it is any time in the near future. there are too many other things to do.”
ON THE RECORD
Name: Kelly Martin.
Age: 50.
Position: chief executive of listed Irish biotech group Elan.
Family: married to Elizabeth with five children, aged between nine and 18.
Career: Graduated from Princeton University with a degree in politics and economics before joining Merrill Lynch on an intern programme.
He spent more than 20 years with the US investment bank, earning a reputation as a troubleshooter and quick learner in areas as diverse as fixed income, equity sales and information technology.
In 2003, he left Merrill and, shortly after, took over as chief executive of Elan.
Something that won’t surprise: He finds managing Elan a full-time job.
Something that might surprise: When he does get a break, he enjoys freshwater fishing or the occasional ski break.
Antwort auf Beitrag Nr.: 37.592.317 von Birgit.Tersteegen am 17.07.09 12:26:12Immer cool bleiben, Birgit
irgendwann werden wir alle reich.
irgendwann werden wir alle reich.
Antwort auf Beitrag Nr.: 37.595.185 von surga am 17.07.09 17:19:58....ja!-auf alle Fälle an ERFAHRUNG....
Antwort auf Beitrag Nr.: 37.595.226 von Birgit.Tersteegen am 17.07.09 17:24:52Wie phonen dann in nächsten Tagen. Ich bin seit gestern wieder im Lande
Es war sehr schöne Zeit dan unten
Am liebsten würde ich gern dort bleiben, es geht im Moment leider noch nicht
Es war sehr schöne Zeit dan unten
Am liebsten würde ich gern dort bleiben, es geht im Moment leider noch nicht
Antwort auf Beitrag Nr.: 37.595.302 von surga am 17.07.09 17:34:15Bin evtl eine Woche im Bootshaus----dann ab 27.7 wieder hier..lieben Gruss! Birgit
Viel Spaß Birgit!!
Juhhhu. (Bezieht sich auf dem Beitrag unten)
All the worry about slowing adoption of Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) multiple sclerosis drug Tysabri seems to have been for naught. Despite increasing numbers of patients on Tysabri coming down with progressive multifocal leukoencephalopathy (PML) -- a life-threatening brain infection -- sales looked pretty good last quarter.
Not only were worldwide sales of Tysabri up 27% to $254 million, but patients are moving onto the drug at a quickening pace. In the first quarter of the year, the companies added about 170 patients per week, while in the second quarter that number increased to more than 260 per week.
There's some concern Biogen and Elan might lose revenue if patients start taking drug holidays to remove the Tysabri from their bodies. (Tysabri inhibits the immune system, which is believed to allow the brain infection.) Fortunately, there doesn't seem to be much of that going on, with revenue per patient holding relatively steady.
Juhhhu. (Bezieht sich auf dem Beitrag unten)All the worry about slowing adoption of Biogen Idec (Nasdaq: BIIB) and Elan's (NYSE: ELN) multiple sclerosis drug Tysabri seems to have been for naught. Despite increasing numbers of patients on Tysabri coming down with progressive multifocal leukoencephalopathy (PML) -- a life-threatening brain infection -- sales looked pretty good last quarter.
Not only were worldwide sales of Tysabri up 27% to $254 million, but patients are moving onto the drug at a quickening pace. In the first quarter of the year, the companies added about 170 patients per week, while in the second quarter that number increased to more than 260 per week.
There's some concern Biogen and Elan might lose revenue if patients start taking drug holidays to remove the Tysabri from their bodies. (Tysabri inhibits the immune system, which is believed to allow the brain infection.) Fortunately, there doesn't seem to be much of that going on, with revenue per patient holding relatively steady.
RNS Number : 9117V
Elan Corporation PLC
17 July 2009
Directorate Change
Elan Corporation, plc announces the resignation of Mr. Jeff Shames from the board of directors with immediate effect.
-Ends -
http://www.investegate.co.uk/Article.aspx?id=200907171758079…
Elan Corporation PLC
17 July 2009
Directorate Change
Elan Corporation, plc announces the resignation of Mr. Jeff Shames from the board of directors with immediate effect.
-Ends -
http://www.investegate.co.uk/Article.aspx?id=200907171758079…
UBS - Updating numbers – Upgrading to Buy
�� Tysabri accelerating enrolment rate – updating numbers
Biogen IDEC reported Tysabri numbers with US$125m and US$129m in sales in
the US and the RoW, respectively. Patients under commercial therapy were 22,000
in the US and 20,700 in the RoW. This Tysabri Q209 update suggests (1) a 3%
increase in treatment costs over Q109 in the US, flat in the RoW; (2) a 100%
increase in monthly enrolment rate in the US over Q109, suggesting that
physicians are getting more comfortable with cases of PML.
�� Revised Tysabri model suggests weaker short-term sales / higher long-term
We revise our Tysabri model by increasing the number of patients under therapy
while reducing average cost by patient. This yields us to reduce US Tysabri sales
by 9-18% in 2009-11E but increase by 3-9% in 2012-2013E. We have increased
our probability of Tysabri achieving our lowered sales from 75% to 100%
�� De-risked balance sheet increases confidence in long-term outlook
Following the deal signed with JNJ & the US$1 billion upfront payment, we view
Elan as a much more sustainable company. We wait for the deal to close before
adjusting our numbers but show a pro-forma P&L in the body of this note.
�� Valuation – Upgrading to Buy – still expect significant volatility
We value Elan using a probability weighted SOTP DCF-based model with a 10.5%
WACC. This model yields our unchanged €6 price target. With c.15% upside
potential from current price, we upgrade our recommendation to Buy (from
Neutral), although we still expect significant volatility in the share price.
http://www.investorvillage.com/smbd.asp?mb=160&mn=369264&pt=…" target="_blank" rel="nofollow ugc noopener">
http://www.investorvillage.com/smbd.asp?mb=160&mn=369264&pt=…
�� Tysabri accelerating enrolment rate – updating numbers
Biogen IDEC reported Tysabri numbers with US$125m and US$129m in sales in
the US and the RoW, respectively. Patients under commercial therapy were 22,000
in the US and 20,700 in the RoW. This Tysabri Q209 update suggests (1) a 3%
increase in treatment costs over Q109 in the US, flat in the RoW; (2) a 100%
increase in monthly enrolment rate in the US over Q109, suggesting that
physicians are getting more comfortable with cases of PML.
�� Revised Tysabri model suggests weaker short-term sales / higher long-term
We revise our Tysabri model by increasing the number of patients under therapy
while reducing average cost by patient. This yields us to reduce US Tysabri sales
by 9-18% in 2009-11E but increase by 3-9% in 2012-2013E. We have increased
our probability of Tysabri achieving our lowered sales from 75% to 100%
�� De-risked balance sheet increases confidence in long-term outlook
Following the deal signed with JNJ & the US$1 billion upfront payment, we view
Elan as a much more sustainable company. We wait for the deal to close before
adjusting our numbers but show a pro-forma P&L in the body of this note.
�� Valuation – Upgrading to Buy – still expect significant volatility
We value Elan using a probability weighted SOTP DCF-based model with a 10.5%
WACC. This model yields our unchanged €6 price target. With c.15% upside
potential from current price, we upgrade our recommendation to Buy (from
Neutral), although we still expect significant volatility in the share price.
http://www.investorvillage.com/smbd.asp?mb=160&mn=369264&pt=…" target="_blank" rel="nofollow ugc noopener">
http://www.investorvillage.com/smbd.asp?mb=160&mn=369264&pt=…
Antwort auf Beitrag Nr.: 37.607.257 von bernie55 am 20.07.09 16:10:39ein UPGRADE und steigende Kurse?
(ich bekomme Angst)
(ich bekomme Angst)
Antwort auf Beitrag Nr.: 37.607.423 von Poppholz am 20.07.09 16:25:52.....times they `re changing...
Antwort auf Beitrag Nr.: 37.607.423 von Poppholz am 20.07.09 16:25:52ein UPGRADE und steigende Kurse?
(ich bekomme Angst)
...und dann noch vor der CC von ELAN !!!!!!
(ich bekomme Angst)
...und dann noch vor der CC von ELAN !!!!!!
DUBLIN--(BUSINESS WIRE)--
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Tuesday, July 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan's second quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public.
This event can be accessed by visiting Elan's website at www.elan.com and clicking on the Investor Relations section, then on the event icon. Following the live webcast, an archived version of the call will be available at the same URL.
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Tuesday, July 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan's second quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public.
This event can be accessed by visiting Elan's website at www.elan.com and clicking on the Investor Relations section, then on the event icon. Following the live webcast, an archived version of the call will be available at the same URL.
Does Tysabri Hold the Key to a JNJ Purchase of Biogen Idec?
Could Johnson & Johnson’s Elan deal be a prescription for a JNJ takeover of Biogen Idec?
By Jeanne Whalen and Dana Cimilluca
On the surface, JNJ agreed this month to buy 18.4% of Elan, an Irish biotechnology company, to get access to Elan’s experimental drugs for Alzheimer’s disease. But Shane Cooke, Elan’s chief financial officer, tells Deal Journal that JNJ and Elan also have “arrangements in place” relating to Biogen and the multiple-sclerosis drug it markets with Elan.
tysabri_D_20090720143026.jpgBloomberg News
Tysabri, a multiple-sclerosis drug made by Biogen Idec and Elan.
When it comes to the drug, Tysabri, Elan and Biogen have a deal: if either company is approached by a potential acquirer, the other party in the Tysabri partnership has the right to buy the targeted company’s share of Tysabri. So, if a large pharmaceutical company wanted to buy control of Biogen, Elan would have the right to buy Biogen’s piece of Tysabri.
Cooke says Elan and JNJ have “certainly had discussions” about Tysabri. “There are arrangements in place that would, could see us working together if there was a change in control to occur” at Biogen, he said in a telephone interview. “We might end up working together to acquire the other half of Tysabri if the circumstances were right,” he said.
Cooke declined to comment further. Elan and JNJ didn’t appear to disclose anything about Tysabri when they announced that JNJ was buying a stake in Elan.
If JNJ does have a lever of control over Tysabri–one of Biogen’s most valuable products–it might make another company think twice about trying to buy Biogen. JNJ has much deeper pockets than Elan does alone, making it more able to fund a buyout of Tysabri.
All of this could signal that JNJ itself has an interest in buying Biogen. There are no indications that talks are underway. Biogen did put itself on the block in late 2007. A JNJ spokesman declined to comment on any interest JNJ may have in Biogen. He also declined to comment on Mr. Cooke’s remarks.
Biogen’s 2007 sale process failed, but the company’s minority shareholder, Carl Icahn, just won two seats on Biogen’s board and has been lobbying the company to either break itself up or sell itself to a large pharmaceutical company.
A Biogen spokeswoman said JNJ’s purchase of a stake in Elan doesn’t change the terms of the Tysabri agreement Biogen has with Elan. She declined to comment further.
http://blogs.wsj.com/deals/2009/07/20/does-tysabri-hold-the-…
Could Johnson & Johnson’s Elan deal be a prescription for a JNJ takeover of Biogen Idec?
By Jeanne Whalen and Dana Cimilluca
On the surface, JNJ agreed this month to buy 18.4% of Elan, an Irish biotechnology company, to get access to Elan’s experimental drugs for Alzheimer’s disease. But Shane Cooke, Elan’s chief financial officer, tells Deal Journal that JNJ and Elan also have “arrangements in place” relating to Biogen and the multiple-sclerosis drug it markets with Elan.
tysabri_D_20090720143026.jpgBloomberg News
Tysabri, a multiple-sclerosis drug made by Biogen Idec and Elan.
When it comes to the drug, Tysabri, Elan and Biogen have a deal: if either company is approached by a potential acquirer, the other party in the Tysabri partnership has the right to buy the targeted company’s share of Tysabri. So, if a large pharmaceutical company wanted to buy control of Biogen, Elan would have the right to buy Biogen’s piece of Tysabri.
Cooke says Elan and JNJ have “certainly had discussions” about Tysabri. “There are arrangements in place that would, could see us working together if there was a change in control to occur” at Biogen, he said in a telephone interview. “We might end up working together to acquire the other half of Tysabri if the circumstances were right,” he said.
Cooke declined to comment further. Elan and JNJ didn’t appear to disclose anything about Tysabri when they announced that JNJ was buying a stake in Elan.
If JNJ does have a lever of control over Tysabri–one of Biogen’s most valuable products–it might make another company think twice about trying to buy Biogen. JNJ has much deeper pockets than Elan does alone, making it more able to fund a buyout of Tysabri.
All of this could signal that JNJ itself has an interest in buying Biogen. There are no indications that talks are underway. Biogen did put itself on the block in late 2007. A JNJ spokesman declined to comment on any interest JNJ may have in Biogen. He also declined to comment on Mr. Cooke’s remarks.
Biogen’s 2007 sale process failed, but the company’s minority shareholder, Carl Icahn, just won two seats on Biogen’s board and has been lobbying the company to either break itself up or sell itself to a large pharmaceutical company.
A Biogen spokeswoman said JNJ’s purchase of a stake in Elan doesn’t change the terms of the Tysabri agreement Biogen has with Elan. She declined to comment further.
http://blogs.wsj.com/deals/2009/07/20/does-tysabri-hold-the-…
Antwort auf Beitrag Nr.: 37.611.079 von surga am 21.07.09 07:05:27Grüß dich, surga....
..werde die heutige CC nicht verfolgen können....
....vielleicht du oder Poppie....
...Birgit kann ja nicht.... ist ja mit ihrem U Boot unterwegs.....
.....ansonsten später mal Kurzinfos zur CC....
LG
bernie55
..werde die heutige CC nicht verfolgen können....
....vielleicht du oder Poppie....
...Birgit kann ja nicht.... ist ja mit ihrem U Boot unterwegs.....
.....ansonsten später mal Kurzinfos zur CC....
LG
bernie55
...uuupppss...gerade gekommen.....auf die schnelle reingestellt......bis später..
Elan Reports Second Quarter 2009 Financial Results
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc today reported its second quarter 2009 financial results.
Elan CEO Kelly Martin said, “During the first six months of 2009, we grew revenues, added an additional approach to Alzheimer’s disease and successfully completed our strategic review with the announcement of a transformative transaction with Johnson & Johnson. Our focus will remain squarely on a disciplined and continuous investment in science and advancing our diversified clinical portfolio to patients.�
Commenting on the second quarter results, Elan executive vice president and chief financial officer, Shane Cooke said that the company results reflected the strong performance of both the Biopharmaceuticals business and Elan Drug Technologies (EDT). Revenues were up by 14%, led by a 30% increase in revenues from Tysabri and a 10% increase in revenues from EDT. The increase in revenues combined with lower SG&A costs led to the company reporting a 54% reduction in operating losses and almost $20 million in positive Adjusted EBITDA for the quarter.
“We are particularly pleased to see that the initiatives implemented earlier in the year resulted in an acceleration of the growth in Tysabri, with a 55% increase in the number of net patients added compared to the first quarter 2009.�
Mr. Cooke added, “We were also delighted to announce earlier this month that we had entered a definitive agreement with Johnson & Johnson which marks the end of the strategic review that had started in January. The completion of this transaction will give us financial resources and access to commercial infrastructure which will enable the acceleration of the development and commercialization of our pipeline and product portfolio, while allowing our existing shareholders to continue to participate in the resulting potential long term value creation. Consistent with our stated objectives, it will also de-risk our balance sheet, reduce our future costs and accelerate our return to profitability. For the full year 2009, we remain on target to record double-digit revenue growth and to be profitable on an Adjusted EBITDA basis.�
http://finance.yahoo.com/news/Elan-Reports-Second-Quarter-bw…
Finanzen.net
Elan buy
von Quelle: Finanzen.net / Aktiencheck.de AG
Montag 20. Juli 2009, 16:43 Uhr
Rating-Update:
Zürich (aktiencheck.de AG) - Die Analysten der UBS (Virt-X: UBSN.VX - Nachrichten) stufen die Aktie von Elan (Dublin: DRX.IR - Nachrichten) (ISIN IE0003072950/ WKN 903801) von "neutral" auf "buy" herauf. (20.07.2009/ac/a/u) Analyse-Datum: 20.07.2009
Elan buy
von Quelle: Finanzen.net / Aktiencheck.de AG
Montag 20. Juli 2009, 16:43 Uhr
Rating-Update:
Zürich (aktiencheck.de AG) - Die Analysten der UBS (Virt-X: UBSN.VX - Nachrichten) stufen die Aktie von Elan (Dublin: DRX.IR - Nachrichten) (ISIN IE0003072950/ WKN 903801) von "neutral" auf "buy" herauf. (20.07.2009/ac/a/u) Analyse-Datum: 20.07.2009
Antwort auf Beitrag Nr.: 37.611.283 von bernie55 am 21.07.09 08:24:35positives Ergebnis für das zweite Quartal, dass "so groß" ist, dass auch die Zahlen für die ersten sechs Monate in den postiven Bereich rutschen.
Die Einnahmen sind gestiegen und die Kosten wurden reduziert. So weit so gut.
Weiß jemand von Euch, was mit "Other net cahrges" gemeint ist? Hier sind für die ersten sechs Monate 27,6 mio ausgewiesen. Im Vergleich zu den ersten sechs Monaten von 2008, wo diese nur 5,6 mio ausgemacht haben ist die Steigerung schon enorm.
Danke
Die Einnahmen sind gestiegen und die Kosten wurden reduziert. So weit so gut.
Weiß jemand von Euch, was mit "Other net cahrges" gemeint ist? Hier sind für die ersten sechs Monate 27,6 mio ausgewiesen. Im Vergleich zu den ersten sechs Monaten von 2008, wo diese nur 5,6 mio ausgemacht haben ist die Steigerung schon enorm.
Danke
Antwort auf Beitrag Nr.: 37.611.735 von Poppholz am 21.07.09 09:39:48schon gefunden, hätte erst einmal bis zum Schluss lesen sollen.
finanzen.net
Elan kann Verlust im zweiten Quartal reduzieren, Planungen bestätigt
Dienstag 21. Juli 2009, 09:35 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) konnte seinen Verlust im zweiten Quartal verringern.
Demnach lagen die Umsatzerlöse im Berichtszeitraum mit 280,9 Mio. Dollar über dem Vorjahreswert von 245,6 Mio. Dollar, teilte der Konzern am Dienstag mit. Unter dem Strich wurde ein Nettoverlust von 68,2 Mio. Dollar bzw. 14 Cents je Aktie verbucht, nach einem Nettoverlust von 71,5 Mio. Dollar bzw. 15 Cents je Aktie im Vorjahreszeitraum. Deutliche Zuwachsraten konnte Elan (Dublin: DRX.IR - Nachrichten)beim Multiple Sklerose-Medikament Tsybari erzielen, welches die Umsatzerlöse gegenüber dem Vorjahreswert um 30 Prozent steigern konnte.
Für das Gesamtjahr peilt Elan weiterhin ein zweistelliges Umsatzplus sowie ein positives EBITDA vor Einmaleffekten an. Im zweiten Quartal hat der Pharmakonzern ein positives EBITDA vor Einmaleffekten von 19, Mio. Dollar erzielt, nachdem man im Vorjahreszeitraum auf vergleichbarer Basis ein negatives EBITDA von 6,2 Mio. Dollar verbucht hatte.
Die Aktie von Elan notierte zuletzt an der Heimatbörse bei 5,63 Euro. (21.07.2009/ac/n/a)
http://de.biz.yahoo.com/21072009/85/elan-verlust-quartal-red…
Elan kann Verlust im zweiten Quartal reduzieren, Planungen bestätigt
Dienstag 21. Juli 2009, 09:35 Uhr
Dublin (aktiencheck.de AG) - Der irische Pharmakonzern Elan Corp. plc (ISIN IE0003072950/ WKN 903801) konnte seinen Verlust im zweiten Quartal verringern.
Demnach lagen die Umsatzerlöse im Berichtszeitraum mit 280,9 Mio. Dollar über dem Vorjahreswert von 245,6 Mio. Dollar, teilte der Konzern am Dienstag mit. Unter dem Strich wurde ein Nettoverlust von 68,2 Mio. Dollar bzw. 14 Cents je Aktie verbucht, nach einem Nettoverlust von 71,5 Mio. Dollar bzw. 15 Cents je Aktie im Vorjahreszeitraum. Deutliche Zuwachsraten konnte Elan (Dublin: DRX.IR - Nachrichten)beim Multiple Sklerose-Medikament Tsybari erzielen, welches die Umsatzerlöse gegenüber dem Vorjahreswert um 30 Prozent steigern konnte.
Für das Gesamtjahr peilt Elan weiterhin ein zweistelliges Umsatzplus sowie ein positives EBITDA vor Einmaleffekten an. Im zweiten Quartal hat der Pharmakonzern ein positives EBITDA vor Einmaleffekten von 19, Mio. Dollar erzielt, nachdem man im Vorjahreszeitraum auf vergleichbarer Basis ein negatives EBITDA von 6,2 Mio. Dollar verbucht hatte.
Die Aktie von Elan notierte zuletzt an der Heimatbörse bei 5,63 Euro. (21.07.2009/ac/n/a)
http://de.biz.yahoo.com/21072009/85/elan-verlust-quartal-red…
jetzt haben wir doch wieder das gewohnte Bild:
Zwei Kaufempfehlungen und gute Quartalszahlen ...
... und der Kurs geht runter.
Zwei Kaufempfehlungen und gute Quartalszahlen ...
... und der Kurs geht runter.
Was soll denn der Scheiß!!
Das ist doch nicht zu erstehen.
Die besten Nachrichten und der Kurs geht nach unten.
Kann das jemand erklären?
Schero
Das ist doch nicht zu erstehen.
Die besten Nachrichten und der Kurs geht nach unten.
Kann das jemand erklären?
Schero
Pharmaceutical giant Johnson & Johnson has cut a deal that gives it significant influence over the future of biotech firm Biogen Idec Inc., a partner of both companies said Tuesday.
As part of an agreement earlier this month to buy 18.4% of Irish biotech firm Elan Corp., J&J also acquired the chance to snatch away one of Biogen's most valuable drugs in the event of a change of control at Biogen, Elan officials said. Neither Elan nor J&J disclosed ...
Was soll denn noch geschehen. J&J wird jetzt auch langsam die Führung übernehmen.
As part of an agreement earlier this month to buy 18.4% of Irish biotech firm Elan Corp., J&J also acquired the chance to snatch away one of Biogen's most valuable drugs in the event of a change of control at Biogen, Elan officials said. Neither Elan nor J&J disclosed ...
Was soll denn noch geschehen. J&J wird jetzt auch langsam die Führung übernehmen.
Elan gives J&J potential option to buy Biogen MS stake
Tue Jul 21, 2009 12:29pm EDT
* J&J can finance Elan purchase of 50 pct Tysabri stake
* Deal contingent on change of control at Biogen
* J&J and Elan would enter fresh 50-50 collaboration
* Elan shares up 1.2 pct
By Padraic Halpin
DUBLIN, July 21 (Reuters) - Ireland's Elan (ELN.I) said on Tuesday it gave U.S. healthcare conglomerate Johnson & Johnson (JNJ.N) the potential option to acquire Biogen Idec Inc's (BIIB.O) 50 percent stake in multiple sclerosis drug Tysabri.
The potential option is part of a recent deal in which J&J agreed to pay $1 billion for an 18.4 percent stake in Elan and $500 million for a majority stake in its pipeline of experimental Alzheimer's disease drugs.
Elan and Biogen, which is based in Cambridge, Massachusetts, have a 50-50 partnership under which each has the right to acquire full control of Tysabri should there be a change of control at either company.
But in the event of a change of control at Biogen, J&J can now choose to finance a possible Elan purchase of Biogen's rights to Tysabri, which is on track to make $1 billion a year.
"We have entered into an arrangement with Johnson & Johnson that would allow them to finance us to purchase the other 50 percent of Tysabri in the event that there was a change of control at Biogen," Elan Chief Financial Officer Shane Cooke told a news conference. "If J&J were to finance us to do that, then we would enter into a collaboration with J&J on a 50-50 basis," he said, adding that its change-of-control agreement with Biogen was unchanged.
GOOD PARTNER
Analysts said the arrangement, while hypothetical, gives Elan more control over the fate of Tysabri and takes an element of risk out of the partnership with Biogen.
"My initial reaction was 'what are they doing here' but it is really just covering their position," Ian Hunter, an analyst at Goodbody Stockbrokers said.
"They now know who their potential partner could be if anything happened at Biogen Idec. There's no uncertainty."
Dublin-based Elan confirmed the new agreement after Reuters learned of it from sources with knowledge of the $1.5 billion deal.[ID:nN20149879].
Elan, which beat expectations with a 14 percent rise in second-quarter revenues, said around 43,300 patients worldwide were on Tysabri therapy at the end of June.
Biogen and Elan originally predicted 100,000 patients would be taking Tysabri by the end of 2010. While they still expect to reach that figure, which would generate $2 billion to $3 billion a year, they don't expect to reach it within that timeframe.
"J&J would be a pretty good partner in the event that all these things triggered that particular situation," said Jack Gorman, an analyst at Davy brokerage.
"J&J would bring plenty of commercial clout, autoimmune and infusion expertise and, given they're a big pharma with biotech capability, presumably they'd also have manufacturing capability."
Elan shares were down 2.3 percent at 5.58 euros by 1545 GMT after jumping 9 percent on Monday following media reports that it may invest in a biologics operation in Ireland.
http://www.reuters.com/article/marketsNews/idINLL31379520090…
Tue Jul 21, 2009 12:29pm EDT
* J&J can finance Elan purchase of 50 pct Tysabri stake
* Deal contingent on change of control at Biogen
* J&J and Elan would enter fresh 50-50 collaboration
* Elan shares up 1.2 pct
By Padraic Halpin
DUBLIN, July 21 (Reuters) - Ireland's Elan (ELN.I) said on Tuesday it gave U.S. healthcare conglomerate Johnson & Johnson (JNJ.N) the potential option to acquire Biogen Idec Inc's (BIIB.O) 50 percent stake in multiple sclerosis drug Tysabri.
The potential option is part of a recent deal in which J&J agreed to pay $1 billion for an 18.4 percent stake in Elan and $500 million for a majority stake in its pipeline of experimental Alzheimer's disease drugs.
Elan and Biogen, which is based in Cambridge, Massachusetts, have a 50-50 partnership under which each has the right to acquire full control of Tysabri should there be a change of control at either company.
But in the event of a change of control at Biogen, J&J can now choose to finance a possible Elan purchase of Biogen's rights to Tysabri, which is on track to make $1 billion a year.
"We have entered into an arrangement with Johnson & Johnson that would allow them to finance us to purchase the other 50 percent of Tysabri in the event that there was a change of control at Biogen," Elan Chief Financial Officer Shane Cooke told a news conference. "If J&J were to finance us to do that, then we would enter into a collaboration with J&J on a 50-50 basis," he said, adding that its change-of-control agreement with Biogen was unchanged.
GOOD PARTNER
Analysts said the arrangement, while hypothetical, gives Elan more control over the fate of Tysabri and takes an element of risk out of the partnership with Biogen.
"My initial reaction was 'what are they doing here' but it is really just covering their position," Ian Hunter, an analyst at Goodbody Stockbrokers said.
"They now know who their potential partner could be if anything happened at Biogen Idec. There's no uncertainty."
Dublin-based Elan confirmed the new agreement after Reuters learned of it from sources with knowledge of the $1.5 billion deal.[ID:nN20149879].
Elan, which beat expectations with a 14 percent rise in second-quarter revenues, said around 43,300 patients worldwide were on Tysabri therapy at the end of June.
Biogen and Elan originally predicted 100,000 patients would be taking Tysabri by the end of 2010. While they still expect to reach that figure, which would generate $2 billion to $3 billion a year, they don't expect to reach it within that timeframe.
"J&J would be a pretty good partner in the event that all these things triggered that particular situation," said Jack Gorman, an analyst at Davy brokerage.
"J&J would bring plenty of commercial clout, autoimmune and infusion expertise and, given they're a big pharma with biotech capability, presumably they'd also have manufacturing capability."
Elan shares were down 2.3 percent at 5.58 euros by 1545 GMT after jumping 9 percent on Monday following media reports that it may invest in a biologics operation in Ireland.
http://www.reuters.com/article/marketsNews/idINLL31379520090…
Antwort auf Beitrag Nr.: 37.621.121 von bernie55 am 22.07.09 11:32:23So wie ich es nun verstanden habe, ist diese mögliche Option somit Bestandteil des Deals zwischen J&J und ELAN...
....das heißt also , dass im Falle einer Übernahme von BIIB , nun die 50% Anteile der TY Rechte von BIIB finanziell von J&J übernommen werden könnten....
....das heißt also , dass im Falle einer Übernahme von BIIB , nun die 50% Anteile der TY Rechte von BIIB finanziell von J&J übernommen werden könnten....
Davy
Elan Corp (USc)
ELN US
After turbulent year, Elan begins to look outward again
Jack Gorman
Closing Price $7.69 Rating: Outperform 30/06/09
Once the mechanics of another quarterly result were out of the way, our further discussions with the Elan management team allowed us to gain additional insights on how business strategy is being shaped after what has been a very turbulent year.
Although understating the depth of discussions about the many issues discussed, we can perhaps highlight three below. Several key development (AD) and commercial (Tysabri) challenges still face Elan. However, with a more stable financial base and the addition of J&J as a partner, we believe the risk/reward profile is much enhanced.
Tysabri's risk profile: Elan/BIIB have done an excellent job to re-emphasise Tysabri's efficacy message in the last six months to the extent that net additions have re-accelerated despite new PML cases. The next step is to better characterise the risk profile of the drug, in particular the risk factors associated with PML.
If this risk can be prospectively identified, patients and physicians will be better able to choose therapies. Successfully done, Tysabri can ultimately migrate towards the market of first-line therapies – potentially leaving behind the newer oral MS therapies that may face significant risk/benefit issues.
The importance of J&J: Management is naturally delighted to have secured a partner of such commercial and scientific standing. We know also of the terms of J&J's agreement. However, it sounds like J&J could potentially become a much deeper part of the Elan story over time – plainly as a financing vehicle for a Tysabri stake but also as Elan's access to diagnostic, biomarker, biomanufacturing and emerging market expertise.
Investment opportunities: Elan's neurology research expertise and its clinical know-how could help the company to become a preferred partner in licencing and collaborations. The latest Pharmatrophix deal on AD technology is a good example of this. Management has identified a sweet spot in late pre-clinical/early clinical where many candidates are available that may be attractive to Elan. This could extend to many neurology niches. Investment opportunities are also readily available for EDT, and we would expect that division to add to its pipeline over the course of 2009/2010.
http://www.investorvillage.com/smbd.asp?mb=160&mn=370070&pt=…
Elan Corp (USc)
ELN US
After turbulent year, Elan begins to look outward again
Jack Gorman
Closing Price $7.69 Rating: Outperform 30/06/09
Once the mechanics of another quarterly result were out of the way, our further discussions with the Elan management team allowed us to gain additional insights on how business strategy is being shaped after what has been a very turbulent year.
Although understating the depth of discussions about the many issues discussed, we can perhaps highlight three below. Several key development (AD) and commercial (Tysabri) challenges still face Elan. However, with a more stable financial base and the addition of J&J as a partner, we believe the risk/reward profile is much enhanced.
Tysabri's risk profile: Elan/BIIB have done an excellent job to re-emphasise Tysabri's efficacy message in the last six months to the extent that net additions have re-accelerated despite new PML cases. The next step is to better characterise the risk profile of the drug, in particular the risk factors associated with PML.
If this risk can be prospectively identified, patients and physicians will be better able to choose therapies. Successfully done, Tysabri can ultimately migrate towards the market of first-line therapies – potentially leaving behind the newer oral MS therapies that may face significant risk/benefit issues.
The importance of J&J: Management is naturally delighted to have secured a partner of such commercial and scientific standing. We know also of the terms of J&J's agreement. However, it sounds like J&J could potentially become a much deeper part of the Elan story over time – plainly as a financing vehicle for a Tysabri stake but also as Elan's access to diagnostic, biomarker, biomanufacturing and emerging market expertise.
Investment opportunities: Elan's neurology research expertise and its clinical know-how could help the company to become a preferred partner in licencing and collaborations. The latest Pharmatrophix deal on AD technology is a good example of this. Management has identified a sweet spot in late pre-clinical/early clinical where many candidates are available that may be attractive to Elan. This could extend to many neurology niches. Investment opportunities are also readily available for EDT, and we would expect that division to add to its pipeline over the course of 2009/2010.
http://www.investorvillage.com/smbd.asp?mb=160&mn=370070&pt=…
Antwort auf Beitrag Nr.: 37.621.789 von bernie55 am 22.07.09 12:42:07wie wir alle wissen ist der Preis momentan ein "schlechter Scherz".
Wenn das so weiter geht übernimmt J&J unser Baby noch vollständig (nachdem Biogen übernommen wurde) und der Kurs wird bis zur vollständigen Übernahme den Kurs von $8,- nicht überstiegen haben.
Wenn das so weiter geht übernimmt J&J unser Baby noch vollständig (nachdem Biogen übernommen wurde) und der Kurs wird bis zur vollständigen Übernahme den Kurs von $8,- nicht überstiegen haben.
Antwort auf Beitrag Nr.: 37.628.733 von Poppholz am 23.07.09 09:33:22.....na,das wollen wir aber nicht hoffen...grüsse Euch-reinkarniert-vom Fluss----laaange schlafen,Schwimmen schon vor dem Frühstück(heute im Regen),Krimi lesen,Stadtbummeln,Kochen,Kneipe + Kino......ich könnte immer urlauben....haltet die Stellung---früher ist der Kurs in meinen Urlauben meistens gestiegen...also:Haltet Euch ´ran...
Euch-reinkarniert-vom Fluss----laaange schlafen,Schwimmen schon vor dem Frühstück(heute im Regen),Krimi lesen,Stadtbummeln,Kochen,Kneipe + Kino......ich könnte immer urlauben....haltet die Stellung---früher ist der Kurs in meinen Urlauben meistens gestiegen...also:Haltet Euch ´ran...
Antwort auf Beitrag Nr.: 37.629.644 von Tebi am 23.07.09 11:05:19Erfahrungsgemäß,
wenn Du verreist, geht der Kurs hoch
Viel Spaß noch
wenn Du verreist, geht der Kurs hoch
Viel Spaß noch
Antwort auf Beitrag Nr.: 37.631.668 von surga am 23.07.09 14:39:04anscheinend ist Sie noch nicht weg:
Antwort auf Beitrag Nr.: 37.633.884 von Poppholz am 23.07.09 17:49:35
Hallo an Alle.
Ich bin sprachlos.
Biogen Id. steigt wie blöde.
Was muss noch passieren, damit der Kurs von Elan steigen kann?
Bitte um Komentare.
Schero
Ich bin sprachlos.
Biogen Id. steigt wie blöde.
Was muss noch passieren, damit der Kurs von Elan steigen kann?
Bitte um Komentare.
Schero
Bristol hat Medarex übernommen. Die Madarex ist um 90% gestiegen.
Also, Elan könnte doch jetzt wirklich um einige Punkte steigen.
Also, Elan könnte doch jetzt wirklich um einige Punkte steigen.
Antwort auf Beitrag Nr.: 37.636.567 von Schero am 23.07.09 22:40:15.....kommt noch!
Biogen reports 11th Tysabri brain infection case
Fri Jul 24, 2009 6:00pm EDT
* Biogen reports 11th case of Tysabri brain infection
* Tysabri seen as key growth driver for Biogen
* Company says won't report new cases on website
BOSTON, July 24 (Reuters) - An 11th patient taking Biogen
Idec Inc's (BIIB.O) multiple sclerosis drug Tysabri has
developed a potentially deadly brain infection since July 2006,
when it was reintroduced to the market.
The Cambridge, Massachusetts-based biotech company released
the news on its website late on Friday.
Tysabri, which Biogen sells in conjunction with Irish
drugmaker Elan Corp Plc (ELN.I), is considered critical to the
future growth of both companies.
The drug was temporarily withdrawn from the market in 2005
after it was linked with a brain infection known as progressive
multifocal leukoencephalopathy, or PML. It was brought back in
2006 with stricter safety warnings.
Biogen has recently adopted a more aggressively upbeat tone
in marketing the drug, insisting physicians are becoming more
comfortable with risk of PML.
That approach appears to be working. Sales of Tysabri
accelerated in the second quarter, rising to $254 million from
$200 million a year ago. The company said the drug is on track
to generate some $1 billion in sales this year.
Even so, some analysts believe doctors may take patients
off the drug for certain periods of time.
At the end of June, about 43,300 patients were on Tysabri,
compared with 40,000 at the end of March.
Biogen and Elan originally predicted 100,000 patients would
be taking the drug by the end of 2010. The companies still
believe they will reach that figure, but not within that time
frame.
This is the last case of PML that the company plans to
announce on its website. Biogen said on its earnings conference
call earlier this month that it would in future communicate new
cases by word of mouth to physicians and patient advocacy
groups.
http://www.reuters.com/article/marketsNews/idINN244872332009…
Fri Jul 24, 2009 6:00pm EDT
* Biogen reports 11th case of Tysabri brain infection
* Tysabri seen as key growth driver for Biogen
* Company says won't report new cases on website
BOSTON, July 24 (Reuters) - An 11th patient taking Biogen
Idec Inc's (BIIB.O) multiple sclerosis drug Tysabri has
developed a potentially deadly brain infection since July 2006,
when it was reintroduced to the market.
The Cambridge, Massachusetts-based biotech company released
the news on its website late on Friday.
Tysabri, which Biogen sells in conjunction with Irish
drugmaker Elan Corp Plc (ELN.I), is considered critical to the
future growth of both companies.
The drug was temporarily withdrawn from the market in 2005
after it was linked with a brain infection known as progressive
multifocal leukoencephalopathy, or PML. It was brought back in
2006 with stricter safety warnings.
Biogen has recently adopted a more aggressively upbeat tone
in marketing the drug, insisting physicians are becoming more
comfortable with risk of PML.
That approach appears to be working. Sales of Tysabri
accelerated in the second quarter, rising to $254 million from
$200 million a year ago. The company said the drug is on track
to generate some $1 billion in sales this year.
Even so, some analysts believe doctors may take patients
off the drug for certain periods of time.
At the end of June, about 43,300 patients were on Tysabri,
compared with 40,000 at the end of March.
Biogen and Elan originally predicted 100,000 patients would
be taking the drug by the end of 2010. The companies still
believe they will reach that figure, but not within that time
frame.
This is the last case of PML that the company plans to
announce on its website. Biogen said on its earnings conference
call earlier this month that it would in future communicate new
cases by word of mouth to physicians and patient advocacy
groups.
http://www.reuters.com/article/marketsNews/idINN244872332009…
Antwort auf Beitrag Nr.: 37.645.570 von bernie55 am 25.07.09 12:02:22Hallo Berni,
was meinst Du?
Wird der Kurs nächste Woche wieder abschmieren?
LG
Schero
was meinst Du?
Wird der Kurs nächste Woche wieder abschmieren?
LG
Schero
Antwort auf Beitrag Nr.: 37.646.196 von Schero am 25.07.09 16:36:17...nach " abschmieren " sieht es zumindest aktuell nicht aus....
After Hours: 7.71 N/A (N/A) 7:39AM ET
Pre-Market
Last: $ 7.67
Pre-Market
High: $ 7.73
Pre-Market
Volume: 9,590
Pre-Market
Low: $ 7.64
..anscheinend haben die Meldungen von PML Fällen nicht mehr die Auswirkungen von früher...
....da ist der Kurs von ELAN mal eben um 40 bis 50 % nach unten katapultiert worden.......
After Hours: 7.71 N/A (N/A) 7:39AM ET
Pre-Market
Last: $ 7.67
Pre-Market
High: $ 7.73
Pre-Market
Volume: 9,590
Pre-Market
Low: $ 7.64
..anscheinend haben die Meldungen von PML Fällen nicht mehr die Auswirkungen von früher...
....da ist der Kurs von ELAN mal eben um 40 bis 50 % nach unten katapultiert worden.......
Antwort auf Beitrag Nr.: 37.652.070 von bernie55 am 27.07.09 14:05:13Davy
Price $7.64 Rating: Outperform Issued: 30/06/09
BIIB signed off on its weekly updates with an eleventh case of PML, this time
reported in the US in respect of a patient who had taken 29 doses of Tysabri.
It is now three years since the re-launch in the US and launch in RoW of Tysabri,
and 12 months since PML cases were first confirmed in the commercial setting. Set
against the imperfect calculation of a 1/1,000 incidence that was used upon relaunch,
data so far indicate the following:
- 11 cases in a population of 56,500 who have been treated in a commercial
setting (or 1/5,136);
- 11 cases in those 30,600 patients who have received at least one year of therapy
(or 1/2781);
- 7 cases in those 10,000 patients who have received at least two years of therapy
(or 1 / 1429).
In this context, BIIB's and ELN's key focus in the short term is to better characterise
the risk profile of the drug, in particular the risk factors associated with PML. If this
risk can be prospectively identified, patients and physicians will be better able to
choose therapies. It is hoped that more definitive work in this area could be
completed by year-end (see our research note Elan - Q2 results ahead of forecast;
upgrading numbers to reflect higher Tysabri uptake, issued July 22nd for more
detail).
BIIB and ELN will continue to regularly update the regulators and medical
community on Tysabri's safety profile. More formal updates will be provided at
medical conferences and at quarterly results — the next update may be provided at
the ECTRIMS conference (September 9th-12th) or at Q3 results (end-October).
http://www.investorvillage.com/smbd.asp?mb=160&mn=371404&pt=…
Price $7.64 Rating: Outperform Issued: 30/06/09
BIIB signed off on its weekly updates with an eleventh case of PML, this time
reported in the US in respect of a patient who had taken 29 doses of Tysabri.
It is now three years since the re-launch in the US and launch in RoW of Tysabri,
and 12 months since PML cases were first confirmed in the commercial setting. Set
against the imperfect calculation of a 1/1,000 incidence that was used upon relaunch,
data so far indicate the following:
- 11 cases in a population of 56,500 who have been treated in a commercial
setting (or 1/5,136);
- 11 cases in those 30,600 patients who have received at least one year of therapy
(or 1/2781);
- 7 cases in those 10,000 patients who have received at least two years of therapy
(or 1 / 1429).
In this context, BIIB's and ELN's key focus in the short term is to better characterise
the risk profile of the drug, in particular the risk factors associated with PML. If this
risk can be prospectively identified, patients and physicians will be better able to
choose therapies. It is hoped that more definitive work in this area could be
completed by year-end (see our research note Elan - Q2 results ahead of forecast;
upgrading numbers to reflect higher Tysabri uptake, issued July 22nd for more
detail).
BIIB and ELN will continue to regularly update the regulators and medical
community on Tysabri's safety profile. More formal updates will be provided at
medical conferences and at quarterly results — the next update may be provided at
the ECTRIMS conference (September 9th-12th) or at Q3 results (end-October).
http://www.investorvillage.com/smbd.asp?mb=160&mn=371404&pt=…
..tja... aktuell 7,61 USD > -039%
..extremes Abschmieren sieht anders aus...
..extremes Abschmieren sieht anders aus...
Antwort auf Beitrag Nr.: 37.652.994 von bernie55 am 27.07.09 15:59:41Ich bin immer wieder überrascht. Wenn es nach oben gehen muss, dann geht der Wert nach unten. Wenn es eigentlich nach unten gehen muss, geht der Wert nach oben. Wie auch immer. Toll das es nach oben geht.
Antwort auf Beitrag Nr.: 37.652.070 von bernie55 am 27.07.09 14:05:13Gute News > der Kurs geht runter
Schlechte News > der Kurs steigt.
unser Baby verhält sich halt nicht immer nach den Regeln der Anderen.
Schlechte News > der Kurs steigt.
unser Baby verhält sich halt nicht immer nach den Regeln der Anderen.
mein Tipp:
Schlusskurs: $ 8,03
Schlusskurs: $ 8,03
Antwort auf Beitrag Nr.: 37.653.323 von Poppholz am 27.07.09 16:31:24ich nehme an, daß TEBI sich noch im Urlaub befindet, daher ist der Anstieg
Antwort auf Beitrag Nr.: 37.653.392 von surga am 27.07.09 16:40:27NEIN NEIN------ICH musste es ja zaubern ,weil IHR Süssen Euch NICHT genug angestrengt habt....
Surga,gibts was Neues??Lass uns mal BM´men oder telefonieren....
Surga,gibts was Neues??Lass uns mal BM´men oder telefonieren....
Antwort auf Beitrag Nr.: 37.653.313 von Poppholz am 27.07.09 16:30:47Du hast die komatösen Phasen vergessen:O....Schnuggel ist eben eine Selbsterfahrungsmethode um Geduld + Gelassenheit zu üben....tja Schero-wir wollten Dir das zu Beginn in diesem Club nicht so DIREKT sagen--es handelt sich hier nicht um ein Investment der üblichen Art....
Antwort auf Beitrag Nr.: 37.653.781 von Tebi am 27.07.09 17:27:21...es handelt sich hier nicht um ein Investment der üblichen Art....
..sondern der besonderen Art..
..diese Investment verursacht oder besser gesagt provoziert gewisse Extrasystolen = Herzschläge, die außerhalb des normalen Herzrhythmus auftreten......
....untenstehende Pfeile = besondere events bei ELAN...
..................................................... ........................................
..
..sondern der besonderen Art..
..diese Investment verursacht oder besser gesagt provoziert gewisse Extrasystolen = Herzschläge, die außerhalb des normalen Herzrhythmus auftreten......
....untenstehende Pfeile = besondere events bei ELAN........................................................ .
.........................................
Antwort auf Beitrag Nr.: 37.654.036 von bernie55 am 27.07.09 18:01:52----zudem Depression,Panickattacken,Lachanfälle,Mordgelüste----die ganze emotionale + psychosomatische Bandbreite des Lebens ist nur über den Besitz dieses Wertpapier zu erfahren....Bernie-wir sollten das therapeutisch vermarkten....
----zudem Depression,Panickattacken,Lachanfälle,Mordgelüste----die ganze emotionale + psychosomatische Bandbreite des Lebens ist nur über den Besitz dieses Wertpapier zu erfahren....Bernie-wir sollten das therapeutisch vermarkten....
Hi ELANITES und ELANIACS,
....Sommerferien ...Yepp !!!
...und dann geht es natürlich in den Urlaub...
..werde vielleicht mal ab und zu ins Board schauen....
..euch allen eine schöne Zeit..
..bis denn..
Schöne Grüße
bernie55
....Sommerferien ...Yepp !!!
...und dann geht es natürlich in den Urlaub...
..werde vielleicht mal ab und zu ins Board schauen....
..euch allen eine schöne Zeit..
..bis denn..
Schöne Grüße
bernie55
Birgit und Bernie im Urlaub.
Das werden interessante zwei Wochen.
Erholt Euch gut.
Das werden interessante zwei Wochen.
Erholt Euch gut.
Antwort auf Beitrag Nr.: 37.677.048 von Poppholz am 30.07.09 12:43:41nee,bin doch extra zum Kursheben zurück!!!!Erst im September seid Ihr mich wieder los....
Antwort auf Beitrag Nr.: 37.677.048 von Poppholz am 30.07.09 12:43:41Das werden interessante zwei Wochen
..nö.......bin ein bisschen länger weg...
...bis Ende August/Anfang September...
....und mal zur Abwechslung wieder nach NL.....
Groet
bernie55
..nö.......bin ein bisschen länger weg...
...bis Ende August/Anfang September...
....und mal zur Abwechslung wieder nach NL.....
Groet
bernie55
Antwort auf Beitrag Nr.: 37.678.940 von bernie55 am 30.07.09 15:44:19alleine die Ankündigung das Du in den Urlaub fährst bringt unser Baby nach oben:
Wenn ich jetzt auch noch schreibe, dass ich nachkaufen möchte geht der Kurs über die $8,00
Wenn ich jetzt auch noch schreibe, dass ich nachkaufen möchte geht der Kurs über die $8,00
Antwort auf Beitrag Nr.: 37.677.462 von Tebi am 30.07.09 13:24:44Hallo Birgit
••(¯`•.______________________.••(¯`•.
....HERZLICHEN GLÜCKWUNSCH.....
..•..•Ž¯)•¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯.•Ž¯)••.
¨`•.•´¨) zum Geburtstag
.`•.¸(¨`•.•´¨)viel glück und Gesundheit
.... ×`•.¸.•´× (¨`•.•´¨)mögen all deine
....(¨`•.•´¨). ×`•.¸.•´×.Wünsche
... ×`•.¸.•´in Erfüllung gehen.
.••(¯`•.______________________.••(¯`•.
................VIEL GLÜCK.............
Noogmann
••(¯`•.______________________.••(¯`•.
....HERZLICHEN GLÜCKWUNSCH.....
..•..•Ž¯)•¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯.•Ž¯)••.
¨`•.•´¨) zum Geburtstag
.`•.¸(¨`•.•´¨)viel glück und Gesundheit
.... ×`•.¸.•´× (¨`•.•´¨)mögen all deine
....(¨`•.•´¨). ×`•.¸.•´×.Wünsche
... ×`•.¸.•´in Erfüllung gehen.
.••(¯`•.______________________.••(¯`•.
................VIEL GLÜCK.............
Noogmann
NEWS
DEALTALK-Biogen silence on J&J deal may presage legal storm
Fri Jul 31, 2009 4:20pm EDT
By Toni Clarke
BOSTON, July 31 (Reuters) - There has been radio silence from biotechnology company Biogen Idec Inc (BIIB.O) since Elan Corp Plc (ELN.I) and Johnson & Johnson (JNJ.N) announced a deal that many believe rules out any potential bidder for Biogen except J&J.
But with billionaire Carl Icahn's representatives on Biogen's board, it is inconceivable that the company won't challenge the legitimacy of the deal, no doubt through the courts and no doubt soon.
"I expect they are going to litigate this until they're blue in the face," said Larry Feinberg, who runs Oracle Investment Management Inc, a $1 billion healthcare hedge fund that owns Biogen shares. "Biogen can't just sit there."
Icahn's ultimate, though not necessarily short-term, goal is to engineer a sale of Biogen, which makes the multiple sclerosis drugs Avonex and Tysabri. But the best way to get a high premium is for there to be a competitive bidding process.
J&J's recent deal with Elan -- which includes an indirect route to an option on the Irish drugmaker's side of its 50-50 partnership with Biogen in marketing Tysabri -- means it has cleverly placed itself in a position in which it could bid for Biogen with little if any competition.
History indicates that companies sold when one bidder has already established a dominant position go for less than where there is competitive bidding.
For example, when Swiss drugmaker Roche Holding AG (ROG.VX) made its offer for the 44 percent of biotechnology company Genentech that it did not already own, its majority position was enough to deter any competing bids.
Its initial offer represented a premium of 8.8 percent and its final successful offer was at a premium of 16 percent.
Compare that with what Roche had to do to acquire the independent diagnostics company Ventana Medical Systems. After its initial bid was rejected it ended up paying a premium of 72.3 percent over Ventana's share price before Roche announced its initial offer.
Now, there is nothing to stop J&J making a hostile bid for Biogen, without fear of someone topping them, and therefore picking it up relatively cheap.
"This does suggest it reduces the value of Biogen by some billions," said Samuel Isaly, managing partner at OrbiMed Advisors, which holds 2.1 million shares of Biogen, 8.8 million shares of Elan, and 2.8 million shares of J&J. "It's a muddy situation but on balance I'm less happy."
J&J has agreed to pay $1 billion for an 18.4 percent stake in debt-ridden Elan and $500 million for a majority stake in Elan's pipeline of experimental Alzheimer's disease drugs.
It also gives J&J an option to acquire a half share in Tysabri, which is on track to generate $1 billion this year. That part of the deal, however, was not disclosed and only emerged after questions from reporters.
Elan markets Tysabri in a 50-50 partnership with Biogen. Under the terms of their contract, each has the right to acquire full control of Tysabri should there be a change of control at either company.
Neither company has the right to assign the other's share of Tysabri to a third party without permission, though that permission cannot be unreasonably withheld.
DEALTALK-Biogen silence on J&J deal may presage legal storm
Fri Jul 31, 2009 4:20pm EDT
By Toni Clarke
BOSTON, July 31 (Reuters) - There has been radio silence from biotechnology company Biogen Idec Inc (BIIB.O) since Elan Corp Plc (ELN.I) and Johnson & Johnson (JNJ.N) announced a deal that many believe rules out any potential bidder for Biogen except J&J.
But with billionaire Carl Icahn's representatives on Biogen's board, it is inconceivable that the company won't challenge the legitimacy of the deal, no doubt through the courts and no doubt soon.
"I expect they are going to litigate this until they're blue in the face," said Larry Feinberg, who runs Oracle Investment Management Inc, a $1 billion healthcare hedge fund that owns Biogen shares. "Biogen can't just sit there."
Icahn's ultimate, though not necessarily short-term, goal is to engineer a sale of Biogen, which makes the multiple sclerosis drugs Avonex and Tysabri. But the best way to get a high premium is for there to be a competitive bidding process.
J&J's recent deal with Elan -- which includes an indirect route to an option on the Irish drugmaker's side of its 50-50 partnership with Biogen in marketing Tysabri -- means it has cleverly placed itself in a position in which it could bid for Biogen with little if any competition.
History indicates that companies sold when one bidder has already established a dominant position go for less than where there is competitive bidding.
For example, when Swiss drugmaker Roche Holding AG (ROG.VX) made its offer for the 44 percent of biotechnology company Genentech that it did not already own, its majority position was enough to deter any competing bids.
Its initial offer represented a premium of 8.8 percent and its final successful offer was at a premium of 16 percent.
Compare that with what Roche had to do to acquire the independent diagnostics company Ventana Medical Systems. After its initial bid was rejected it ended up paying a premium of 72.3 percent over Ventana's share price before Roche announced its initial offer.
Now, there is nothing to stop J&J making a hostile bid for Biogen, without fear of someone topping them, and therefore picking it up relatively cheap.
"This does suggest it reduces the value of Biogen by some billions," said Samuel Isaly, managing partner at OrbiMed Advisors, which holds 2.1 million shares of Biogen, 8.8 million shares of Elan, and 2.8 million shares of J&J. "It's a muddy situation but on balance I'm less happy."
J&J has agreed to pay $1 billion for an 18.4 percent stake in debt-ridden Elan and $500 million for a majority stake in Elan's pipeline of experimental Alzheimer's disease drugs.
It also gives J&J an option to acquire a half share in Tysabri, which is on track to generate $1 billion this year. That part of the deal, however, was not disclosed and only emerged after questions from reporters.
Elan markets Tysabri in a 50-50 partnership with Biogen. Under the terms of their contract, each has the right to acquire full control of Tysabri should there be a change of control at either company.
Neither company has the right to assign the other's share of Tysabri to a third party without permission, though that permission cannot be unreasonably withheld.
Antwort auf Beitrag Nr.: 37.693.044 von Tebi am 01.08.09 19:43:19Hallo Tebi,
im Mai habe ich noch eine Meldung gelesen, dass sich Bristol-Myers an Elan beteiligen wolle. Ist da was bekannt - bzw. hat sich das durch den Deal mit Johnsen & Johnsen erledigt??
Dass sich die großen Pharmakonzerne für Elan interessieren ist ja außerordentlich positv.
Aklamat
im Mai habe ich noch eine Meldung gelesen, dass sich Bristol-Myers an Elan beteiligen wolle. Ist da was bekannt - bzw. hat sich das durch den Deal mit Johnsen & Johnsen erledigt??
Dass sich die großen Pharmakonzerne für Elan interessieren ist ja außerordentlich positv.
Aklamat
Antwort auf Beitrag Nr.: 37.695.043 von Aklamat am 02.08.09 18:32:18.....das scheint dadurch erledigt zu sein.Gruss!
Elan Drug Technologies announces first approval of a long acting injectable formulation using NanoCrystal® Technology
Fifth product approved by the US FDA licensing Elan’s NanoCrystal® technology for various formulations
*
DUBLIN--(BUSINESS WIRE)--Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN - News) announces the first approval of a long-acting injectable formulation using Elan Drug Technologies’ proprietary NanoCrystal® technology.
Late last week, Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, announced the approval of INVEGA® SUSTENNA™, the first once monthly atypical antipsychotic injection, by the United States Food and Drug Administration.
“The approval of INVEGA® SUSTENNA™, is an important milestone for our NanoCrystal® technology as it marks the first long-acting injectable product approved by regulatory authorities using the technology,” announced Shane Cooke, Executive Vice President and Head of Elan Drug Technologies. “Our versatile NanoCrystal® technology in this instance, allowed for a stable, low viscosity, high drug-loaded formulation in a small injection volume, to be developed.”
The NanoCrystal® technology, a technology enabling the formulation of poorly water soluble compounds for all routes of administration, allows for a ready-to-use one month duration intramuscular depot formulation of paliperidone palmitate which can be administered by healthcare professionals. The intramuscular injection is administered using a small bore needle and small volume syringe, negating the need for a power injector. By applying the NanoCrystal® technology to paliperidone palmitate, for the first time, healthcare professionals will be able to provide patients with consistent medication coverage for one month potentially allowing them to improve compliance for schizophrenic patients.
NanoCrystal® technology, is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates. INVEGA® SUSTENNA™ is the fifth licensed product approved by the US FDA using Elan’s NanoCrystal® technology for various formulations.
Fifth product approved by the US FDA licensing Elan’s NanoCrystal® technology for various formulations
*
DUBLIN--(BUSINESS WIRE)--Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN - News) announces the first approval of a long-acting injectable formulation using Elan Drug Technologies’ proprietary NanoCrystal® technology.
Late last week, Janssen, a division of Ortho-McNeil-Janssen Pharmaceuticals, announced the approval of INVEGA® SUSTENNA™, the first once monthly atypical antipsychotic injection, by the United States Food and Drug Administration.
“The approval of INVEGA® SUSTENNA™, is an important milestone for our NanoCrystal® technology as it marks the first long-acting injectable product approved by regulatory authorities using the technology,” announced Shane Cooke, Executive Vice President and Head of Elan Drug Technologies. “Our versatile NanoCrystal® technology in this instance, allowed for a stable, low viscosity, high drug-loaded formulation in a small injection volume, to be developed.”
The NanoCrystal® technology, a technology enabling the formulation of poorly water soluble compounds for all routes of administration, allows for a ready-to-use one month duration intramuscular depot formulation of paliperidone palmitate which can be administered by healthcare professionals. The intramuscular injection is administered using a small bore needle and small volume syringe, negating the need for a power injector. By applying the NanoCrystal® technology to paliperidone palmitate, for the first time, healthcare professionals will be able to provide patients with consistent medication coverage for one month potentially allowing them to improve compliance for schizophrenic patients.
NanoCrystal® technology, is a proprietary technology developed by Elan Drug Technologies through Elan Pharma International Limited and other Elan affiliates. INVEGA® SUSTENNA™ is the fifth licensed product approved by the US FDA using Elan’s NanoCrystal® technology for various formulations.
http://www.investegate.co.uk/Article.aspx?id=200908041559488…
Die Norweger steigen "groß" in ELAN ein.
Die Norweger steigen "groß" in ELAN ein.
Antwort auf Beitrag Nr.: 37.709.217 von Poppholz am 04.08.09 17:53:44Poppi, bist Du auch bei ABK investiert
Läuft seit gestern ganz gut
Läuft seit gestern ganz gut
verstehe ich das richtig??
ELAN wird von der Börse in LONDON entfernt?
Gibt es dafür einen Grund?
http://www.investegate.co.uk/Article.aspx?id=200908051724259…
ELAN wird von der Börse in LONDON entfernt?
Gibt es dafür einen Grund?
http://www.investegate.co.uk/Article.aspx?id=200908051724259…
BOSTON (MarketWatch) -- Elan Corp. /quotes/comstock/13*!eln/quotes/nls/eln (ELN 7.68, -0.33, -4.12%) said Thursday that it has filed suit in federal court asking that the court find that its recently announced transaction with Johnson & Johnson /quotes/comstock/13*!jnj/quotes/nls/jnj (JNJ 59.75, -0.70, -1.16%) is not in violation of its marketing agreement with Biogen Idec /quotes/comstock/15*!biib/quotes/nls/biib (BIIB 46.55, -1.07, -2.25%) for the multiple sclerosis drug Tysabri. According to Elan, Biogen has asserted that the J&J deal, which calls for J&J to invest over $1 billion in Elan, violates the companies' 2000 commercialization pact for Tysabri. Elan recently said that J&J has agreed to help Elan purchase Biogen's rights to Tysabri if Biogen is acquired by another entity. Some Biogen shareholders, such as activist investor Carl Icahn, have been pushing for a sale of Biogen to a larger pharmaceutical company
Kann mir jemand sagen, wie der Text oben zu verstehen ist?
LG
Schero
LG
Schero
....es scheint so zu sein,dass Biogen meint,dass der beabsichtigte Deal mit J&J das Vermarktungsabkommen,dass Biogen + Elan in bezug auf Iysabri haben,verletzt....(im Klartext-so verstehe ICH das,passt ihnen nicht,dass ,wenn Biogen übernommen würde,nun Elan mit dem Geld von J&J Tysabri aus Biogen herauskaufen könnte...)Aber alles nur eine Ahnung--muss mich erst einlesen...Gruss!
Msg 373680 of 373749 at 8/6/2009 2:13:18 PM by
till_tomorrow_2004
Some things to contemplate while we see what we see....
1) BIIB shot off the mouth prior to JnJ about some such that would realize more value for both companies
2) After the JnJ deal we heard from ELN that $750M was offered by BIIB to remove CoC (not sure of those details as it was Reuters)
3) SC put out in a media meeting the details of ELN getting support for financing buying the other half of Tysabri SHOULD BIIB undergo a CoC
4) Then we had the MSActive source (We pay HALF of by the way) web page update FINALLY listing Tysabri as an approved therapy choice
5) Now we see BIIB sent a nasty gram to us citing breach
6) We counter with a LAWSUIT to bring clarity
HMMM.... all very interesting. I thought the MS Active thing was an initial point of reference of interest in tea leaf reading.
I think ELN has sent some missives to BIIB about lack of fulfilling on the marketing of Tysabri and the direct conflict of interest with various citations as evidence (MS Active source presentations, PML weekly updates, Avonex/Ty sales force, who knows what else and in what manner). In our weakened state BIIB basically said pound sand.
SO while I will applaud the Tysabri if you need more efficacy as a safe route to promotion in a positive light. I have never agreed with the MS Active source blemishes. I would have liked resolution under the Joint Committee from the agreement but for some reason that never occurred that we are aware. Anyway we were perceived as the weak sister to this relationship and it has shown many times over.
So BIIB is mad about the JnJ deal. They offered (possibly) money to remove the CoC provision. Obviously their will be no deal that will be better for both BIIB and ELN based on what has transpired. Now BIIB has shot a large grenade over the fence and ELN basically threw it back quickly.
I think I smell BIIB might have been courting and basically has been told you can court JnJ or no one at all. As well we have notified you that the previously DOCUMENTED breaches we have cited are now going to require more than just lip service.
I certainly can be 100% wrong. However, the details and steps seem to line up for some reason. Probably that glass of cherry koolaid I am enjoying.
Secondly I have run the NPV on ELN. BAsed on the JnJ deal closing, expense (cough, cough) remaining kinda the same. Sales of Tysabri ramping along with Famp, Palp and Abraxane royalties coming in. Giving ZERO value to AIP (let's us Orla's $5 to be conservative) and using the 588 MM O/S shares guess what ELN is worth .....
TA DA $16.84
Add back in ALZ from my rose colored glasses the other day (which I kinda disagree with) and ELN is then worth on a NPV/DCF basis....
TA DA $39.50
SO choose your path and do so wisely...
Lot of smoke these days...
No more fireworks for now till the fog clears...lol
Till
Msg 373680 of 373749 at 8/6/2009 2:13:18 PM by
till_tomorrow_2004
Some things to contemplate while we see what we see....
1) BIIB shot off the mouth prior to JnJ about some such that would realize more value for both companies
2) After the JnJ deal we heard from ELN that $750M was offered by BIIB to remove CoC (not sure of those details as it was Reuters)
3) SC put out in a media meeting the details of ELN getting support for financing buying the other half of Tysabri SHOULD BIIB undergo a CoC
4) Then we had the MSActive source (We pay HALF of by the way) web page update FINALLY listing Tysabri as an approved therapy choice
5) Now we see BIIB sent a nasty gram to us citing breach
6) We counter with a LAWSUIT to bring clarity
HMMM.... all very interesting. I thought the MS Active thing was an initial point of reference of interest in tea leaf reading.
I think ELN has sent some missives to BIIB about lack of fulfilling on the marketing of Tysabri and the direct conflict of interest with various citations as evidence (MS Active source presentations, PML weekly updates, Avonex/Ty sales force, who knows what else and in what manner). In our weakened state BIIB basically said pound sand.
SO while I will applaud the Tysabri if you need more efficacy as a safe route to promotion in a positive light. I have never agreed with the MS Active source blemishes. I would have liked resolution under the Joint Committee from the agreement but for some reason that never occurred that we are aware. Anyway we were perceived as the weak sister to this relationship and it has shown many times over.
So BIIB is mad about the JnJ deal. They offered (possibly) money to remove the CoC provision. Obviously their will be no deal that will be better for both BIIB and ELN based on what has transpired. Now BIIB has shot a large grenade over the fence and ELN basically threw it back quickly.
I think I smell BIIB might have been courting and basically has been told you can court JnJ or no one at all. As well we have notified you that the previously DOCUMENTED breaches we have cited are now going to require more than just lip service.
I certainly can be 100% wrong. However, the details and steps seem to line up for some reason. Probably that glass of cherry koolaid I am enjoying.
Secondly I have run the NPV on ELN. BAsed on the JnJ deal closing, expense (cough, cough) remaining kinda the same. Sales of Tysabri ramping along with Famp, Palp and Abraxane royalties coming in. Giving ZERO value to AIP (let's us Orla's $5 to be conservative) and using the 588 MM O/S shares guess what ELN is worth .....
TA DA $16.84
Add back in ALZ from my rose colored glasses the other day (which I kinda disagree with) and ELN is then worth on a NPV/DCF basis....
TA DA $39.50
SO choose your path and do so wisely...
Lot of smoke these days...
No more fireworks for now till the fog clears...lol
Till
Antwort auf Beitrag Nr.: 37.721.903 von Poppholz am 06.08.09 10:20:01ist schon Wochen alt...Elan will Geld sparen.
-------------------------------------------------
UPDATE: Biogen Seeks Tysabri Control By Alleging Elan Breach
UPDATE: Biogen Seeks Tysabri Control By Alleging Elan Breach
Last update: 8/6/2009 12:26:33 PM
(Updates throughout with additional information, stock prices.)
By Thomas Gryta
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) is attempting to take full control of multiple sclerosis treatment Tysabri by alleging that Elan Corp. PLC (ELN) breached their collaboration agreement when it reached a recent deal with Johnson & Johnson (JNJ).
In July, J&J agreed to buy 18.4% of the Irish biotech firm in an agreement that also gives the New Brunswick, N.J., company an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point.
The details of that agreement, expected to be finalized in the second half of the year, haven't been fully disclosed by Elan and J&J; however, the initial analysis of the agreement has raised speculation that J&J's leverage could serve as a deterrent to any interested acquirer of Biogen.
Elan is seeking a declaratory judgment in a New York federal court that it hasn't breached the agreement. Elan said Biogen made the allegation in a letter dated July 28.
Biogen officials declined to comment on the matter.
Shares of Biogen recently dropped 77 cents, or 1.6%, to $46.85; Elan fell 3.9% to $7.70.
Tysabri, generating nearly $1 billion in total revenue a year, is the major growth driver for both companies and its loss would have a significant business impact for both the winner and loser.
Under the Tysabri agreement, signed in 2000, if one company breaches the terms of the collaboration, and the offense isn't fixed within 60 days, the nonbreaching party can terminate the agreement and take full control of the drug.
Elan is requesting expedited proceedings from the court and is asking that the court blocks Biogen from ending the deal based on the July letter.
Although it wouldn't comment, Biogen is likely contesting that the breach comes from a section of the agreement that prevents the assignment of any rights from the deal without permission of the other partner.
Elan stated that "there's nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec."
The Tysabri agreement includes a change-in-control clause that gives each company the right to buy out its partner if that partner is taken over. The amount paid for the Tysabri stake is determined through several different methodologies, including a third-party valuation.
But the sales of Tysabri may make the ultimate value too expensive for Elan to handle by itself, given its $3.7 billion market value and 2008 revenue of $1 billion.
The agreement with Johnson & Johnson would provide financing for such a takeover - and its existence may dissuade any potential buyers of Biogen because they could lose one of Biogen's most valuable assets.
Biogen has been considered a potential takeover target, although a deal failed to materialize in 2007 after the company shopped itself around at the prodding of billionaire investor Carl Icahn.
Earlier this year, Icahn succeeded in obtaining two seats on Biogen's board and has reiterated his belief that it should eventually be sold to a large pharmaceutical company.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
August 06, 2009 12:26 ET (16:26 GMT)
-------------------------------------------------
UPDATE: Biogen Seeks Tysabri Control By Alleging Elan Breach
UPDATE: Biogen Seeks Tysabri Control By Alleging Elan Breach
Last update: 8/6/2009 12:26:33 PM
(Updates throughout with additional information, stock prices.)
By Thomas Gryta
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) is attempting to take full control of multiple sclerosis treatment Tysabri by alleging that Elan Corp. PLC (ELN) breached their collaboration agreement when it reached a recent deal with Johnson & Johnson (JNJ).
In July, J&J agreed to buy 18.4% of the Irish biotech firm in an agreement that also gives the New Brunswick, N.J., company an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point.
The details of that agreement, expected to be finalized in the second half of the year, haven't been fully disclosed by Elan and J&J; however, the initial analysis of the agreement has raised speculation that J&J's leverage could serve as a deterrent to any interested acquirer of Biogen.
Elan is seeking a declaratory judgment in a New York federal court that it hasn't breached the agreement. Elan said Biogen made the allegation in a letter dated July 28.
Biogen officials declined to comment on the matter.
Shares of Biogen recently dropped 77 cents, or 1.6%, to $46.85; Elan fell 3.9% to $7.70.
Tysabri, generating nearly $1 billion in total revenue a year, is the major growth driver for both companies and its loss would have a significant business impact for both the winner and loser.
Under the Tysabri agreement, signed in 2000, if one company breaches the terms of the collaboration, and the offense isn't fixed within 60 days, the nonbreaching party can terminate the agreement and take full control of the drug.
Elan is requesting expedited proceedings from the court and is asking that the court blocks Biogen from ending the deal based on the July letter.
Although it wouldn't comment, Biogen is likely contesting that the breach comes from a section of the agreement that prevents the assignment of any rights from the deal without permission of the other partner.
Elan stated that "there's nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec."
The Tysabri agreement includes a change-in-control clause that gives each company the right to buy out its partner if that partner is taken over. The amount paid for the Tysabri stake is determined through several different methodologies, including a third-party valuation.
But the sales of Tysabri may make the ultimate value too expensive for Elan to handle by itself, given its $3.7 billion market value and 2008 revenue of $1 billion.
The agreement with Johnson & Johnson would provide financing for such a takeover - and its existence may dissuade any potential buyers of Biogen because they could lose one of Biogen's most valuable assets.
Biogen has been considered a potential takeover target, although a deal failed to materialize in 2007 after the company shopped itself around at the prodding of billionaire investor Carl Icahn.
Earlier this year, Icahn succeeded in obtaining two seats on Biogen's board and has reiterated his belief that it should eventually be sold to a large pharmaceutical company.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
August 06, 2009 12:26 ET (16:26 GMT)
Elan IR
Haven't had time to read the board so if any of this info is repeat, I apologize in advance:
1. Elan received letter from BIIB indicating that BIIB believed that ELN had violated the Tysabri agreement.
2. Elan stonglt beleives that the agrement wiith JNJ does not violate Tysabei agrrement.
3. Elan offered to let BIIB review the ELN/JNJ agreement with regards to Tysabri if BIIB signed a standard confidentiality agreement.
4. BIIB never responded to Elan
5. Elan was forced to take dispute to court.
6. Elan beleives the agreement with JNJ protects elan shareholders. IF (very hypotheical, NVS wanted to take control of BIIB, Eln might understandably have strong objections. Yet, before JNJ agreement, Eln had no marketing, manufacturing, or financing to protect its rights regarding Tysabri. Now it has those protections, ONLY ASSUMING there is a change of control at BIIB
Haven't had time to read the board so if any of this info is repeat, I apologize in advance:
1. Elan received letter from BIIB indicating that BIIB believed that ELN had violated the Tysabri agreement.
2. Elan stonglt beleives that the agrement wiith JNJ does not violate Tysabei agrrement.
3. Elan offered to let BIIB review the ELN/JNJ agreement with regards to Tysabri if BIIB signed a standard confidentiality agreement.
4. BIIB never responded to Elan
5. Elan was forced to take dispute to court.
6. Elan beleives the agreement with JNJ protects elan shareholders. IF (very hypotheical, NVS wanted to take control of BIIB, Eln might understandably have strong objections. Yet, before JNJ agreement, Eln had no marketing, manufacturing, or financing to protect its rights regarding Tysabri. Now it has those protections, ONLY ASSUMING there is a change of control at BIIB
Elan starts legal action in drug row with Biogen
http://www.ft.com/cms/s/0/f7fe7f32-82bd-11de-ab4a-00144feabd…
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging a claim from Biogen Idec, based in Boston, that Elan’s recent $1.5bn (£893m) deal with Johnson & Johnson placed it in “material breach” of their profit-sharing agreement for Tysabri.
In a filing with the US District Court, Elan said it had received a letter from Biogen Idec at the end of last month giving it notice that it was terminating the collaboration agreement first signed to develop and commercialise Tysabri in 2000.
That letter gives the two companies 60 days – until late September – to finalise a restructuring of their Tysabri partnership, only days after J&J’s equity investment and funding deal is set to be completed with Elan.
Biogen Idec argued that following Elan’s deal with J&J, announced last month, its partner was in “material breach” of the agreement, which is rendered void by any delegation of rights.
Shane Cooke, Elan’s chief financial officer, told investors in a conference call last month that J&J had agreed in a confidential aspect of its deal to help finance the purchase of Biogen Idec’s share in Tysabri in the event that there was any change of control.
However, in a view that Elan maintained in Thursday’s court filings, Mr Cooke also stressed that the J&J deal did not in itself represent any change in control that would affect the existing Tysabri partnership with Biogen Idec.
Elan has since offered to share the full terms of the J&J financing agreement with Biogen Idec, and has now filed them with the court in an attempt to win a ruling that there is no violation.
It says in the filing that termination of the partnership would result in Elan forfeiting all rights to Tysabri or the ability to buy out Biogen Idec’s rights to the drug, and imposing on it “draconian penalties”.
Elan said on Thursday: “There’s nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri ... This is the same agreement we have been operating under for the last nine years. It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”
Biogen Idec was unavailable for comment on Thursday night.
Shares in Elan closed up 5.5 cents at €5.56 in Dublin.
http://www.ft.com/cms/s/0/f7fe7f32-82bd-11de-ab4a-00144feabd…
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging a claim from Biogen Idec, based in Boston, that Elan’s recent $1.5bn (£893m) deal with Johnson & Johnson placed it in “material breach” of their profit-sharing agreement for Tysabri.
In a filing with the US District Court, Elan said it had received a letter from Biogen Idec at the end of last month giving it notice that it was terminating the collaboration agreement first signed to develop and commercialise Tysabri in 2000.
That letter gives the two companies 60 days – until late September – to finalise a restructuring of their Tysabri partnership, only days after J&J’s equity investment and funding deal is set to be completed with Elan.
Biogen Idec argued that following Elan’s deal with J&J, announced last month, its partner was in “material breach” of the agreement, which is rendered void by any delegation of rights.
Shane Cooke, Elan’s chief financial officer, told investors in a conference call last month that J&J had agreed in a confidential aspect of its deal to help finance the purchase of Biogen Idec’s share in Tysabri in the event that there was any change of control.
However, in a view that Elan maintained in Thursday’s court filings, Mr Cooke also stressed that the J&J deal did not in itself represent any change in control that would affect the existing Tysabri partnership with Biogen Idec.
Elan has since offered to share the full terms of the J&J financing agreement with Biogen Idec, and has now filed them with the court in an attempt to win a ruling that there is no violation.
It says in the filing that termination of the partnership would result in Elan forfeiting all rights to Tysabri or the ability to buy out Biogen Idec’s rights to the drug, and imposing on it “draconian penalties”.
Elan said on Thursday: “There’s nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri ... This is the same agreement we have been operating under for the last nine years. It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”
Biogen Idec was unavailable for comment on Thursday night.
Shares in Elan closed up 5.5 cents at €5.56 in Dublin.
Antwort auf Beitrag Nr.: 37.727.580 von Schero am 06.08.09 20:28:38meines Wissens nach gibt es ein Abgkommen zwischen ELAN und BIOGEN, dass im Falle einer Übernahme eines der Partner, die Rechta an Tysabri an den anderen Partner übergehen.
Wenn ELAN also von J&J übernommen werden würde, würden die Rechte an Tysabri automatisch an BIOGEN gehen.
Wenn ELAN also von J&J übernommen werden würde, würden die Rechte an Tysabri automatisch an BIOGEN gehen.
Antwort auf Beitrag Nr.: 37.729.954 von Poppholz am 07.08.09 09:39:45Es steht NICHT zur Debatte dass ELAN übernommen wird vonJ+J....sie beteiligen sich nnur----diese ganze Geschichte geht über die Frage,was passiert vwenn BIOGEN übernommen wird---dann kann jetzt Elan Biogens Hälfte mit J+J´s Geld kaufen--das gefällt Biogen nicht...
--------------------------------------------------------------
Full Financial Times Report on Elan suit of BIIB
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging a claim from Biogen Idec, based in Boston, that Elan’s recent $1.5bn (£893m) deal with Johnson & Johnson placed it in “material breach” of their profit-sharing agreement for Tysabri.
EDITOR’S CHOICE
Key to pharma future - Aug-03Drug groups to reap swine-flu billions - Jul-20Solvay whittles bidders down to two - Jul-14Call for action on HIV drug patents - Jul-14Roche looks at extensions to Tamiflu doses - Jul-12Brussels to probe drug patent abuses - Jul-08In a filing with the US District Court, Elan said it had received a letter from Biogen Idec at the end of last month giving it notice that it was terminating the collaboration agreement first signed to develop and commercialise Tysabri in 2000.
That letter gives the two companies 60 days – until late September – to finalise a restructuring of their Tysabri partnership, only days after J&J’s equity investment and funding deal is set to be completed with Elan.
Biogen Idec argued that following Elan’s deal with J&J, announced last month, its partner was in “material breach” of the agreement, which is rendered void by any delegation of rights.
Shane Cooke, Elan’s chief financial officer, told investors in a conference call last month that J&J had agreed in a confidential aspect of its deal to help finance the purchase of Biogen Idec’s share in Tysabri in the event that there was any change of control.
However, in a view that Elan maintained in Thursday’s court filings, Mr Cooke also stressed that the J&J deal did not in itself represent any change in control that would affect the existing Tysabri partnership with Biogen Idec.
Elan has since offered to share the full terms of the J&J financing agreement with Biogen Idec, and has now filed them with the court in an attempt to win a ruling that there is no violation.
It says in the filing that termination of the partnership would result in Elan forfeiting all rights to Tysabri or the ability to buy out Biogen Idec’s rights to the drug, and imposing on it “draconian penalties”.
Elan said on Thursday: “There’s nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri ... This is the same agreement we have been operating under for the last nine years. It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”
Biogen Idec was unavailable for comment on Thursday night.
Shares in Elan closed up 5.5 cents at €5.56 in Dublin.
Copyright The Financial Times Limited 2009
--------------------------------------------------------------
Full Financial Times Report on Elan suit of BIIB
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging a claim from Biogen Idec, based in Boston, that Elan’s recent $1.5bn (£893m) deal with Johnson & Johnson placed it in “material breach” of their profit-sharing agreement for Tysabri.
EDITOR’S CHOICE
Key to pharma future - Aug-03Drug groups to reap swine-flu billions - Jul-20Solvay whittles bidders down to two - Jul-14Call for action on HIV drug patents - Jul-14Roche looks at extensions to Tamiflu doses - Jul-12Brussels to probe drug patent abuses - Jul-08In a filing with the US District Court, Elan said it had received a letter from Biogen Idec at the end of last month giving it notice that it was terminating the collaboration agreement first signed to develop and commercialise Tysabri in 2000.
That letter gives the two companies 60 days – until late September – to finalise a restructuring of their Tysabri partnership, only days after J&J’s equity investment and funding deal is set to be completed with Elan.
Biogen Idec argued that following Elan’s deal with J&J, announced last month, its partner was in “material breach” of the agreement, which is rendered void by any delegation of rights.
Shane Cooke, Elan’s chief financial officer, told investors in a conference call last month that J&J had agreed in a confidential aspect of its deal to help finance the purchase of Biogen Idec’s share in Tysabri in the event that there was any change of control.
However, in a view that Elan maintained in Thursday’s court filings, Mr Cooke also stressed that the J&J deal did not in itself represent any change in control that would affect the existing Tysabri partnership with Biogen Idec.
Elan has since offered to share the full terms of the J&J financing agreement with Biogen Idec, and has now filed them with the court in an attempt to win a ruling that there is no violation.
It says in the filing that termination of the partnership would result in Elan forfeiting all rights to Tysabri or the ability to buy out Biogen Idec’s rights to the drug, and imposing on it “draconian penalties”.
Elan said on Thursday: “There’s nothing in the pending transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri ... This is the same agreement we have been operating under for the last nine years. It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”
Biogen Idec was unavailable for comment on Thursday night.
Shares in Elan closed up 5.5 cents at €5.56 in Dublin.
Copyright The Financial Times Limited 2009
Antwort auf Beitrag Nr.: 37.730.915 von Tebi am 07.08.09 11:07:34ich sehe in der Beteiligung von J&J auch keine Übernahme.
Welche Details in der Tysabri-Vereinbarung getroffen sind, ob jeweils der andere Partner die Anteile "automatisch" übernimmt oder zu einem bestimmten Wert kaufen kann, kann ich nicht sagen. Ich weiß nur, dass es eine Vereinbarung in diese Richtung gibt.
Welche Details in der Tysabri-Vereinbarung getroffen sind, ob jeweils der andere Partner die Anteile "automatisch" übernimmt oder zu einem bestimmten Wert kaufen kann, kann ich nicht sagen. Ich weiß nur, dass es eine Vereinbarung in diese Richtung gibt.
Antwort auf Beitrag Nr.: 37.731.430 von Poppholz am 07.08.09 12:02:21Biogen wirft Elan vor,durch die Vereinbarung mit J+J schon zu präjudizieren,dass bei einer Biogen-Übernahme die Biogen Hälfte von TY an J+J gehen würde;sie begreifen das als Vertragsverletzung,die ihnen jetzt (sozusagen als Strafe)die volle Kontrolle über Ty rechtlich ermöglicht.Dagegen klagt jetzt Elan (ZURECHT!) Gruss!
Msg 373944 of 373954 at 8/7/2009 6:02:15 AM by
px00001
Lawsuit
the way i look at this is biogen is arguing that elan sold it's rights to purchase ty from biogen to j&j. elan is arguing that it sold a minority stake in elan to j&j, and with that sale, got access to financing to purchase ty back, only if there was a change of control at biogen. i see the argument in elan's favor, since it requires biogen to pull the trigger, so to speak, with biogen initiating a change of control, for elan's subsequent purchase of ty. sort of like a chess game. no matter what move biogen makes, biogen moves into a checkmate situation, and the next move is biogen's. if carl ichan wasn't so intent on selling biogen, then this probably wouldn't have bothered biogen at all. in essence, biogen is trying to hold elan responsible for having to sell tysabri back to elan. carl ichan will most likely make them, because he wants the $$$$. the biogen shareholders are probably very disenfanchized with Ty, mostly because JM has sabotaged his own product. tysabri doesn't belong there. and if j&j walks on the deal with elan, then biogen is liable for interfering with an advantageous business relationship.
Case law on the point: http://www.corporatelawnotes.com/?p=68
“There are four elements required to establish interference with advantageous business relations: (1) the plaintiff has a business relationship for economic benefit with a third party, (2) the defendants knew of that relationship, (3) the defendants interfered with that relationship through improper motive or means, and (4) the plaintiff’s loss of the advantage resulted directly from the defendants’ conduct.” McNamee v. Jenkins, 52 Mass. App. Ct. 503, 508 (2001). The “improper motive or means” element requires proof of the defendant’s “actual malice,” i.e., a “spiteful, malignant purpose, unrelated to the legitimate corporate interest.” Shea v. Emmanuel College, 425 Mass. 761, 764 (1997), quoting from Wright v. Shriners Hosp. for Crippled Children
px00001
Lawsuit
the way i look at this is biogen is arguing that elan sold it's rights to purchase ty from biogen to j&j. elan is arguing that it sold a minority stake in elan to j&j, and with that sale, got access to financing to purchase ty back, only if there was a change of control at biogen. i see the argument in elan's favor, since it requires biogen to pull the trigger, so to speak, with biogen initiating a change of control, for elan's subsequent purchase of ty. sort of like a chess game. no matter what move biogen makes, biogen moves into a checkmate situation, and the next move is biogen's. if carl ichan wasn't so intent on selling biogen, then this probably wouldn't have bothered biogen at all. in essence, biogen is trying to hold elan responsible for having to sell tysabri back to elan. carl ichan will most likely make them, because he wants the $$$$. the biogen shareholders are probably very disenfanchized with Ty, mostly because JM has sabotaged his own product. tysabri doesn't belong there. and if j&j walks on the deal with elan, then biogen is liable for interfering with an advantageous business relationship.
Case law on the point: http://www.corporatelawnotes.com/?p=68
“There are four elements required to establish interference with advantageous business relations: (1) the plaintiff has a business relationship for economic benefit with a third party, (2) the defendants knew of that relationship, (3) the defendants interfered with that relationship through improper motive or means, and (4) the plaintiff’s loss of the advantage resulted directly from the defendants’ conduct.” McNamee v. Jenkins, 52 Mass. App. Ct. 503, 508 (2001). The “improper motive or means” element requires proof of the defendant’s “actual malice,” i.e., a “spiteful, malignant purpose, unrelated to the legitimate corporate interest.” Shea v. Emmanuel College, 425 Mass. 761, 764 (1997), quoting from Wright v. Shriners Hosp. for Crippled Children
Was ist mit demS zenario daß J&J sowohl bei Elan als auch bei Biogen Ty-Anteile erwirbt?
Bei Elan macht man sich ja immer vor daß man dann Cash hat. Aber wofür? Wenn dann wieder was da ist wirds wieder mal vermurkst. Und die Konkurrenz hat aufgeholt.
Im Verkaufen von Tafelsilber bzw. völliges Mißmanagment mit Ausbluten der Vorteile/Produkte/Technologien ist Elan ja bisher Spitze gewesen.
Oder?
Bei Elan macht man sich ja immer vor daß man dann Cash hat. Aber wofür? Wenn dann wieder was da ist wirds wieder mal vermurkst. Und die Konkurrenz hat aufgeholt.
Im Verkaufen von Tafelsilber bzw. völliges Mißmanagment mit Ausbluten der Vorteile/Produkte/Technologien ist Elan ja bisher Spitze gewesen.
Oder?
Antwort auf Beitrag Nr.: 37.737.939 von moneyseeker am 08.08.09 12:55:10....nun biste aber böhhhse....
Vielleicht kauft J+J Biogen und dann sollte es mit der Vermarktung von Ty doch wohl klappen----und Kelly wird Gärtner im Unternehmen...da muss er wenigstensweder sprechen noch planen..
Vielleicht kauft J+J Biogen und dann sollte es mit der Vermarktung von Ty doch wohl klappen----und Kelly wird Gärtner im Unternehmen...da muss er wenigstensweder sprechen noch planen..
Todays Independent.ie View On The Deal
Elan dispute with Biogen to go before federal court
Drugmaker says agreement with J&J doesn’t violate deal
Tuesday August 11 2009
A NEW York federal judge has scheduled an August 31 hearing in the dispute between drugmaker Elan and Biogen Idec over their collaboration agreement to sell multiple sclerosis treatment Tysabri.
The move follows a suit filed by Elan against its research partner Biogen in a bid to block the latter from sabotaging a $1.5bn deal between Elan and Johnson & Johnson (J&J).
Last week Elan filed the suit seeking a declaration that the Irish company’s recent agreement with (J&J) doesn’t violate an existing deal with Biogen in relation to Tysabri.
The Tysabri agreement includes a change-in-control clause that gives each company the right to buy out the other if either partner is taken over.
The amount that could potentially be paid for the Tysabri stake is determined through several different methodologies, including a third party valuation.
If Biogen's assertion is upheld in court, it could end the agreement and gain full rights to a drug that generates nearly $1bn in annual revenue and is the major growth driver for both companies.
Agreement The judge has ordered Biogen to argue why the court shouldn't expedite the proceedings related to Elan's request to block Biogen from terminating the agreement.
The judge also wants to hear arguments about consolidating the preliminary injunction hearing together with a hearing on the merits of Elan's request for a declaratory judgment about the dispute.
In July, J&J agreed to buy 18.4pc of Elan in an agreement that also gives the New Jersey company an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point.
Biogen claims that arrangement breaches the collaboration.
Elan dispute with Biogen to go before federal court
Drugmaker says agreement with J&J doesn’t violate deal
Tuesday August 11 2009
A NEW York federal judge has scheduled an August 31 hearing in the dispute between drugmaker Elan and Biogen Idec over their collaboration agreement to sell multiple sclerosis treatment Tysabri.
The move follows a suit filed by Elan against its research partner Biogen in a bid to block the latter from sabotaging a $1.5bn deal between Elan and Johnson & Johnson (J&J).
Last week Elan filed the suit seeking a declaration that the Irish company’s recent agreement with (J&J) doesn’t violate an existing deal with Biogen in relation to Tysabri.
The Tysabri agreement includes a change-in-control clause that gives each company the right to buy out the other if either partner is taken over.
The amount that could potentially be paid for the Tysabri stake is determined through several different methodologies, including a third party valuation.
If Biogen's assertion is upheld in court, it could end the agreement and gain full rights to a drug that generates nearly $1bn in annual revenue and is the major growth driver for both companies.
Agreement The judge has ordered Biogen to argue why the court shouldn't expedite the proceedings related to Elan's request to block Biogen from terminating the agreement.
The judge also wants to hear arguments about consolidating the preliminary injunction hearing together with a hearing on the merits of Elan's request for a declaratory judgment about the dispute.
In July, J&J agreed to buy 18.4pc of Elan in an agreement that also gives the New Jersey company an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point.
Biogen claims that arrangement breaches the collaboration.
http://www.investorvillage.com/smbd.asp?mb=160&mn=375054&pt=…
Bloxham stockbrokers Dublin
Elan – Biogen dispute commentary
• The latest twist in the complex relationship between Elan and Biogen is set to result in a
court hearing on August 31st. The dispute centers around the recent deal between Elan and
J&J, which saw J&J invest $1bn in the firm and provide an additional $500m in financing
costs for access to Elan’s Alzheimers division. The deal however was not well received by
Biogen, Elan’s partner in the development of the MS drug Tysabri. This complex partnership
saw a clause allowing either party to purchase the full rights to Tysabri should either
company see a change in ownership. The dispute arose when it emerged that Elan’s deal
with J&J also included an option for J&J to finance Elan’s purchase of Tysabri should the
opportunity ever arise. Biogen sees that clause as a violation of the original deal.
• The stakes are high with Tysabri estimated to be worth between $4bn-$5bn, with current
sales already hitting $1bn. When Carl Icahn, the dissident shareholder on Biogen’s board, is
also factored in the situation gets even more complex. Speculation is now growing that he is
attempting to facilitate Elan’s purchase of Tysabri to help unlock value in Biogen.
• How this will all finish is difficult to predict, with a long drawn out court battle the most likely
outcome. It is also unknown if Elan’s newfound ability to access capital through a new
partner is outside the current terms of its agreement with Biogen. What is known is that
should Elan acquire Tysabri in conjunction with such a strong strategic partner as J&J, it
would be taken very positively.
Bloxham stockbrokers Dublin
Elan – Biogen dispute commentary
• The latest twist in the complex relationship between Elan and Biogen is set to result in a
court hearing on August 31st. The dispute centers around the recent deal between Elan and
J&J, which saw J&J invest $1bn in the firm and provide an additional $500m in financing
costs for access to Elan’s Alzheimers division. The deal however was not well received by
Biogen, Elan’s partner in the development of the MS drug Tysabri. This complex partnership
saw a clause allowing either party to purchase the full rights to Tysabri should either
company see a change in ownership. The dispute arose when it emerged that Elan’s deal
with J&J also included an option for J&J to finance Elan’s purchase of Tysabri should the
opportunity ever arise. Biogen sees that clause as a violation of the original deal.
• The stakes are high with Tysabri estimated to be worth between $4bn-$5bn, with current
sales already hitting $1bn. When Carl Icahn, the dissident shareholder on Biogen’s board, is
also factored in the situation gets even more complex. Speculation is now growing that he is
attempting to facilitate Elan’s purchase of Tysabri to help unlock value in Biogen.
• How this will all finish is difficult to predict, with a long drawn out court battle the most likely
outcome. It is also unknown if Elan’s newfound ability to access capital through a new
partner is outside the current terms of its agreement with Biogen. What is known is that
should Elan acquire Tysabri in conjunction with such a strong strategic partner as J&J, it
would be taken very positively.
Nun seit vielen Tagen das gleiche Bild.
Bald sind wir bei $ 6,--. Bis zum 31.08. wer weiss wo?
Habt Ihr ein Rat?
Bald sind wir bei $ 6,--. Bis zum 31.08. wer weiss wo?
Habt Ihr ein Rat?
Antwort auf Beitrag Nr.: 37.813.946 von Schero am 19.08.09 22:09:11bei unserem Baby sind Kursschwankungen von vielen Prozent über die nächsten Wochen und Monate möglich, ohne das "entscheidene" News kommen.
Dies ist in der Vergangenheit auch der Fall gewesen und auch der Kurssturz von $40,- auf jetzt $6,- ist "eigentlich" nicht gerechtfertigt gewesen.
Alles ist möglich.
Ich gehe aber davon aus, dass auf lange Sicht der Kurs steigen wird, auch wenn dies noch Jahre dauern kann.
Dies ist in der Vergangenheit auch der Fall gewesen und auch der Kurssturz von $40,- auf jetzt $6,- ist "eigentlich" nicht gerechtfertigt gewesen.
Alles ist möglich.
Ich gehe aber davon aus, dass auf lange Sicht der Kurs steigen wird, auch wenn dies noch Jahre dauern kann.
Kelly Martin scheint zum aktuellen Kurs eher fallende Kurse zu erwarten:
http://www.investegate.co.uk/Article.aspx?id=200908191715007…
Er verkauft 36.077 Aktien.
http://www.investegate.co.uk/Article.aspx?id=200908191715007…
Er verkauft 36.077 Aktien.
Antwort auf Beitrag Nr.: 37.817.545 von Poppholz am 20.08.09 13:47:47Das finde ich nicht so alarmierend.
Der gute Mann hat eben etwas Geld gebraucht. Die Anzahl der Stücke sagt aus, dass er einen bestimmten Betrag gebraucht hat. Sonst hätte er eine glatte Menge verkauft. Wie auch immer.
Der gute Mann hat eben etwas Geld gebraucht. Die Anzahl der Stücke sagt aus, dass er einen bestimmten Betrag gebraucht hat. Sonst hätte er eine glatte Menge verkauft. Wie auch immer
.
Antwort auf Beitrag Nr.: 37.822.248 von Schero am 20.08.09 23:08:27werde nun auch nicht verkaufen, aber merkwürdig finde ich das Verhalten der Geschäftsleitung schon.
Judge Moves Biogen, Elan Tysabri Hearing To Sept. 10
By Thomas Gryta
Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)- A federal court delayed a key hearing in the dispute over Biogen Idec Inc. (BIIB) and Elan Corp.'s (ELN) collaboration agreement for the multiple-sclerosis treatment Tysabri until Sept. 10, allowing more time for Biogen to prepare.
The hearing, originally set for Aug. 31 in a federal district court in New York City, will focus on whether the court should block Biogen from ending that agreement.
In an order filed last week, Biogen was granted quick access to documents related to a July agreement for Johnson & Johnson (JNJ) to buy 18.4% of Elan along with an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point. The deal is expected to close in early September.
Biogen claims that the J&J deal breaches the Tysabri collaboration, which prevents the assignment of any related rights without permission of the other partner.
Shares of Biogen recently were down 39 cents to $49.58 while Elan dropped 2% to $7.30.
An Elan spokeswoman said the company is pleased that the court is "promptly reviewing" the company's claims. A Biogen spokeswoman declined to comment.
If Biogen's assertion proves correct, and Elan doesn't fix the issue, Biogen could end the agreement and gain full rights to a drug that generates nearly $1 billion in annual revenue and is the major growth driver for both companies.
Under the agreement, signed in 2000, if one company breaches the collaboration and the offense isn't fixed within 60 days, the non-breaching party can terminate the pact and take full control of Tysabri.
That 60-day period will expire Sept. 26, based on Biogen sending a letter on July 28 that alleged the breach.
Elan is seeking a declaratory judgment that the two agreements don't conflict and that it hasn't breached the agreement. Elan also asked the court to block Biogen from ending the deal.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
08-24-091239ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://news.morningstar.com/newsnet/ViewNews.aspx?article=/D…
By Thomas Gryta
Of DOW JONES NEWSWIRES
NEW YORK -(Dow Jones)- A federal court delayed a key hearing in the dispute over Biogen Idec Inc. (BIIB) and Elan Corp.'s (ELN) collaboration agreement for the multiple-sclerosis treatment Tysabri until Sept. 10, allowing more time for Biogen to prepare.
The hearing, originally set for Aug. 31 in a federal district court in New York City, will focus on whether the court should block Biogen from ending that agreement.
In an order filed last week, Biogen was granted quick access to documents related to a July agreement for Johnson & Johnson (JNJ) to buy 18.4% of Elan along with an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point. The deal is expected to close in early September.
Biogen claims that the J&J deal breaches the Tysabri collaboration, which prevents the assignment of any related rights without permission of the other partner.
Shares of Biogen recently were down 39 cents to $49.58 while Elan dropped 2% to $7.30.
An Elan spokeswoman said the company is pleased that the court is "promptly reviewing" the company's claims. A Biogen spokeswoman declined to comment.
If Biogen's assertion proves correct, and Elan doesn't fix the issue, Biogen could end the agreement and gain full rights to a drug that generates nearly $1 billion in annual revenue and is the major growth driver for both companies.
Under the agreement, signed in 2000, if one company breaches the collaboration and the offense isn't fixed within 60 days, the non-breaching party can terminate the pact and take full control of Tysabri.
That 60-day period will expire Sept. 26, based on Biogen sending a letter on July 28 that alleged the breach.
Elan is seeking a declaratory judgment that the two agreements don't conflict and that it hasn't breached the agreement. Elan also asked the court to block Biogen from ending the deal.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
08-24-091239ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://news.morningstar.com/newsnet/ViewNews.aspx?article=/D…
Ist zwar vom 27.08. Donnerstag, aber sehr interessant!
Elan (NYSE: ELN) is Johnson & Johnson's (NYSE: JNJ) new best buddy.
First J&J bought half of Elan's Alzheimer drug pipeline, and agreed to become Elan's partner on Tysabri if Biogen Idec (Nasdaq: BIIB) were ever acquired. Now Johnson & Johnson is kicking partner Alkermes (Nasdaq: ALKS) to the curb in favor of Elan's technology.
Yesterday, Alkermes said that J&J was discontinuing the development of a once-monthly version of its antipsychotic Risperdal. The company currently markets Risperdal Consta, developed using Alkermes' long-lasting technology, which allows the drug to be taken once every two weeks.
The development halt seems purely commercial in nature. As the patent expiration on Risperdal approached, Johnson & Johnson developed a follow-on drug called Invega, and then used Elan's NanoCrystal technology to develop a long-lasting version of the drug, called Invega Sustenna, which was approved by the Food and Drug Administration a few weeks ago.
Since Invega Sustenna is dosed once a month, sorry, Alkermes -- your services are no longer needed. Welcome to the party, Elan! Sit down and have a beer! We've got the U.S. market all to ourselves, at least until Eli Lilly (NYSE: LLY) finally clears up issues with its once-monthly Zyprexa.
Ironically, Eli Lilly is now Alkermes' ticket to getting out of the doghouse with investors. Eli Lilly and Amylin Pharmaceuticals (Nasdaq: AMLN) have a once-weekly version of their diabetes drug, Byetta, under review by the FDA, developed using -- you guessed it -- Alkermes' long-lasting technology.
Elan (NYSE: ELN) is Johnson & Johnson's (NYSE: JNJ) new best buddy.
First J&J bought half of Elan's Alzheimer drug pipeline, and agreed to become Elan's partner on Tysabri if Biogen Idec (Nasdaq: BIIB) were ever acquired. Now Johnson & Johnson is kicking partner Alkermes (Nasdaq: ALKS) to the curb in favor of Elan's technology.
Yesterday, Alkermes said that J&J was discontinuing the development of a once-monthly version of its antipsychotic Risperdal. The company currently markets Risperdal Consta, developed using Alkermes' long-lasting technology, which allows the drug to be taken once every two weeks.
The development halt seems purely commercial in nature. As the patent expiration on Risperdal approached, Johnson & Johnson developed a follow-on drug called Invega, and then used Elan's NanoCrystal technology to develop a long-lasting version of the drug, called Invega Sustenna, which was approved by the Food and Drug Administration a few weeks ago.
Since Invega Sustenna is dosed once a month, sorry, Alkermes -- your services are no longer needed. Welcome to the party, Elan! Sit down and have a beer! We've got the U.S. market all to ourselves, at least until Eli Lilly (NYSE: LLY) finally clears up issues with its once-monthly Zyprexa.
Ironically, Eli Lilly is now Alkermes' ticket to getting out of the doghouse with investors. Eli Lilly and Amylin Pharmaceuticals (Nasdaq: AMLN) have a once-weekly version of their diabetes drug, Byetta, under review by the FDA, developed using -- you guessed it -- Alkermes' long-lasting technology.
Birgit,
bist du noch an Bord?
posimist
bist du noch an Bord?
posimist
Antwort auf Beitrag Nr.: 37.892.603 von posimist am 01.09.09 12:32:52naa klaaaaaaaaaaaaaaaaaaaaar--vor 2010 verlässt kein Schätzchen das Boot--und NICHT unter 20€-----GRUSS!
Antwort auf Beitrag Nr.: 37.892.632 von Tebi am 01.09.09 12:37:40
REG-Elan Corporation plc Total Voting Rights
Mon Aug 31, 2009 7:19am EDT
LONDON--(Business Wire)--
ELAN CORPORATION, PLC
TOTAL VOTING RIGHTS
In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC)
Regulations 2007, Elan Corporation, plc announces that:
Elan Corporation, plc`s issued share capital as at 31 August 2009 consists of 476,248,693 Ordinary Shares of nominal value €0.05 each with voting rights. Elan Corporation, plc holds no Ordinary Shares in treasury, therefore, the total number of voting rights in Elan Corporation, plc is 476,248,693.
The above figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Elan Corporation, plc under the Transparency (Directive 004/109/EC) Regulations 2007 and the Interim Transparency Rules of the Financial Regulator.
CONTACTS:
William F. Daniel
EVP & Company Secretary
Elan Corporation plc
Copyright Business Wire 2009
http://www.reuters.com/article/pressRelease/idUS109521+31-Au…
Mon Aug 31, 2009 7:19am EDT
LONDON--(Business Wire)--
ELAN CORPORATION, PLC
TOTAL VOTING RIGHTS
In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC)
Regulations 2007, Elan Corporation, plc announces that:
Elan Corporation, plc`s issued share capital as at 31 August 2009 consists of 476,248,693 Ordinary Shares of nominal value €0.05 each with voting rights. Elan Corporation, plc holds no Ordinary Shares in treasury, therefore, the total number of voting rights in Elan Corporation, plc is 476,248,693.
The above figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Elan Corporation, plc under the Transparency (Directive 004/109/EC) Regulations 2007 and the Interim Transparency Rules of the Financial Regulator.
CONTACTS:
William F. Daniel
EVP & Company Secretary
Elan Corporation plc
Copyright Business Wire 2009
http://www.reuters.com/article/pressRelease/idUS109521+31-Au…
die Kursentwicklung der erseten 15 Minuten ziehen wir jetzt bis heute Abend durch:
Antwort auf Beitrag Nr.: 37.894.214 von Poppholz am 01.09.09 15:47:01ok!
JU HU, alle sind wieder vom Urlaub zurück. Jetzt kann es wieder losgehen!
Ich grüße alle.
Gibt es neues zum Schnuggel??
Schero
Ich grüße alle.
Gibt es neues zum Schnuggel??
Schero
Antwort auf Beitrag Nr.: 37.914.438 von Schero am 03.09.09 20:37:02Heute Abend wird Schnuggel gross oder bekommt einen auf die Rübe---heute ist die Anhörung in dem Konflikt mit Biogen in bezug auf den J+J-Deal....
NEW YORK (Dow Jones)--A federal judge has moved a key hearing regarding Biogen Idec Inc. (BIIB) and Elan Corp.'s (ELN) collaboration agreement for the multiple-sclerosis treatment Tysabri to Thursday morning, from its previously scheduled Sept. 10.
No reason for the rescheduling was given in Judge Deborah Batts' order in a federal district court in New York City. She struck three "extraneous submissions" made by Elan and set the hearing for 11 a.m. EDT.
Shares of Biogen recently rose 14 cents to $49.37, while Elan dropped nearly 1% to $7.05.
The hearing, which will focus on whether the court should block Biogen from ending the agreement, comes after Biogen sent a letter alleging that Elan's recent deal with Johnson & Johnson (JNJ) is a breach of the Tysabri agreement.
If Biogen's assertion proves correct, and Elan doesn't fix the issue, Biogen could end the agreement and gain full rights to a drug that generates nearly $1 billion in annual revenue and is the major growth driver for both companies.
Under the agreement, signed in 2000, if one company breaches the collaboration and the offense isn't fixed within 60 days, the non-breaching party can terminate the pact and take full control of Tysabri.
That 60-day period will expire Sept. 26, based on Biogen sending its letter on July 28.
In July, J&J agreed to buy 18.4% of Elan along with an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point. The deal is expected to close in early September.
Biogen claims that the arrangement breaches the collaboration, which prevents the assignment of any related rights without permission of the other partner.
Elan is seeking a declaratory judgment that the two agreements don't conflict and that it hasn't breached the agreement. Elan also asked that the court to block Biogen from ending the deal.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
NEW YORK (Dow Jones)--A federal judge has moved a key hearing regarding Biogen Idec Inc. (BIIB) and Elan Corp.'s (ELN) collaboration agreement for the multiple-sclerosis treatment Tysabri to Thursday morning, from its previously scheduled Sept. 10.
No reason for the rescheduling was given in Judge Deborah Batts' order in a federal district court in New York City. She struck three "extraneous submissions" made by Elan and set the hearing for 11 a.m. EDT.
Shares of Biogen recently rose 14 cents to $49.37, while Elan dropped nearly 1% to $7.05.
The hearing, which will focus on whether the court should block Biogen from ending the agreement, comes after Biogen sent a letter alleging that Elan's recent deal with Johnson & Johnson (JNJ) is a breach of the Tysabri agreement.
If Biogen's assertion proves correct, and Elan doesn't fix the issue, Biogen could end the agreement and gain full rights to a drug that generates nearly $1 billion in annual revenue and is the major growth driver for both companies.
Under the agreement, signed in 2000, if one company breaches the collaboration and the offense isn't fixed within 60 days, the non-breaching party can terminate the pact and take full control of Tysabri.
That 60-day period will expire Sept. 26, based on Biogen sending its letter on July 28.
In July, J&J agreed to buy 18.4% of Elan along with an option to finance Elan's purchase of Biogen's Tysabri stake, if Biogen were to be acquired at some point. The deal is expected to close in early September.
Biogen claims that the arrangement breaches the collaboration, which prevents the assignment of any related rights without permission of the other partner.
Elan is seeking a declaratory judgment that the two agreements don't conflict and that it hasn't breached the agreement. Elan also asked that the court to block Biogen from ending the deal.
-By Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
seite 2. !
http://www.thestreet.com/story/10594057/2/dont-fret-over-all…
Elan, Biogen Go to Court On Tysabri: BioBuzz
BOSTON, Mass. (TheStreet) -- Elan(ELN Quote) and Biogen Idec(BIIB Quote) head to court today for the initial hearing in their legal custody battle over the multiple sclerosis drug Tysabri, reports the research firm Cowen in a note to clients. The legal tussle is bit convoluted, but I'll give it a whirl: When Johnson & Johnson bought a minority stake in Elan in July for $1.5 billion, J&J also obtained the right to help Elan finance a purchase of Biogen's 50% ownership in Tysabri, should Biogen be acquired.
Biogen balked at that provision, claiming that Elan was breaching its part of the Tysabri partnership agreement, which could force the company to give up rights to the drug
Elan countered by filing suit against Biogen, asking a federal judge for an injunction to prevent Biogen from acting on its breach-of-contract threat, and ultimately to rule on the legality of its Tysabri financing option with J&J.
Confused? Well, the lawyers get to sort all this out in court starting today.
Says Cowen: "We estimate that Tysabri now accounts for 40-50% of Elan's share valuation, so an adverse ruling in this breech-of-contract dispute and the potential forfeiture of Elan's Tysabri rights would be devastating to Elan's share value. We believe Elan has a solid legal case, but this dispute is a wildcard."
http://www.thestreet.com/story/10594057/2/dont-fret-over-all…
Elan, Biogen Go to Court On Tysabri: BioBuzz
BOSTON, Mass. (TheStreet) -- Elan(ELN Quote) and Biogen Idec(BIIB Quote) head to court today for the initial hearing in their legal custody battle over the multiple sclerosis drug Tysabri, reports the research firm Cowen in a note to clients. The legal tussle is bit convoluted, but I'll give it a whirl: When Johnson & Johnson bought a minority stake in Elan in July for $1.5 billion, J&J also obtained the right to help Elan finance a purchase of Biogen's 50% ownership in Tysabri, should Biogen be acquired.
Biogen balked at that provision, claiming that Elan was breaching its part of the Tysabri partnership agreement, which could force the company to give up rights to the drug
Elan countered by filing suit against Biogen, asking a federal judge for an injunction to prevent Biogen from acting on its breach-of-contract threat, and ultimately to rule on the legality of its Tysabri financing option with J&J.
Confused? Well, the lawyers get to sort all this out in court starting today.
Says Cowen: "We estimate that Tysabri now accounts for 40-50% of Elan's share valuation, so an adverse ruling in this breech-of-contract dispute and the potential forfeiture of Elan's Tysabri rights would be devastating to Elan's share value. We believe Elan has a solid legal case, but this dispute is a wildcard."
http://www.investorvillage.com/smbd.asp?mb=160&mn=378261&pt=…
Report from the Courthouse
No ruling yet, arguements will continue later this afternoon. Judge Batts called a 90 minute lunch break starting at 1:30 pm, reconvening at 3:00 pm ET. Arguments are exactly what we have been debating on IV the past few weeks. My understanding (very noisy cell phone conversation with Thurly) is that ELN has decided to purchase BIIB's 50% if there is a COC, with the assumption that the price would be in line with value to ELN. JNJ appears to have an option to finance the purchase if JNJ agrees with the price, and may have an option to own that 50% once ELN controls 100%. All of this would take place only after a COC at BIIB, so not a breach of the BIIB-ELN collaboration agreement.
There is a possibility that KM and/or SC could be called to testify, and both are in the courthouse. Hearing could possibly continue to tomorrow or another date. ELN still pressing to enjoin the 60 day notice period for material breach, and in my view if Judge Batts does not rule today or in the next few days, she will enjoin the notice period to give ELN adequate time to cure the breach should she rule for BIIB. I hope to get another report later today.
Bloomberg and other media are in the courtroom, so we should get media reports later today -- perhaps even a story during the lunch break.
Everyone should thank Thurly for taking the day to attend -- he had to find a baby sitter after the first one bailed (possibly had ties to hedge funds or BIIB).
Report from the Courthouse
No ruling yet, arguements will continue later this afternoon. Judge Batts called a 90 minute lunch break starting at 1:30 pm, reconvening at 3:00 pm ET. Arguments are exactly what we have been debating on IV the past few weeks. My understanding (very noisy cell phone conversation with Thurly) is that ELN has decided to purchase BIIB's 50% if there is a COC, with the assumption that the price would be in line with value to ELN. JNJ appears to have an option to finance the purchase if JNJ agrees with the price, and may have an option to own that 50% once ELN controls 100%. All of this would take place only after a COC at BIIB, so not a breach of the BIIB-ELN collaboration agreement.
There is a possibility that KM and/or SC could be called to testify, and both are in the courthouse. Hearing could possibly continue to tomorrow or another date. ELN still pressing to enjoin the 60 day notice period for material breach, and in my view if Judge Batts does not rule today or in the next few days, she will enjoin the notice period to give ELN adequate time to cure the breach should she rule for BIIB. I hope to get another report later today.
Bloomberg and other media are in the courtroom, so we should get media reports later today -- perhaps even a story during the lunch break.
Everyone should thank Thurly for taking the day to attend -- he had to find a baby sitter after the first one bailed (possibly had ties to hedge funds or BIIB).
Antwort auf Beitrag Nr.: 37.914.560 von Tebi am 03.09.09 20:48:34Heute Abend wird Schnuggel gross oder bekommt einen auf die Rübe---heute ist die Anhörung in dem Konflikt mit Biogen in bezug auf den J+J-Deal....
wir nehmen wiedermal die rübe für eln gelle.....
wir nehmen wiedermal die rübe für eln gelle.....
Elan hat das Prozess verloren!!!!!
Tia,
und was passiert jetzt??
und was passiert jetzt??
Birgit und Bernie,
seid ihr noch da?
posimist
seid ihr noch da?
posimist
Antwort auf Beitrag Nr.: 37.917.332 von posimist am 04.09.09 10:03:25ich bin noch da.
Ist schon ein Kreuz mit unserer ELAN.
Habe noch keine Aktien verkauft, kann aber über die "Unfähigkeit" der Unternehmensspitze nur den Kopf schütteln.
Die können nicht einmal vernünftige Anwälte bauftragen, die vernünftige Verträge aufsetzen, die dann auch vor Gericht bestand haben.
Jetzt hat Elan erst einmal die Möglichkeit den Vertrag mit J+J zu korrigieren. Mal sehen ob die das wenigstens hinbekommen.
Ist schon ein Kreuz mit unserer ELAN.
Habe noch keine Aktien verkauft, kann aber über die "Unfähigkeit" der Unternehmensspitze nur den Kopf schütteln.
Die können nicht einmal vernünftige Anwälte bauftragen, die vernünftige Verträge aufsetzen, die dann auch vor Gericht bestand haben.
Jetzt hat Elan erst einmal die Möglichkeit den Vertrag mit J+J zu korrigieren. Mal sehen ob die das wenigstens hinbekommen.
Antwort auf Beitrag Nr.: 37.917.494 von Poppholz am 04.09.09 10:19:29vielleicht steigt der Kurs jetzt ja sogar.
Der Kurs reagiert ja oft genug contra-Newsflow.
Der Kurs reagiert ja oft genug contra-Newsflow.
das große MINUS ist vorbörslich und nach Börsenstart ausgeblieben.
Mal schauen, wie sich der Kurs in den nächsten Stunden entwickelt.
Mal schauen, wie sich der Kurs in den nächsten Stunden entwickelt.
Hallo an Allen.
Wie muss eine Änderung des Vertrages aussehen, damit Biogen kein Problem damit hat?
Schero
Wie muss eine Änderung des Vertrages aussehen, damit Biogen kein Problem damit hat?
Schero
Antwort auf Beitrag Nr.: 37.922.911 von Schero am 04.09.09 19:31:23
schließe mich schero an, was ist da los?
ich hatte für heute einen ordentlichen dämpfer erwartet, nun ja vieleicht kommt der ja am dienstag.
schließe mich schero an, was ist da los?
ich hatte für heute einen ordentlichen dämpfer erwartet, nun ja vieleicht kommt der ja am dienstag.
Antwort auf Beitrag Nr.: 37.917.332 von posimist am 04.09.09 10:03:25Na klar----Birgit heisst nun Tebi---und Bernie ist auch noch da-----ich bin auf Kreta + Bernie in Holland-----und wir verkoofen nicht vor 20€,,,,,,Aber dieses Management ist UNGLAUBLICH......
Irish Times comment on Court case result
Setback unlikely to spoil relations with J&J
*
DOMINIC COYLE
ANALYSIS: Neither party to the $1.5 billion deal between two pharma giants would be happy to see it collapse
THE DECISION of Manhattan district court judge Deborah Batt is a setback for Elan but not one that is likely to derail its $1.5 billion deal with pharmaceuticals giant Johnson Johnson (JJ).
Having unveiled JJ as a major investor just two months ago following an extensive review of its funding options, Elan would find itself vulnerable if the deal were to collapse at this late stage.
JJ would be equally discomfited to see the access the deal gives it to some of the most advanced development programme for Alzheimer’s disease therapies snatched away.
The two companies had intended to complete their arrangement by September 15th, so the 23-day window given by the Judge Batt to unravel the current difficulties should not be insurmountable.
The expectation must be that Elan has put in place contingency arrangements since the matter first blew up in mid-July.
Analysts were confident even before the outcome of the case that any breach could be resolved easily by simply removing the Tysabri financing clause from the agreement with Johnson Johnson.
That is now clearly what must happen.
What is more interesting is the price the US group might demand to sign away the option it was granted that could have given it a 50 per cent share of the blockbuster Tysabri drug for multiple sclerosis in the event of a change of ownership at Elan’s partner in that venture, Biogen.
Intriguingly, the option was not highlighted by either company when the deal was first announced and, when it did emerge, both companies insisted that it had not been a material issue requiring disclosure.
At that time, it was made clear that the Alzheimer’s programme being run in conjunction with Wyeth was the core attraction for JJ in taking its 18.4 per cent stake in the Irish firm.
However, there is no denying that it would have been the icing on the cake for JJ in what has the potential to be a very rewarding investment.
JJ could look for a greater share of the Alzheimer’s programme – under the deal, it currently holds 50.1 per cent of Elan’s stake in the programme with Wyeth.
Alternatively, it could seek rights on one or more of Elan’s other Alzheimers drugs.
Whatever happens, Elan will not be ceding its rights to Tysabri as a result of this court battle. After its early hiccups, Tysabri is now a success, on course for sales this year of about $1 billion and reckoned by Goodbody analyst Ian Hunter to account for about 60 per cent of the current value of the company.
----Birgit heisst nun Tebi---und Bernie ist auch noch da-----ich bin auf Kreta + Bernie in Holland-----und wir verkoofen nicht vor 20€,,,,,,Aber dieses Management ist UNGLAUBLICH......Irish Times comment on Court case result
Setback unlikely to spoil relations with J&J
*
DOMINIC COYLE
ANALYSIS: Neither party to the $1.5 billion deal between two pharma giants would be happy to see it collapse
THE DECISION of Manhattan district court judge Deborah Batt is a setback for Elan but not one that is likely to derail its $1.5 billion deal with pharmaceuticals giant Johnson Johnson (JJ).
Having unveiled JJ as a major investor just two months ago following an extensive review of its funding options, Elan would find itself vulnerable if the deal were to collapse at this late stage.
JJ would be equally discomfited to see the access the deal gives it to some of the most advanced development programme for Alzheimer’s disease therapies snatched away.
The two companies had intended to complete their arrangement by September 15th, so the 23-day window given by the Judge Batt to unravel the current difficulties should not be insurmountable.
The expectation must be that Elan has put in place contingency arrangements since the matter first blew up in mid-July.
Analysts were confident even before the outcome of the case that any breach could be resolved easily by simply removing the Tysabri financing clause from the agreement with Johnson Johnson.
That is now clearly what must happen.
What is more interesting is the price the US group might demand to sign away the option it was granted that could have given it a 50 per cent share of the blockbuster Tysabri drug for multiple sclerosis in the event of a change of ownership at Elan’s partner in that venture, Biogen.
Intriguingly, the option was not highlighted by either company when the deal was first announced and, when it did emerge, both companies insisted that it had not been a material issue requiring disclosure.
At that time, it was made clear that the Alzheimer’s programme being run in conjunction with Wyeth was the core attraction for JJ in taking its 18.4 per cent stake in the Irish firm.
However, there is no denying that it would have been the icing on the cake for JJ in what has the potential to be a very rewarding investment.
JJ could look for a greater share of the Alzheimer’s programme – under the deal, it currently holds 50.1 per cent of Elan’s stake in the programme with Wyeth.
Alternatively, it could seek rights on one or more of Elan’s other Alzheimers drugs.
Whatever happens, Elan will not be ceding its rights to Tysabri as a result of this court battle. After its early hiccups, Tysabri is now a success, on course for sales this year of about $1 billion and reckoned by Goodbody analyst Ian Hunter to account for about 60 per cent of the current value of the company.
So wie ich es verstehe, sind einige der Investoren darüber froh der Deal – in dieser Form - geplatzt zu sehen. Anders kann die Reaktion am Freitag nicht verstanden werden.
Vielleicht war das wirklich ein Segen. Trotzdem ist das Management sehr miserabel.
Schero
Vielleicht war das wirklich ein Segen. Trotzdem ist das Management sehr miserabel.
Schero
Antwort auf Beitrag Nr.: 37.928.110 von Schero am 06.09.09 17:58:20....ich glaube,die Meisten verstehen,dass sich an dem Deal nichts ändert----die Gelder von J+J werden nur anders genannt....Gruss!
Antwort auf Beitrag Nr.: 37.928.110 von Schero am 06.09.09 17:58:20die Kursreaktionen sind nicht auf die News zu beziehen.
Leider.
Der Kurs ist in der Vergangenheit so dermaßen nach unten gegangen, obwohl die Nachrichten "nicht so dramatisch" gewesen sind.
Tiefer kann der Kurs eigentlich gar nicht mehr fallen. Wir sind auf einem Niveau angekommen, wo wir damals noch nicht einmal mit der Zulassung von Tysabri gerechnet haben.
Damals gab es keine "Zusammenarbeit" mit J+J und auch mit Wyeth waren wir noch lange nicht so weit.
Der Kurs ist zum aktuellen Zeitpunkt ein "schlechter Scherz" und meiner Meinung nach stark manipuliert.
Ist natürlich nur meine Meinung.
Leider.
Der Kurs ist in der Vergangenheit so dermaßen nach unten gegangen, obwohl die Nachrichten "nicht so dramatisch" gewesen sind.
Tiefer kann der Kurs eigentlich gar nicht mehr fallen. Wir sind auf einem Niveau angekommen, wo wir damals noch nicht einmal mit der Zulassung von Tysabri gerechnet haben.
Damals gab es keine "Zusammenarbeit" mit J+J und auch mit Wyeth waren wir noch lange nicht so weit.
Der Kurs ist zum aktuellen Zeitpunkt ein "schlechter Scherz" und meiner Meinung nach stark manipuliert.
Ist natürlich nur meine Meinung.
Antwort auf Beitrag Nr.: 37.928.842 von Tebi am 06.09.09 22:02:07sehe ich genau so.
Das sind "Spitzfindigkeiten".
Ist aber schon schlimm, dass dies nicht sofort ordentlich aufgestellt wurde.
Das sind "Spitzfindigkeiten".
Ist aber schon schlimm, dass dies nicht sofort ordentlich aufgestellt wurde.
Habe ein gutes Gefühl was unser Baby und den damit verbundenen Kurs angeht.
Heute wird schön Grün.
Heute wird schön Grün.
Antwort auf Beitrag Nr.: 37.936.650 von Poppholz am 08.09.09 11:21:40habe noch einmal 600 Stück (871331) zu 5,14 Euro hinzugekauft.
hängt ja auch alles miteinander zusammen:
Biogen Idec will Facet für 355 Millionen Dollar kaufen
New York - Das US-Biotech-Unternehmen Biogen Idec will den Entwicklungspartner Facet Biotech für 355 Mio. Dollar übernehmen. Biogen Idec habe dem Facet-Verwaltungsrat 14,50 Dollar je Aktie oder einen Aufschlag von 64 Prozent auf den Schlusskurs vom 3. September angeboten, teilte Biogen mit.
http://moneycab.presscab.com/de/templates/?a=68238
Biogen Idec will Facet für 355 Millionen Dollar kaufen
New York - Das US-Biotech-Unternehmen Biogen Idec will den Entwicklungspartner Facet Biotech für 355 Mio. Dollar übernehmen. Biogen Idec habe dem Facet-Verwaltungsrat 14,50 Dollar je Aktie oder einen Aufschlag von 64 Prozent auf den Schlusskurs vom 3. September angeboten, teilte Biogen mit.
http://moneycab.presscab.com/de/templates/?a=68238
http://seekingalpha.com/article/160334-facet-biotech-should-…
ein Aufschlag von knapp über 60% dürfte aber nicht ausreichen.
ein Aufschlag von knapp über 60% dürfte aber nicht ausreichen.
Antwort auf Beitrag Nr.: 37.939.376 von Poppholz am 08.09.09 16:21:05der Chart von gestern ist schon "auffallend".
Bei $7,60 wurde geschmissen, keine Chance das der Kurs nach oben geht.
bin auf heute gespannt.
Bei $7,60 wurde geschmissen, keine Chance das der Kurs nach oben geht.
bin auf heute gespannt.
Antwort auf Beitrag Nr.: 37.959.986 von Poppholz am 11.09.09 09:31:35....ich auch! Gruss aus Kreta!
11.09.2009 00:03
Elan to Present at Morgan Stanley Global Healthcare Unplugged Conference
Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York, NY, on Monday, September 14, 2009, at 2:45 p.m. British Summer Time; and 9:45 a.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
Contacts:
Elan Corporation, plc
MEDIA:
Mary Stutts, 650 794 4403
Niamh Lyons, 353-1-663-3602
or
INVESTORS:
Chris Burns, 800 252 3526
David Marshall, 353 1 709 4444
© 2009 Business Wire
http://www.finanznachrichten.de/nachrichten-2009-09/14920499…
Elan to Present at Morgan Stanley Global Healthcare Unplugged Conference
Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York, NY, on Monday, September 14, 2009, at 2:45 p.m. British Summer Time; and 9:45 a.m. Eastern Time.
Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations section of the Elan website at www.elan.com, then clicking on the event icon. Following the live webcast, an archived version of the presentation will be available at the same URL.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
Contacts:
Elan Corporation, plc
MEDIA:
Mary Stutts, 650 794 4403
Niamh Lyons, 353-1-663-3602
or
INVESTORS:
Chris Burns, 800 252 3526
David Marshall, 353 1 709 4444
© 2009 Business Wire
http://www.finanznachrichten.de/nachrichten-2009-09/14920499…
Link: http://www.rte.ie/business/2009/morningrep/download/0914blox…
Elan - J&J set to renegotiate its $1.5bn deal for Alzheimers portfolio
• According to the WSJ J&J is set to renegotiate the price of previously agreed $1.5bn deal for an 18% stake in Elan. The renegotiation is as a result of the federal ruling last week that the
deal in its current form breaches the existing partnership between Elan and Biogen to develop the MS drug Tysabri. The original deal was for a $1billion cash payment in return for an 18.4% stake in Elan allowing J&J access to Elan’s Alzheimer’s drug portfolio. The deal also included a pledge for $500m in development costs to be paid to fund continuing research projects by Elan. Biogen took legal action after the deal was announced, citing the complex arrangement it had with Elan meant J&J had now in effect bought an option to buy its share of Tysabri, the highly profitable MS drug. It is now understood that J&J are to seek at least a $100m reduction in the upfront offering for its stake.
Elan - J&J set to renegotiate its $1.5bn deal for Alzheimers portfolio
• According to the WSJ J&J is set to renegotiate the price of previously agreed $1.5bn deal for an 18% stake in Elan. The renegotiation is as a result of the federal ruling last week that the
deal in its current form breaches the existing partnership between Elan and Biogen to develop the MS drug Tysabri. The original deal was for a $1billion cash payment in return for an 18.4% stake in Elan allowing J&J access to Elan’s Alzheimer’s drug portfolio. The deal also included a pledge for $500m in development costs to be paid to fund continuing research projects by Elan. Biogen took legal action after the deal was announced, citing the complex arrangement it had with Elan meant J&J had now in effect bought an option to buy its share of Tysabri, the highly profitable MS drug. It is now understood that J&J are to seek at least a $100m reduction in the upfront offering for its stake.
Elan Corp (USc)
ELN US
Revised terms of Elan/J&J deal may be announced soon
Jack Gorman
Price $7.61 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
Weekend media reports suggested that the revised terms of Elan's collaboration agreement with J&J could emerge over the coming days. Revisions were expected following the legal ruling that the terms of the Tysabri contingent financing clause were in breach of Elan's agreement with BiogenIdec.
According to the reports, a reduction of the overall cash injection from J&J looks the likely option, rather than increasing dilution or giving away rights to another piece of the Elan pipeline. The cited reduction of at least $100m would imply a drop of at least 6.7% on the original $1.5bn deal. Although a cash reduction was not our favoured revision to the terms, something around $100m would not hinder Elan's balance sheet plans unduly.
From a broader investment perspective, the most important implication of the reports is that the overall deal with J&J will be completed.
ELN US
Revised terms of Elan/J&J deal may be announced soon
Jack Gorman
Price $7.61 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
Weekend media reports suggested that the revised terms of Elan's collaboration agreement with J&J could emerge over the coming days. Revisions were expected following the legal ruling that the terms of the Tysabri contingent financing clause were in breach of Elan's agreement with BiogenIdec.
According to the reports, a reduction of the overall cash injection from J&J looks the likely option, rather than increasing dilution or giving away rights to another piece of the Elan pipeline. The cited reduction of at least $100m would imply a drop of at least 6.7% on the original $1.5bn deal. Although a cash reduction was not our favoured revision to the terms, something around $100m would not hinder Elan's balance sheet plans unduly.
From a broader investment perspective, the most important implication of the reports is that the overall deal with J&J will be completed.
Johnson & Johnson will Preis für Elan-Übernahme drücken
Frankfurt am Main - Der US-Konsumgüter- und Medizintechnikkonzern Johnson & Johnson versucht Kreisen zufolge den Preis für die angekündigte Übernahme der irischen Biotech-Firma Elan Corp zu drücken. Hintergrund ist das Gerichtsurteil, wonach der Schulterschluss in Teilen gegen Elans Partnerschaft mit Biogen verstosse, wie aus Verhandlungskreisen verlautete.
Johnson & Johnson will demnach den bisherigen Preis von 1,0 Milliarden Dollar für eine 18,4 Prozent-Beteiligung um mindestens 100 Millionen Dollar senken. Die Amerikaner hatten im Juli angekündigt, Elan in Teilen zu übernehmen und weitere 500 Millionen Dollar in dessen Biotech-Geschäft zu investieren. (awp/mc/ps/25)
http://moneycab.presscab.com/de/templates/?a=68548
Frankfurt am Main - Der US-Konsumgüter- und Medizintechnikkonzern Johnson & Johnson versucht Kreisen zufolge den Preis für die angekündigte Übernahme der irischen Biotech-Firma Elan Corp zu drücken. Hintergrund ist das Gerichtsurteil, wonach der Schulterschluss in Teilen gegen Elans Partnerschaft mit Biogen verstosse, wie aus Verhandlungskreisen verlautete.
Johnson & Johnson will demnach den bisherigen Preis von 1,0 Milliarden Dollar für eine 18,4 Prozent-Beteiligung um mindestens 100 Millionen Dollar senken. Die Amerikaner hatten im Juli angekündigt, Elan in Teilen zu übernehmen und weitere 500 Millionen Dollar in dessen Biotech-Geschäft zu investieren. (awp/mc/ps/25)
http://moneycab.presscab.com/de/templates/?a=68548
15.09.2009 11:21
J&J zahlt für Einstieg bei Elan weniger
NEW YORK (Dow Jones)--Der Pharmakonzern Johnson&Johnson (J&J) muss für den Einstieg bei der Elan Corp weniger zahlen. Man habe sich geeinigt, den Kaufpreis um 115 Mio USD zu senken, teilte die Elan am Montag mit. Allerdings sei das Multiple-Sklerose-Mittel "Tysabri" nun nicht mehr Teil der Vereinbarung.
Bei Tysabri arbeitet Elan seit neun Jahren mit Biogen Idec zusammen. Das Medikament ist der Hauptwachstumstreiber beider Unternehmen. Beide haben auch das Recht, bei einem Eigentümerwechsel des Partners dessen Anteil zu übernehmen.
J&J hatte im Juli ihren Einstieg bei Elan amgekündigt. Eine Vertragsklausel räumte dem Konzern aus New Brunswick im Bundesstaat New York das Recht ein, einen möglichen Kauf des Biogen-Anteils an Tysabri durch Elan zu finanzieren. J&J hätte dann diesen Anteil übernommen. Dieser relative leichte Zugang zu Tysabri könnte laut Marktteilnehmern andere interessierte Käufer von Biogen abschrecken.
Nach dem Urteil eines US-Bundesrichters von September verstieß der Deal mit J&J gegen die bestehende Partnerschaft zwischen Elan und Biogen Idec Inc. Laut dem Urteil musste Elan die Vereinbarung mit J&J bis zum 26. September abändern. Andernfalls riskierte das irische Biotechnologieunternehmen den Verlust sämtlicher Rechte an Tysabri.
Daraufhin hat J&J den Preis für den Einstieg gedrückt. Für den Kauf eines Anteil von 18,4% an Elan wird der Pharmakonzern nun 885 Mio USD statt wie Anfang Juli vereinbart 1 Mrd USD in bar zahlen. Der Pharmakonzern werde aber unverändert 500 Mio USD in die Entwicklung von Elan-Medikamenten stecken und erhält weiterhin Rechte an vielen Alzheimermedikamenten an denen Elan forscht. Die Transaktion soll nach Angaben von Elan "so bald wie möglich" abgeschlossen werden.
http://www.finanznachrichten.de/nachrichten-2009-09/14949889…
J&J zahlt für Einstieg bei Elan weniger
NEW YORK (Dow Jones)--Der Pharmakonzern Johnson&Johnson (J&J) muss für den Einstieg bei der Elan Corp weniger zahlen. Man habe sich geeinigt, den Kaufpreis um 115 Mio USD zu senken, teilte die Elan am Montag mit. Allerdings sei das Multiple-Sklerose-Mittel "Tysabri" nun nicht mehr Teil der Vereinbarung.
Bei Tysabri arbeitet Elan seit neun Jahren mit Biogen Idec zusammen. Das Medikament ist der Hauptwachstumstreiber beider Unternehmen. Beide haben auch das Recht, bei einem Eigentümerwechsel des Partners dessen Anteil zu übernehmen.
J&J hatte im Juli ihren Einstieg bei Elan amgekündigt. Eine Vertragsklausel räumte dem Konzern aus New Brunswick im Bundesstaat New York das Recht ein, einen möglichen Kauf des Biogen-Anteils an Tysabri durch Elan zu finanzieren. J&J hätte dann diesen Anteil übernommen. Dieser relative leichte Zugang zu Tysabri könnte laut Marktteilnehmern andere interessierte Käufer von Biogen abschrecken.
Nach dem Urteil eines US-Bundesrichters von September verstieß der Deal mit J&J gegen die bestehende Partnerschaft zwischen Elan und Biogen Idec Inc. Laut dem Urteil musste Elan die Vereinbarung mit J&J bis zum 26. September abändern. Andernfalls riskierte das irische Biotechnologieunternehmen den Verlust sämtlicher Rechte an Tysabri.
Daraufhin hat J&J den Preis für den Einstieg gedrückt. Für den Kauf eines Anteil von 18,4% an Elan wird der Pharmakonzern nun 885 Mio USD statt wie Anfang Juli vereinbart 1 Mrd USD in bar zahlen. Der Pharmakonzern werde aber unverändert 500 Mio USD in die Entwicklung von Elan-Medikamenten stecken und erhält weiterhin Rechte an vielen Alzheimermedikamenten an denen Elan forscht. Die Transaktion soll nach Angaben von Elan "so bald wie möglich" abgeschlossen werden.
http://www.finanznachrichten.de/nachrichten-2009-09/14949889…
Antwort auf Beitrag Nr.: 37.982.442 von Poppholz am 15.09.09 14:57:17Na seht Ihr, habe ich doch etwas recht gehabt.
Das Deal ist nun langfristig für Elan besser als vorher. Deshalb ist der Kurs letztens nicht abgestürzt.
Bis bald
Schero
Das Deal ist nun langfristig für Elan besser als vorher. Deshalb ist der Kurs letztens nicht abgestürzt.
Bis bald
Schero
..nach einem kleinen Urlaub in NL und nach vollzogener Renovierung des Hausdaches nun wieder im WO...
....nun erst mal checken " wat Sache ist "....
....nun erst mal checken " wat Sache ist "....
US FDA says no new warnings on Biogen, Elan MS drug
* Brain infection rate still below 1 in 1,000 - FDA
* No changes to warnings, risk management plan - FDA
* Biogen says brain infection remains rare (Adds FDA, company comments)
WASHINGTON, Sept 16 (Reuters) - A Biogen Idec (BIIB.O) and Elan Corp (ELN.I) multiple sclerosis drug does not need new warnings despite additional reports of a life-threatening brain infection, U.S. regulators said on Wednesday.
Thirteen cases of progressive multifocal leukoencephalopathy (PML) have been confirmed through Sept. 8 in MS patients treated with Tysabri as a stand-alone therapy, the Food and Drug Administration said. Four of the cases were reported in U.S. patients.
The PML rate remains below one per 1,000 patients, the FDA said. Tysabri was temporarily withdrawn from the market in 2005 because of its links to PML, which can be fatal.
"At this time, the FDA is not requiring changes regarding PML to the Tysabri prescribing information or to the Tysabri risk management plan," the agency said in a notice posted here
Biogen Idec spokeswoman Jennifer Neiman said PML remained rare and the incidence "was within what was expected when Tysabri was reintroduced more than three years ago."
The FDA said the risk of developing PML "appears to increase with the number of Tysabri infusions received." For the 13 patients with confirmed PML, the number of monthly infusions ranged from 12 to 35, the agency said.
The average number of infusions received before diagnosis of PML was 25.
On Tuesday, Biogen officials told investors at a Morgan Stanley healthcare conference it would be premature to conclude that the risk of developing PML increased the longer patients are treated with Tysabri.
The drug carries a boxed warning, the strongest type for prescription drugs, about the PML risk. All patients must enroll in a monitoring program for PML or other serious infections.
Tysabri also is approved for treating the bowel disorder Crohn's disease. No PML cases have been reported in Crohn's patients, the FDA said. Less than 2 percent of the drug's use in the United States has been for Crohn's disease.
The drug's generic name is natalizumab.
Biogen shares gained nearly 0.3 percent on Nasdaq, while Elan (ELN.N) shares fell 2.8 percent on the New York Stock Exchange. (Reporting by Lisa Richwine, editing by Carol Bishopric)
http://www.reuters.com/article/marketsNews/idCNN164480592009…
* Brain infection rate still below 1 in 1,000 - FDA
* No changes to warnings, risk management plan - FDA
* Biogen says brain infection remains rare (Adds FDA, company comments)
WASHINGTON, Sept 16 (Reuters) - A Biogen Idec (BIIB.O) and Elan Corp (ELN.I) multiple sclerosis drug does not need new warnings despite additional reports of a life-threatening brain infection, U.S. regulators said on Wednesday.
Thirteen cases of progressive multifocal leukoencephalopathy (PML) have been confirmed through Sept. 8 in MS patients treated with Tysabri as a stand-alone therapy, the Food and Drug Administration said. Four of the cases were reported in U.S. patients.
The PML rate remains below one per 1,000 patients, the FDA said. Tysabri was temporarily withdrawn from the market in 2005 because of its links to PML, which can be fatal.
"At this time, the FDA is not requiring changes regarding PML to the Tysabri prescribing information or to the Tysabri risk management plan," the agency said in a notice posted here
Biogen Idec spokeswoman Jennifer Neiman said PML remained rare and the incidence "was within what was expected when Tysabri was reintroduced more than three years ago."
The FDA said the risk of developing PML "appears to increase with the number of Tysabri infusions received." For the 13 patients with confirmed PML, the number of monthly infusions ranged from 12 to 35, the agency said.
The average number of infusions received before diagnosis of PML was 25.
On Tuesday, Biogen officials told investors at a Morgan Stanley healthcare conference it would be premature to conclude that the risk of developing PML increased the longer patients are treated with Tysabri.
The drug carries a boxed warning, the strongest type for prescription drugs, about the PML risk. All patients must enroll in a monitoring program for PML or other serious infections.
Tysabri also is approved for treating the bowel disorder Crohn's disease. No PML cases have been reported in Crohn's patients, the FDA said. Less than 2 percent of the drug's use in the United States has been for Crohn's disease.
The drug's generic name is natalizumab.
Biogen shares gained nearly 0.3 percent on Nasdaq, while Elan (ELN.N) shares fell 2.8 percent on the New York Stock Exchange. (Reporting by Lisa Richwine, editing by Carol Bishopric)
http://www.reuters.com/article/marketsNews/idCNN164480592009…
Antwort auf Beitrag Nr.: 37.998.082 von bernie55 am 17.09.09 10:24:51Biogen shares gained nearly 0.3 percent on Nasdaq, while Elan (ELN.N) shares fell 2.8 percent on the New York Stock Exchange. (Reporting by Lisa Richwine, editing by Carol Bishopric)
das ist doch auch wieder bezeichnend.
das ist doch auch wieder bezeichnend.
FDA Updates Tysabri Safety Info To Include PML Cases
NEW YORK -(Dow Jones)- The Food and Drug Administration has updated the safety information related to multiple sclerosis treatment Tysabri, sold by Biogen Idec Inc. (BIIB) and Elan PLC (ELN), to include information about incidences of a rare brain infection.
The drug's label hasn't changed, and the agency stressed that the overall rate of patients developing progressive multifocal leukoencephalopathy, or PML, remains below the one-in-1,000 rate implied on the label.
Tysabri, widely considered to be a highly effective treatment for the debilitating disease, was pulled from the U.S. market in 2005 for 18 months because of PML concerns, and 13 cases of the infection have been confirmed since its relaunch.
"Tysabri is a compelling option for the treatment of MS, and PML remains a rare adverse event," a Biogen spokeswoman said.
In its update, the agency warned that the risk of developing PML "appears to increase with the number of Tysabri infusions received" and that the average number of infusions received before the diagnosis of PML was 25.
"There is minimal experience in patients who have received more than 35 infusions of Tysabri," the update said. Tysabri is delivered through an intravenous infusion about once a month.
Duration of therapy is widely believed to play a role in Tysabri's PML risk. Biogen has said there is no clear connection to duration and has opposed patients taking treatment breaks - referred to as "drug holidays" - because it can cause MS symptoms to return.
"It wouldn't be prudent to draw any conclusion at this time, based on the small number of patients that have developed PML," the Biogen spokeswoman said regarding the duration issue.
As of June 30, about 43,300 patients were taking Tysabri, with more than 30, 000 on it for more than a year, and about 10,000 on it for more than two years.
Although the rate of PML infection remains below 1-per-1,000 patients, the FDA said the current rate of PML in patients who have received at least 24 infusions ranges from 0.4 to 1.3 per 1,000 patients.
"At this time, the FDA is not requiring changes regarding PML to the Tysabri prescribing information or to the Tysabri risk management plan, called the TOUCH Prescribing Program," the update stated.
Tysabri is key to the future growth of both Biogen and Elan, and Wall Street has focused on the PML cases. The drug receives strong support from patients and doctors because of its perceived effectiveness. That support has remained steady because patients are well aware of the PML risk before they start taking Tysabri for the otherwise debilitating disease of MS.
Tysabri is one of several immune system-suppressing therapies that have been linked to PML, including Rituxan, sold by Biogen with Roche Holding AG (ROG.VX) unit Genentech, and Raptiva, a psoriasis drug that Genentech pulled from the market earlier this year because of the issue.
-Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
09-16-091744ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://news.morningstar.com/newsnet/ViewNews.aspx?article=/D…
NEW YORK -(Dow Jones)- The Food and Drug Administration has updated the safety information related to multiple sclerosis treatment Tysabri, sold by Biogen Idec Inc. (BIIB) and Elan PLC (ELN), to include information about incidences of a rare brain infection.
The drug's label hasn't changed, and the agency stressed that the overall rate of patients developing progressive multifocal leukoencephalopathy, or PML, remains below the one-in-1,000 rate implied on the label.
Tysabri, widely considered to be a highly effective treatment for the debilitating disease, was pulled from the U.S. market in 2005 for 18 months because of PML concerns, and 13 cases of the infection have been confirmed since its relaunch.
"Tysabri is a compelling option for the treatment of MS, and PML remains a rare adverse event," a Biogen spokeswoman said.
In its update, the agency warned that the risk of developing PML "appears to increase with the number of Tysabri infusions received" and that the average number of infusions received before the diagnosis of PML was 25.
"There is minimal experience in patients who have received more than 35 infusions of Tysabri," the update said. Tysabri is delivered through an intravenous infusion about once a month.
Duration of therapy is widely believed to play a role in Tysabri's PML risk. Biogen has said there is no clear connection to duration and has opposed patients taking treatment breaks - referred to as "drug holidays" - because it can cause MS symptoms to return.
"It wouldn't be prudent to draw any conclusion at this time, based on the small number of patients that have developed PML," the Biogen spokeswoman said regarding the duration issue.
As of June 30, about 43,300 patients were taking Tysabri, with more than 30, 000 on it for more than a year, and about 10,000 on it for more than two years.
Although the rate of PML infection remains below 1-per-1,000 patients, the FDA said the current rate of PML in patients who have received at least 24 infusions ranges from 0.4 to 1.3 per 1,000 patients.
"At this time, the FDA is not requiring changes regarding PML to the Tysabri prescribing information or to the Tysabri risk management plan, called the TOUCH Prescribing Program," the update stated.
Tysabri is key to the future growth of both Biogen and Elan, and Wall Street has focused on the PML cases. The drug receives strong support from patients and doctors because of its perceived effectiveness. That support has remained steady because patients are well aware of the PML risk before they start taking Tysabri for the otherwise debilitating disease of MS.
Tysabri is one of several immune system-suppressing therapies that have been linked to PML, including Rituxan, sold by Biogen with Roche Holding AG (ROG.VX) unit Genentech, and Raptiva, a psoriasis drug that Genentech pulled from the market earlier this year because of the issue.
-Thomas Gryta, Dow Jones Newswires; 212-416-2169; thomas.gryta@dowjones.com
(END) Dow Jones Newswires
09-16-091744ET
Copyright (c) 2009 Dow Jones & Company, Inc.
http://news.morningstar.com/newsnet/ViewNews.aspx?article=/D…
Was Fehlt?
Die Finanzierung ist durch.
Welsche Kräfte ziehen den Schnuggel nach unten?
Was fehlt denn?
Bitte um Einschätzungen.
Schero
Die Finanzierung ist durch.
Welsche Kräfte ziehen den Schnuggel nach unten?
Was fehlt denn?
Bitte um Einschätzungen.
Schero
Antwort auf Beitrag Nr.: 38.004.525 von Schero am 17.09.09 21:00:12aus rationalen Gründen und den positiven Zukunftsaussichten müßte der Kurs um einiges höher stehen. Meiner Meinung nach sind Kurse von $20,- bis $25,- realistisch sind. Ziel sollten Kurse von $40,- sein.
Da in der Vergangenheit die Kurse schon in dieser Region gelegen haben und das bei "schlechteren" Vorraussetzungen, sind diese Zahlen kein "Pushergelaber".
Aber generell ist das natürlich nur meine bescheidene Meinung und soll keine Kauf- oder Verkaufsempfehlung darstellen.
Da in der Vergangenheit die Kurse schon in dieser Region gelegen haben und das bei "schlechteren" Vorraussetzungen, sind diese Zahlen kein "Pushergelaber".
Aber generell ist das natürlich nur meine bescheidene Meinung und soll keine Kauf- oder Verkaufsempfehlung darstellen.
MS-Medikament verursacht gefährliche Infektionen
Die Meldungen über schwere Nebenwirkungen durch das Medikament Tysabri häufen sich: Die hoch wirksame Arznei kann bei Patienten mit Multipler Sklerose eine gefährliche Infektion im Gehirn auslösen. Nach SPIEGEL-Informationen traten bereits mehrere Fälle in Deutschland auf - derzeit liegt eine kranke Frau in der Uni-Klinik Bochum.
http://www.spiegel.de/wissenschaft/medizin/0,1518,650061,00.…
Die Meldungen über schwere Nebenwirkungen durch das Medikament Tysabri häufen sich: Die hoch wirksame Arznei kann bei Patienten mit Multipler Sklerose eine gefährliche Infektion im Gehirn auslösen. Nach SPIEGEL-Informationen traten bereits mehrere Fälle in Deutschland auf - derzeit liegt eine kranke Frau in der Uni-Klinik Bochum.
http://www.spiegel.de/wissenschaft/medizin/0,1518,650061,00.…
Antwort auf Beitrag Nr.: 38.015.664 von Huges am 19.09.09 16:22:16das ist bekannt.
Allerdings sind die Anzahl der betroffenen Patienten "gering".
Die Patienten, die mit Tysabri behandelt werden stehen unter besonderer Beobachtung bezüglich der angesprochenen Nebenwirkungen.
Bis zu einem Verhältnis von 1 : 1000 ist laut FDA der Nutzen höher als der Schaden. Die Patienten können bei Feststellung der Nebenwirkung auch behandelt werden.
Wir werden sehen was die Zukunft bringt.
Allerdings sind die Anzahl der betroffenen Patienten "gering".
Die Patienten, die mit Tysabri behandelt werden stehen unter besonderer Beobachtung bezüglich der angesprochenen Nebenwirkungen.
Bis zu einem Verhältnis von 1 : 1000 ist laut FDA der Nutzen höher als der Schaden. Die Patienten können bei Feststellung der Nebenwirkung auch behandelt werden.
Wir werden sehen was die Zukunft bringt.
Antwort auf Beitrag Nr.: 38.020.494 von Poppholz am 21.09.09 10:24:33Eines verstehe ich nicht.
Warum sind die Hälfte aller PML Fälle in Deutschland??
Warum sind die Hälfte aller PML Fälle in Deutschland??
Antwort auf Beitrag Nr.: 38.022.105 von Schero am 21.09.09 13:42:31wie die Verteilung ist kann ich nicht genau sagen, da bin ich momentan nicht auf dem Laufenden.
Habe mich heute mit einigen Positionen von ELAN getrennt.
Die Masse bleibt zwar investiert, aber ich brauchte ein wenig "Spielgeld", da es momentan eine Vielzahl von Aktien gibt, die kurzfristig gutes Kurspotential bieten.
(Somit handelt es sich hiermit um eine gute Voraussetzung für steigende Kurse bei ELAN)
Die Masse bleibt zwar investiert, aber ich brauchte ein wenig "Spielgeld", da es momentan eine Vielzahl von Aktien gibt, die kurzfristig gutes Kurspotential bieten.
(Somit handelt es sich hiermit um eine gute Voraussetzung für steigende Kurse bei ELAN)
Antwort auf Beitrag Nr.: 38.023.403 von Poppholz am 21.09.09 16:02:25Hallo Poppholz,
welsche Aktien willst Du kaufen?
welsche Aktien willst Du kaufen?
Antwort auf Beitrag Nr.: 38.024.554 von Schero am 21.09.09 18:19:42habe gestern mehrere ALLOS THERAPEUTICS gekauft.
Außerdem habe ich PAION gekauft.
Diese sollten gut laufen, mal sehen.
Außerdem habe ich PAION gekauft.
Diese sollten gut laufen, mal sehen.
Johnson & Johnson completes deal with Elan, acquiring its Alzheimer's assets
Mon. September 21, 2009; Posted: 03:49 AM
Stocks RSS
You too can increase your ETF trading!
Look up the PowerRating of ELN,JNJ and see how it has performed over the past week as well as the current proprietary PowerRating.
Sep 21, 2009 (M2 EQUITYBITES via COMTEX) -- JNJ | Quote | Chart | News | PowerRating -- Healthcare products supplier Johnson & Johnson (NYSE:JNJ) confirmed on Thursday that it has completed its acquisition of substantially all of the assets and rights of Irish drug developer Elan Corporation plc (NYSE:ELN) related to its Alzheimer's Immunotherapy Program (AIP).
The transaction was carried out through JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson.
Additionally, Johnson & Johnson, through its affiliate Janssen Pharmaceutical, has invested USD885m in exchange for newly issued American Depositary Receipts (ADRs) of Elan representing 18.4% of its outstanding ordinary shares.
The AIP represented Elan's interest in a collaboration with pharmaceutical and healthcare company Wyeth (NYSE:WYE) to develop products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. JANSSEN Alzheimer Immunotherapy will now assume Elan's activities with Wyeth under the AIP.
Mon. September 21, 2009; Posted: 03:49 AM
Stocks RSS
You too can increase your ETF trading!
Look up the PowerRating of ELN,JNJ and see how it has performed over the past week as well as the current proprietary PowerRating.
Sep 21, 2009 (M2 EQUITYBITES via COMTEX) -- JNJ | Quote | Chart | News | PowerRating -- Healthcare products supplier Johnson & Johnson (NYSE:JNJ) confirmed on Thursday that it has completed its acquisition of substantially all of the assets and rights of Irish drug developer Elan Corporation plc (NYSE:ELN) related to its Alzheimer's Immunotherapy Program (AIP).
The transaction was carried out through JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson.
Additionally, Johnson & Johnson, through its affiliate Janssen Pharmaceutical, has invested USD885m in exchange for newly issued American Depositary Receipts (ADRs) of Elan representing 18.4% of its outstanding ordinary shares.
The AIP represented Elan's interest in a collaboration with pharmaceutical and healthcare company Wyeth (NYSE:WYE) to develop products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. JANSSEN Alzheimer Immunotherapy will now assume Elan's activities with Wyeth under the AIP.
Antwort auf Beitrag Nr.: 38.029.111 von Tebi am 22.09.09 12:30:26der Link zum Artikel:
http://www.tradingmarkets.com/.site/news/Stock%20News/253700…
http://www.tradingmarkets.com/.site/news/Stock%20News/253700…
REG-Elan Corporation plc Director/PDMR Shareholding
Mon Sep 21, 2009 12:14pm
Featured Broker sponsored link
http://www.businesswire.com/news/home/20090921006151/en
LONDON--(Business Wire)--
SCHEDULE 11
Notification of Transactions of Directors/Persons Discharging Managerial
Responsibility and Connected Persons
This form is intended for use by an issuer to make a RIS notification required
by the Market Abuse Rules and section 53 (as extended by section 64 of the
Companies Act 1990) or entered into the issuer`s register in accordance with
section 59 of the Companies Act 1990.
(1) An issuer making a notification in respect of a transaction relating to the
shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative relating to the
shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options granted to a
director/person discharging managerial responsibilities should complete boxes 1
to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial instrument
relating to the shares of the issuer (other than a debenture) should complete
the boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
All relevant boxes should be completed in block capital letters
1 Name of the Issuer 2 State whether the notification relates to:
(i) a transaction notified in accordance with Market Abuse Rules;
ELAN CORPORATION, PLC
(ii) a disclosure made in accordance with section 53 (as extended by section 64 of the Companies Act 1990) or entered into the issuer`s register in accordance with section 59 of the Companies Act 1990; or
(iii) both (i) and (ii).
(iii) BOTH (i) AND (ii)
3 Name of person discharging managerial responsibilities/director 4 State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person
KELLY MARTIN
AS IN 3 ABOVE
5 Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 6 Description of shares (including class) debentures or derivatives or financial instruments relating to shares
AS IN 3 ABOVE
OPTIONS OVER ORDINARY SHARES OF €0.05 EACH AS REPRESENTED BY AMERICAN DEPOSITORY SHARES
7 Name of registered shareholder(s) and, if more than one, number of shares held by each of them 8 State the nature of the transaction
AS IN 3 ABOVE
GRANT OF OPTIONS
9 Number of shares, debentures or financial instruments relating to shares acquired 10 Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)
11 Number of shares, debentures or financial instruments relating to shares disposed 12 Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
13 Price per share or value of transaction 14 Date and place of transaction
15 Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16 Date issuer informed of transaction
If a person discharging managerial responsibilities has been granted options by
the issuer, complete the following boxes:
17 Date of grant 18 Period during which or date on which it can be exercised
18 SEPTEMBER 2009
OPTIONS ARE EXERCISABLE FROM 19 MARCH 2012.
19 Total amount paid (if any) for grant of the option 20 Description of shares or debentures involved (class and number)
NIL
OPTION TO ACQUIRE 150,000 ORDINARY SHARES AS REPRESENTED BY AMERICAN DEPOSITORY SHARES
21 Exercise price (if fixed at time of grant) or indication that the price is to be fixed at the time of exercise 22 Total number of shares or debentures over which options are held following notification
$7.18
4,008,445
23 Any additional information 24 Name of contact and telephone number for queries
NONE
WILLIAM DANIEL: 01 709 4000
Name and signature of duly designated officer of issuer responsible for making notification
____________________________________________________
WILLIAM DANIEL - COMPANY SECRETARY
DATE OF NOTIFICATION: 21 SEPTEMBER 2009
Elan Corporation plc
Copyright Business Wire 2009
http://www.reuters.com/article/pressRelease/idUS120512+21-Se…
Mon Sep 21, 2009 12:14pm
Featured Broker sponsored link
http://www.businesswire.com/news/home/20090921006151/en
LONDON--(Business Wire)--
SCHEDULE 11
Notification of Transactions of Directors/Persons Discharging Managerial
Responsibility and Connected Persons
This form is intended for use by an issuer to make a RIS notification required
by the Market Abuse Rules and section 53 (as extended by section 64 of the
Companies Act 1990) or entered into the issuer`s register in accordance with
section 59 of the Companies Act 1990.
(1) An issuer making a notification in respect of a transaction relating to the
shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative relating to the
shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options granted to a
director/person discharging managerial responsibilities should complete boxes 1
to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial instrument
relating to the shares of the issuer (other than a debenture) should complete
the boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
All relevant boxes should be completed in block capital letters
1 Name of the Issuer 2 State whether the notification relates to:
(i) a transaction notified in accordance with Market Abuse Rules;
ELAN CORPORATION, PLC
(ii) a disclosure made in accordance with section 53 (as extended by section 64 of the Companies Act 1990) or entered into the issuer`s register in accordance with section 59 of the Companies Act 1990; or
(iii) both (i) and (ii).
(iii) BOTH (i) AND (ii)
3 Name of person discharging managerial responsibilities/director 4 State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person
KELLY MARTIN
AS IN 3 ABOVE
5 Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 6 Description of shares (including class) debentures or derivatives or financial instruments relating to shares
AS IN 3 ABOVE
OPTIONS OVER ORDINARY SHARES OF €0.05 EACH AS REPRESENTED BY AMERICAN DEPOSITORY SHARES
7 Name of registered shareholder(s) and, if more than one, number of shares held by each of them 8 State the nature of the transaction
AS IN 3 ABOVE
GRANT OF OPTIONS
9 Number of shares, debentures or financial instruments relating to shares acquired 10 Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)
11 Number of shares, debentures or financial instruments relating to shares disposed 12 Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)
13 Price per share or value of transaction 14 Date and place of transaction
15 Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16 Date issuer informed of transaction
If a person discharging managerial responsibilities has been granted options by
the issuer, complete the following boxes:
17 Date of grant 18 Period during which or date on which it can be exercised
18 SEPTEMBER 2009
OPTIONS ARE EXERCISABLE FROM 19 MARCH 2012.
19 Total amount paid (if any) for grant of the option 20 Description of shares or debentures involved (class and number)
NIL
OPTION TO ACQUIRE 150,000 ORDINARY SHARES AS REPRESENTED BY AMERICAN DEPOSITORY SHARES
21 Exercise price (if fixed at time of grant) or indication that the price is to be fixed at the time of exercise 22 Total number of shares or debentures over which options are held following notification
$7.18
4,008,445
23 Any additional information 24 Name of contact and telephone number for queries
NONE
WILLIAM DANIEL: 01 709 4000
Name and signature of duly designated officer of issuer responsible for making notification
____________________________________________________
WILLIAM DANIEL - COMPANY SECRETARY
DATE OF NOTIFICATION: 21 SEPTEMBER 2009
Elan Corporation plc
Copyright Business Wire 2009
http://www.reuters.com/article/pressRelease/idUS120512+21-Se…
ap
Moody's upgrades ratings on Elan
Moody's Investors Service upgrades Elan ratings following completion of J&J deal
On Friday September 25, 2009, 12:39 pm EDT
NEW YORK (AP) -- Moody's Investors Service upgraded Elan Corp.'s ratings Friday, citing the completion of Elan's financing deal with Johnson & Johnson.
Last week, J&J completed a deal to buy a stake in Elan and obtain rights to the company's Alzheimer's disease treatment program. New Brunswick, N.J.-based J&J paid $885 million for an 18.4 percent stake in Elan. Also, J&J will commit up to $500 million for development of bapineuzumab, which is aimed at treating Alzheimer's disease.
Moody's upgraded Ireland-based Elan's corporate family rating to "B2" from "B3," both of which are non-investment grade. Moody's also reaffirmed a positive outlook.
Moody's said just under $1.77 billion in debt is affected by the rating.
"The cash inflow from J&J represents a significant liquidity infusion for Elan and a reduction in its net debt position, prompting Moody's upgrade," said Moody's senior vice president Michael Levesque, in a statement.
American depository shares of Elan rose 7 cents to $7.25 in afternoon trading.
http://finance.yahoo.com/news/Moodys-upgrades-ratings-on-apf…
Moody's upgrades ratings on Elan
Moody's Investors Service upgrades Elan ratings following completion of J&J deal
On Friday September 25, 2009, 12:39 pm EDT
NEW YORK (AP) -- Moody's Investors Service upgraded Elan Corp.'s ratings Friday, citing the completion of Elan's financing deal with Johnson & Johnson.
Last week, J&J completed a deal to buy a stake in Elan and obtain rights to the company's Alzheimer's disease treatment program. New Brunswick, N.J.-based J&J paid $885 million for an 18.4 percent stake in Elan. Also, J&J will commit up to $500 million for development of bapineuzumab, which is aimed at treating Alzheimer's disease.
Moody's upgraded Ireland-based Elan's corporate family rating to "B2" from "B3," both of which are non-investment grade. Moody's also reaffirmed a positive outlook.
Moody's said just under $1.77 billion in debt is affected by the rating.
"The cash inflow from J&J represents a significant liquidity infusion for Elan and a reduction in its net debt position, prompting Moody's upgrade," said Moody's senior vice president Michael Levesque, in a statement.
American depository shares of Elan rose 7 cents to $7.25 in afternoon trading.
http://finance.yahoo.com/news/Moodys-upgrades-ratings-on-apf…
Kamloops at centre of Alzheimer’s drug test (ALL ABOUT BAPI)
Dr. Chris Outram speaks with patient Huguette Vezina at his Columbia Street office. Outram is the principal investigator on a new drug therapy for Alzheimer’s patients.
Published: September 28, 2009 4:00 PM
Updated: September 28, 2009 4:50 PM
The hobbies you once loved no longer hold any interest.
Simple tasks performed for years are difficult to complete.
Mood swings are common and uncontrollable.
It’s increasingly hard to remember things and people.
These are just some of the many debilitating and irreversible symptoms of Alzheimer’s disease.
And, as people are living longer worldwide, the disease is surging in senior populations.
However, there is an investigational new drug being tested in Kamloops and other Interior communities that could stave off or reduce the effects of Alzheimer’s.
Dr. Chris Outram, principle investigator with the Medical Arts and Health Research Group in Kamloops, is testing a new drug called Bapineuzumab, which could control the progression of the disease.
“Alzheimer’s patients have a protein in their brain that interferes with the transmission of the nerve impulses in the brain,” Outram said of the Bapi 301 study.
“This medication tries to help remove that protein to slow the progress of the disease.”
Current treatments are mediocre — effective for some patients and fairly costly.
These treatments try to change the neurotransmitters in the brain, whereas the Bapi 301 study attempts to clear a residual junk protein left in the brain.
“It’s an ever-growing problem with a growing population,” Outram said.
“The average age in North America is increasing all the time and Alzheimer’s is also increasing commensurately.”
As a result, wait lists for proper care are long and, if a better treatment isn’t found, society will become overwhelmed in terms of finding safe places to take care of people living with Alzheimer’s, Outram said.
“It’s more than a 24-hour day taking care of them and we need more and more places for full-time care,” he said.
“If we can slow the process and keep their thinking clear for longer, it will obviously be a help.”
The study is in its third phase, with 900 of the 1,100 test spots across Canada filled.
Patients being tested are between 50 and 88 years of age, with mild to moderate Alzheimer’s.
Bapineuzumab is given to patients by intravenous infusion 13 times over a span of 72 weeks.
Although phase three has been taking place during the past three years, it’s still not know when the drug could be made available to the public.
Outram said it has to meet Health Canada’s requirements, which could take years.
Nevertheless, he said the response to the drug has been positive, with patients having more clarity of thought, suggesting a slower pace in the degenerative disease, but there are no firm conclusions at this point.
“I’d like to see a drug that makes a real difference to Alzheimer’s patients’ lives and their families’ lives,” Outram said.
“At the moment, there are no medications that can make a phenomenal difference.”
To learn more about the Bapi 301 study, go online to icarastudy.com or call 250-682-3576.
http://www.investorvillage.com/smbd.asp?mb=160&mn=383697&pt=…
Dr. Chris Outram speaks with patient Huguette Vezina at his Columbia Street office. Outram is the principal investigator on a new drug therapy for Alzheimer’s patients.
Published: September 28, 2009 4:00 PM
Updated: September 28, 2009 4:50 PM
The hobbies you once loved no longer hold any interest.
Simple tasks performed for years are difficult to complete.
Mood swings are common and uncontrollable.
It’s increasingly hard to remember things and people.
These are just some of the many debilitating and irreversible symptoms of Alzheimer’s disease.
And, as people are living longer worldwide, the disease is surging in senior populations.
However, there is an investigational new drug being tested in Kamloops and other Interior communities that could stave off or reduce the effects of Alzheimer’s.
Dr. Chris Outram, principle investigator with the Medical Arts and Health Research Group in Kamloops, is testing a new drug called Bapineuzumab, which could control the progression of the disease.
“Alzheimer’s patients have a protein in their brain that interferes with the transmission of the nerve impulses in the brain,” Outram said of the Bapi 301 study.
“This medication tries to help remove that protein to slow the progress of the disease.”
Current treatments are mediocre — effective for some patients and fairly costly.
These treatments try to change the neurotransmitters in the brain, whereas the Bapi 301 study attempts to clear a residual junk protein left in the brain.
“It’s an ever-growing problem with a growing population,” Outram said.
“The average age in North America is increasing all the time and Alzheimer’s is also increasing commensurately.”
As a result, wait lists for proper care are long and, if a better treatment isn’t found, society will become overwhelmed in terms of finding safe places to take care of people living with Alzheimer’s, Outram said.
“It’s more than a 24-hour day taking care of them and we need more and more places for full-time care,” he said.
“If we can slow the process and keep their thinking clear for longer, it will obviously be a help.”
The study is in its third phase, with 900 of the 1,100 test spots across Canada filled.
Patients being tested are between 50 and 88 years of age, with mild to moderate Alzheimer’s.
Bapineuzumab is given to patients by intravenous infusion 13 times over a span of 72 weeks.
Although phase three has been taking place during the past three years, it’s still not know when the drug could be made available to the public.
Outram said it has to meet Health Canada’s requirements, which could take years.
Nevertheless, he said the response to the drug has been positive, with patients having more clarity of thought, suggesting a slower pace in the degenerative disease, but there are no firm conclusions at this point.
“I’d like to see a drug that makes a real difference to Alzheimer’s patients’ lives and their families’ lives,” Outram said.
“At the moment, there are no medications that can make a phenomenal difference.”
To learn more about the Bapi 301 study, go online to icarastudy.com or call 250-682-3576.
http://www.investorvillage.com/smbd.asp?mb=160&mn=383697&pt=…
Davy
ELN US
Announces debt restructuring
Jack Gorman
Price $7.34 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
Elan has moved quickly to restructure its debt profile following the closure of the J&J deal and the subsequent upgrade of its credit rating by Moody's.
Firstly, it has announced a cash tender offer for the existing senior fixed-rate notes ($850m, due 2011). Elan will fund this with cash and through the issuance of new senior fixed-rate notes, due 2016. The new bond will carry similar covenants to those attaching to existing debt. As we understand it, pricing could be announced later today (September 29th).
Elan had flagged that it would use the cash infusion from J&J to restructure debt, so the move comes as no surprise. The net effect is broadly similar to our own working assumptions contained in our forecasts. At first glance, the only changes are to mix: net debt will be modestly higher (c.$50m) than forecast, but there will also be higher gross cash retained on Elan's balance sheet.
Extending the maturity profile of Elan's debt, and reducing the overall gross debt burden from $1.765m to $1.515m, is a positive development for the shares.
http://www.investorvillage.com/smbd.asp?mb=160&mn=383699&pt=…
ELN US
Announces debt restructuring
Jack Gorman
Price $7.34 Rating: Outperform 30/06/09
--------------------------------------------------------------------------------
Elan has moved quickly to restructure its debt profile following the closure of the J&J deal and the subsequent upgrade of its credit rating by Moody's.
Firstly, it has announced a cash tender offer for the existing senior fixed-rate notes ($850m, due 2011). Elan will fund this with cash and through the issuance of new senior fixed-rate notes, due 2016. The new bond will carry similar covenants to those attaching to existing debt. As we understand it, pricing could be announced later today (September 29th).
Elan had flagged that it would use the cash infusion from J&J to restructure debt, so the move comes as no surprise. The net effect is broadly similar to our own working assumptions contained in our forecasts. At first glance, the only changes are to mix: net debt will be modestly higher (c.$50m) than forecast, but there will also be higher gross cash retained on Elan's balance sheet.
Extending the maturity profile of Elan's debt, and reducing the overall gross debt burden from $1.765m to $1.515m, is a positive development for the shares.
http://www.investorvillage.com/smbd.asp?mb=160&mn=383699&pt=…
Elan prices offering of $625 million senior notes
Elan prices offering of $625 million senior notes due 2016 being made by 2 subsidiaries
On Wednesday September 30, 2009, 9:09 am EDT
NEW YORK (AP) -- Elan Corp. said it priced an offering of $625 million senior notes due 2016 being made by subsidiaries Elan Finance Corp. and Elan Finance public limited company.
The notes will have an 8.75 percent coupon each year.
The neuroscience-based biotechnology company said late Tuesday that it will use the offering's proceeds to refinance some existing debt, to pay fees and expenses and for general corporate purposes.
The offering is targeted to close on Friday.
http://finance.yahoo.com/news/Elan-prices-offering-of-625-ap…
Elan prices offering of $625 million senior notes due 2016 being made by 2 subsidiaries
On Wednesday September 30, 2009, 9:09 am EDT
NEW YORK (AP) -- Elan Corp. said it priced an offering of $625 million senior notes due 2016 being made by subsidiaries Elan Finance Corp. and Elan Finance public limited company.
The notes will have an 8.75 percent coupon each year.
The neuroscience-based biotechnology company said late Tuesday that it will use the offering's proceeds to refinance some existing debt, to pay fees and expenses and for general corporate purposes.
The offering is targeted to close on Friday.
http://finance.yahoo.com/news/Elan-prices-offering-of-625-ap…
07.10.2009 22:32
Elan Announces Webcast of Third Quarter 2009 Financial Results
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, October 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s third quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public.
This event can be accessed by visiting Elan’s website at www.elan.com and clicking on the Investor Relations section, then on the event icon. Following the live webcast, an archived version of the call will be available at the same URL.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs. Elan shares trade on the New York and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.
Contacts:
Elan Corporation
INVESTOR:
Chris Burns, 800-252-3526
David Marshall, 353-1-709-4444
or
MEDIA:
Mary Stutts, 650-794-4403
Niamh Lyons 353-1-663-3602
© 2009 Business Wire
Elan Announces Webcast of Third Quarter 2009 Financial Results
Elan Corporation, plc (NYSE: ELN) announced today that it will host a conference call on Wednesday, October 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s third quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public.
This event can be accessed by visiting Elan’s website at www.elan.com and clicking on the Investor Relations section, then on the event icon. Following the live webcast, an archived version of the call will be available at the same URL.
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by bringing innovations in science to fill significant unmet medical needs. Elan shares trade on the New York and Dublin Stock Exchanges. For additional information about the company, please visit www.elan.com.
Contacts:
Elan Corporation
INVESTOR:
Chris Burns, 800-252-3526
David Marshall, 353-1-709-4444
or
MEDIA:
Mary Stutts, 650-794-4403
Niamh Lyons 353-1-663-3602
© 2009 Business Wire
Antwort auf Beitrag Nr.: 38.138.724 von Poppholz am 08.10.09 12:16:31hoffentlich haben diese Kurse bald mal ein Ende.
Antwort auf Beitrag Nr.: 38.139.038 von Poppholz am 08.10.09 12:56:21...echt! Bis nächstes Jahr müssen wir noch durchhalten!
Also gut, hängen wir noch ein Jährchen dran.
Hatte Elan sowieso bis 2010 Zeit eingeräumt,die Alzheimerentwicklung entscheidend voran zu bringen.
posimist
Hatte Elan sowieso bis 2010 Zeit eingeräumt,die Alzheimerentwicklung entscheidend voran zu bringen.
posimist
Antwort auf Beitrag Nr.: 38.143.946 von posimist am 08.10.09 22:02:17Hallo zusammmen,
was haltet Ihr denn von der Pipline von Vernalis: Halte diese schon länger.......
Freue mich über Einschätzungen!
Gruß
quickclick
was haltet Ihr denn von der Pipline von Vernalis: Halte diese schon länger.......
Freue mich über Einschätzungen!
Gruß
quickclick
Antwort auf Beitrag Nr.: 38.143.946 von posimist am 08.10.09 22:02:17Hatte den Link vergessen:
http://www.vernalis.com/ver/rdc2/pipeline/
http://www.vernalis.com/ver/rdc2/pipeline/
Antwort auf Beitrag Nr.: 38.145.224 von Poppholz am 09.10.09 09:02:36....mach Dir nix draus--ist ganz normal....
sollte heute ein grüner Tag werden?
Antwort auf Beitrag Nr.: 38.160.140 von Poppholz am 12.10.09 16:23:04Was für ein Trauerspiel.
Hoffentlich werden die Quartalszahlen eine Besserung bringen.
Was meint Ihr wann eine Besserung des Kurses zu sehen sein wird??
Gruß Schero
Hoffentlich werden die Quartalszahlen eine Besserung bringen.
Was meint Ihr wann eine Besserung des Kurses zu sehen sein wird??
Gruß Schero
Elan Announces Webcast of Third Quarter 2009 Financial Results
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) announced today that it will host a conference call on Wednesday, October 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s third quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
http://finance.yahoo.com/news/Elan-Announces-Webcast-of-bw-3…
DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN - News) announced today that it will host a conference call on Wednesday, October 21, 2009 at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan’s third quarter 2009 financial results, which will be released before the European and U.S. financial markets open.
http://finance.yahoo.com/news/Elan-Announces-Webcast-of-bw-3…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 231 | ||
| 85 | ||
| 76 | ||
| 74 | ||
| 70 | ||
| 48 | ||
| 40 | ||
| 40 | ||
| 33 | ||
| 24 |
| Wertpapier | Beiträge | |
|---|---|---|
| 20 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 16 | ||
| 16 | ||
| 15 | ||
| 15 | ||
| 14 |
